M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838340] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2/ [ADDRESS_838341] ure ............... 5 0 
2. 1 I n vesti gati o nal Sites ................................ ............................................ 5 0 
2. 2 Trial C o or di nati o n / M o nit ori n g ......................................................... [ADDRESS_838342] ...................................................... 5 2 
3. 2 
3. 2. 1 
3. 2. 2 P har mac o ki netics / I m m u n o ge nicit y  Fi n di n gs ................................... 5 8 
3. 2. 3 T o xic ol o g y ................................ .......................................................... 5 9 
3. 3 Brief S u m mar y  of t he Cli nical Fi n di n gs f or M S B 0 0 1 1 3 5 9 C ............. 6 1 
3. 4 
3. 4. 1 
3. 4. 2 
3. 5 S u m mar y  of t he O verall Be nefit a n d Ris k .......................................... 6 9 
3. 5. 1 I n f usi o n- relate d Reacti o ns / H y perse nsiti vit y .................................... 7 0 
3. 5. 2 I m m u ne -relate d A d verse E ve nts / A ut oi m m u ne Dis or ders................ [ADDRESS_838343] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838344] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3/ 1 9 3 4. 1 Pri mar y  O bjecti ves ................................ ................................ ............. 7 4 
4. 2 Sec o n d ar y O bjecti ves ................................ ......................................... 7 4 
4. 3 
5 I n vesti gati o nal Pla n ................................ ............................................ 7 5 
5. 1 O verall Trial Desi g n a n d Pla n ............................................................ 7 5 
5. 1. 1 O verall Trial Desi g n ................................ ........................................... 7 6 
5. 1. 2 Trial Me dicati o n A d mi nistrati o n a n d Sc he d ule .................................. 8 0 
5. 1. 3 M S B 0 0 1 1 3 5 9 C D ose Escalati o n ........................................................ 8 1 
5. 1. 4 E x pa nsi o n C o h orts ................................ .............................................. 8 3 
5. 1. 5 Pla n ne d N u m ber of S u bjects .............................................................. 8 3 
5. 1. 6 Pla n ne d Treat me nt D urati o n ............................................................... 8 3 
5. 1. 7 D ose M o dificati o n a n d A D Rs Re q uiri n g Treat me nt 
Disc o nti n uati o n ................................ ................................ ................... 8 4 
5. 1. 8 A nal y sis C ut off Dates ................................ ......................................... 8 6 
5. 2 Disc ussi o n of Trial Desi g n ................................ ................................. 8 7 
5. 2. 1 I n cl usi o n of S pecial P o p ulati o ns ................................ ........................ 8 8 
5. 3 Selecti o n of Trial P o p ulati o n .............................................................. 8 8 
5. 3. 1 I n cl usi o n Criteria ................................ ................................................ 8 8 
5. 3. 2 E xcl usi o n Criteria ( A p plica ble t o All S u bjects, I ncl u di n g All 
E x pa nsi o n C o h orts) ................................ ................................ ............ [ADDRESS_838345] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838346] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5/ [ADDRESS_838347] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI C CI 
C CI 
C CI 
C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838348] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6/ [ADDRESS_838349] Files .......................................................... 1 7 4 
1 0. 3 I n vesti gat or Site File a n d Arc hi vi n g ................................................. 1 7 5 
1 0. 4 M o nit ori n g, Q ualit y Ass ura nce, a n d I ns pecti o n b y Healt h 
A ut h orities ................................ ........................................................ 1 7 5 
1 0. 5 C ha n ges t o t he Cli nical Trial Pr ot oc ol .............................................. 1 7 5 
1 0. 6 Cli nical Trial Re p ort a n d P u blicati o n P olic y .................................... 1 7 6 
1 0. 6. 1 Cli nical Trial Re p ort ................................ ......................................... 1 7 6 
1 0. 6. 2 P u blicati o n ................................ ........................................................ 1 7 6 
1 0. 7 Rec or d Re te nti o n i n Ja pa n ................................ ................................ 1 7 6 
1 1 Refere nces Cite d i n t he Te xt ............................................................. 1 7 7 
1 2 A p pe n dices ................................ ....................................................... 1 8 3 
A p pe n di x 1 Easter n C o o perati ve O nc ol o g y  Gr o u p Perf or ma nce Stat us .............. 1 8 4 
A p pe n di x 2 G ui da nce o n C o ntrace pti o n .............................................................. 1 8 5 
A p pe n di x 3 Si g nat ure Pa ges a n d Res p o nsi ble Pers o ns f or t he Trial................... 1 8 6 
Si g nat ure Pa ge –Pr ot oc ol L ea d ................................ ....................................................... 1 8 7 
Si g nat ure Pa ge –C o or di nati n g I n vesti gat or................................ ................................ .... 1 8 8 
Si g nat ure Pa ge –Pri nci pal I n vesti gat or ................................ ........................................... [ADDRESS_838350] of C ha n ges ..................................... 1 9 1 
C ha n ges fr o m Versi o n 7. 1 t o Versi o n 7. 2 i ncl u de d i n t he A me n d me nt: ......................... [ADDRESS_838351] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838352] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7/ 1 9 3 T a ble of I n -Te xt T a bles 
Ta ble 1 Sc he d ule of Assess me nts – D ose Escalati o n P hase............................ 3 3 
Ta ble 2 Sc he d ule of Assess me nts – E x pa nsi o n P hase ..................................... 3 8 
Ta ble 3 Sc he d ule of Assess me nts – P har mac o ki netic Sa m pli n g,  
, a n d Ge ne E x pressi o n Sa m pli n g ......................................... 4 4 
Ta ble 4 M o dificati o n of D ose Escalati o n Base d o n D L T O bser vati o ns .......... 8 2 
Ta ble 5 Wait Peri o ds Bet wee n D osi n g of S u bjects Wit hi n a D ose / 
E x pa nsi o n C o h ort ................................ ............................................. 1 0 4 
Ta ble 6 Treat me nt M o dificati o n f or S y m pt o ms of I nf usi o n -relate d 
Reacti o ns Ca use d b y M S B 0 0 1 1 3 5 9 C ............................................... 1 0 5 
Ta ble 7 Ma na ge me nt of I m m u ne -Relate d A d verse E ve nts ........................... 1 0 8 
Ta ble 8 Assess me nt of Tar get Lesi o n Res p o nse: C o n ve nti o nal R E CI S T 
a n d m R E CI S T Assess me nt f or He pat ocell ular Carci n o ma 
F oll o wi n g t he A merica n Ass ociati o n f or t he St u d y of L i ver 
Disease –J o ur nal of t he Nati o nal Ca ncer I nstit ute G ui deli ne .......... [ADDRESS_838353] ors ................................ ................................................. 1 3 8 
Ta ble 1 0 S u m mar y  of Pr o p ose d R A N O Res p o nse Criteria ............................. 1 3 9 
Ta ble 1 1 Re q uire d La b orat or y  Pa nel Tests ...................................................... 1 4 7 
Ta ble 1 2 T he 9 5 % E xact ( Cl o p per -Pears o n) C o nfi de nce I nter vals f o r O R R 
Base d o n [ADDRESS_838354] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838355] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8/ [ADDRESS_838356] 
A F P al p ha -fet o pr otei n 
A L K a na plastic l y m p h o ma ki nase 
A L T ala ni ne a mi n otra nsferase 
A N A a nti n uclear a nti b o d y 
A N C a bs ol ute ne utr o p hil c o u nt 
a P T T acti vate d partial t hr o m b o plasti n ti me 
A S T as partate a mi n otra nsferase 
A U C area u n der t he c o nce ntrati o n -ti me c ur ve 
A U C 0- ∞ area u n der t he c o nce ntrati o n -ti me c ur ve fr o m t he ti me of 
d osi n g e xtra p olate d t o i nfi nit y 
A U C 0-t area u n der t he c o nce ntrati o n -ti me c ur ve fr o m t he ti me of 
d osi n g t o t he ti me of t he last o bser vati o n 
β- H C G β- h u ma n c h ori o nic g o na d otr o pi n 
B O R best o verall res p o nse 
C A - [ADDRESS_838357] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838358] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9/ 1 9 3 C T c o m p ute d t o m o gra p h y 
C T C A E C o m m o n Ter mi n ol o g y  Criteria f or A d verse E ve nts 
C T L A- 4 c y t ot o xic T l y m p h oc y te a nti ge n - 4 
Ctr o u g h tr o u g h c o nce ntrati o n 
D C R disease c o ntr ol rate 
D L T d ose -li miti n g t o xicit y 
E C 5 0 effecti ve c o nce ntrati o n e xerti n g 5 0 % effect 
E C G electr ocar di o gra m 
E C O G P S Easter n C o o perati ve O nc ol o g y  Gr o u p perf or ma nce stat us 
e C R F electr o nic case re p ort f or m 
E G F R e pi [INVESTIGATOR_171633] o wt h fact or rece pt or 
E M A E ur o pea n Me dici nes A ge nc y 
E O R T C Q L Q- B N 2 0 E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer 
Q ualit y  of Life Q uesti o n naire Brai n M o d ule 
E O R T C Q L Q- C 3 0 E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer 
Q ualit y  of Life Q uesti o n naire C ore i nstr u me nt 
E O R T C Q L Q- C X 2 4 E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer 
Q ualit y  of Life Q uesti o n naire Cer vical Ca ncer M o d ule 
E O R T C Q L Q- 
H C C 1 8 - M E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer 
Q ualit y  of Life Q uesti o n naire He pat ocell ular Carci n o ma 
M o d ule –M o difie d 
E O R T C Q L Q- O E S [ADDRESS_838359] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838360] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 / 1 9 3 F F P E f or mali n fi xe d, paraffi n e m be d de d 
F H SI - 8 F A C T He pat o biliar y  S y m pt o m I n de x –8 q uesti o ns 
FI S H fl u oresce nce i n sit u h y bri dizati o n 
F O L F O X oxali plati n, 5 -fl u or o uracil, a n d f oli nic aci d 
F S H f ollicle -sti m ulati n g h or m o ne 
G C P G o o d Cli nical Practice 
G G T ga m ma -gl uta m y ltra nsferase 
G L P G o o d La b orat or y  Practice 
H A H A h u ma n a nti h u ma n a nti b o d y 
H B V he patitis B vir us 
H C C he pat ocell ular carci n o ma 
H C V he patitis C vir us 
H D V he patitis D vir us 
H g b he m o gl o bi n 
HI V h u ma n i m m u n o deficie nc y vir us 
H P V h u ma n pa pi[INVESTIGATOR_4382] o ma vir us 
I B I n vesti gat or’s Br oc h ure 
I C 5 0 5 0 % i n hi bit or y  c o nce ntrati o n 
I C F I n f or me d C o nse nt F or m 
I C H I nte r nati o nal C o u ncil f or Har m o nisati o n 
I E C I n de pe n de nt Et hics C o m mittee 
I g i m m u n o gl o b uli n 
I H C i m m u n o hist oc he mistr y 
I M P I n vesti gati o nal Me dici nal Pr o d uct 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838361] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 / [ADDRESS_838362] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838363] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 / [ADDRESS_838364] u gs 
N S C L C n o n- s mall cell l u n g ca ncer 
N S C L C-S A Q N o n - S mall Cell L u n g Ca ncer S y m pt o m Assess me nt 
Q uesti o n naire 
O S o verall s ur vi val 
P B M C peri p heral bl o o d m o n o n uclear cell 
P D pr o gressi ve disease 
P D - 1 pr o gra m me d deat h 1 
P D -L 1 pr o gra m me d deat h li ga n d 1 
P F S pr o gressi o n -free s ur vi val 
P GI S Patie nt Gl o bal I m pressi o n of Se verit y 
P h E ur E ur o pea n P har mac o peia 
P K p har mac o ki netic(s) 
P R partial res p o nse 
p S M A D p h os p h or y late d S M A D 
P T pr ot hr o m bi n ti me 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838365] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 / [ADDRESS_838366] or 
S A E seri o us a d verse e ve nt 
S A P Statistical A nal y sis Pla n 
S C C H N sq ua m o us cell carci n o ma hea d a n d nec k 
S D sta ble disease 
S M C Safet y  M o nit ori n g C o m mittee 
S U S A R s us pecte d u ne x pecte d seri o us a d verse reacti o n 
t1/ [ADDRESS_838367] ca ncer 
T N M T u m or N o de Metastasis Classificati o n of Mali g na nt T u m ors 
( UI C C) 
Tre g re g ulat or y  T- cells 
T S H t h y r oi d -sti m ulati n g h or m o ne 
T T P ti me t o pr o gressi o n 
UI C C U ni o n I nter nati o nale C o ntre le Ca ncer 
U L N u p per li mit of n or mal 
U S P U nite d States P har mac o peia 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838368] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 / [ADDRESS_838369] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838370] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 / 1 9 3 Met h o d ol o g y: 
T his is a P hase I,  o pe n -la bel, d ose- escalati o n trial wit h c o nsec uti ve parallel -gr o u p e x pa nsi o n 
i n selecte d s oli d t u m or i n dicati o ns. 
D ose esc al ati o n 
T he c urre nt trial is c o m p ose d of a sta n dar d d ose escalati o n “ 3 + 3” c o h ort desi g n, f or w hic h 
3t o 6 s u bjects will be e nr olle d at eac h d ose le vel de pe n di n g o n t he occ urre nce of d ose -li miti n g 
t o xicities ( D L Ts), f oll o we d b y  a c o nsec uti ve parallel -gr o u p e x pa nsi o n i n selecte d s oli d t u m or 
i n dicati o ns.  
C o h orts of 3 s u bjects wit h metastatic or l ocall y  a d va nce d s oli d t u m ors, f or w hic h n o sta n dar d 
effe cti ve t hera p y  e xists or sta n dar d t hera p yhas faile d, will recei ve M S B 0 0 1 1 3 5 9 C at escalati n g 
d ose le vels.  T he starti n g M S B 0 0 1 1 3 5 9 C d ose is 1m g/ k g; t he hi g hest e n visa ge d d ose i n t he 
d ose escalati o n part is 2 0 m g/ k g , b ut t his m a y  b e e x pa n de d base d o n t he st u d y  s afet y d ata .  T he 
d ose ra n ge a n d sc he d ule f or t his trial were de vel o pe d base d o n safet y c o nsi derati o ns as well as 
o n precli nical P K /  a n d e x perie nce wit h t he pare nt 
a vel u ma b a nti b o d yc urre ntl y  u n der cli nical de vel o p me nt .
D ose esc al ati o n ( 3 + 3 desi g n) will be perf or me d at t he f oll o wi n g d ose le vels 
1m g/ k g 
3m g/ k g 
1 0 m g/ k g 
2 0 m g/ k g 
3 0 m g/ k g 
[ADDRESS_838371] d osi n g at n o less t ha n 4 8 -h o ur i nter vals 
bet wee n s u bjects. A D L T is defi ne d as a n y Gra de ≥ 3 a d verse e ve nt (A E )assesse d t o be relate d 
t o in vesti gati o nal me dici nal pr o d uct (I M P) b y  t h e I n vesti gat or a n d / or S p o ns or occ urri n g i n 
t he D L T e val uati o n peri o d ( [ADDRESS_838372] a d mi nistrati o n of M S B 0 0 1 1 3 5 9 C ) c o nfir me d b y 
t he Safet y M o nit ori n g C o m mittee ( S M C) t o be rele va nt f or t he I M P treat me nt.  T he M T D is 
defi ne d as t he hi g hest d ose le vel at w hic h n o m ore t ha n [ADDRESS_838373] o ut of 6 s u bjects treate d i n a 
c o h ort a n d e val ua ble f or D L T deter mi nati o n e x perie nces a D L T. 
At eac h d ose le vel, s u bjects will recei ve M S B 0 0 1 1 3 5 9 C as a 1 -h o ur i ntra ve n o us (I V) i nf usi o n 
( 1 2 0 mi n utes f or t he 3 0 m g/ k g a n d 2 4 0 0 m g  f lat -d ose c o h orts) o nce e ver y  2 wee ks u ntil 
pr o gressi ve disease ( P D) has bee n c o nfir me d b y  a  s u bse q ue nt sca n, u nacce pta ble t o xicit y , or 
occ urre nce of a n y c riteri o n f or wit h dra wal fr o m t he trial or t he I M P as o utli ne d i n t his pr ot oc ol.  
I n or der t o miti gate p ote ntial i nf usi o n -relate d reacti o ns, pre me dicati o n wit h a n a nti hista mi ne 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838374] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 / 1 9 3 a n d wit h paraceta m ol (aceta mi n o p he n) (f or e xa m ple, 2 5 - 5 0 m g di p he n h y dra mi ne a n d 
5 0 0- 6 5 0 m g paraceta m ol [aceta mi n o p he n] I V or oral e q ui vale nt) a p pr o xi matel y  [ADDRESS_838375] 2 i nf usi o ns, after 
w hic h pre me dicati o n is o pti o nal a n d at t he discreti o n of t he I n vesti gat or .  S ter oi ds as 
pre me dicati o n are n ot per mitte d .   
As t he 2 0 m g / k g c o h ort i n t he d ose escalati o n p orti o n has cleare d S M C e val uati o n, a n 
a d diti o nal c o h ort at t he 3 0 m g/ k g d ose le vel will be i nitiate d, i n parallel t o t he o n g oi n g 
e x pa nsi o n c o h orts.  T he 3 0 m g/ k g c o h ort will be e nr olle d i n a 3 + [ADDRESS_838376] 3 s u bjects a n d n o m ore t ha n 6e val ua ble s u bjects t o be e nr olle d .  T his c o h ort 
s h o ul d pr o vi de a d diti o nal i nsi g ht i nt o d ose pr o p orti o nalit y  o f P K a n d  para meters 
a n d s u p p ort safet y c o nsi derati o ns at hi g her e x p os ures t ha n t he e x pa nsi o n -p hase d ose 
of 1 2 0 0 m g o nce e ver y  2- wee ks . 
Wit h t he sa fet y  of t he 3 0 m g/ k g c o h ort esta blis he d, afi xe d d ose c o h ort of 2 4 0 0 m g o nce e ver y 
2 wee ks will be e nr olle d i n a 3 + [ADDRESS_838377] u dies .
F or P K / p ur p oses, after at least t he first [ADDRESS_838378] orat or y P K /   relati o ns hi ps, a decisi o n will be ma de t o 
i nitiate u p t o 2 c o h orts of 3 s u bjects eac h, o ne at 0. 1 m g/ k g a n d o ne at 0. 3 m g/ k g, w hic h will 
i ncrease o n t he sec o n d d ose a n d all s u bse q ue nt d oses t o a 1 2 0 0 m g /i nf usi o n flat d ose de pe n de nt 
u p o n S M C cleara nce a n d o nl y  if t he S p o ns or a n d C o or di nati n g I n vesti gat or ha ve deter mi ne d a 
mea ni n gf ul d ose f or t he i ntras u bject escalati o n .  A fter t he M T D ha s bee n reac he d or t he 
2 0 m g/ k g c o h ort has bee n declare d b y  t he S M C as t he hi g hest n o n- M T D d ose assesse d, t he n 
f urt her P K a nal ys es m a y  b e perf or me d.  I f dee me d necessar y , t he 1, 3, 1 0, a n d 2 0 m g/ k g c o h orts 
ma y  e ac h e nr oll u p t o a n a d diti o nal 1 0 s u bjects ( u p t o 4 0 t otal) f or t he p ur p ose of esta blis hi n g 
t he P K /  relati o ns hi p .  O n t he sec o n d d ose a n d all s u bse q ue nt d oses , t he 1 m g / k g 
c o h ort m a y  i ncrease t o a 1 2 0 0 m g/i nf usi o n flat d ose. N o D L T e val uati o ns will be perf or me d 
i n t hese s u p ple me ntal c o h orts. 
E x p a nsi o n 
After deter mi nati o n of t he M T D, a M S B 0 0 1 1 3 5 9 C d ose f or f urt her i n vesti gati o n will b e 
selecte d a n d e nr oll me nt i n e x pa nsi o n c o h orts i n selecte d t u m or i n dicati o ns will be o pe ne d t o 
deter mi ne t he safet y a n d cli nical acti vit y  o f M S B 0 0 1 1 3 5 9 C .  T he i n dicati o ns were c h ose n si nce 
t he y  offer t he p ote ntial f or tra nsf or mati ve treat me nt wit h a bilit y  t o esta blis h a n i nitial pr o of of 
pri nci ple of a ntit u m or acti vit y  of M S B 0 0 1 1 3 5 9 C wit h g o o d fea si bilit y .
T he selecte d d ose of M S B 0 0 1 1 3 5 9 C f or t he e x pa nsi o n c o h orts will be i nf usi o ns of 1 2 0 0 m g 
f or all e x pa nsi o n c o h orts e xce pt f or t he sec o n d -li ne N S C L C c o h ort.  T he sec o n d -li ne N S C L C
c o h ort will be ra n d o mize d t o 1of 2d ose le vels 5 0 0 m g ( 4 0 s u bjects )a n d 1 2 0 0 m g ( 4 0 s u bjects ). 
T hese d oses will be a d mi nistere d as “flat” d oses i n de pe n de nt of t he b o d y  w ei g ht as 1- h o ur I V  
i nf usi o ns o nce e ver y [ADDRESS_838379] u d y , pre me dicati o n wit h a n a nti hista mi ne a n d wit h 
paraceta m ol (aceta mi n o p he n) has bee n ma n dat or y  i n or der t o miti gate p ote ntial 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
C CI 
C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838380] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 9 / 1 9 3 i nf usi o n -relate d rea cti o ns.  Bas e d o n a n i nitia l safet y  assess me nt i n t he d ose -escalati o n c o h orts 
at d ose le vels of 1, 3, 1 0 , a n d 2 0 m g/ k g wit h a c ut off date of [ADDRESS_838381] was 
re p orte d wit h a treat me nt -e mer ge nt a d verse e ve nt ( T E A E) wi t h a Preferre d Ter m of 
i nf usi o n- relate d reacti o n; h o we ver usi n g a p ost -re p orti n g a nal ys is acc or di n g t o criteria o utli ne d 
i n t he Statistical A nal ys is Pla n, 3 s u bjects were re p orte d wit h T E A Es t hat were classifie d as 
“i nf usi o n -relate d reacti o ns,” wit h t he Preferre d Ter ms of a b d o mi nal pa i n, p y re xia, a n d bac k 
pai n ( N ote: t hese e ve nts are u n der g oi n g f urt her re vie w) . Base d o n t he a b o ve o bser vati o ns a n d 
i n or der t o f urt her i n vesti gate t he p ote ntial f or i nf usi o n -relate d reacti o ns, f or s u bjects i n t he 
N S C L C bi o mar ker c o h ort bei n g treate d at t h e U nite d States (U S )Nati o nal Ca ncer I nstit ute 
( N CI) , pre me dicati o n will be o pti o nal. T his a p pr oac h i n t he li mite d n u m ber of s u bjects 
e nr olle d i n t he N S C L C bi o mar ker c o h ort a n d u n der cl o se s ur veilla nce of e x perie nce d 
In vesti gat ors at t he N CI i n vesti gati o nal site a p pears t o be j ustifie d. For all ot her escalati o n a n d 
e x pa nsi o n c o h orts, pre me dicati o n is ma n dat or y f or at least t he first 2i nf usi o ns, a n d t hereafter, 
o pt i o nal at t he discreti o n of t he In vesti gat or.  If Gra de ≥ [ADDRESS_838382] i nf usi o ns .  
Res p o nse t o tre at me nt 
S u bjects fr o m eit her t he d ose -escalati o n or t he e x pa nsi o n p orti o ns of t he trial w h o ha ve 
e x perie nce d sta ble disease ( S D), a partial res p o nse ( P R), or a c o m plete res p o nse ( C R) s h o ul d 
be treate d t hr o u g h t he e n d of [ADDRESS_838383] m a y  b e nefit fr o m treat me nt b e y o n d 1 2 m o nt hs, it ma y  b e 
per missi ble after disc ussi o n wit h t he Me dical M o nit or a n d t he S p o ns or Me dical Res p o nsi ble .  
I n t he case of P D, s u bjects s h o ul d c o nti n ue treat me nt t hr o u g h t heir ne xt t u m or assess me nt, if 
t he y  m eet t he criteria descri be d i n t his pr ot oc ol.  I f t here is f urt her e vi de nce of P D t hereafter, 
trial treat me nt s h o ul d be disc o nti n ue d; h o we ver c o nti n ue d tre at me nt is p ossi ble i n c o ns ultati o n 
wit h t he Me dical M o nit or.  F or s u bjects w h o ac hie ve S D, a C R or P R o n M S B [ADDRESS_838384] a n ne d n u m ber of s u bjects: 
D ose escalati o n: fr o m 3 t o 8 2 s u bjects. 
E x pa nsi o n:  U p t o a p pr o xi matel y  5 6 6 s u bjects .
Pri m ar y e n d p oi nts: 
T he pri mar y  e n d p oi nts f or t he d ose -escalati o n part of t he trial are t he: 
N u m ber, se verit y, a n d d urati o n of T E A Es acc or di n g t o t he N CI C o m m o n Ter mi n ol o g y  
Criteria f or A d verse E ve nts ( C T C A E) v 4. [ADDRESS_838385] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838386] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 0 / 1 9 3 N u m ber, se verit y a n d d urati o n of treat me nt -relate d a d verse e ve nts (A Es )f or all d ose gr o u ps 
/ i n dicati o ns acc or di n g t o C T C A E v 4. 0 3 
Occ urre nce of D L Ts d uri n g t he first 3 wee ks ( 2 1 da y s) of treat me nt i n t he d ose -escalati o n 
part of t he trial 
E xce pt f or t he gli o blast o ma c o h ort, t he pri mar y efficac y  e n d p oi nt f or t he d ose -e x pa nsi o n part 
of t he trial is t he c o nfir me d B O R acc or di n g t o R E CI S T 1. 1 as a dj u dicate d b y  t he I n de pe n de nt 
E n d p oi nt Re vie w C o m mittee (I R C) a n d will be e val uate d b y  c o nfir me d o bjecti ve res p o nse rate 
( O R R) .  F or gli o blast o ma, t he pri mar y e n d p oi nt will be disease c o nt r ol acc or di n g t o R A N O as 
a dj u dicate d b y t he I R C .
Sec o n d ar y e n d p oi nts:  
T he s ec o n d ar y e n d p oi nts f or t he d ose- esc al ati o n p art of t he tri al are t he: 
M S B 0 0 1 1 3 5 9 C P K pr ofile (f or d ose escalati o n), i ncl u di n g area u n der t he c o nce ntrati o n -
ti me c ur ve (A U C ), ma xi m u m ser u m c o nce ntrati o n o bser ve d p ost d ose ( C ma x ), mi ni m u m 
ser u m c o nce ntrati o n o bser ve d p ost d ose (Cmi n ), a n d ter mi nal half -life (t 1/ 2 )
Ser u m titers of a nti M S B 0 0 1 1 3 5 9 C a nti b o dies 
B O R acc or di n g t o R E CI S T 1. 1 per I n vesti gat or assess me nt .
T he sec o n d ar y e n d p oi nts f or t he e x p a nsi o n p art of t he tri al are t he: 
M S B 0 0 1 1 3 5 9 C P K pr ofile (f or d ose escalati o n), i ncl u di n g A U C, C ma x , C mi n , a n d t1/ 2 
Ser u m titers of a nti M S B 0 0 1 1 3 5 9 C a nti b o dies 
N u m ber, se verit y, a n d d urati o n of T E A Es a n d treat me nt -relate d T E A Es acc or di n g t o t he 
N CI -C T C A E v 4. 0 3 
B O R acc or di n g t o R E CI S T 1. [ADDRESS_838387] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838388] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 1 / [ADDRESS_838389] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838390] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 5 / 1 9 3 F or asce n di n g d ose -p orti o n a n d d ose -e x p a nsi o n p orti o n: 
U ni nfecte d, H C V, a n d H B V -i nfecte d s u bjects are eli gi ble. If me dicall y  i n dicate d, 
su bjects i nfecte d wit h H B V m ust be treate d a n d o n a sta ble d ose of a nti virals (e g, 
e nteca vir , te n of o vir , or la mi v u di ne ;a def o vir or i nterfer o n are n ot all o we d) at st u d y  e ntr y 
a n d wit h pla n ne d m o nit ori n g a n d ma na ge me nt acc or di n g t o a p pr o priate la beli n g 
g ui da nce.  S u bjects o n acti ve H C V t hera p y at st u d y  e ntr y  m ust be o n a sta ble d ose 
wit h o ut d oc u me nte d cli nicall y  s i g nifica nt li ver f u ncti o n test or he mat ol o gic 
a b n or malities ( m ust meet criteria bel o w) a n d wit h pla n ne d m o nit ori n g a n d ma na ge me nt 
acc or di n g t o a p pr o priate la beli n g g ui da n ce .  
A d diti o nal criteria f or all H C C s u bjects i ncl u de: 
oC hil d -P u g h A or B 7 
oE C O G P S 0 or 1 
oAl b u mi n ≥2. 8 g/ d L 
oInter nati o nal n or malize d rati o (I N R) < 1. 7 
oA de q uate he mat ol o gical f u ncti o n defi ne d b y W B C c o u nt ≥ 2. 5 × 1 0 9/ L  wit h a bs ol ute 
ne utr o p hil c o u nt ( A N C) ≥ 1. 5 × 1 0 9/ L , l y m p h oc y te c o u nt ≥ 0. 5 × 1 0 9/ L , platelet c o u nt 
≥ 5 0 × 1 0 9/ L , a n d he m o gl o bi n ≥ 9 g/ d L  
oS u bjects wit h n o aller gies t o c o ntrast a n d a ble t o t olerate c o m p ute d t o m o gra p h y  ( C T) 
or ma g netic res o na nce i ma gi n g ( M RI) c o ntrast i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or 
N S C L C, sec o n d li ne:   Hist ol o gicall y c o nfir me d Sta ge III b/I V or rec urre nt N S C L C.  
M ust n ot ha ve recei ve d c hec k p oi nt i n hi bit or pre vi o usl y  ( c o ns ult wit h Me dical M o nit or 
if necessar y ).  M ust ha ve e x perie n ce d disease pr o gressi o n after a n acce pta ble t hera p y  
defi ne d as f oll o ws: 
oS u bjects m ust ha ve pr o gresse d d uri n g or after a mi ni m u m of [ADDRESS_838391] or y  o f c o nti n uati o n ( use of a n o n- plati n u m a ge nt fr o m i nitial 
c o m bi nati o n) or s witc h ( use of a differe nt a ge nt) mai nte na nce t hera p y  i s per mitte d 
pr o vi de d t here was n o pr o gressi o n after t he i nitial c o m bi nati o n.  A s witc h of a ge nts 
d uri n g treat me nt f or t he ma na ge me nt of t o xicities is als o per mitte d pr o v i de d t here was 
n o pr o gressi o n after t he i nitial c o m bi nati o n 
O R 
oS u bjects m ust ha ve pr o gresse d wit hi n 6 m o nt hs of c o m pleti o n of a plati n u m -base d 
a dj u va nt, ne oa dj u va nt, or defi niti ve c he m ot hera p y, or c o nc o mita nt c he m ora diati o n 
re gi me n f or l ocall y  a d va nce d disease 
S u bjects wit h n o n-s q ua m o us cell N S C L C of u n k n o w n m utati o nal stat us will re q uire 
testi n g (l ocal la b orat or y , or ce ntral la b orat or y  if l ocal testi n g is n ot a vaila ble). S u bjects 
wit h k n o w n E G F R m utati o n a n d / or A L K tra nsl ocati o n are eli gi ble if t he y  h a ve recei ve d 
at least 1li ne of t y r osi ne ki nase i n hi bit or t hera p y.  S u bjects wit h R O S [ADDRESS_838392] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838393] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 6 / 1 9 3 d o n ot re q uire pri or trea t me nt wit h s y ste mic c he m ot hera p y .  S u bjects wit h lar ge cell 
ne ur oe n d ocri ne ca ncer of t he l u n g are n ot eli gi ble   
N S C L C, a nti -P D - 1 / a nti -P D -L 1 f ail ure:   S u bjects wit h hist ol o gicall y c o nfir me d Sta ge 
I V ( metastatic) or rec urre nt N S C L C ( per 7t h I nter nati o nal Ass ociati o n f or t he St u d y  o f 
L u n g Ca ncer classificati o n) w h o ha ve e x ha uste d sta n dar d treat me nt o pti o ns i n t he 
o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or are t o be e nr olle d.  At a mi ni m u m, s u bjects nee d t o ha ve 
recei ve d a n d faile d plati n u m -base d c he m ot hera p y a n d m ust ha ve recei ve d a nti -P D - 1 or 
a nti -P D -L 1 as m o n ot hera p y  a n d faile d wit h disease pr o gressi o n.  I n a d diti o n, s u bjects 
s h o ul d ha ve e x ha uste d ot her i n dicate d dri ver m utati o n t hera p y , as a p pr o priate   
Mel a n o m a, a nti -P D - 1 / a nti -P D -L 1 f ail ure:   S u bjects wit h unresecta ble Sta ge III or 
metastatic ( Sta ge I V) mela n o ma w h o ha ve e x ha uste d sta n dar d treat me nt o pti o ns i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or are t o be e nr olle d. At a mi ni m u m, s u bjects nee d t o ha ve 
recei ve d a nti -P D -[ADDRESS_838394] ha ve faile d a p pr o priate s y ste mic t hera pi[INVESTIGATOR_014] i ncl u di n g 
B R A F i n hi bit or if B R A F V 6 0 0 m utati o n p ositi ve 
P a ncre atic a de n oc arci n o m a, sec o n d li ne or gre ater:  Hist ol o gicall y  c o nfir me d 
pa ncreatic a de n ocarci n o ma (s u bjects wit h e n d ocri ne or aci nar pa ncreatic carci n o ma are 
n ot eli gi ble).  M ust ha ve u nresecta ble or l ocall y  a d va nce d or metastatic disease 
oPri or t hera p y wit h ≥ 1 s y ste mic c he m ot hera p y re gi me n f or u nresecta ble or metastatic 
pa ncreatic ca ncer or u n willi n g / u na ble t o recei ve s y ste mic c he m ot hera p y.  S u bjects 
m ust n ot ha ve recei ve d pre vi o us ra di ot hera p y f or meas ura ble lesi o ns 
oDisease pr o gressi o n w hile recei vi n g or after disc o nti n ui n g palliati ve c he m ot hera p y
C ol orect al c a ncer ( C R C), t hir d li ne or gre ater :  Hist ol o gicall y  c o nfir me d 
a de n ocarci n o ma of t he c ol o n or rect u m 
oS u bjects m ust ha ve pr o gresse d d uri n g or after a sec o n d- li ne of s ys te mic treat me nt 
oPri or faile d t hera p y m ust ha ve i ncl u de d at least a fl u or o p y ri mi di ne, o xali plati n, 
iri n oteca n (si n gle or i n c o m bi nati o n) a n d be vaciz u ma b ( w here a p pr o ve d).  F or 
s u bjects w h o ha d wil d -t y pe R A S t u m ors, cet u xi ma b or pa nit u m u ma b treat me nt m ust 
ha ve occ urre d   
T N B C , sec o n d -li ne or gre ater :  T u m or m ust be c o nfir me d ne gati ve f or estr o ge n 
rece pt ors, pr o gester o ne rece pt or s, a n d H E R 2 
oE R ne gati ve defi ne d b y:   E R I H C< 1 % reacti ve cells 
oP R ne gati ve defi ne d b y:  P R I H C < 1 % reacti ve cells 
oH E R -2 ne gati ve defi ne d b y  o ne of f o ur sit uati o ns bel o w: 
1. H E R [ADDRESS_838395] I H C = [ADDRESS_838396] I H C = 1 + 
3. H E R [ADDRESS_838397] I H C = 2 + A N D FI S H -ne gati ve ( n o n -a m plifie d) 
4. FI S H n o n -a m plifie d 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838398] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 7 / [ADDRESS_838399] -li ne of c he m ot hera p y 
O v ari a n c a ncer, pl ati n u m resist a nt or refr act or y , pre vi o usl y tre ate d s yste mic all y :  
Hist ol o gicall y c o nfir me d e pit helial o varia n, fall o pia n t u be, or perit o neal ca ncer (s u bjects 
wit h n o n- e pit helial t u m or, i ncl u di n g mali g na nt mi xe d M ülleria n t u m ors wit h o ut hi g h 
gra de ser o us c o m p o ne nt, or o varia n t u m or s wit h l o w mali g na nt p ote ntial [ ie, b or derli ne 
t u m ors ] are n ot eli gi ble) 
oM ust n ot be a ca n di date f or s ur gical resecti o n wit h c urati ve i nte nt 
oM ust ha ve plati n u m res ista nt /ref ract or y disease, defi ne d as disease pr o gressi o n 
wit hi n [ADDRESS_838400] a d mi nistere d d ose of plati n u m t hera p y  ( resista nt), 
or lac k of res p o nse or disease pr o gressi o n w hile rec ei vi n g t he m ost rece nt 
plati n u m -base d t hera p y  ( refract or y ), or pr o gressi o n o n / after last n o n- plati n u m -base d 
c he m ot h era p y
oTreat me nt hist or y  o f at least [ADDRESS_838401] be re p orte d if k n o w n 
Es o p h a ge al a de n oc arci n o m a, p ost - pl ati n u m, sec o n d li ne or gre ater:  Hist ol o gicall y 
c o nfir me d rec ur re nt or metastatic es o p ha geal a de n ocarci n o ma .  M ust ha ve u nresecta ble 
( Sta ge III or I V) disease 
oM ust ha ve recei ve d at least o n e pre vi o us plati n u m -c o ntai ni n g c he m ot hera p y re gi me n.  
S u bjects wit h H E R 2- p os iti ve t u m ors m ust ha ve recei ve d pri or trast uz u ma b 
Gli o bl ast o m a, p ost -te m oz ol o mi de / r a di ati o n, sec o n d li ne:  Hist ol o gicall y  c o nfir me d 
Gra de I V mali g na nt gli o ma (s u bjects wit h e x tracra nial metastatic or le pt o me ni n geal are 
n ot eli gi ble)  
oPre vi o us treat me nt wit h ra di ot hera p y a n d te m oz ol o mi de 
oT olera nce t o ga d oli ni u m 
oA n i nter val of at least [ADDRESS_838402] o ma 
oKar n ofs k y Perf or ma nce Stat us ≥ [ADDRESS_838403] or or a ntia n gi o ge nic treat me nts 
S C C H N , sec o n d li ne or gre ater :  Hist ol o gicall y  c o nfir me d rec urre nt or metastatic 
S C C H N ( oral ca vit y , p har y n x, lar y n x), Sta ge III/I V a n d n ot a me na ble t o l ocal t hera p y 
wit h c urati ve i nte nt (s ur ger y  or ra diati o n t hera p y wit h or wit h o ut c he m ot hera p y)   
oT u m or pr o gressi o n or rec urre nce wit hi n [ADDRESS_838404] d ose of plati n u m t hera p y  i n 
t he a dj u va nt (ie wit h ra diati o n after s ur ger y), pri mar y  ( ie, wit h ra diati o n), rec urre nt, 
or metastatic setti n g 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838405] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 8 / [ADDRESS_838406] be re p orte d if k n o w n 
Cer vic al c a ncer, sec o n d li ne or gre ater :  Hist ol o gicall y c o nfir me d rec urre nt or 
persiste nt s q ua m o us cell carci n o ma, a de n os q ua m o us carci n o ma, or a de n ocarci n o ma of 
t he cer vi x f oll o wi n g sta n dar d of care treat me nt wit h s y ste mic t hera p y f or a d va nce d 
disease (t y pi[INVESTIGATOR_1306] y d o u blet c yt ot o xic c he m ot hera p ya n d be vaciz u ma b , w here a p pr o ve d )  
oH u ma n pa pi[INVESTIGATOR_4382] o ma vir us t u m or testi n g m ust be re p orte d if k n o w n 
6. E C O G P S of [ADDRESS_838407] 1u ni di me nsi o nal l y meas ura ble lesi o n b y  
R E CI S T 1. 1 
Ke y e xcl usi o n criteri a ( a p plic a ble t o all s u bjects, i ncl u di n g all e x p a nsi o n c o h orts) 
1. C o nc urre nt treat me nt wit h n o n -per mitte d dr u gs a n d ot her i nter ve nti o ns 
2. E xce pt f or t he a nti -P D - 1 / a nti -P D -L 1 -e x perie nce d N S C L C a n d mela n o ma e x pa nsi o n 
c o h orts, pri or t hera p y wit h a n y  a nti b o d y  / d r u g tar geti n g T- cell c ore g ulat or y  p r otei ns 
(i m m u ne c hec k p oi nts) s uc h as a nti -P D - 1, a nti -P D -L 1 , or a nti -c y t ot o xic T- l y m p h oc y te 
a nti ge n - 4 ( C T L A - 4 a nti b o d y ) is n ot all o we d (c o ns ult wit h Me dical M o nit or as nee de d) , 
i ncl usi ve of i ntra he patic, l ocalize d a d mi nistrati o n of s uc h a ge nts 
3. A ntica ncer treat me nt wit hi n 2 8 da y s bef ore t he start of trial treat me nt, f or e xa m ple 
cyt ore d ucti ve t hera p y, ra di ot hera p y ( wit h t he e xce pti o n of palliati ve ra di ot hera p ydeli vere d 
i n a n or mal or ga n -s pari n g tec h ni q ue ), i m m u ne t hera p y, or c y t o ki ne t hera p y  ( wit h t he 
e xce pti o n of s orafe ni b f or s u bjects wit h H C C, w hic h m ust ha ve bee n st o p pe d wit hi n 
1 4 da y s) 
4. M aj or s ur ger y  w it hi n 2 8 da y s bef ore t he start of trial treat me nt (pri or dia g n ostic bi o ps y  i s 
per mitte d )
5. S y ste mic t hera p y  w it h i m m u n os u p pressi ve a ge nts wit hi n 7 d a y s bef ore t he start of trial 
treat me nt; or use of a n y i n vesti gati o nal dr u g wit hi n 2 8 da y s bef ore t he start of trial treat me nt 
(N ote:   f or s u bjects wit h gli o blast o ma, ster oi d use is all o we d acc or di n g t o sta n d ar d of care 
a n d l ocal g ui deli nes )
6. Pre vi o us mali g na nt disease ( ot her t ha n t he tar get mali g na nc y  t o be i n vesti gate d i n t his trial) 
wit hi n t he last [ADDRESS_838408] or y  of cer vical carci n o ma i n sit u, s u perficial or 
n o n- i n vasi ve bla d der ca ncer, or basal cell or s q ua m o us cell carci n o ma i n sit u pre vi o usl y  
treate d wit h c urati ve i nte nt are N O T e xcl u de d .  S u bjects wit h ot her l ocalize d mali g na ncies 
treate d wit h c urati ve i nte nt nee d t o be disc usse d wit h t he Me dical M o nit or 
7. Ra pi [INVESTIGATOR_2478] y  p r o gressi ve disease whic h, i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or, ma y  p re dis p ose t o 
i na bilit y  t o t olerate treat me nt or trial pr oce d ures 
8. S u bjects wit h acti ve ce ntral ner v o us s y ste m ( C N S) metastases ca usi n g cli nical s y m pt o ms or 
metastases t hat re q uire t hera pe utic i nter ve nti o n are excl u de d .  S u bjects wit h a hist or y  o f 
treate d C N S metastases ( b y  s ur ger y  o r ra diati o n t hera p y ) are n ot eli gi ble u nless t he y  h a ve 
f ull y  r ec o vere d fr o m treat me nt, de m o nstrate d n o pr o gressi o n f or at least [ADDRESS_838409] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838410] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 9 / 1 9 3 n ot re q uire c o nti n ue d ster oi d t hera p y .S u bjects wit h C N S metastases i nci de nt all y  detecte d 
d uri n g Scree ni n g w hic h d o n ot ca use cli nical s y m pt o ms a n d f or w hic h sta n dar d of care 
s u g gests n o t hera pe utic i nter ve nti o n is i n dicate d s h o ul d be disc usse d wit h t he Sp o ns or 
Me dical Res p o nsi ble 
9. Recei pt of a n y or ga n tra ns pla ntati o n, i ncl u di n g all o ge neic ste m -cell tra ns pla ntati o n, b ut 
wit h t he e x ce pti o n of tra ns pla nts t hat d o n ot re q uire i m m u n os u p pressi o n (e g, c or neal 
tra ns pla nt, hair tra ns pla nt) 
A d diti o nal e xcl usi o n criteria f or s u bjects i n t he H C C c o h ort i ncl u de: 
Cli nical ascites (t hat is, n ot per ra di ol o gical assess me nt o nl y ) wit hi n past 6 m o nt hs n ot 
a de q uatel y c o ntr olle d wit h me dical t hera p y ;hist or y  o f variceal blee di n g wit hi n past 
3m o nt hs ; hist or y  of u nc o ntr olle d he patic e nce p hal o pat h y i n t he past 3 m o nt hs ; or hist or y 
of o bstr ucti ve ja u n dice n ot a me na ble t o ste nti n g i n t he past 3 m o nt hs 
He patitis D vir us ( H D V) c o -i nfecti o n wit h he patitis B vir us ( H B V; if H B V s urface a nti ge n 
or H B V D N A p ositi vit y  at S cree ni n g t he n m ust c hec k f or H D V stat us) 
Che m oe m b olizati o n or ra di oe m b olizati o n wit hi n [ADDRESS_838411]: d ose/ m o de of a d mi nistr ati o n/ d osi n g sc he d ule: 
F or t he d ose -escalati o n c o h orts (e xce pt f or t he 2 4 0 0 m g flat -d ose c o h ort) , t he d ose of 
M S B [ADDRESS_838412] u g a d mi nistrati o n.  
F oll o wi n g safet y a n d P K a nal ys is of t he Escalati o n c o h orts, a flat d ose of 1 2 0 0 m g/i nf usi o n 
was c h ose n f or all e x pa nsi o n c o h orts, e xce pt f or t he N S C L C sec o n d -li ne c o h ort, i n w hic h 
4 0 s u bjects will recei ve 5 0 0 m g/i nf usi o n a n d 4 0 s u bjects will recei ve 1 2 0 0 m g/i nf usi o n .
M S B 0 0 1 1 3 5 9 C will be a d mi nistere d o nce e ver y  2 w ee ks as a 1- h o ur (- 1 0 / + 2 0 mi n utes, t hat 
is, over 5 0 t o 8 0 mi n utes) I V i nf usi o n.  S u bjects e nr olle d i n t he 3 0 m g/ k g a n d 2 4 0 0 m g flat -d ose 
c o h ort sm a y  ha ve a t otal i nf usi o n ti me of u p t o 1 2 0 mi n utes. 
I n or der t o miti gate p ote ntial i nf usi o n -relate d reacti o ns, pre me dicati o n wit h a n a nti hista mi ne 
a n d wit h paraceta m ol (aceta mi n o p he n) (f or e xa m ple, 2 5- 5 0 m g di p he n h y dra mi ne a n d 
5 0 0- 6 5 0 m g paraceta m ol [aceta mi n o p he n] I V or oral e q ui vale nt) a p pr o xi matel y  [ADDRESS_838413] 2 i nf usi o ns .  
Pre me dicati o n is o pti o nal a n d at t he discreti o n of t he I n vesti gat or after t he sec o n d i nf usi o n 
( pre me dicati o n is o pti o nal f or all i nf usi o ns f or s u bjects i n t he N S C L C bi o mar ker c o h ort bei n g 
treate d at t he U S N CI ).  If Gra de ≥[ADDRESS_838414] o p pe d.   Ster oi ds as pre me dicati o n are n ot per mitte d. 
Refere nce t her a p y:  d ose/ m o de of a d mi nistr ati o n/ d osi n g sc he d ule: 
N ot a p plica ble .
Pl a n ne d tri al a n d tre at me nt d ur ati o n per s u bject: 
S u bjects will recei ve M S B [ADDRESS_838415] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838416] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 1 / 1 9 3 N S C L C , a nti -P D -1 / a nti -P D -L 1 f ail ure c o h ort : 8 0 s u bjects will be e nr olle d t o c haracterize 
t he t olera bilit y , safet y pr ofile, a n d f or preli mi nar y  e val uati o n of a ntit u m or acti vit y  f or 
pre vi o usl y  a nti -P D -1 / a nti -P D -L [ADDRESS_838417] u d y  h as 
9 2 % p o wer t o r ule o ut a 5 % O R R w he n t he tr ue O R R is 1 5 % wit h [ADDRESS_838418] 4 0 s u bjects are e val ua ble f or res p o nse assess me nt at 1 2 wee ks (t hat is , ha ve eit her 
c o m plete d t he sec o n d t u m or reassess me nt at Wee k [ADDRESS_838419] u d y  b ef ore 
Wee k 1 2). 
Mel a n o m a, a nti -P D -1 / a nti -P D -L 1 f ail ure c o h ort : 3 0 s u bjects will be e nr olle d t o 
c haracterize t he t olera bilit y , safet y p r ofile, a n d f or preli mi nar y e val uati o n of a ntit u m or acti vit y 
f or pre vi o usl y  a nti -P D - 1 / a nti -P D -L 1 treat e d s u bjects .  Wit h 3 0 s u bjects w h o were treate d wit h 
pri or a nti -P D - 1 / a nti -P D -L [ADDRESS_838420] u d y  h as 8 7 % p o wer t o r ule o ut a 5% O R R w he n t he 
tr ue O R R is 2 0 % wit h [ADDRESS_838421] me nt a p plie d t o t he i nteri m a nal y sis.  T he i nteri m a nal ys is will occ ur w he n 
t he 3 0 s u bjects are e val ua ble f or res p o nse assess me nt at 1 2 wee ks (t hat is, ha ve eit her 
c o m plete d t he sec o n d t u m or reassess me nt at Wee k [ADDRESS_838422] u d y  b ef ore 
Wee k 1 2). 
N S C L C , sec o n d -li ne c o h ort :  U p t o 8 0 s u bjects will be e nr olle d (ra n d o mize d i n a 1: 1 rati o t o 
re cei ve eit her 5 0 0 or 1 2 0 0 m g /i nf usi o n ) t o c haracterize t he t olera bilit y , safet y pr ofile, f or 
preli mi nar y  e v al uati o n of a ntit u m or acti vit y, a n d t o s u p p ort t he o verall P K data t o c haracterize 
t he e x p os ure -res p o nse relati o ns hi p.   Wit h 3 0 s u bjects w h o recei ve d 1 2 0 0 m g/i nf usi o n were 
treate d wit h pri or plati n u m -base d t hera p y , t he st u d y  has 8 2 % p o wer t o r ule o ut a ≤2 0 % O R R 
w he n t he tr ue O R R is 4 0 % wit h [ADDRESS_838423] me nt is a p plie d t o t he i nteri m a nal y sis.  T he i nteri m a nal ysis will occ ur w he n 
t he 3 0 s u bjects are e val ua ble f or res p o nse assess me nt at 1 2 wee ks (t hat is , ha ve eit her 
c o m plete d t he sec o n d t u m or rea ssess me nt at Wee k [ADDRESS_838424] u d y  b ef ore 
Wee k 1 2). If ≤ 4 res p o n ders are o bser ve d at t he i nteri m a nal ys is, n o f urt her s u bjects will be 
e nr olle d i nt o t he N S C L C sec o n d -li ne c o h ort .  
P a ncre atic a de n oc arci n o m a , C R C , a n d cer vic al c a ncer c o h orts: U p t o [ADDRESS_838425] 
fr o m eac h c o h ort is e val ua ble f or res p o nse assess me nt at 1 2 wee ks (t hat is , ha ve eit her 
c o m plete d t he sec o n d t u m or reassess me nt at Wee k [ADDRESS_838426] u d y  bef ore Wee k 
1 2). 
Wit h [ADDRESS_838427] u d y  h as a p pr o xi matel y  7 9 % p o wer t o r ule o ut a ≤ 1 0 % O R R 
( n ull h y p ot hesis) w he n t he tr ue O R R is 2 5 % wit h 1 -si de d 0. 1 al p ha. 
O v ari a n c a ncer , T N B C, a n d es o p h a ge al a de n oc arci n o m a c o h orts :  U p t o [ADDRESS_838428] fr o m eac h c o h ort is e val ua ble f or res p o nse assess me nt at 1 2 wee ks ( t hat is , ha ve eit her 
c o m plete d t he sec o n d t u m or reasse ss me nt at Wee k [ADDRESS_838429] u d y  b ef ore 
Wee k 1 2). 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838430] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 2 / [ADDRESS_838431] u d y  h as a p pr o xi matel y  8 7 % p o wer t o r ule o ut a ≤ 1 5 % O R R 
( n ull h y p ot hesis) w he n t he tr ue O R R is 3 5 % wit h [ADDRESS_838432] o m a c o h ort :  U p t o 3 0 s u bjects will be e nr olle d t o c haracterize t he t olera bilit y , safet y 
pr ofile, a n d f or preli mi nar y  e val uati o n of a ntit u m or acti vit y.  O ne i nteri m a nal ys is is pla n ne d 
w he n t he 3 0 s u bjects are e val ua ble f or res p o nse assess me nt at 1 2 wee ks (t hat is , ha v e eit her 
c o m plete d t he sec o n d t u m or reassess me nt at Wee k [ADDRESS_838433] u d y  b ef ore 
Wee k 1 2). 
Wit h [ADDRESS_838434] u d y  h as a p pr o xi matel y  9 7 % p o wer t o r ule o ut a ≤ 5 0 % D C R
(n ull h y p ot hesis) w he n t he tr ue D C R is 8 0 % at t he 5 % t y pe I err or rate ( 1 -si de d). 
S C C H N c o h ort :  U p t o 3 0 s u bjects will be e nr olle d t o c haracterize t he t olera bilit y , safet y 
pr ofile, a n d f or preli mi nar y  e val uati o n of a ntit u m or acti vit y.  O ne i nteri m a nal ys is is pla n ne d 
w he n t he 3 0 s u bjects are e val ua ble f or res p o nse assess me nt at 1 2 wee ks (t hat is , ha ve eit her 
c o m plete d t he sec o n d t u m or reassess me nt at Wee k [ADDRESS_838435] u d y  b ef ore 
Wee k 1 2). 
Wit h [ADDRESS_838436] u d y  h as a p pr o xi matel y  8 7 % p o wer t o r ule o ut a ≤ 1 5 % O R R 
( n ull h y p ot hesis) w he n t he tr ue O R R is 3 5 % at t he 1 0 % t y pe I err or rate ( 1- si de d). 
T he t otal sa m ple size f or t he st u d y  ( d ose escalati o n a n d d ose e x pa nsi o n) is e x pecte d t o be u p 
t o a p pr o xi matel y  6 4 2 s u bjects. 
Statistics f or c o nti n u o us varia bles m a y  i ncl u de mea ns, me dia ns, ra n ges, a n d a p pr o priate 
meas ures of varia bilit y .  Q ualitati ve varia bles will be s u m marize d b y  c o u nts a n d perce nta ges.  
T he u ncertai nt y of esti mates will be assesse d b y c o nfi de nce i nter vals.  T he res ults of t he safet y 
e val uati o ns will be ta b ulate d a n d dis pla y e d b y  d ose le vel / e x pa nsi o n c o h ort.  O nl y  e x pl orat or y 
statistical a nal y sis will be perf or me d.  D escri pti ve statistics will be e xa mi ne d f or i n dicati o ns of 
d ose -relate d t o xicit y .
Listi n gs will be pr o d uce d u p o n c o m pleti o n of eac h d ose -escalati o n c o h ort of s u bjects a n d t he 
decisi o n as t o w het her t o pr ocee d wit h d ose -escalati o n, d ose -re d ucti o n or t o e nr oll a n ot her 
c o h ort at t he sa me d ose le vel will be deter mi ne d b y  r e vie wi n g t hese data.  F ull details of t he 
pla n ne d a nal ys es will be descri be d i n t he trial Statistical A nal ys is Pla n, se paratel y  f or t he 
d ose -escalati o n part a n d t he e x pa nsi o n part. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838437] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 3 / 1 9 3 Sc he d ule of Assess me nts 
T a ble 1 Sc he d ule of Assess me nts –D ose Esc al ati o n P h ase 
Me as ure Scree ni n g 
Assess me nts Tre at me nt P h ase 
(- 3 / + 1 d a ys) aE o T Visit S afet y F oll o w -u p L o n g -ter m 
F oll o w -
u p b, c 
D a y -[ADDRESS_838438] 
Tre at me nt V 1  V 2  V 3  V 4  V 5  V 6  V 7  V 7  V 8  V 9 V 1 0 
U ntil 
Pr o gressi o n O n t he D a y of 
or Wit hi n 
7D a ys of 
Decisi o n t o 
Disc o nti n ue d2 8 D a ys 
( ± 5 d a ys) 
after L ast 
Tre at me nt e1 0 Wee ks 
( ± 2w e e ks) 
after L ast 
Tre at me nt E ver y   
1 2 Wee ks 
( ± 2w e e ks) W 1  W 1 W 2  W 3  W 4  W 5  W 7  W 7  W 9 W 1 1 W 1 3 
D 1  D 2  D 8 D 1 5 D 2 2 D 2 9 D 4 3 D 4 4- 
5 0 aD 5 7 D 7 1 D 8 5 
Writte n i nf or me d c o nse nt X
I ncl usi o n /e xcl usi o n criteria X  X 
Me dical hist or y X
Ca ncer d isease hist or y X
Pri or a ntica ncer dr u g / 
ra di ot hera p y / pr oce d ures X
Ot her pri or me dicati o ns X
De m o gra p hic data X
H B V a n d H C V testi n g X
Op ht hal m ol o g y e xa mi nati o n 
i ncl u di n g slit la m p e val uati o n 
i ncl usi ve of t he a nteri or 
se g me nt a n d wit h vis ual 
ac uit y fX
P h ysical e xa mi n ati o n fX  X  X  X  X  X  X  X  X  X  X 6- wee kl y X X  X 
Der mat ol o gical assess me nt gX X  X  X  X  X  X 6- wee kl y X X  X 
1 2 lea d E C G hX  X / X hX  X  X / X hX/ X hX X 6- wee kl y 
n or mal 
E C Gs X  X 
Vital si g ns i ncl u di n g wei g ht 
a n d hei g ht ( hei g ht at 
Scree ni n g o nl y) iX  X  X  X  X  X  X  X  X  X  X  X 2- wee kl y X X  X 
E C O G P S jX  X jX  X  X  X  X  X  X  X 2- wee kl y X X  X 
E nr oll me nt (if eli gi ble) kX  X k
D oc u me nt N o. 
O bject N o. Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838439] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 4 / 1 9 3 T a ble 1 Sc he d ule of Assess me nts –D ose Esc al ati o n P h ase 
Me as ure Scree ni n g 
Assess me nts Tre at me nt P h ase 
(- 3 / + 1 d a ys) aE o T Visit S afet y F oll o w -u p L o n g -ter m 
F oll o w -
u p b, c 
D a y -[ADDRESS_838440] 
Tre at me nt V 1  V 2  V 3  V 4  V 5  V 6  V 7  V 7  V 8  V 9 V 1 0 
U ntil 
Pr o gressi o n O n t he D a y of 
or Wit hi n 
7D a ys of 
Decisi o n t o 
Disc o nti n ue d2 8 D a ys 
( ± 5 d a ys) 
after L ast 
Tre at me nt e1 0 Wee ks 
( ± 2w e e ks) 
after L ast 
Tre at me nt E ver y   
1 2 Wee ks 
( ± 2w e e ks) W 1  W 1 W 2  W 3  W 4  W 5  W 7  W 7  W 9 W 1 1 W 1 3 
D 1  D 2  D 8 D 1 5 D 2 2 D 2 9 D 4 3 D 4 4- 
5 0 aD 5 7 D 7 1 D 8 5 
He mat ol o g y / 
he m ostase ol o g y lX  X  X  X  X  X  X  X  X  X  X 2- wee kl y X X  X 
C ore ser u m c he mistr y mX  X  X  X  X X  X 2- wee kl y 
F ull ser u m c he mistr y mX X X X 6- wee kl y X X  X 
Ser u m electr o p h oresis X X X
Uri nal ysis nX X X X 6- wee kl y X X  X 
β- H C G pre g na nc y test (if 
a p plica ble) oX  X X  X  X X 4- wee kl y X  X 
T u m or e val uati o n / sta gi n g 
( C T Sca n / M RI /ot her) c, p, q X X X6 wee kl y u p 
t o 1 2 
m o nt hs / 
t he n 
1 2 wee kl y X Xc
D o c u me ntati o n of A Es ,
c o nc o mita nt me dicati o n s, a n d 
pr oce d ures X  X  X  X  X  X  X  X  X  X  X  X 2- wee kl y X XbXbXb
Fr ee T 4 a n d T S H X X X X 6- wee kl y X  X 
A C T H (e xce pt bac kfill 
c o h orts) X
A N A a n d R F X X 6- wee kl y X
P K sa m pli n g See  Ta ble [ADDRESS_838441] N o. Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838442] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 6 / [ADDRESS_838443] u g (see Secti o n 7. 1. 4. 3 f or details) .After c o m pleti o n of t he F oll o w -u p peri o d t he a p pr o priate 
electr o nic Case Re p ort F or m secti o n f or Trial Ter mi nati o n m ust be c o m plete d. 
dAll s u bjects m ust u n der g o a n E n d -of -Treat m e nt visit after disc o nti n uati o n of I M P f or a n y reas o n.  T his visit s h o ul d be perf or me d wit hi n 7 da ys after t he decisi o n t o di sc o nti n ue trial treat me nt 
b ut bef ore a n y ne w a nti ne o plastic t hera p y is starte d (if p ossi ble), w hic he ver occ urs earlier . If it is k n o w n t o t he I n ve sti gat or at t he ti me of t he E n d -of -Treat me nt visit t hat t he s u bject will start 
ne w treat me nt wit hi n [ADDRESS_838444] treat me nt, asse ss me nts ass ociate d wit h t he 
2 8 -Da y S afet y F oll o w -u p visit ma y be c o n d ucte d at t he E n d -of -Treat me nt visit .
fScree ni n g, D a y  1, 2 8 -Da y Safet y F oll o w -u p , a n d 1 0 -Wee k Safet y Foll o w -u p visits s h o ul d i ncl u de a f ull p h ysical e xa m.  All ot her visits s h o ul d ha ve a f oc use d p h ysical e xa m i nati o n .  E ye si g ns 
a n d s y m pt o ms s h o ul d be c hec ke d at eac h visit .  If  c li nicall y rele va nt fi n di n gs t he n a n a p pr o priate o p ht hal m ol o g y e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt 
a n d wit h vis ual ac uit y s h o ul d be o btai ne d wit hi n 2 da ys .
g  A ssess me nts f or s ki n lesi o ns or ras h wit h bi o ps y of s us pi[INVESTIGATOR_37180] o us lesi o ns.  Der mat ol o gical c o ns ults s h o ul d be re q ueste d as nee de d .See Secti o n  6. 5. 4. 5 .
hE C G t o be ta ke n wit hi n 4 h o urs bef ore d osi n g a n d as s o o n as p ossi ble after c o m pleti o n of t he i nf usi o n .  If o nl y a si n gle “ X”, t he n o nl y E C G bef ore d osi n g is re q uire d.  A ll E C Gs u p t o a n d 
i ncl u di n g Wee k 1 3 ( Visit 1 0 ) are t o be ta ke n i n tri plicate wit h di gital u pl oa di n g f or ce ntralize d a nal ysis .  A ll E C Gs after Wee k [ADDRESS_838445] oa de d.   
iVit al si g ns s h o ul d be assesse d pre d ose ( wit hi n 1 5 mi n utes of start of i nf usi o n), t he n e ver y 1 5 ( ± 2) mi n utes after t he start of i nf usi o n ( 1 5, 3 0, 4 5, 6 0 [e n d i nf usi o n] mi n utes after start of i nf usi o n ), 
a n d 1 5 ( ± 5), 3 0 ( ± 5), 6 0 ( ± 5), 1 2 0 ( ± 1 0), a n d 36 0 ( ± 1 5) mi n utes after t he e n d of i nf usi o n f or t he first [ADDRESS_838446] 2 i nf usi o ns, t he n t he vital si g ns sc he d ule f or s u bse q ue nt i nf usi o ns will be pre d ose ( wit hi n 1 5 mi n utes of start of 
i nf usi o n), 1 5 ( ± 2) a n d 3 0 ( ± 2) mi n utes after t he start of i nf usi o n, a n d 3 0 ( ± 5) a n d 6 0 ( ± 5) mi n utes after t he e n d of i nf usi o n .
j If t he Scree ni n g E C O G P S was perf or me d wit hi n [ADDRESS_838447] s h o ul d be rec o nsi dere d .
lHe mat ol o g y (i ncl u di n g c o m plete bl o o d c o u nt) a n d he m ostase ol o g y assess me nts are detaile d i n  Ta ble 1 1 .  F ollicle -sti m ulati n g h or m o ne at Scree ni n g, if a p plica ble (Secti o n 7. 1. 1 ).  C o m ple te 
bl o o d c o u nt res ults m ust als o be dra w n a n d re vie we d wit hi n [ADDRESS_838448] o p i n 
H g b val ue, es peciall y H g b < 8 g/ d L, r o uti ne m o nit ori n g of H g b, re d bl o o d cells, a n d he mat ocrit s h o ul d be perf or me d wee kl y. 
mF ull c he mistr y ( w hic h i ncl u des c ore c he mistr y) a n d c ore ser u m c he mistr y sa m ples are detaile d i n  Ta ble [ADDRESS_838449] be dra w n a n d re vie we d wit hi n 4 8 h o urs 
pri or t o d ose a d mi nistrati o n. 
nA f ull uri nal ysis is re q uire d at Scree ni n g a n d t he 2 8 -Da y Safet y F oll o w -u p visit a n d basic uri nal ysis ( pr otei n c o nte nt o nl y) at eac h visit i n dicate d pri or t o a d mi nistrati o n of st u d y dr u g.  I f 
uri nal ysis (f ull or basic) is p ositi ve f or pr otei n, se di me nt will be e val uate d (see  Ta ble 1 1 f or details). 
oβ- H C G m ust be deter mi ne d fr o m ser u m at Scree ni n g a n d fr o m eit her uri ne or ser u m sa m ple t hereafter at eac h i n dicate d visit .  Res ults of t he m ost rece nt pre g na nc y test s h o ul d be a vaila ble pri or 
t o ne xt d osi n g. 
pT u m or E val uati o ns d uri n g Scree ni n g m ust be perf or me d wit hi n 2 8 da ys pri or t o C ycle 1 Da y 1i n or der t o d oc u me nt t he baseli ne stat us of t he t u m or disease usi n g R E CI S T 1. 1 tar get a n d 
n o n -tar get lesi o ns (see Secti o n 7. 3 ).  S u bse q ue nt t u m or e val uati o ns ha ve a ti me wi n d o w of 5 da ys pri or t o d osi n g ( -5 da ys).  I n case a t u m or res p o nse acc or di n g t o R E CI S T 1. 1 is d o c u me nte d 
d uri n g t he c o urse of t he trial, c o nfir mati o n of t he res p o nse s h o ul d be perf or me d acc or di n g t o R E CI S T 1. 1 n o s o o ner t ha n 4 wee ks ( prefera bl y at t he sc he d ule d 6 -wee k i nter val) after t he i nitial 
d oc u me ntati o n (see Secti o n 7. 3 ). F or s u bjects c o nti n ui n g treat me nt be y o n d 1 2 m o nt hs (i n c o ns ultati o n wit h t he Me dical M o nit or) t u m or e val uati o ns s h o ul d ta ke place e ver y 1 2 we e ks. 
qBrai n C T/ M RI sca n (eit her, wit h c o ntrast preferre d) is re q uire d at Scree ni n g if n ot perf or me d wit hi n t he pre vi o us 6 wee ks.  T hereafter, brai n C T/ M RI sca n s h o ul d be d o ne if cli nicall y i n dicate d 
b y de vel o p me nt of ne w s pecific s y m pt o ms.   A b o ne sca n s h o ul d be d o ne at Scree ni n g a n d be y o n d as cli nicall y i n dicate d. B o ne metastases detecte d at Scree ni n g nee d t o be f oll o we d at t he 
s u bse q ue nt t u m or e val uati o n visits. 
D oc u me nt N o. 
O bject N o. Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838450] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 8 / 1 9 3 T a ble 2 Sc he d ule of Assess me nts –E x p a nsi o n P h ase 
Me as ure Scree ni n g 
Assess me nts Tre at me nt P h ase 
(- 3 /+ 1 d a ys) aE o T Visit S afet y F oll o w -u p L o n g -ter m 
F oll o w -
u p b, c 
D a y -[ADDRESS_838451] 
Tre at me nt V 1  V 2 V 3  V 4  V 5  V 6  V 7  V 7  V 8  V 9  V 1 0 
U ntil 
Pr o gressi o n O n t he D a y of 
or Wit hi n 
7D a ys of 
Decisi o n t o 
Disc o nti n ue d2 8 D a ys 
( ± 5 d a ys) 
after L ast 
Tre at me nt e1 0 Wee ks 
( ± 2w e e ks)  
after L ast 
Tre at me nt eE ver y   
1 2 Wee ks 
( ± 2w e e ks) W 1 W 1  W 2  W 3 W 4  W 5 W 7  W 7 W 9 W 1 1 W 1 3 
D 1  D 2  D 8 D 1 5 D 2 2 D 2 9 D 4 3 D4 4 -
5 0 aD 5 7 D 7 1 D 8 5 
Writte n i nf or me d c o nse nt X
I ncl usi o n /e xcl usi o n criteria X  X 
Me dical hist or y X
Ca ncer d isease hist or y X
Pri or a ntica ncer dr u g / 
ra di ot hera p y / pr oce d ures X
Ot her pri or me dicati o ns X
De m o gra p hic data X
Ra n d omizati o n ( N S C L C 
sec o n d -li ne o nl y : ≤[ADDRESS_838452] d ose )X
Patie nt -re p orte d o utc o mes 
(s u bjects i n H C C , es o p ha geal 
a de n ocarci n o ma, 
gli o blast o ma, mela n o ma, 
o varia n ca ncer, S C C H N, 
T N B C , cer vical ca ncer, a n d 
N S C L C [se c o n d -li ne a n d 
a nti -P D -1/ P D -L 1 fail ure ]
c o h orts )fX  X X  X  X  X  X  X 2- wee kl y u p 
t o Wee k [ADDRESS_838453] N o. Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838454] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 9 / 1 9 3 T a ble 2 Sc he d ule of Assess me nts –E x p a nsi o n P h ase 
Me as ure Scree ni n g 
Assess me nts Tre at me nt P h ase 
(- 3 /+ 1 d a ys) aE o T Visit S afet y F oll o w -u p L o n g -ter m 
F oll o w -
u p b, c 
D a y -[ADDRESS_838455] 
Tre at me nt V 1  V 2 V 3  V 4  V 5  V 6  V 7  V 7  V 8  V 9  V 1 0 
U ntil 
Pr o gressi o n O n t he D a y of 
or Wit hi n 
7D a ys of 
Decisi o n t o 
Disc o nti n ue d2 8 D a ys 
( ± 5 d a ys) 
after L ast 
Tre at me nt e1 0 Wee ks 
( ± 2w e e ks)  
after L ast 
Tre at me nt eE ver y   
1 2 Wee ks 
( ± 2w e e ks) W 1 W 1  W 2  W 3 W 4  W 5 W 7  W 7 W 9 W 1 1 W 1 3 
D 1  D 2  D 8 D 1 5 D 2 2 D 2 9 D 4 3 D4 4 -
5 0 aD 5 7 D 7 1 D 8 5 
F oc use d p h ysical 
e xa mi n ati o n gX  X X  X 6- wee kl y X
Der mat ol o gical assess me nt hX X X  X 6- wee kl y X X  X 
N S C L C bi o mar ker c o h ort 
1 2 -lea d E C G iX X/ X iX  X  X / X iX/ X iX X 6- wee kl y 
n or mal 
E C Gs X  X 
Ot her e x pa nsi o n c o h orts: 
1 2 lea d E C G i X  X X X 6- wee kl y 
n or mal 
E C Gs X  X 
Vital si g ns i ncl u di n g wei g ht 
a n d hei g ht ( hei g ht at 
Scree ni n g o nl y) jX  X X  X  X  X  X  X  X 2- wee kl y X X  X 
E C O G P S kX  X X  X  X  X  X  X 4- wee kl y X X  X 
E nr oll me nt (if eli gi ble) lX  X l
He mat ol o g y / 
he m ostase ol o g y mX  X X  X  X  X  X  X 4- wee kl y X X  X 
C ore ser u m c he mistr y nX X X  X 4- wee kl y 
F ull ser u m c he mistr y nX X X X 8- wee kl y X X  X 
Uri nal ysis oX X X X 8- wee kl y X X  X 
β- H C G pre g na nc y test (if 
a p plica ble) pX  X X X X 4- wee kl y X  X 
T u m or e val uati o n / sta gi n g 
( C T Sca n / M RI /p h ot o gra p hs 
of s ki n lesi o ns / ot her) c, q ,r ,s X X X 6- wee kl y u p 
t o 
1 2 m o nt hs / 
t he n 
[ADDRESS_838456] N o. Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838457] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 1 / 1 9 3 T a ble 2 Sc he d ule of Assess me nts –E x p a nsi o n P h ase 
Me as ure Scree ni n g 
Assess me nts Tre at me nt P h ase 
(- 3 /+ 1 d a ys) aE o T Visit S afet y F oll o w -u p L o n g -ter m 
F oll o w -
u p b, c 
D a y -[ADDRESS_838458] 
Tre at me nt V 1  V 2 V 3  V 4  V 5  V 6  V 7  V 7  V 8  V 9  V 1 0 
U ntil 
Pr o gressi o n O n t he D a y of 
or Wit hi n 
7D a ys of 
Decisi o n t o 
Disc o nti n ue d2 8 D a ys 
( ± 5 d a ys) 
after L ast 
Tre at me nt e1 0 Wee ks 
( ± 2w e e ks)  
after L ast 
Tre at me nt eE ver y   
1 2 Wee ks 
( ± 2w e e ks) W 1 W 1  W 2  W 3 W 4  W 5 W 7  W 7 W 9 W 1 1 W 1 3 
D 1  D 2  D 8 D 1 5 D 2 2 D 2 9 D 4 3 D4 4 -
5 0 aD 5 7 D 7 1 D 8 5 
A D A = a nti dr u g a nti b o d y; A E = a d verse e ve nts; A N A = a nti n uclear a nti b o d y; β- H C G = β -h u ma n c h ori o nic g o na d otr o pi n; C T = c o m p ute dt o m o gra p h y; D L T = d ose -li miti n g 
t o xicit y ; E C G =electr ocar di o gra m; E C O G P S =Easter n C o o perati ve O nc ol o g y Gr o u p Perf or ma nce Stat us; E O R T C Q L Q -B N 2 0 = E ur o pea n Or ga nisati o n f or Researc h a n d 
Treat me nt of Ca ncer Q ualit y of Life Q uesti o n naire Brai n M o d ule ; E O R T C Q L Q -C 3 0 = E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life 
Q uesti o n naire C ore i nstr u me nt; E O R T C Q L Q -C X 2 4 = E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life Q uesti o n naire Cer vical Ca ncer M o d ule; 
E O R T C QL Q -O E S 1 8 = Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life Q uesti o n naire Oes o p ha geal M o d ule ; E O R T C Q L Q -H C C 1 8 - M = E ur o pea n 
Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life Q uesti o n naire He pat ocell ular Carci n o ma M o d ule –M o difie d ; E O R T C Q L Q -O V 2 8 = E ur o pea n Or ga nisati o n 
f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life Q uesti o n naire O varia n M o d ule ;E o T = E n d -of - Treat me nt; F H SI -8 = F A C T [ F u ncti o nal Assess me nt of Ca ncer T hera p y ] 
He pat o biliar y S y m pt o m I n de x –8 q uesti o ns ; F S H =f ollicle -sti m ulati n g h or m o ne; H B V =he patitis B vir us; H C V =he patitis C vir us; H g b = he m o gl o bi n; HI V =h u ma n 
i m m u n o deficie nc y vir us; I M P = i n vesti gati o nal me dici nal pr o d uct; I V =i ntra ve n o us; M RI =ma g netic res o na nce i ma gi n g; N S C L C -S A Q = N o n -s mall C ell L u n g Ca ncer S y m pt o m 
Assess me nt Q uesti o n naire; P D = p r o gressi ve disease; P G I S =Patie nt Gl o bal I m pressi o n of Se verit y ;P K =p har mac o ki netics; R E CI S T = Res p o nse E val uati o n Criteria i n S oli d 
T u m ors ;R F = r he u mat oi d fact or; S M C = Safet y M o nit ori n g C o m mittee; T G F β = tra nsf or mi n g gr o wt h fact or beta; T S H =t h yr oi d -sti m ulati n g h o r m o ne; T 4 =free t h yr o xi ne. 
After at le ast 50 s u bjects acr oss t he d ose esc al ati o n a n d all e x p a nsi o n c o h orts h a ve bee n e v al u ate d f or s afet y b y t he S M C ,wit h a p pr o pri ate S M C s afet y rec o m me n d ati o n a n d if t he 
S p o ns or c o nsi ders P K c h ar acteriz ati o n a de q u at e, t he n D a y 2, 8, a n d 2 2 visits m a y be s ki p pe d.  Als o, t he S afet y F oll o w -u p visit ( [ADDRESS_838459] d ose) m a y be c o n d ucte d b y p h o ne 
wit h o ut t he sc he d ule d assess me nts .
U nless st ate d ot her wise i n a f o ot n ote, all pr oce d ures a n d s a m ples s h o ul d occ ur pri or t o tri al dr u g a d mi nistr ati o n. 
aA ti me wi n d o w of u p t o 3 da ys bef ore or 1 da y after t he sc he d ule d visit da y ( -3 / + 1 da ys) will be per mitte d f or all pr oce d ures (e xce pt Da y 2 a n d t he Da y 4 4 -5 0 visit).  T he bi -wee kl y 1 4 -da y  
sc he d ule s h o ul d be strictl y a d here d t o, ret ur ni n g t o t he tar get date e ve n if t he pre vi o us visit was off sc he d ule. If a n y Scree ni n g pr oce d ures are c o n d ucte d wit hi n 3 da ys pri or t o Da y 1 of trial 
treat me nt ( Wee k 1, Da y 1), t he assess me nts sc he d ule d o n Wee k 1, Da y 1 d o n ot nee d t o be re peate d e xce pt f or t he e val uati o n of A Es a n d c o nc o mita nt me dicati o ns .T he Da y 4 4 -5 0 visit is t o 
acc o m m o date c ollecti o n of t u m or bi o ps y material a n d ass ociate d P K  a n d  sa m pli n g (see  Ta ble 3); t he Da y 4 4 -5 0 visit is o nl y t o occ ur if t he t u m or bi o ps y a n d ass ociate d P K  sa m pli n g 
ca n n ot be perf or me d at t he Da y 4 3 visit. 
bSee Secti o n 7. 4. 1. 3 f or defi niti o n of t he A E Re p orti n g peri o d a n d Secti o n 7. 4. 1. 6 f or m o nit ori n g of s u bjects wit h A Es. 
cS u bjects wit h o ut pr o gressi ve disease at 2 8 -Da y Safet y F oll o w -u p visit will be f oll o we d u p f or disease pr o gressi o n ( C T / M RI sca ns e ver y [ADDRESS_838460] assess me nt 1 2 w ee ks after 
t he pre vi o us t u m or assess me nt [sc he d ule d ti me p oi nt ]) u ntil P D.  I n a d diti o n, s u bjects will be f oll o we d e ver y 1 2 wee ks f or s ur vi val (i ncl u di n g assess me nt of a n y f urt her t u m or t hera p y).  T he 
s ur vi val f oll o w- u p will c o nti n ue u ntil [ADDRESS_838461] u g (see Secti o n 7. 1. 4. 3 f or details). After c o m pleti o n of t he F oll o w- u p peri o d t he a p pr o priate 
electr o nic Case Re p ort F or m secti o n f or Trial Ter mi nati o n m ust be c o m plete d. 
dAll s u bjects m ust u n der g o a n E n d -of -Treat m e nt visit after disc o nti n uati o n of I M P f or a n y reas o n.  T his visit s h o ul d be perf or me d wit hi n 7 da ys after t he decisi o n t o di sc o nti n ue trial treat me nt 
b ut bef ore a n y ne w a nti ne o plastic t hera p y is starte d (if p ossi ble), w hic he ver occ urs earlier . If it is k n o w n t o t he I n ve sti gat or at t he ti me of t he E n d -of -Treat me nt visit t hat t he s u bject will start 
ne w treat me nt wit hi n [ADDRESS_838462] N o. Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838463] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 3 / 1 9 3 u P re me dicati o n wit h a n a nti hista mi ne a n d wit h paraceta m ol (aceta mi n o p he n) (f or e xa m ple, 2 5 -5 0 m g di p he n h y dra mi ne a n d 5 0 0 - 6 5 0 m g paraceta m ol [aceta mi n o p he n] I V or oral e q ui vale nt) 
a p pr o xi matel y [ADDRESS_838464] i gat or after t he sec o n d i nf usi o n ( pre me dicati o n is o pti o na l f or all i nf usi o ns 
f or s u bjects i n t h e N S C L C bi o mar ker c o h ort bei n g treate d at t he U S Nati o nal Ca ncer I nstit ute ).  If Gra de ≥ [ADDRESS_838465] o p pe d.  Ster oi ds as pre me dicati o n are n ot per mitte d. M S B 0 0 1 1 3 5 9 C s h o ul d be a d mi nistere d b y I V i nf usi o n o ver 1 h o ur (- 1 0 mi n utes / + 2 0 mi n utes, t hat is, o ver 5 0 t o 8 0 mi n utes ).  
S u bjects m ust be o bser ve d f or at least [ADDRESS_838466] N o. Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838467] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 1 / 1 9 3 Har m o nisati o n (I C H) T o pic E 6 G o o d C li nical Practice ( G C P; hereafter referre d t o as I C H G C P) .  
T he C o or di nati n gI n vesti gat or will pr o vi d ee x pert me dical i n p ut a n d a d vice relati n g t o trial desi g n 
a n d e xec uti o n a n d is res p o nsi ble f or t he re vie w a n d si g n off of t he cli nical trial re p ort. 
Si g nat ure pa ges f or t he Pr ot oc ol Lea d a n d t he C o or di nati n g I n vesti gat or as well as a list of S p o ns or 
res p o nsi ble pers o ns are i n A p pe n di x 3 .
T he trial will a p pear i n Cli nical Trials . g o v , E u dra C T ,a n d all ot her re q uire d re gistries .
2. 2. 1 S afet y M o nit ori n g C o m mittee 
T o e ns ure s u bjects’ safet y d uri n g t he d ose -escalati o n part of t he trial as well as t he e x pa nsi o n part, 
a Sa fet y M o nit ori n g Co m mittee ( S M C) will re vie w t he safet y data o n a re g ular basis. T he S M C 
c o nsists of per ma ne nt c ore me m ber s fr o m t he S p o ns or a n d C R O (at least t he Me dical Res p o nsi ble, 
t he Gl o bal Dr u g Safet y Pr o d uct Lea d er , a n d t he Bi os tatisticia n f or t he e x pa nsi o n part ), th e 
C o or di nati n g In vesti gat or, a n d a n e xter nal e x pert wit h e x pertise i n t he ma na ge me nt of ca ncer 
patie nts . D uri n g t he d ose -escalati o n p orti o n of t he trial , t he S M C will e val uate t he safet y  a n d P K 
data a n d will deci de o n d ose -li miti n g t o xicities ( D L Ts) rele va nt f or t he treat me nt a n d will a d vise 
o n d ose escalati o n or s us pe nsi o n of e nr oll me nt, wit h t he fi nal a dj u dicati o n bei n g a S p o ns or 
prer o gati ve.  D uri n g t he d ose -asce nsi o n p hase of t he he pat ocell ular carci n o ma ( H C C) c o h ort, t he 
S M C will e val uate t he safet y  data of eac h c o h ort pri or t o o pe ni n g e nr oll me nt t o eac h s u bse q ue nt 
c o h ort.  D uri n g t he e nr oll me nt p hase of t he e x pa nsi o n part of t he trial (see Secti o n 3. 4. 1) ,t he S M C 
will m o nit or o n a n o n g oi n g basis (f or e xa m ple , w he n [ADDRESS_838468] 4wee ks ), all safet y i nf or mati o n of t he part ici pati n g 
s u bjects a n d will deci de b y  c o nse ns us o n c o nti n uati o n, m o dificati o n, or s us pe nsi o n of t he trial or 
of a partic ular e x pa nsi o n c o h ort. T he S M C ma y m o dif y  t he fre q ue nc y  o f meeti n gs as dee me d 
a p pr o priate b y  t he S M C d uri n g t he c o urse of t he trial.  T he s pecific w or ki n g pr oce d ures will be 
descri be d i n a n S M C c harter, w hic h will be esta blis he d pri or t o t he start of recr uit me nt .
2. 2. 2 Ce ntr al Re a der a n d I n de pe n de nt E n d p oi nt Re vie w 
C o m mittee 
A ce ntral facilit y  m a y rea d a n d i nter pret all ra di o gra p hic sca ns f or s u bjects e nr olle d i n t he 
e x pa nsi o n c o h ort s ( f or d ose escalati o n, ra di o gra p hic sca ns will be rea d l ocall y ; h o we ver, a ce ntral 
re vie w ma y  o c c ur at S p o ns or re q uest ). T he data f or all i ma ges will be tra nsferre d fr o m trial sites 
t o t he ce ntral rea di n g ce nter f or e val uati o n. Sca ns will be e val uate d at t he ce ntral facilit y  i n 
acc or da nce wit h Res p o nse E val uati o n Criteria i n S oli d T u m ors versi o n 1. 1 ( R E CI S T 1. 1 , 
Eise n ha uer 2 0 0 9) or Res p o nse Assess me nt i n Ne ur o - O nc ol o g y  ( R A N O) f or s u bjects i n t he 
gli o blast o ma c o h ort (We n 2 0 1 0) a n d a d diti o nall y  usi n g i m m u ne -relate d R E CI S T (ir R E CI S T) , 
m o difie d i m m u ne -relate d R A N O (i R A N O; O ka da 2 0 1 5) f or s u bjects i n t he gli o blast o ma ,a n d 
m o difie d R E CI S T ( m R E CI S T) f or s u bjects i n t he H C C c o h ort (see  Le nci o ni 2 0 1 0 ). T he i ma gi n g 
data will be tra nsferre d t o t he S p o ns or or desi g nee at re g ular i nter vals. A ma n ual fr o m t he ve n d or 
will be pr o vi de d t o eac h trial site. T he res ults of t he ce ntral rea d will n ot be a vaila ble i n real ti me 
a n d will n ot be use d f or trial s u bject ma na ge me nt.  L ocal i nter pretati o n of ra di o gra p hic sca ns will 
be us e d b y t he I n vesti gat or f or real -ti me trial s u bject ma na ge me nt decisi o ns. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838469] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 5 / 1 9 3 were o bser ve d a n d 1 5 m g / k g, t he hi g hest d ose teste d, was deter mi ne d t o be safe ( M orris 2 0 1 4 ). 
T he maj or A E was e mer ge nt s ki n t u m ors a n d h y per kerat osis. I n  a s mall trial of i di o pat hic 
p ul m o nar y  f i br osis, t he m ost c o m m o n A E was fati g ue (L o n ni n g 2 0 1 1 ). I n  a  st u d y  of [ADDRESS_838470] ular ras h i n 2 s u bjects 
(Trac ht ma n 2 0 1 1 ). T β M 1 , a n a nti b o d y  i n hi biti n g t he T G F II rece pt or, was well t olerate d w he n 
st u die d at d oses as hi g h as 2 4 0 m g wit h diarr hea as t he o nl y  D L T e ve nt (C o h n 2 0 1 4 ). N ota bl y , 
o ne e ve nt of l o w he m o gl o bi n ( H g b) was o bser ve d i n t he hi g h -d ose gr o u p. Im p orta ntl y , t he 
precli nical pr ofile of M S B 0 0 1 1 3 5 9 C is pre d o mi na ntl y  b e ni g n a n d hi g hl y c o m para ble t o t hat of 
a vel u ma b. O verall, e vi de nce s u g gests n o n- o verla p pi n g t o xicit y  p r ofiles f or a nti -P D -L 1 a n d 
a nti -T G F β a ge nt classes. T here is a t he oretical p ote ntia lof i m m u ne -relate d a d verse e ve nts (ir A Es) 
t hat w o ul d be t he c o nse q ue nce of a d o u ble bl oc ka de of ne gati ve re g ulat or y l o o ps of t he i m m u ne 
s y ste m ; ho we ver, ta ke n t o get her, t he precli nical pr ofile of M S B 0 0 1 1 3 5 9 C a n d cli nical e vi de nce 
of eac h pat h wa y  s u g gests a l o w ris k of s y ner gistic t o xicit y  s te m mi n g fr o m t he d ual -f u ncti o nalit y 
of M S B 0 0 1 1 3 5 9 C. 
T he safet y pr ofile is descri be d i n t he I B f or a vel u ma b a n d is briefl y s u m marize d here (refer t o t he 
c urre nt a vel u ma b I B).  A s of a c ut off date of [ADDRESS_838471] e ve nts eit her i n li ne wit h t h ose e x pecte d i n s u bjects wit h a d va nce d s oli d t u m ors or wit h 
si milar class effects of mo n ocl o nal a nti b o dies bl oc ki n g t he P D - 1 / P D -L 1 a xis.  I nf usi o n-relate d 
reacti o ns i ncl u di n g h y perse nsiti vit y  a n d ir A Es / a ut oi m m u ne dis or ders ha ve bee n i de ntifie d as 
i m p orta nt ris ks f or a vel u ma b a n d t h us c o nsi dere d p ote ntial ris ks f or M S B [ADDRESS_838472] u g i nterr u pti o n /disc o nti n uati o n , 
a n d s u p p orti ve ma na ge me nt . A nti -P D -L 1  h as s h o w n a n o verall rate of i n f usi o n reacti o ns of 
a p pr o xi matel y  1 0 % ( Gra de 3 / 4 a p pr o xi matel y  0. 4 % [fell t o 0. 2 % wit h ma n dat or y  p re me dicati o n]; 
n o Gra de 5 ).  
A brief s u m mar y  o f safet y  e x perie nce wit h t he P D - 1 i n hi bit ors ni v ol u ma b ( O p di v o ®) a n d 
pe m br oliz u ma b ( Ke y tr u da ®) is gi ve n here, base d o n prescri bi n g i nf or mati o n (refer t o c urre nt la bel 
i nf or mati o n f or u p date d i nf or mati o n) .  F or pe m br oliz u ma b t he secti o n o n War ni n gs a n d 
Preca uti o ns i ncl u des a d verse reacti o ns of i m m u ne -me diate d p ne u m o nitis ( 2. 9 %), 
i m m u ne -me diate d c olitis ( 1 %), i m m u ne -me diate d he patitis ( 0. 5 %), i m m u ne -me diate d 
h y p o p h y sitis ( 0. 5 %), re nal fail ure ( 0. 5 %) a n d i m m u ne -me diate d ne p hritis ( 0. 7 %), 
i m m u ne -me diate d h y pert h y r oi dis m ( 1. 2 %) a n d h y p ot h y r oi dis m ( 8. 3 %), a n d a variet y  o f ot her 
i m m u ne -me diate d a d verse reacti o ns occ urri n g i n less t ha n 1 % of patie nts.  I n a d diti o n, a war ni n g 
f or e m br y ofetal t o xic it y  i s pr o vi de d.  F or ni v ol u ma b the secti o n o n War ni n g a n d Preca uti o ns 
i ncl u des a d verse reacti o ns of i m m u ne -me diate d p ne u m o nitis ( 2. 2 %) wit h fatal i m m u ne -me diate d 
p ne u m o nitis i n 0. 9 % ( 5/ 5 7 4), i m m u ne - m e dicate d c olitis ( 2. 2 %), i m m u ne -me diate d he patitis 
( 1. 1 % ), i m m u ne -me diate d ne p hritis a n d re nal d y sf u ncti o n ( 0. 7 %), i m m u ne -me diate d 
h y pert h y r oi dis m ( 3 %) a n d h y p ot h y r oi dis m ( 8 % ) a n d a variet y of ot her i m m u ne -me diate d a d verse 
reacti o ns occ urri n g i n less t ha n 1 % of patie nts . I n a d diti o n ,a war ni n g f or e m br y ofetal t o xicit y  is 
pr o vi de d .   
Safet y  e x perie nce wit h vari o us T G F tar geti n g a ge nts descri be d i n t he literat ure s u g gests n o 
o verla p pi n g i m m u ne -relate d pr ofile wit h c o m p o u n ds of t he a nti -P D - 1 / a nti -P D -L [ADDRESS_838473] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838474] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 1 / 1 9 3 o pt i o nal at t he discreti o n of t he In vesti gat or.  If Gra de ≥ [ADDRESS_838475] i nf usi o ns 
S pecial preca uti o ns f or m o nit ori n g of s u bjects a n d ma na ge me nt of i nf usi o n -relate d 
reacti o ns /h y perse nsiti vit y  as descri be d i n Secti o ns   6. 5. 4. 1 a n d  6. 5. 4. 2   
I n f usi o n-relate d reacti o ns / h y perse nsiti vit y  ( a n y gra de) are c o nsi dere d as A E SI re q uiri n g 
e x pe dite d re p orti n g fr o m t he I n vesti gat or t o t he S p o ns or.  F or n o nseri o us A E SI s, a n A E SI 
Re p ort F or m has t o be c o m plete d; f or seri o us e ve nts, a n S A E Re p ort F or m has t o be use d (see 
Secti o n  7. 4. 1. 4) .
3. 5. 2 I m m u ne -rel ate d A d verse E ve nts / A ut oi m m u ne Dis or ders 
I m m u ne -relate d A Es are A E SI s. 
T he f oll o wi n g ir A Es are i m p orta nt i de ntifie d ris ks f or M S B 0 0 1 1 3 5 9 C. 
I m m u ne -relate d p ne u m o nitis 
I m m u ne -relate d he patitis 
I m m u ne -relate d c olitis 
I m m u ne -relate d ne p hritis a n d re nal d ys f u ncti o n 
I m m u ne -relate d e n d ocri n o pat hies (t h y r oi d dis or ders, a dre nal i ns ufficie nc y , t y pe 1 dia betes 
mellit us, pit uitar y  dis or ders) 
I m m u ne -relate d ras h 
Ot her i m m u ne- relate d e ve nts ( m y ositis, m y oca r ditis, e nce p halitis) 
T he f oll o wi n g ir A Es are i m p orta nt p ote ntial ris ks f or M S B 0 0 1 1 3 5 9 C: 
G uillai n -Barré s y n dr o me 
U veitis 
Pa ncreatitis 
M y ast he nia gra vis/ m yast he nic s y n dr o me 
I m m u ne -relate d A Es / a ut oi m m u ne dis or ders are e ve nts t hat are relate d t o t he p har mac ol o g y  o f 
c hec k p oi nt i n hi bit ors a n d ca n be e x plai ne d b y a n i m m u ne -p he n o me n o n after ot her eti ol o gies ha ve 
bee n r ule d o ut. Rele va nt cli nical safet y e x perie nce has bee n ge nerate d wit h t he pare nt a nti -P D -L 1 
a vel u ma b a nti b o d y. 
As of 0 5 N o ve m ber 2 0 1 4, a c u m ulati ve re vie w re veale d 5 6 cases of p ote ntial ir A Es o ut of 
4 8 0 s u bje cts ( 1 1. 7 %) treate d i n t he d ose -e x pa nsi o n part of Trial E M R 1 0 0 0 7 0 -0 0 1 a n d 4 cases 
o ut of 5 0 s u bj ects ( 8. 0 %) treate d i n t he d ose -escalati o n part of Trial E M R [ADDRESS_838476] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838477] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 2 / [ADDRESS_838478] o mize d Me dical Dicti o nar y  f or Re g ulat or y  A cti vities ( Me d D R A) q uer y was use d f or data 
retrie val fr o m t he cli nical data base wit h pre defi ne d Preferre d Ter ms of p ote ntial ir A Es .
Of 6 9 p ote ntial ir A Es re p orte d, 1 3 were S A Es ( 1 8. 8 %) a n d 5 6 were n o nseri o us A Es ( 8 1. 1 %).  
I n t he maj orit y of t he cases, t here was a pla usi ble te m p oral ass ociati o n bet wee n t he e ve nt o nset 
a n d t he dr u g a d mi nistrati o n.  O f t hese 6 9 e ve nts, 4 6 e ve nts ( 6 6. 7 %) were assesse d as 
treat me nt -relate d b y  t he In vesti gat or a n d 2 3 e ve nts ( 3 3. 3 %) were assesse d as n ot 
treat me nt -relate d b y t he In vesti gat or. 
T we nt y -si x e ve nts were assesse d as Gra de 1, 2 9 e ve nts as Gra de 2, 1 1 e ve nts as Gra de 3, 
2e ve nts as Gra de 4, a n d 1 e ve nt ( p ne u m o nitis) as Gra de 5 ( n ote:   2 m ore e ve nts of a ut oi m m u ne 
he patitis ha d a fatal o utc o me; h o we ver, t he y  w ere assesse d as Gra de 3 wit h a s u b se q ue nt fatal 
li ver fail ure). 
Base d o n t he ir A E cases t hat ha ve bee n o bser ve d wit h a vel u ma b , all trial In vesti gat ors will be 
trai ne d t o be ma de a ware of t he fre q ue nc y  a n d se verit y  o f t he o bser ve d e ve nts a n d t o pr oacti vel y 
a d mi nister ster oi d treat me nt f or a n y s us pi[INVESTIGATOR_37180] o n of ir A Es.  
Base d o n cli nical e x perie nce wit h a vel u ma b a n d wit h ot her a ge nts bl oc ki n g t he P D -1 / P D -L 1  
pat h wa y , ir A Es /a ut oi m m u ne dis or ders are a n i m p orta nt p ote ntial ris k f or M S B 0 0 1 1 3 5 9 C. Ris k 
ma na ge me nt meas ures si milar t o t he lea d pr o gra m i ncl u de: 
I nstr ucti o ns f or trial treat me nt disc o nti n uati o n or i nterr u pti o n i n case of ir A Es /a ut oi m m u ne 
dis or ders (see Secti o n  6. 5. 4. 3 ). 
G ui da nce f or t he me dical ma na ge me nt of ir A Es /a ut oi m m u ne dis or ders i ncl u di n g s pecific 
g ui da nce wit h re gar d t o t he affecte d or ga n /b o d y  s y ste m (see Secti o n  6. 5. 4. 3 ).  
ir A Es /a ut oi m m u ne dis or ders (a n y gra de) are c o nsi dere d as A E SI sre q uiri n g e x pe dite d 
re p orti n g fr o m t he I n vesti gat or t o t he S p o ns or. F or n o nseri o us A E SIs ,a n A E SI  Re p ort F or m 
has t o be c o m plete d; f or seri o us e ve nts ,a n S A E Re p ort F or m has t o be use d. 
Re g ular la b orat or y  tests o n para meters i n dicati ve f or a ut oi m m u ne dis or ders will be perf or me d 
as detaile d i n t he Sc he d ules of Assess me nts (see  Ta ble 1a n d  Ta ble 2).
T o hel p m o nit or f or a ut oi m m u ne effects, baseli ne o p ht hal m ol o g y e xa mi nati o n i ncl u di n g slit 
la m p i ncl usi ve of t he a nteri or se g me nt a n d i ncl u di n g vis ual ac uit y .  I f cli nicall y  r ele va nt e y e 
si g ns or s y m pt o ms d uri n g t he st u d y , a p pr o priate o p ht hal m ol o g y  e xa mi nati o n wit hi n 2 da y s 
i ncl u di n g slit la m p i ncl usi ve of t he a nteri o r se g me nt a n d i ncl u di n g vis ual ac uit y .
3. 5. 3 T G F β I n hi biti o n Me di ate d S ki n Re acti o ns 
S ki n A Es, p ossi bl y  d ue t o T G F β i n hi biti o n, i ncl u di n g h y per kerat osis, K A, a n d/ or c S C C, are A E SI s 
a n d i m p orta nt i de ntifie d ris ks f or M S B 0 0 1 1 3 5 9 C . T he distri b uti o n of lesi o ns te n d s t o be i n s u n 
e x p ose d areas. 
F or n o nseri o us A E SIs ,a n A E SI  Re p ort F or m has t o be c o m plete d; f or seri o us e ve nts ,a n S A E 
Re p ort F or m has t o be use d (see Secti o n  7. 4. 1. 4) .
See Secti o n  6. 5. [ADDRESS_838479] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838480] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 4 / [ADDRESS_838481] be nefit is c o nsi dere d u nl i kel y  f or partici pa nts i n t his Phase I trial, es peciall y  i n t he l o w 
d ose s of t he d ose -escalati o n part; theref ore ,o nl y  s u bjects wit h mali g na ncies f or w hic h n o sta n dar d 
effecti ve t hera p y e xists or s u bjects ha vi n g e x perie nce d a fail ure of sta n dar d t hera p y are eli gi ble 
f or t his part of t he trial .  H o we ver, preli mi nar y  r es ults fr o m t he E M R [ADDRESS_838482] wit h pa ncreatic ca ncer ( 3 m g / k g c o h ort) has bee n re p orte d wit h a 
c o nfir me d P R acc or di n g t o R E CI S T ( o n g oi n g at 6 m o nt hs).  I n a d diti o n, S D has bee n re p orte d 
5s u bjects ( 4 1. 7 %), i ncl u di n g [ADDRESS_838483] i n t he 1 m g/ k g c o h ort, a n d 2 s u b jects i n eac h of t he 3 a n d 
1 0 m g/ k g c o h orts. Fi ve s u bjects ( 4 1. 7 %) were re p orte d wit h a B O R of P D.  At t he ti me of t he data 
c ut off, 8 s u bjects ( 6 6. 7 %) re mai ne d o n treat me nt. 
I n c o ncl usi o n, t he ris k- be nefit rati o of treat me nt wit h M S B 0 0 1 1 3 5 9 C i n t he tar gete d trial 
p o p ulati o n a p pears p ositi ve gi ve n t he p o or pr o g n osis of s u bjects wit h a d va nce d mali g na ncies wit h 
n o sta n dar d treat me nt o pti o ns. 
T his cli nical trial will be c o n d ucte d i n c o m plia nce wit h t he cli nical trial pr ot oc ol, t he sta n dar ds  
sti p ulate d  i n Article 1 4, Para gra p h 3, a n d Article 8 0- 2 of t he P har mace utical Affairs La w i n Ja pa n; 
a n d t he “ Mi nisterial Or di na nce o n t he Sta n dar ds f or t he I m ple me ntati o n of Cli nical St u dies o n 
P har mace utical Pr o d uct” ( G o o d Cli nical Practice [ G C P]) i n Ja pa n ,G C P (I C H T o pic E 6 ),a n d t he 
a p plica ble nati o nal re g ulat or y  re q uire me nts. 
[ADDRESS_838484] u d y  is t o deter mi ne t he safet y, t olera bilit y, 
a n d t he ma xi m u m -t olerate d d ose ( M T D) of M S B [ADDRESS_838485] o verall res p o nse ( B O R) acc or di n g t o Res p o nse E val uati o n Criteria i n S oli d T u m ors 
versi o n 1. 1 ( R E CI S T 1. 1).  F or gli o blast o ma, t he pri mar y o bjecti ve is t o assess t he disease c o ntr ol 
rate ( D C R) acc or di n g t o R A N O .
4. 2 Sec o n d ar y O bjecti ves 
T he s ec o n dar y  o bjecti ve sare: 
T o c haracterize t he P K pr ofile of M S B 0 0 1 1 3 5 9 C 
T o e val uate t he i m m u n o ge nicit y  of M S B [ADDRESS_838486] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838487] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 7 / [ADDRESS_838488] after wee ks of treat me nt ( Attia 2 0 0 5 , Cala br o 2 0 1 0,  Di Giac o m o 2 0 1 1,  Kae hler 2 0 1 0 , 
P ha n 2 0 0 3,  W olc h o k 2 0 1 0 ). S uc h i m m u ne -me diate d a d verse e ve nts ma y i ncl u de p ne u m o nitis , 
c olitis, he patitis, h y p o p h y sitis , ne p hritis, a n d t h y r oi ditis ( h y p o or h y pert h yr oi dis m).  
T he i de ntifie d a n d p ote ntial ris ks are f urt her descri be d (see Secti o ns 3. 5 a n d  6. 5. 4) .
All D L Ts will be m o nit ore d ce ntrall y, a n d t he decisi o n t o escalate t o t he ne xt d ose le vel will be 
deter mi ne d b y  t he S M C as o utli ne d i n Secti o n 2. 2. 1.  
After t he 1 a n d 3 m g/ k g c o h orts ha ve c o m plete d t he D L T e val uati o n peri o d, a preli mi nar y P K 
a nal ys is will be perf or me d.  D e pe n di n g o n t he res ults of t his a nal y sis ,i ncl u di n g P K li nearit y, a 
decisi o n will be ma de t o i nitiate u p t o 2 c o h orts of 3 s u bjects eac h, o ne at 0. 1 m g/ k g a n d o ne at 
0. 3 m g/ k g, w hic h will i ncrease o n t he sec o n d d ose a n d all s u bse q ue nt d oses t o a 1 2 0 0 m g/i nf usi o n 
flat d ose , de pe n de nt u p o n S M C cleara nce a n d o nl y  i f t he S p o ns or a n d C o or di nati n g I n vesti gat or 
ha ve deter mi ne d a mea ni n gf ul d ose f or t he i ntras u bject escalati o n.  N o D L T e val uati o ns will be 
perf or me d i n t hese fle xi ble c o h orts.    
After t he M T D has bee n reac he d or t he 2 0 m g / k g c o h ort has bee n declare d b y  t he S M C as t he 
hi g hest n o n- M T D d ose assesse d, t he n f urt her P K a nal y ses m a y be perf or me d. If dee me d necessar y , 
t he 1, 3, 1 0 , a n d 2 0 m g / k g c o h orts ma y  eac h e nr ol l u p t o a n a d diti o nal 1 0 s u bjects ( u p t o 4 0 t otal) 
f or t he p ur p ose of P K pr ofile a n d p ossi ble P K /  m o deli n g if t here has bee n S M C 
cleara nce at t he hi g her or sa me ( 2 0 m g / k g) d ose le vel.  O n t he sec o n d d ose a n d all s u bse q ue nt 
d oses , t he 1 m g/ k g c o h o rt ma y  i ncrease t o a 1 2 0 0 m g/i nf usi o n flat d ose. N o D L T e val uati o ns will 
be perf or me d i n t hese s u p ple me ntal c o h orts.  T hese l o wer d ose c o h ort e x pa nsi o ns f or P K pr ofile 
a n d P K /  p ur p oses m a y  p r ocee d i n parallel wit h t he e x pa nsi o n c o h ort sif dee me d 
a p pr o priate b y t he S p o ns or a n d C o or di nati n g I n vesti gat or base d o n t he M T D al o ne .
I n t he c o h orts recei vi n g 0. 1 m g/ k g a n d 0. 3 m g/ k g a n d i n t he a d diti o nal s u bjects e nr olle d f or t he 
p ur p ose of P K pr ofile a n d p ossi ble P K /  m o deli n g, it is i n te n de d t o i nte nsif y  t he P K 
a nal ys is b y  t a ki n g 3a d diti o nal P K sa m ples d uri n g t he first treat me nt c y cle. T hese sa m ples are 
sc he d ule d t o be ta ke n at [ADDRESS_838489] be rec or de d. T hese sa m ples are la belle d as o pti o nal i n t he Sc he d ule of 
Assess me nts (Ta ble 3) b ut t he y  a re hi g hl y i m p orta nt t o all o w a s ufficie ntl y  d etaile d a nal ys is a n d 
descri pti o n of t he M S B 0 0 1 1 3 5 9 C P K pr ofile. 
As t he 2 0 m g/ k g c o h ort i n t he d ose escalati o n p orti o n has cleare d S M C e val uati o n, a d diti o nal 
c o h ort sat 3 0 m g/ k g a n d 2 4 0 0 m g flat d ose will be i nitiate d, i n parallel t o t he o n g oi n g e x pa nsi o n 
c o h orts.  T he 3 0 m g/ k g a n d t he 2 4 0 0 m g flat -d ose c o h ort swill be e nr olle d i n a 3 +[ADDRESS_838490] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
C CI 
C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838491] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 8 / 1 9 3 5. 1. 1. 2 E x p a nsi o n C o h orts 
T he d ose f or t he e x pa nsi o n c o h orts was deter mi ne d b y  t he S p o ns or base d o n t he safet y 
o bser vati o ns a n d P K /  data fr o m t he d ose escalati o n part of t he trial. T he flat d oses f or 
e xte nsi o n part will be i m ple me nte d after cleara nce of 2 0 m g / k g escalati o n c o h ort b y  t he S M C.  
E xce pt f or t he sec o n d -li ne N S C L C c o h ort, all s u bjects i n e x pa nsi o n c o h orts will be recei vi n g 
1 2 0 0 m g (flat d ose) e ver y 2 wee ks.  S u bjects i n t he sec o n d -li ne N S C L C c o h ort will be ra n d o mize d 
t o recei ve eit her 5 0 0 or 1 20 0 m g e ver y  2 wee ks (see Secti o n  3. 4. 1. 1 f or rati o nales) .  
S u bjects i n t he e x pa nsi o n c o h orts will recei ve M S B 0 0 1 1 3 5 9 C as a 1 -h o ur I V i nf usi o n o n ce e ver y  
2 wee ks u ntil P D has bee n c o nfir me d b y  a s u bse q ue nt sca n , u nacce pta ble t o xicit y,  o r occ urre nce 
of a n ycriteri o n f or wit h dra wal fr o m t he trial or t he I M P ( see Secti o n  5. 5) .  
Su bjects w h o ha ve e x perie nce d S D, P R ,or C R s h o ul d c o nti n ue treat me nt t hr o u g h t he e n d of 
[ADDRESS_838492] 
ma y  b e nefit fr o m treat me nt b e y o n d 1 2 m o nt hs, it ma y  b e per miss i ble after disc ussi o n wit h t he 
Me dical M o nit or a n d t he S p o ns or Me dical Res p o nsi ble .I n t he case of P D, s u bjects s h o ul d 
c o nti n ue treat me nt t hr o u g h t heir ne xt t u m or assess me nt, if t he y  m eet t he criteria descri be d i n 
Secti o n  5. 5. 1 .  If t here is f urt her e vi de nce of P D t hereafter , trial treat me nt s h o ul d be disc o nti n ue d ; 
h o we ver ,c o nti n ue d treat me nt is p ossi ble i n c o ns ultati o n wit h t he Me dical M o nit or .  F or s u bjects 
w h o ac hie ve S D, a C R or P R o n M S B [ADDRESS_838493] o p pi n g t h era p y, b ut pri or t o t he e n d of t he trial, 1 re -i nitiati o n c o urse of 
treat me nt at t he sa me d ose a n d sc he d ule a n d treat me nt d urati o n u p t o 1 2 m o nt hs is all o we d at t he 
discreti o n of t he I n vesti gat or a n d a gree me nt of t he trial Me dical Res p o nsi ble (see Secti o n  5. 1. 6) .
T he I n vesti gat or will nee d t o c o nfir m t hat t he be nefit of re -i nitiati n g treat me nt o ut wei g hs a n y ris k 
i n v ol ve d, s uc h as t hat w hic h le d t o i nitial treat me nt disc o nti n uati o n. M ore o ver, f or s u b jects i n 
w hic h B O R was S D, t he In vesti gat or s h o ul d c o nfir m n o ot her reas o na ble treat me nt o pti o ns are 
a vaila ble. 
For s u bjects i n t he mela n o ma, S C C H N, a n d T N B C c o h orts o nl y , s y m pt o m se verit y  w ill be 
assesse d usi n g 2 patie nt -re p orte d o utc o mes q uesti o n naires: 
Patie nt Gl o bal I m pressi o n of Se verit y ( P GI S )
Select ite ms fr o m t he E O R T C Q L Q- C 3 0 
For s u bjects i n t he es o p ha geal a de n ocarci n o ma c o h ort o nl y , s y m pt o m se verit y  w ill be assesse d 
usi n g 3 patie nt -re p orte d o utc o mes q uesti o n naires: 
P GI S
Select ite ms fr o m t he E O R T C Q L Q- C 3 0 
Select ite ms fr o m t he E O R T C Q L Q- O E S [ADDRESS_838494] o ma c o h ort o nl y , s y m pt o m se verit y  w ill be assesse d usi n g 2patie nt -
re p orte d o utc o mes q uesti o n naires: 
P GI S
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838495] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 9 / 1 9 3 Select ite ms fr o m t he E O R T C Q L Q- B N 2 0 
For s u bjects i n t he o varia n ca ncer c o h ort o nl y, s y m pt o m se verit y  will be assesse d usi n g 3 patie nt -
re p orte d o utc o mes q uesti o n naires: 
P GI S
Select ite ms fr o m t he E O R T C Q L Q- C 3 0 
Select ite ms fr o m t he E O R T C Q L Q- O V 2 8 
For s u bjects i n t he N S C L C sec o n d -li ne a n d a nti -P D -1/ P D -L 1  f ail ure c o h orts o nl y, s y m pt o m 
se verit y will be assesse d usi n g 2 patie nt -re p orte d o utc o mes q uesti o n naires: 
P GI S
N S C L C S y m pt o m Assess me nt Q uesti o n naire ( N S C L C- S A Q) 
For s u bjects i n t he H C C e x pa nsi o n c o h ort o nl y , s y m pt o m se verit y will be assesse d usi n g 
2patie nt -re p orte d o utc o mes q uesti o n naires: 
P GI S
E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y  o f Li fe Q uesti o n naire 
He pat ocell ular Carci n o ma M o d ule –M o difie d ( E O R T C Q L Q- H C C 1 8 -M) 
F or s u bjects i n t he cer vical ca ncer c o h ort o nl y , s y m pt o m se verit y  w ill be assesse d usi n g 
3patie nt -re p orte d o utc o mes q uesti o n naires: 
P GI S
Select ite ms fr o m t he E O R T C Q L Q- C 3 0 
Select ite ms fr o m t he E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of 
Life Q uesti o n naire Cer vical C a ncer M o d ule ( E O R T C Q L Q- C X 2 4) .
Asce n di n g D ose H C C 
After t he 3 m g / k g c o h ort i n t he d ose escalati o n p orti o n has cleare d S M C e val uati o n, t he 3 m g/ k g 
H C C c o h ort ma y  i nitiate.  O nce t h e 20 m g/ k g d ose -escalati o n c o h ort has bee n cleare d a n d dee me d 
safe b y t he S M C, a n H C C asce n di n g [ADDRESS_838496] si n t he H C C 1 2 0 0 m g asce n di n g -d ose c o h ort o nl y, s y m pt o m se verit y will be assesse d 
usi n g 2 patie nt -re p orte d o utc o mes q uesti o n naires: 
P GI S
F u ncti o nal Assess me nt of Ca ncer T hera p y ( F A C T) He pat o biliar y  S y m pt o m I n de x – 8 q uesti o ns 
( F H SI - 8). 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838497] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 1 / [ADDRESS_838498] arti n g D ose 
The starti n g d ose of M S B 0 0 1 1 3 5 9 C will be 1 m g/ k g. 
5. 1. 3. 2 D ose Esc al ati o n 
T he d ose escalati o n will use a sta n dar d 3 + 3 sc he me wit h t he f oll o wi n g pla n ne d d oses ( o nce e ver y 
2 wee ks) :
1 m g/ k g 
3m g/ k g 
1 0 m g/ k g 
2 0 m g/ k g 
3 0 m g/ k g 
[ADDRESS_838499] ca n i nitiate d osi n g.  O n ce t he 3or 6 s u bjects 
ha ve passe d t he 2 1- d a y  D L T  e val uati o n peri o d t he S M C will re vie w t he safet y a n d a vaila ble P K 
data t o deci de u p o n f urt her d ose escalati o n . P har mac o ki netic data fr o m t he pre vi o us c o h ort will 
be re q uire d f or S M C re vie w (f or e xa m ple, w he n t he S M C is re vie wi n g safet y data fr o m t he 
1 0 m g/ k g c o h ort, a vaila ble P K data fr o m t he 3 m g/ k g c o h ort); h o we ver, P K data fr o m t he c o h ort 
u n der re vie w will n ot be re q uire d .
T he criteria f or m o vi n g fr o m 1d ose le vel t o a n ot her d o n ot all o w escalati o n t o t he ne xt c o h ort i n 
cases w here ≥ [ADDRESS_838500] d ose le vel ( 3 0 m g/ k g) n o D L Ts 
occ urre d i n t he first [ADDRESS_838501] shas e x perie nce d a D L T at a 
d ose bel o w 1 0 m g / k g, d ose escalati o n will be m o difie d (Ta ble 4) .
T he D L T criteria will n ot a p pl y  t o a n y of t he e x pa nsi o n c o h orts. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838502] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 2 / 1 9 3 T a ble 4 M o dific ati o n of D ose Esc al ati o n B ase d o n D L T O bser v ati o ns 
D ose Esc al ati o n Sc he d ule Sce n ari os D ose of M S B 0 0 1 1 3 5 9 C ( m g/ k g) 
D ose Le vels N o D L T at 
D ose Le vel D L T at Le vel 1 ( 1 m g / k g) or 
D L T at Le vel 2 ( 3 m g / k g) 
Le vel 1 1m g/ k g 1
Le vel 2 3m g/ k g 3
Le vel 3 1 0 m g/ k g 7a
Le vel 4 2 0 m g/ k g 1 0 
Le vel 5 3 0 m g/ k g 2 0 
Le vel 6 2 4 0 0 m g N o m o dificati o n 
D L T = d ose -li miti n g t o xicit y. 
a  If 1 of 6 s u bjects has a D L T at d ose le vel 1 or 2. 
5. 1. 3. 3 D ose -Li miti n g T o xicit y 
A D L T is defi ne d as a n y  Gra de ≥ 3 A E assesse d as relate d t o t he I M P b y  t he I n vesti gat or a n d / or 
S p o ns or (t hat is ,Gra de ≥ 3A D R ; gra di n g acc or di n g t o t he N CI -C o m m o n Ter mi n ol o g y  C riteria 
f or A d verse E ve nts versi o n v 4. 0 3 [ C T C A E v 4. 0 3] ) occ urri n g i n t he D L T e val uati o n peri o d 
( [ADDRESS_838503] a d mi nistrati o n of M S B 0 0 1 1 3 5 9 C) c o nfir me d b y t he S M C t o be rele va nt f or t he 
I M P treat me nt.   T he S M C rec o g nizes t hat i n t he a bse nce of pri or h u ma n e x perie nce wit h 
M S B [ADDRESS_838504] u g 
e xce pt w here a clear relati o ns hi p t o t he u n derl yi n g disease or rec o g nize d c o m or bi ditie s is e vi de nt. 
A D L T is s pecific all y defi ne d as t he f oll o wi n g: 
A n y  G ra de ≥ 3 a d verse e ve nt t hat is relate d t o M S B 0 0 1 1 3 5 9 C, occ urri n g d uri n g t he D L T 
e val uati o n peri o d ( [ADDRESS_838505] a d mi nistrati o n of M S B 0 0 1 1 3 5 9 C), e xce pt f or t h ose liste d 
bel o w.   Als o, ele vate d ala ni ne a mi n otra nsferase ( A L T) or as partate a mi n otra nsferase ( A S T) 
3ti mes t he u p per li mit of n or mal ( U L N) ra n ge a n d a c o nc o mita nt ele vati o n of bilir u bi n [ADDRESS_838506] u g c o nstit utes a D L T. 
Gra de 3 i nf usi o n -relate d reacti o ns res ol vi n g wit hi n 6 h o urs fr o m t he e n d of i nf usi o n a n d 
c o ntr olle d wit h me dical ma na ge me nt. 
Tra nsie nt (≤ 6 h o urs) Gra de 3 fl u -li ke s y m pt o ms or fe ver, w hic h is c o ntr olle d wit h me dical 
ma na ge me nt. 
Tra nsie nt ( ≤ 2 4 h o urs) Gra de 3 fati g ue, l ocal reacti o ns, hea dac he, na usea, e mesis t hat res ol ves 
t o Gra de ≤ 1. 
Gra de 3 H g b decrease ( < 8. 0 g/ d L) t hat res ol ves t o at least 9 g/ d L wit hi n [ADDRESS_838507] or use. 
Mali g na nt s ki n lesi o n t hat is l ocal a n d ca n be resecte d wit h ne gati ve resecti o n mar gi n. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838508] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 3 / [ADDRESS_838509] d. 
5. 1. 4 E x p a nsi o n C o h ort s
After a n M S B 0 0 1 1 3 5 9 C d ose f or f urt her i n vesti gati o n is esta blis he d, e nr oll me nt of se veral 
e x pa nsi o n c o h orts will be o pe ne d t o deter mi ne t he safet y a n d cli nical acti vit y  o f M S B 0 0 1 1 3 5 9 C 
i n s pecific i n dicati o ns (see Secti o n  3. 4. 2 f or details) . 
F oll o wi n g safet y a n d P K a nal y sis of t he escalati o n c o h orts, a flat d ose of 1 2 0 0 m g/i nf usi o n was 
c h ose n f or all e x pa nsi o n c o h orts, e xce pt f or t he N S C L C sec o n d -li ne c o h ort, i n w hic h 4 0 s u bjects 
will recei ve 5 0 0 m g/i nf usi o n a n d 4 0 s u bjects will recei ve 1 20 0 m g/i nf usi o n .
5. 1. 5 Pl a n ne d N u m ber of S u bjects 
T he pla n ne d n u m ber of t he e val ua ble s u bjects f or t his trial is deri ve d fr o m t he d ose -escalati o n 
“ 3 +3” desi g n a n d t he e x pa nsi o n c o h ort sizes: 
D ose -escalati o n p hase: 3t o 8 2 s u bjects. 
E x pa nsi o n c o h ort s: U p t o a p pr o xi matel y  [ADDRESS_838510] y  of I M P, t he scree ni n g of 
ne w s u bjects f or a n y c o h ort ma y be te m p oraril y pa use d wit h 2 4 h o urs’ n otice t o I n vesti gat or s. 
5. 1. [ADDRESS_838511] is esti mate d t o be u p t o 2 y ears . T his i ncl u des a 2 8- d a y Scree ni n g 
peri o d ( decisi o n will be ma de i n t his peri o d f or s u bjects’ trial i ncl usi o n if all eli gi bilit y  criteria are 
met), a treat me nt d urati o n u ntil c o nfir me d P D , unacce pta ble t o xicit y , or a n y  c riteri o n f or 
wit h dra wal fr o m t he trial or I M P occ urs (see Secti o n 5. 5 ) a n d a [ADDRESS_838512] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838513] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 4 / [ADDRESS_838514] be a va ila ble a n d verifie d pri or t o re -i nitiati n g of treat me nt . S u bjects w h o 
re -i nitiate treat me nt will sta y  o n trial a n d will be treate d a n d m o nit ore d acc or di n g t o t he Sc he d ules 
of Assess me nt f or t he E x pa nsi o n p orti o n of t he trial starti n g at Wee k 1, Da y  1 (see  Ta ble 2) .
M ore o ver, a n y A D Rs s h o ul d be f oll o we d u ntil t he y  res ol ve, ret ur n t o B aseli ne, or are irre versi ble 
(see Secti o n  7. 1. 4 f or details). 
Pla n ne d first s u bject i n: Q 3, [ADDRESS_838515] o ut ( d ose escalati o n , i ncl u di n g f oll o w - u p ): Q 3, [ADDRESS_838516] o ut (after e x pa nsi o n a n d f oll o w- u p): Q 4, 2 0 2 1. 
5. 1. 7 D ose M o dific ati o n a n d A D Rs Re q uiri n g Tre at me nt 
Disc o nti n u ati o n 
5. 1. 7. 1 D ose M o dific ati o n 
F or t he d ose -escalati o n c o h orts (e xce pt f or t he 2 4 0 0 m g flat -d ose c o h ort) , t he d ose of 
M S B [ADDRESS_838517] o p pe d.   D osi n g m o dificati o ns (c ha n ges i n i nf usi o n rate) a n d d ose dela y s are descri be d i n 
Secti o ns  5. 1. 7. [ADDRESS_838518] u g Re acti o ns Re q uiri n g Tre at me nt 
Disc o nti n u ati o n 
Certai n A D Rs , defi ne d as a n A E assesse d as relate d t o M S B 0 0 1 1 3 5 9 C b y  t he I n vesti gat or a n d / or 
S p o ns or ,ma y  re q uire per ma ne nt treat me nt disc o nti n uati o n of M S B 0 0 1 1 3 5 9 C (liste d bel o w).  F or 
certai n A D R sassesse d t o be i m m u ne -relate d,  Ta ble 7criteria m a y s u perse de t his secti o n. T hese 
criteria m a y  a ll o w t he s u bject t o c o nti n ue o n st u d y  i f me dicall y i n dicate d after c o ns ultati o n wit h 
Me dical Mo nit or. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838519] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 5 / 1 9 3 A n y Gr a de 4 A D Rs re q uire per m a ne nt tre at me nt disc o nti n u ati o n e x ce pt f or si n gle la b orat or y 
val ues o ut of n or mal ra n ge t hat d o n ot ha ve a n y cli nical c orrelate a n d res ol ve t o Gra de ≤ 1or 
Baseli ne gra de wit hi n 7 da y s wit h a de q uate me dical ma na ge me nt. 
A n y Gr a de 3 A D Rs re q uire tre at me nt disc o nti n u ati o n e xce pt f or a n y of t he f oll o wi n g:   
Tra nsie nt (≤ 6 h o urs) Gra de 3 fl u -li ke s y m pt o ms or fe ver, w hic h is c o ntr olle d wit h me dical 
ma na ge me nt. 
Tra nsie nt ( ≤ 2 4 h o urs) Gra de 3 fati g ue, l ocal reacti o ns , hea dac he, na usea, e mesis t hat res ol ves 
t o ≤ Gra de 1 or Baseli ne gra de . 
T u m or flare p he n o me n o n defi ne d as l ocal pai n, irritati o n, or ras h l ocalize d at sites of k n o w n or 
s us pecte d t u m or. 
A n y  G ra de ≥ [ADDRESS_838520] u d y  Me dical M o nit or s h o ul d be c o ns ulte d f or 
s uc h Gra de ≥ [ADDRESS_838521] ati o ns of pa ncreatitis has n ot res ol ve d t o 
Gra de ≤ 1 wit hi n t he s u bse q ue nt 2 c y cles ( 2 8 d a y s), t he s u bject s h o ul d per ma ne ntl y  d isc o nti n ue 
treat me nt wit h M S B [ADDRESS_838522] fr o m site I n vesti gat o r. 
Gra de 3 H g b decrease ( < 8. 0 g/ d L) t hat is cli nicall y  m a na gea ble wit h bl o o d tra nsf usi o ns or 
er yt hr oi d gr o wt h fact or use d oes n ot re q uire treat me nt disc o nti n uati o n. D uri n g t he 
2 1- D a y -D L T peri o d, a Gra de 3 H g b decrease ( < 8. 0 g/ d L) re q uires treat me nt disc o nti n uati o n, 
u nless it res ol ves t o at least 9 g/ d L wit hi n [ADDRESS_838523] or use. 
I n creases i n Easter n Co o perati ve O nc ol o g y  G r o u p perf or ma nce stat us ( E C O G P S) ≥ 3t hat 
res ol ve st o 2 b y Da y 1 of t he ne xt c y cle (i nf usi o ns s h o ul d n ot be gi ve n if t he E C O G P S is ≥3 
o n t he da y  of I M P a d mi nistrati o n a n d s h o ul d be dela ye d u ntil E C O G P S ≤ 2 ). 
Kerat oaca nt h o ma a n d s q ua m o us cell carci n o ma of t he s ki n. A n y s us pi[INVESTIGATOR_37180] o us s ki n lesi o n s h o ul d 
be bi o psie d a n d be s ur gicall y  re m o ve d. T he St u d y Me dical M o nit or s h o ul d be c o ns ulte d. 
Gra de 3 or 4 d e r mat ol o gical ir A Es, treat me nt s h o ul d be dela y e d a n d treat me nt starte d acc or di n g 
t o Ta ble 7, if c o n diti o n i m pr o ves t o Gra de 1, treat me nt ma y  b e res u me d .  I f ≥2 c o nsec uti ve 
d oses are misse d , t he Me dical M o nit or s h o ul d be c o ns ulte d .  
Gra de 3 or 4 s y m pt o matic e n d ocri n o pat hies (e g, t h yr oi ditis or h y p o p h y sitis ), treat me nt s h o ul d 
be dela y e d a n d treat me nt starte d acc or di n g t o Ta ble 7,  if c o n diti o n i m pr o ves t o Gra de 1, 
treat me nt m a y  b e res u me d .  I f ≥ 2 c o nsec uti ve d oses are misse d , t he Me dical M o nit or s h o ul d 
be c o ns ulte d  
Ot her i m m u ne- relate d A D Rs, see  Ta ble 7. 
A n y Gr a de 2 A D R s h o ul d be m a n a ge d as f oll o ws: 
If a Gra de 2 A D R res ol ves t o Gra de ≤ [ADDRESS_838524] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838525] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 6 / 1 9 3 If a Gra de 2 A D R d oes n ot res ol ve t o Gra de ≤ [ADDRESS_838526] d a y  o f t he c urre nt c y cle b ut it is 
ma na gea ble a n d / or n ot cli nicall y  r ele va nt , t he A D R s h o ul d be disc usse d wit h t he Me dical 
Mo nit or a n d base d u p o n disc ussi o n it is p ossi ble t he i nf usi o n will be gi ve n o n t he f o ll o wi n g 
c y cle.  I f at t he e n d of t he f oll o wi n g c y cle, t he e ve nt has n ot res ol ve d t o Gra de 1, disc ussi o n 
s h o ul d be ha d wit h t he Me dical Mo nit or a b o ut per ma ne ntl y  d isc o nti n ui n g treat me nt wit h 
M S B 0 0 1 1 3 5 9 C .
U p o n t he sec o n d occ urre nce of t he sa me Gra de [ADDRESS_838527] (e xce pt f or fati g ue 
a n d h or m o ne i ns ufficie ncies t hat ca n be ma na ge d b y  r e place me nt t hera p y ), c o nti n uati o n of 
treat me nt wit h M S B 0 0 1 1 3 5 9 C has t o be disc usse d wit h t he Me dical M o nit or a n d mi g ht be 
per ma ne ntl y disc o nti n ue d .
I n f usi o n -relate d reacti o ns a n d h y perse nsiti vit y  r eacti o ns ( Gra des 1 t o 4) s h o ul d be ha n dle d 
acc or di n g t o t he g ui deli nes pr o vi de d i n Secti o ns 6. 5. 4. 1 a n d  6. 5. 4. 2 , res pecti vel y .
A ne mia s h o ul d be ha n dle d acc or di n g t o t he g ui deli nes pr o vi de d i n Secti o n  6. 5. 4. 4 .
If i m m u ne- relate d A D R, see  Ta ble 7. 
5. 1. 8 A n al ysis C ut o ff D ates 
After t he e n d of t he d ose -escalati o n part of t he trial, a f ull a nal y sis f or safet y  a n d P K / 
data will be perf or me d . T he data c ut off date will be [ADDRESS_838528] of t he escalati o n 
part has recei ve d his / her first a d mi nistrati o n of M S B [ADDRESS_838529] d ose .
F or t he N S C L C a nti -P D -1/ a nti -P D -L [ADDRESS_838530] i n t he c o h ort starte d treat me nt. 
F or t he mela n o ma a nti -P D - 1 / a nti -P D -L [ADDRESS_838531] i n t hat c o h ort starte d treat me nt ( [ADDRESS_838532] f or t he H C C c o h ort). 
Fi nal data c ut off will be after s u bjects are eit her e nr olle d i nt o a r oll -o ver trial or wit h dra w n after 
c o m plet i n g at least t he Safet y  F oll o w -u p visit at 1 0 Wee ks (± 2 wee ks) after Last Tr eat me nt (see 
Ta ble 1) . 
.
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838533] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 7 / 1 9 3 5. 2 Disc ussi o n of Tri al Desi g n 
T his is a P hase I, o pe n -la bel, d ose -escalati o n trial wit h pla n ne d e x pa nsi o n c o h orts . A n o pe n -la bel, 
u n bli n de d desi g n is a p pr o priate f or a d ose -escalati o n trial wit h c o nsec uti ve e x pa nsi o n c o h orts i n 
a d va nce d ca ncer s u bjects si nce s u bjects ha ve e x ha uste d treat me nt o pti o ns .
I n  t his trial, t he assess me nt of t he safet y  a n d t olera bilit y  of t he IM P wit h t he deter mi nati o n of t he 
M T D (i n t he d ose -escalati o n part o nl y ) is set t o be t he pri mar y  o bjecti ve. T he deter mi nati o n of 
t he M T D is o ne of t he first maj or ste ps i n t he de vel o p me nt of a c o m p o u n d e nteri n g earl y  c li nical 
de vel o p me nt beca use it mi g ht be deter mi ne d t hat t he hi g hest t olera ble d ose is i m p orta nt i n f ut ure 
cli nical de vel o p me nt i n or der t o ac hie ve t he best efficac y  t o ris k rati o f or s u bjects. T he M T D will 
be deter mi ne d usi n g a sta n dar d “ 3 + 3 s u bjects” d ose -escalati o n desi g n base d o n D L T as sess me nts, 
w hic h is c o m m o nl y  u se d i n first -i n -ma n o nc ol o g y trials (Cr o wle y  2 0 0 6 ). T he ai m of t his desi g n 
is t o ma xi mize t he pr otecti o n t o s u bjects a n d re d uce t he c ha nces of m ore s u bjects t o be e x p ose d t o 
p ossi ble dr u g t o xicities . All t hese assess me nts will be c orrelate d t o P K / para meters t o 
p ote ntiall y  ai d selecti o n of t he m ost mea ni n gf ul d ose f or t he e x pa nsi o n c o h ort sor f ut ure st u dies .
T he e nric h me nt of d ose -escalati o n c o h orts bel o w t he M T D are reas o na bl e f or i m m u n ot hera pe utic 
a ntica ncer c o m p o u n ds ( w hic h is i n c o ntrast t o m ost c he m ot hera pi[INVESTIGATOR_014], t hat are t y pi[INVESTIGATOR_1306] y gi ve n at t he 
M T D), as t he o pti mal bi ol o gical effects mi g ht n ot be e xcl usi vel y  o bser ve d at t he M T D le vel 
(T o pali a n 2 0 1 2 b) a n d si nce it ma y  f acilitate c haracterizati o n of t he P K a n d P K /
pr ofiles.  T he i ncl usi o n of l o w -d ose i ntras u bject escalati o n c o h orts is reas o na ble si nce it facilitates 
c haracterizati o n of t he P K pr ofile a n d acc o u nts f or escalat i o n t o a mea ni n gf ul d ose le vel .
A reas o na bl y safe starti n g d ose of 1m g / k g has bee n c h ose n ta ki n g als o i nt o acc o u nt t he 
i nf or mati o n fr o m t he cli nical e x perie nce wit h t he pare nt m o n ocl o nal a nti b o d y , a vel u ma b , a n d t he 
pre dicte d lac k of o verla p pi n g i m m u ne -relate d sa fet y  p r ofile wit h T G F βi n hi biti o n, as pre vi o usl y  
disc usse d . I nitial d ose setti n g f oll o ws t he pri nci ple t hat t he start i n g d ose s h o ul d be 
p har mac ol o gicall y  acti ve b ut als o reas o na bl y safe t o use. T his i nitial d ose esti mati o n al g orit h m is 
pr o p ose d i n G ui del i ne I C H S 9 (E M E A/ C H M P/I C H/ 6 4 6 1 0 7/ 2 0 0 8 )a n d a p plica ble f or a n e n d- sta ge 
ca ncer p o p ulati o n. I n  t he c urre nt st u d y , t he 1m g/ k g starti n g d ose is pr ojecte d t o ha ve 
a p pr o xi matel y  2 0 % of f ull a ntit u m or acti vit y  a n d t heref ore ac hie ves a n a p pr o priate bala nce of 
p ote ntial f or t hera pe utic acti vit y  a s well as reas o na ble fracti o n of bi ol o gic acti vit y , w hic h mi g ht 
ha ve safet y i m plicati o ns.  I n a d diti o n, precli nical e vi de nce di d n ot s u g gest i m m u ne -relate d 
t o xicities. 
I n a d diti o n t o deter mi ni n g t he M T D, t he trial will ser ve t o e x pl ore bi ol o gic a n d cli nical para meters 
after e x p os ure t o M S B [ADDRESS_838534] c urre nt scie ntific k n o wle d ge. 
T he tar get p o p ulati o n f or t he d ose -escalati o n part c o m prises s u bjects wit h metastatic or l ocall y  
a d va nce d s oli d t u m ors w h o ha ve e x ha uste d sta n dar d treat me nt o pti o ns . Base d o n t he cli nical 
literat ure, N S C L C has s o me res p o nsi ve ness t o t he a nti -P D - 1 / P D -L 1  c lass (Getti n ger 2 0 1 4 ) a n d 
t o a vel u ma b (refer t o c urre nt a vel u ma b I B) a n d is t heref ore j ustifie d here f or b ot h t he a nti -P D -1 / 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838535] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 8 / [ADDRESS_838536] -plati n u m d o u blet pr o gressi o n 
a n d, as a p pr o priate, dri ver m utati o n t hera p y.  I n  o r der t o o btai n a tre n d of bi ol o gical / cli nical 
acti vit y , t o assess tar get e n ga ge me nt base d o n t u m or bi o ps y  s a m ples a n d t o c ollect f urt her safet y 
data, a treat me nt e x pa nsi o n at a mea ni n gf ul d ose le vel t o be i de ntifie d d uri n g t he d ose -escalati o n 
part t o e ns ure f urt her de vel o p me nt i n selecte d setti n gs is j ustifie d. F urt her m ore, t he re q uire me nt 
of baseli ne a n d o n- treat me nt t u m or bi o psies i n t he e x pa nsi o n p hase is j ustifie d si nce t he bi ol o gic 
g oal is t o assess tar get e n ga ge me nt t o ai d f ut ure de vel o p me nt.  Data fr o m t he e x pa nsi o n c o h ort s
will all o w e x pl orati o n of w h et her t he e x pressi o n of t u m or or peri p heral P D -L 1 pat h wa y 
bi o mar kers or T G F βpat h wa y  bi o mar kers are ass ociate d wit h cli nical res p o nse t o M S B 0 0 1 1 3 5 9 C 
a n d w het her P D -L 1 e x pressi o n or mar kers relate d t o T G F mi g ht ser ve as mar kers f or patie nt 
selecti o n i n t he f ut ure de vel o p me nt pr o gra m of M S B [ADDRESS_838537]’s r o uti ne me dical 
care, t he I n vesti gat or will e ns ure t hat t he s u bject has pr o vi de d writte n i nf or me d c o nse nt f oll o wi n g 
t he pr oce d ure descri be d i n Secti o n  9. 2. 
5. 3. [ADDRESS_838538] y wit h all pr oce d ures 
2. Male or fe male s u bjects a ge d ≥ [ADDRESS_838539] ol o gicall y or c yt ol o gicall y  pr o ve n metastatic or l ocall y a d va nce d s oli d t u m ors, f or w hic h 
n o effecti ve sta n dar d t hera p y  e xists or sta n dar d t hera p y has faile d 
4. Life e x pecta nc y  ≥ [ADDRESS_838540] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838541] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 9 / 1 9 3 7. A de q uate he mat ol o gical f u ncti o n defi ne d b y  w hite bl o o d cell ( W B C) c o u nt ≥ 3 × 1 0 9/ L  wit h 
a bs ol ute ne utr o p hil c o u nt ( A N C) ≥ 1. 5 × 1 0 9/ L , l y m p h oc y te c o u nt ≥ 0. 5 × 1 0 9/ L , platelet c o u nt 
≥ 1 2 0 × 1 0 9/ L , a n d H g b ≥9 g/ d L 
8. A de q uate he patic f u ncti o n defi ne d b y  a t otal bilir u bi n le vel ≤ 1. 5 × U L N, a n A S T 
le vel ≤ 2. 5 × U L N, a n d a n A L T le vel ≤ 2. 5 × U L N .F or s u bjects wit h li ver i n v ol ve me nt i n 
t heir t u m or , A S T ≤ 5. 0 × U L N, A L T ≤ 5. 0 × U L N, a n d bilir u bi n ≤ 3. 0 ×U L N is acce pta ble 
9. A de q uate re nal f u ncti o n defi ne d b y a n esti mate d creati ni ne cleara nce > 5 0 m L / mi n acc or di n g 
t o t he C oc kcr oft -Ga ult f or m ula or b y  m eas ure of creati ni ne cleara nc e fr o m 2 4- h o ur uri ne 
c ollecti o n 
1 0. Hi g hl y effecti ve c o ntrace pti o n (t hat i s, met h o ds wit h a fail ure rate of less t ha n 1 % per ye ar) 
f or b ot h male a n d fe male s u bjects if t he ris k of c o nce pti o n e xists ( N ote: T he effects of t he 
trial treat me nt o n t he de vel o pi n g h u ma n fet us are u n k n o w n; t h us, w o me n of c hil d beari n g 
p ote ntial a n d me n m ust a gree t o use hi g hl y effecti ve c o ntrace pti o n, defi ne d i n  A p pe n di x 2or 
as sti p ulate d i n nati o nal or l ocal g ui deli nes ). Hi g hl y effecti ve c o ntrace pti o n m ust be use d 
[ADDRESS_838542] is < 2 0 ye ars, t he writte n 
i nf or me d c o nse nt fr o m his/ her pare nt or g uar dia n will be re q uire d i n a d diti o n t o t he s u bject ’s 
writte n c o nse nt 
2. Male or fe male s u bjects a ge d ≥ 1 8 y ears 
3. A vaila bilit y  of fres h t u m or bi o psies (e xcl u di n g b o ne bi o psies) is ma n dat or y  f or eli gi bilit y  i n 
t he N S C L C bi o mar ker e x pa nsi o n , N S C L C a nti -P D -1/ P D -L 1  f ail ure a n d mela n o ma 
a nti -P D -1/ P D -L 1 fail ure c o h ort s ( it is prefera ble t o n ot bi o ps y  a  t ar get lesi o n; h o we ver, if o nl y 
o ne lesi o n is a me na ble f or bi o ps y  a n d it is t he o nl y  t ar get lesi o n, t he M e dical M o nit or s h o ul d 
be c o ns ulte d f or s u bject eli gi bilit y ).  T he bi o ps y  o r s ur gical s peci me n m ust ha ve bee n 
c ollecte d wit hi n [ADDRESS_838543] I M P a d mi nistrati o n.  F or ot her e x pa nsi o n c o h ort s, 
availa bilit y  of eit her t u m or arc hi val material or fres h bi o psies wit hi n 2 8 d a y s is acce pta ble 
(e xcl u di n g b o ne bi o psies) wit h o ne of t hese bei n g ma n dat or y  ( where p ossi ble fres h bi o psies 
are preferre d ). If n o arc hi val material is a vaila ble a n d o nl y o ne l esi o n is a me na ble f or bi o ps y 
a n d it is t he o nl y t ar get lesi o n, t he Me dical M o nit or s h o ul d be c o ns ulte d f or s u bject eli gi bilit y .
T u m or bi o psies a n d t u m or arc hi val material m ust be s uita ble f or bi o mar ker assess me nt as 
descri be d i n t he La b orat or y  fl o wc hart 
4. Life e x pecta nc y  ≥ [ADDRESS_838544] ha ve o ne of t he f oll o wi n g:  
N S C L C bi o m ar ker c o h ort:   Su bjects m ust ha ve hist ol o gicall y  o r c y t ol o gicall y  c o nfir me d 
Sta ge III b or I V N S C L C wit h rela pse d, refract or y  o r pr o gressi ve disease o n or after a si n gle 
li ne of plati n u m -base d c he m ot hera p y.  I n a d diti o n, s u bjects s h o ul d ha ve e x ha uste d ot her 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838545] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 0 / 1 9 3 i n dicate d treat me nt o pti o ns s uc h as dri ver m utati o n t hera p y .  P re vi o us treat me nt wit h 
c o m bi nati o n i m m u n ot hera p y is pr o hi bite d.   S u bjects wi t h n o n-s q ua m o us cell N S C L C of 
u n k n o w n m utati o nal stat us will re q uire testi n g (l ocal la b orat or y , or ce ntral la b orat or y  i f 
l ocal testi n g is n ot a vaila ble). T h ose s u bjects wit h e pi [INVESTIGATOR_171633] o wt h fact or rece pt or 
( E G F R) m utati o n a n d / or ana plastic l y m p h o ma ki n ase ( A L K) tra nsl ocati o n m ust ha ve 
recei ve d pri or t y r osi ne ki nase i n hi bit or t hera p y  a n d t h ose wit h R O S [ADDRESS_838546] 
ha ve recei ve d pri or t y r osi ne ki nase i n hi bit or t hera p y  i f l ocall y a p pr o ve d.  P ri or plati n u m -
base d c he m ot hera p y is n ot re q uire d i n t hese s u bjects .  S u bjects wit h lar ge cell 
ne ur oe n d ocri ne ca ncer of t he l u n g are n ot eli g i ble f or t his c o h ort.  
E nr oll me nt will a d diti o nall y  be as f oll o ws: 
a. Su bjects w h o are naï ve t o t he a nti -P D - 1 / a nti -P D -L 1  c lass – [ADDRESS_838547] or y, or pr o gressi ve disease f oll o wi n g a n a nti -P D - 1 
or a nti -P D -L 1 a ge nt –1 5 s u bjects wit h paire d bi o psies   
H C C, sec o n d li ne or s or afe ni b i nt oler a nt :  Hist ol o gicall y  c o nfir me d H C C.  M ust be 
unresecta ble or a d va nce d disease n ot a me na ble t o c urati ve resecti o n.  M ust ha ve ha d 
pr o gressi o n f oll o wi n g 1 li ne of pri or s orafe ni b t hera p y  ( m ust ha ve recei ve d at least [ADDRESS_838548] 4 0 0 m g per da y ) or pre vi o usl y  c o nsi dere d t o be s orafe ni b i nt olera nt   
T he H C C c o h ort will be c o m p os e d of 2 p orti o ns, a n asce n di n g -d ose p orti o n a n d a n 
e x pa nsi o n p orti o n: 
F or t he asce n di n g - d ose p orti o n: 
1) 3 m g/ k g d ose c o h ort , u p t o N = 6 
2) 1 2 0 0 m g flat - d ose c o h ort , u p t o N = 3 0 
F or asce n di n g - d ose p orti o n a n d d ose -e x p a nsi o n p orti o n: 
U ni nfecte d, H C V, a n d H B V -i nfecte d s u bjects are eli gi ble .If me dicall y i n dicate d, su bjects 
i nfecte d wit h H B V m ust be treate d a n d o n a sta ble d ose of a nti virals (e g, e nteca vir , 
te n of o vir , or la mi v u di ne ;a def o vir or i nterfer o n are n ot all o we d) at st u d y  e ntr y  a n d wit h 
pla n ne d m o nit ori n g a n d ma na ge me nt acc or di n g t o a p pr o priate la beli n g g ui da nce.  S u bjects 
o n acti ve H C V t hera p y at st u d y  e ntr y  m ust be o n a sta ble d ose wit h o ut d oc u me nte d 
cli nicall y  s i g nifica nt li ver f u ncti o n test or he mat ol o gic a b n or malities ( m ust meet criteria 
bel o w) a n d wit h pla n ne d m o nit ori n g a n d ma na ge me nt acc or di n g t o a p pr o priate la beli n g 
g ui da nce .  
A d diti o nal criteria f or all H C C, sec o n d -li ne c o h ort s u bjects i ncl u de: 
oC hil d -P u g h A or B 7 
oE C O G 0 or 1 
oAl b u mi n ≥2. 8 g/ d L 
oInter nati o nal n or malize d rati o (I N R) < 1. [ADDRESS_838549] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838550] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 1 / 1 9 3 oA de q uate he mat ol o gical f u ncti o n defi ne d b y  W B C c o u nt ≥ 2. 5 × 1 0 9/ L wit h 
A N C ≥ 1. 5 × 1 0 9/ L , l y m p h oc y te c o u nt ≥ 0. 5 × 1 0 9/ L , platelet c o u nt ≥ 5 0 × 1 0 9/ L , a n d 
he m o gl o bi n ≥ 9 g/ d L 
oS u bjects wit h n o aller gies t o c o ntras ta n d a ble t o t olerate c o m p ute d t o m o gra p h y ( C T) or 
ma g netic res o na nce i ma gi n g ( M RI) c o ntrast i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or 
N S C L C, sec o n d li ne:   Hist ol o gicall y  c o nfir me d Sta ge III b/I V or rec urre nt N S C L C.  M ust 
n ot ha ve recei ve d c hec k p oi nt i n hi bit or pre vi o usl y  ( c o ns ult wit h Me dical M o nit or if 
necessar y ).  M ust ha ve e x perie n ce d disease pr o gressi o n after a n acce pta ble t hera p y  d efi ne d 
as f oll o ws: 
oS u bjects m ust ha ve pr o gresse d d uri n g or after a mi ni m u m of [ADDRESS_838551] or y  o f c o nti n uati o n ( use of a n o n- plati n u m a ge nt fr o m i nitial c o m bi nati o n) or s witc h 
( use of a differe nt a ge nt) mai nte na nce t hera p y is per mitte d pr o vi de d t here was n o 
pr o gressi o n after t he i nitial c o m bi nati o n.  A s witc h of a ge nts d uri n g treat me nt f or t he 
ma na ge me nt of t o xicities is als o per mitte d pr o vi de d t here was n o pr o gressi o n after t he 
i nitial c o m bi nati o n 
O R 
oS u bjects m ust ha ve pr o gresse d wit hi n 6 m o nt hs of c o m pleti o n of a plati n u m - b ase d 
a dj u va nt, ne oa dj u va nt, or defi niti ve c he m ot hera p y , or c o nc o mita nt c he m ora diati o n 
re gi me n f or l ocall y  a d va nce d disease 
S u bjects wit h n o n -s q ua m o us cell N S C L C of u n k n o w n m utati o nal stat us will re q uire testi n g 
(l ocal la b orat or y, or ce ntral la b orat or y if l ocal testi n g is n ot a vaila ble). S u bjects wit h k n o w n 
E G F R m utati o n a n d / or A L K tra nsl ocati o n are eli gi ble if t he y  h a ve recei ve d at least [ADDRESS_838552] ha ve recei ve d 
t y r osi ne ki nase i n hi bit or t hera p y if l ocall y a p pr o ve d.  T hese s u bjects d o n ot re q uire pri or 
treat me nt wit h s y ste mic c he m ot hera p y.  S u bjects wit h lar ge cell ne ur oe n d ocri ne ca ncer of 
t he l u n g are n ot eli g i ble 
N S C L C, a nti -P D -1/ a nti -P D -L 1 f ail ure: S u bjects wit h hist ol o gicall y  c o nfir me d Sta ge 
I V ( metastatic) or rec urre nt N S C L C ( per 7t h I nter nati o nal Ass ociati o n f or t he St u d y  o f 
L u n g Ca ncer classificati o n) w h o ha ve e x ha uste d sta n dar d treat me nt o pti o ns i n t h e o pi [INVESTIGATOR_9384] o n 
of t he In vesti gat or are t o be e nr olle d. At a mi ni m u m, s u bjects nee d t o ha ve recei ve d a n d 
faile d plati n u m -base d c he m ot hera p y a n d m ust ha ve recei ve d a nti -P D - 1 or a nti -P D -L 1  a s 
m o n ot hera p y a n d faile d wit h disease pr o gressi o n.  I n a d diti o n, s u bjects s h o ul d ha ve 
e x ha uste d ot her i n dicate d dri ver m utati o n t hera p y, as a p pr o priate   
Mel a n o m a, a nti -P D - 1 / a nti -P D -L 1 f ail ure:   S u bjects wit h unresecta ble Sta ge III or 
metastatic ( Sta ge I V ) mela n o ma w h o ha ve e x ha uste d sta n dar d treat me nt o pti o ns i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or are t o be e nr olle d. At a mi ni m u m, s u bjects nee d t o ha ve 
recei ve d a nti -P D - [ADDRESS_838553] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838554] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 2 / 1 9 3 P a ncre atic a de n oc arci n o m a, sec o n d li ne or gre ater:  Hist ol o gicall y  c o nfir me d 
pa ncreatic a de n ocarci n o ma (s u bjects wit h e n d ocri ne or aci nar pa ncreatic carci n o ma are n ot 
eli gi ble).  M ust ha ve u nresecta ble or l ocall y a d va nce d or metastatic disease 
oPri or t hera p y wit h ≥ 1 s y ste mic c he m ot hera p y re gi me n f or u nresecta ble or metastatic 
pa ncreatic ca ncer or u n willi n g / u na ble t o recei ve s y ste mic c he m ot hera p y .  S u bjects 
m ust n ot ha ve recei ve d pre vi o us ra di ot hera p y f or meas ura ble lesi o n s
oDisease pr o gressi o n w hile recei vi n g or after disc o nti n ui n g palliati ve c he m ot hera p y
C ol orect al c a ncer ( C R C), t hir d li ne or gre ater :  Hist ol o gicall y  c o nfir me d 
a de n ocarci n o ma of t he c ol o n or rect u m 
oS u bjects m ust ha ve pr o gresse d d uri n g or after a sec o n d- li ne of s ys te mic treat me nt 
oPri or faile d t hera p y  m ust ha ve i ncl u de d at least a fl u or o p yr i mi di ne, o xali plati n, 
iri n oteca n (si n gle or i n c o m bi nati o n) a n d be vaciz u ma b ( w here a p pr o ve d).  F or s u bjects 
w h o ha d wil d -t y pe R A S t u m ors, cet u xi ma b or pa nit u m u ma b treat me nt m ust ha ve 
occ urre d 
Tri ple -ne g ati ve bre ast c a ncer ( T N B C), sec o n d li ne or gre ater :  T u m or m ust be 
c o nfir me d ne gati ve f or estr o ge n rece pt ors, pr o gester o ne rece pt ors, a n d H E R 2 defi ne d as 
f oll o ws: 
oE R n e gati ve defi ne d b y:   E R I H C< 1 % reacti ve cells 
oP R ne gati ve defi ne d b y:  P R I H C < 1 % reacti ve cells 
oH E R -2 ne gati ve defi ne d b y  o ne of f o ur sit uati o ns bel o w: 
1. H E R [ADDRESS_838555] I H C = [ADDRESS_838556] I H C = 1 + 
3. H E R [ADDRESS_838557] I H C = 2 + A N D fl u oresce nce i n sit u h y bri dizati o n (FI S H )- ne gati ve 
( n o n -a m plifie d) 
4. FI S H n o n -a m plifie d 
oS u bjects m ust ha ve pr o gresse d d uri n g or after first li ne of c he m ot hera p y 
O v ari a n c a ncer, pl ati n u m resist a nt or refr act or y, pre vi o usl y s yste mic all y tre ate d :  
Hist ol o gicall y c o nfir me d e pit helial o varia n, fa ll o pia n t u be, or perit o neal ca ncer (s u bjects 
wit h n o n- e pit helial t u m or, i ncl u di n g mali g na nt mi xe d M ülleria n t u m ors wit h o ut hi g h gra de 
ser o us c o m p o ne nt, or o varia n t u m or s wit h l o w mali g na nt p ote ntial [ ie, b or derli ne t u m ors ] 
are n ot eli gi ble)   
oM ust n ot be a ca n di date f or s ur gical resecti o n wit h c urati ve i nte nt 
oM ust ha ve plati n u m res ista nt /ref ract or y disease, defi ne d as disease pr o gressi o n wit hi n 
[ADDRESS_838558] a d mi nistere d d ose of plati n u m t hera p y (resista nt), or lac k of 
res p o nse or disease pr o gressi o n w hile rec ei vi n g t he m ost rece nt plati n u m -base d t hera p y 
(refract or y ), or pr o gressi o n o n / after last n o n -plati n u m - base d c he m ot hera p y 
oTreat me nt hist or y  o f at least [ADDRESS_838559] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838560] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 3 / [ADDRESS_838561] be re p orte d if k n o w n 
Es o p h a ge al a de n oc arci n o m a, p ost -pl ati n u m, sec o n d li ne or gre ater:  Hist ol o gicall y 
c o nfir me d rec urre nt or metastatic es o p ha geal a de n ocarci n o ma .  M ust ha ve unresecta ble 
( Sta ge III or I V) disease 
oM ust ha ve recei ve d at lea st o n e pre vi o us plati n u m -c o ntai ni n g c he m ot hera p y  r e gi me n.  
S u bjects wit h H E R 2- p os iti ve t u m ors m ust ha ve recei ve d pri or trast uz u ma b 
Gli o bl ast o m a, post -te m oz ol o mi de / r a di ati o n, sec o n d li ne:  Hist ol o gicall y  c o nfir me d 
Gra de I V mali g na nt gli o ma (s u bjects wit h e x tracra nial metastatic or le pt o me ni n geal are 
n ot eli gi ble)  
oPre vi o us treat me nt wit h ra di ot hera p y a n d te m oz ol o mi de 
oT olera nce t o ga d oli ni u m 
oA n i nter val of at least [ADDRESS_838562] o ma 
oKar n ofs k y Perf or ma nce Stat us ( K P S) ≥ [ADDRESS_838563] or or a ntia n gi o ge nic treat me nts 
S q u a m o us cell carci n o m a he a d a n d nec k ( S C C H N), sec o n d li ne or gre ater:   
Hist ol o gicall y c o nfir me d rec urre nt or metastatic S C C H N ( oral ca vit y, p har y n x, lar y n x), 
Sta ge III/I V a n d n ot a me na ble t o l ocal t hera p y  w it h c urati ve i nte nt (s ur ger y or ra diati o n 
t hera p y wit h or wit h o ut c he m ot hera p y) 
oT u m or pr o gressi o n or rec urre nce wit hi n [ADDRESS_838564] d ose of plati n u m t hera p y i n t he 
a dj u va nt (ie wit h ra diati o n after s ur ger y ), pri mar y  ( ie, wit h ra diati o n), rec urre nt, or 
metastatic setti n g. 
oS u bjects ma y  ha ve recei ve d pri or cet u xi ma b 
oH P V t u m or testi n g m ust be re p orte d if k n o w n 
Cer vic al c a ncer, sec o n d li ne or gre ater :  Hist ol o gicall y  c o nfir me d rec urre nt or persiste nt 
s q ua m o us cell carci n o ma, a de n o s q ua m o us carci n o ma, or a de n ocarci n o ma of t he cer vi x 
f oll o wi n g sta n dar d of care treat me nt wit h s yste mic t hera p y f or a d va nce d disease (t y pi[INVESTIGATOR_1306] y 
d o u blet c y t ot o xic c he m ot hera p ya n d be vaciz u ma b , w here a p pr o ve d )  
oH P V t u m or testi n g m ust be re p orte d if k n o w n 
6. E C O G perf or ma nce stat us of [ADDRESS_838565] 1u ni di me nsi o nal l y meas ura ble lesi o n b y  
R E CI S T 1. 1. 
8. A de q uate he mat ol o gical f u ncti o n defi ne d b y  w hite bl o o d cell ( W B C) c o u nt ≥ 3 × 1 0 9/ L  wit h 
A N C ≥ 1. 5 × 1 0 9/ L , l y m p h oc y te c o u nt ≥ 0. 5 × 1 0 9/ L , platelet c o u nt ≥ 1 2 0 × 1 0 9/ L , a n d 
H g b ≥ 9 g/ d L 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838566] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 4 / 1 9 3 9. A de q uate he patic f u ncti o n defi ne d b y  a t otal bilir u bi n le vel ≤ 1. 5 × t he U L N , a n A S T 
le vel ≤ 2. 5 × U L N, a n d a n A L Tle vel ≤ 2. 5 × U L N .  F or s u bjects wit h li ver i n v ol ve me nt i n 
t heir t u m or , A S T ≤ 5. 0 × U L N, A L T ≤ 5. 0 × U L N, a n d bilir u bi n ≤ 3. 0 is acce pta ble 
1 0. A de q uate re nal f u ncti o n defi ne d b y a n esti mate d creati ni ne cleara nce > 5 0 m L / mi n acc or di n g 
t o t he C oc kcr oft -Ga ult f or m ula or b y  m eas ure of creati ni ne cleara nc e fr o m 2 4- h o ur uri ne 
c ol lecti o n 
1 1. Hi g hl y effecti ve c o ntrace pti o n (t hat is, met h o ds wit h a fail ure rate of less t ha n 1 % per ye ar) 
f or b ot h male a n d fe male s u bjects if t he ris k of c o nce pti o n e xists ( N ote: T he effects of t he 
trial treat me nt o n t he de vel o pi n g h u ma n fet us are u n k n o w n; t h us, w o me n of c hil d beari n g 
p ote ntial a n d me n m ust a gree t o use hi g hl y effecti ve c o ntrace pti o n, defi ne d i n  A p pe n di x 2or 
as sti p ulate d i n nati o nal or l ocal g ui deli nes ). Hi g hl y effe cti ve c o ntrace pti o n m ust be use d 
[ADDRESS_838567] 
s he is pre g na nt w hile s he or her part ner is partici pati n g i n t his trial, t he treati n g p h y sicia n 
s h o ul d be i nf or me d i m me diatel y. 
5. 3. 2 E xcl usi o n Criteri a ( A p plic a ble t o All Su bjects, Incl u di n g All 
E x p a nsi o n C o h orts) 
S u bjects are n ot eli gi ble f or t his trial if t he y  f ulfill a n y  of t he f oll o wi n g e xcl usi o n criteria: 
1. C o nc urre nt treat me nt wit h n o n -per mitte d dr u gs a n d ot her i nter ve nti o ns (see Secti o n  6. 5. 2 a n d 
Secti o n  6. 5. 3 , res pecti vel y ). 
2. E xce pt f or t he a nti -P D - 1 / a nti -P D -L 1 -e x perie nce d N S C L C e x pa nsi o n a n d mela n o ma 
e x pa nsi o n c o h orts , p ri or t hera p y wit h a n y a nti b o d y /dr u g tar geti n g T-cell c o re g ulat or y  p r otei ns 
(i m m u ne c hec k p oi nts) s uc h as a nti -P D - 1, a nti -P D -L 1 , or a nti -C T L A -4 a nti b o d y (c o ns ult 
Me dical Mo nit or if necessar y )is n ot all o we d (c o ns ult wit h Me dical M o nit or as nee de d) , 
i ncl usi ve of i ntra he patic, l ocalize d a d mi nistrati o n of s uc h a ge nts 
3. A ntica ncer treat me nt wit hi n 2 8 da y s bef ore t he start of trial treat me nt, f or e xa m ple ,
cyt ore d ucti ve t hera p y , ra di ot hera p y ( wit h t he e xce pti o n of palliati ve ra di ot hera p ydeli vere d i n 
an or mal or ga n -s pari n g tec h ni q ue ), i m m u ne t hera p y , or c y t o ki ne t hera p y( wit h t he e xce pti o n 
of s orafe ni b f or s u bjects wit h H C C, w hic h m ust ha ve bee n st o p pe d wit hi n 1 4 da ys) 
4. M aj or s ur ger y  w it hi n 2 8 d a y s bef ore t he start of trial tre at me nt (pri or dia g n ostic bi o ps y  i s 
per mitte d )
5. S y ste mic t hera p y  w it h i m m u n os u p pressi ve a ge nts wit hi n 7 d a y s bef ore t he start of trial 
treat me nt; or use of a n y i n vesti gati o nal dr u g wit hi n 2 8 da y s bef ore t he start of trial treat me nt 
(N ote:   f or s u bjects wit h gli o blast o ma, ster oi d use is all o we d acc or di n g t o sta n dar d of care a n d 
l ocal g ui deli nes )
6. Pre vi o us mali g na nt disease ( ot her t ha n t he tar get mali g na nc y  t o be i n vesti gate d i n t his trial) 
wit hi n t he last [ADDRESS_838568] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838569] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 5 / 1 9 3 wit h c urati ve i nte nt are N O T e xcl u de d .  S u bjects wit h ot her l ocalize d mali g na ncies treate d 
wit h c urati ve i nte nt nee d t o be disc usse d wit h t he Me dical M o nit or 
7. Ra pi [INVESTIGATOR_2478] y  p r o gressi ve disease w hic h, i n t he o pi [INVESTIGATOR_9384] o n of t he In vesti gat or, ma y  p re dis p ose t o 
i na bilit y  t o t olerate treat me nt or trial pr oce d ures 
8. S u bjects wit h acti ve ce ntral ner v o us s y ste m ( C N S) metastases ca usi n g cli nical s y m pt o ms or 
metastases t hat re q uire t hera pe utic i nter ve nti o n are e xcl u de d.  S u bjects wit h a hist or y  o f treate d 
C N S metastases ( b y s ur ger y  o r ra diati o n t hera p y ) are n ot eli gi ble u nless t he y  h a ve f ull y 
rec o vere d fr o m treat me nt, de m o nstrate d n o pr o gressi o n f or at least 2 m o nt hs, a n d d o n ot 
re q uire c o nti n ue d ster oi d t hera p y.  S u bjects wit h C N S metastases i nci de ntall y  detecte d d uri n g 
Scree ni n g w hic h d o n ot ca use cli nical s y m pt o ms a n d f or w hic h sta n dar d of care s u g gests n o 
t hera pe utic i nter ve nti o n is i n dicate d s h o ul d be dis c usse d wit h t he Sp o ns or Me dical 
Res p o nsi ble 
9. Recei pt of a n y or ga n tra ns pla ntati o n ,i ncl u di n g all o ge neic ste m -cell tra ns pla ntati o n , b ut wit h 
t he e xce pti o n of tra ns pla nts t hat d o n ot re q uire i m m u n os u p pressi o n (e g, c or neal tra ns pla nt, 
hair tra ns pla nt) 
1 0. Si g nifi ca nt ac ute or c hr o nic i nfecti o ns i ncl u di n g, a m o n g ot hers: 
K n o w n hist or y  of testi n g p ositi ve test f or h u ma n i m m u n o deficie nc y  vir us ( HI V) or k n o w n 
ac q uire d i m m u n o deficie nc y  s y n dr o me 
E xce pt f or t he H C C c o h ort, H B V or H C V i nfecti o n (H B V s urface a nti ge n p ositi ve a n d H B V 
c ore a nti b o d y  p ositi ve wit h refle x t o p ositi ve H B V D N A or H B V c ore a nti b o d y  p ositi ve 
al o ne wit h refle x t o p ositi ve H B V D N A or p ositi ve H C V a nti b o d y  w it h refle x t o p ositi ve 
H C V R N A )
S u bjects wit h acti ve t u berc ul osis ( hist or y  o f e x p os ure or hist or y  o f p ositi ve t u berc ul osis test; 
pl us ,prese nce of cli nical s y m pt o ms, p h y sical or ra di o gra p hic fi n di n gs) 
1 1. Acti ve a ut oi m m u ne disease t hat mi g ht deteri orate w he n recei vi n g a n i m m u n osti m ulat or y  
a ge nt: 
S u bjects wit h dia betes t y pe I,  v itili g o, al o pecia, ps oriasis, h y p o- or h y pert h y r oi d disease 
n ot re q uiri n g i m m u n os u p pressi ve treat me nt are eli gi ble 
S u bjects re q uiri n g h or m o ne re place me nt wit h c ortic oster oi ds are eli gi ble if t he ster oi ds are 
a d mi nistere d o nl y f or t he p ur p ose of h or m o nal re place me nt a n d at d ose s ≤ 1 0 m g of 
pre d nis o ne or e q ui vale nt per da y 
A d mi nistrati o n of ster oi ds f or ot her c o n diti o ns t hr o u g h a r o ute k n o w n t o res ult i n a mi ni mal 
s y ste mic e x p os ure (t o pi[INVESTIGATOR_2855], i ntra nasal, i ntr o- oc ular, or i n halati o n) is acce pta ble 
1 2. K n o w n se vere h y perse nsiti vit y  r eacti o ns t o m o n ocl o nal a nti b o dies ( Gra de ≥ 3 N CI -C T C A E 
v 4. 0 3) or rece nt, wit hi n [ADDRESS_838570] h ma (ie, [ADDRESS_838571] h ma) 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838572] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 6 / 1 9 3 1 3. Persisti n g t o xicit y  (e xce pt al o pecia a n d vitili g o) rel ate d t o pri or t hera p yGra de >1 
N CI -C T C A E v 4. 0 3 ;h o we ver ,se ns or y  ne ur o pat h y Gra de ≤ [ADDRESS_838573] u g a b use 
1 6. Cli nicall y  s i g nifica nt car di o vasc ular / cere br o vasc ular disease as f oll o ws: cere bra l vasc u lar 
acci de nt /str o ke ( < 6m o nt hs pri or t o e nr oll me nt), m y ocar dial i nfarcti o n ( < 6 m o nt hs pri or t o 
e nr oll me nt), u nsta ble a n gi na, c o n gesti ve heart fail ure ( Ne w Y or k Heart Ass ociati o n 
Classificati o n Class ≥II), or seri o us car diac arr h yt h mia 
1 7. Cli nicall y  r ele va nt diseases (f or e xa m ple, i nfla m mat or y  b o wel disease) a n d / or u nc o ntr olle d 
me dical c o n diti o ns , w hic h, i n t he o pi [INVESTIGATOR_9384] o n of t he In vesti gat or, mi g ht i m pair t he s u bject’s 
t olera nce or a bilit y t o partici pate i n t he trial 
1 8. A n y  p s y c hiatric c o n diti o n t hat w o ul d pr o hi bit t he u n dersta n di n g or re n deri n g of i nf or me d 
c o nse nt 
1 9. Le gal i nca pacit y or li mite d le gal ca pacit y
2 0. Vacci ne a d mi nistrati o n wit hi n 4 wee ks of I M Pa d mi nistrati o n. Vacci nati o n wit h li ve vacci nes 
w hile o n trial is pr o hi bite d. Ad mi nistrati o n of i nacti vate d vacci nes is all o we d (f or e xa m ple, 
i nacti vate d i nfl ue nza vacci nes) 
A d diti o n al e xcl usi o n criteri a f or s u bjects i n t he H C C c o h ort i ncl u de: 
2 1. Cli nical ascites (t hat is, n ot per ra di ol o gical assess me nt o nl y ) wit hi n past 6 m o nt hs n ot 
ade q uatel y c o ntr olle d wit h me dical t hera p y; hist or y  of variceal blee di n g wit hi n past 3 m o nt hs ; 
hist or y  of u nc o ntr olle d he patic e nce p hal o pat h yi n t he past 3 m o nt hs ; or hist or y  o f o bstr ucti ve 
ja u n dice n ot a me na ble t o ste nti n g i n t he past 3 m o nt hs 
2 2. He patitis D vir us ( H D V) c o -i nfecti o n wit h he patitis B vir us ( H B V; if H B V s urface a nti ge n or 
H B V D N A p ositi vit y  at S cree ni n g t he n m ust c hec k f or H D V stat us) 
[ADDRESS_838574] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838575] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 7 / [ADDRESS_838576] a w al Fr o m Tri al Tre at me nt   
S u bjects will be wit h dra w n fr o m trial treat me nt f or a n y of t he f oll o wi n g reas o ns: 
C o nfir me d P D per R E CI S T 1. [ADDRESS_838577] o ma : Su bjects s h o ul d 
c o nti n ue treat me nt b e y o n d t he i nitial deter mi nati o n of P D, t hr o u g h t heir ne xt t u m or assess me nt, 
pr o vi de d: 
a. T here are n o ne w Gra de [ADDRESS_838578] d oes n ot re q uire ne w a ntica ncer t hera p y .
S u bjec ts s h o ul d be disc o nti n ue d fr o m treat me nt t here after if f urt her e vi de nce of P D ; h o we ver ,
c o nti n ue d treat me nt is p ossi ble i n c o ns ultati o n wit h t he Me dical M o nit or 
Occ urre nce of a n e xcl usi o n criteri o n, w hic h is cli nicall y  r ele va nt a n d affects t he s u bject’s 
safet y, if disc o nti n uati o n is c o nsi dere d necessar y  b y  t he I n vesti gat or a n d /or S p o ns or 
T hera pe utic fail ure re q uiri n g ur ge nt a d diti o nal ca ncer t hera p y  
Occ urre nce of Gra de ≥ 3 A D Rs or re petiti ve Gra de 2 A D Rs e xce pt as all o we d as defi ne d i n 
Secti o n  5. 1. 7. 2 
Occ urre nce of A Es, at t he I n vesti gat or’s discreti o n 
Pre g na nc y 
Use of pr o hi bite d c o nc o mita nt dr u g , as defi ne d i n Secti o n 6. 5. 2,  w here t he pre defi ne d 
c o nse q ue nce is wit h dra wal fr o m t he I M P 
N o n -a d here nce / n o n -c o m plia nce t o t he trial pr ot oc ol or trial re q uire me nts ( see Secti o n  6. 9) 
Wit h dra wal of c o nse nt 
Partici pati o n i n a n y  ot her trial .
F or s u bjects w h o miss ≥ [ADDRESS_838579] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838580] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 8 / [ADDRESS_838581] be wit h dra w n i fa n y of t he f oll o wi n g occ ur d uri n g t he trial :
Wit h dra wal of t he s u bjec t’s c o nse nt 
Partici pati o n i n a n y  o t her t hera pe utic trial d uri n g t he tr eat me nt d urati o n of t his trial; h o we ver, 
s u bjects will c o nti n ue t o be f oll o we d f or s ur vi val 
If a s u bject fails t o atte n d sc he d ule d trial assess me nts, t he I n vesti gat or m ust deter mi ne t he reas o ns 
a n d t he circ u msta nces as c o m pletel y  a n d acc uratel y  as p ossi ble. 
I n case of wit h dra wal fr o m t he trial, t he assess me nts sc he d ule d f or t he last visit ( 2 8- Da y  S afet y 
F oll o w -u p visit) s h o ul d be perf or me d (see Secti o n 7. 1. 3 ), if p ossi ble, wit h f oc us o n t he m ost 
rele va nt assess me nts.  I n a n y cas e, t he a p pr o priate 2 8- D a y  S afet y F oll o w -u p electr o nic case re p ort 
f or m (e C R F) visit m ust be c o m plete d. I n case of wit h dra wal, s u bjects will be as ke d t o c o nti n ue 
safet y a n d s ur vi val f oll o w - u p, w hic h i ncl u des t he c ollecti o n of data o n s ur vi val a n d s u bse q ue n t 
a ntica ncer t hera p y. After c o m pleti o n of t he F oll o w -u p peri o d or after t he E n d - of- Treat me nt visit, 
w hate ver is a p plica ble, t he a p pr o priate e C R F secti o n f or Trial Ter mi nati o n m ust be c o m plete d. 
If a s u bject is wit h dra w n pri or t o disease pr o gressi o n f or a n y reas o n i n t he e x pa nsi o n part of t he 
trial , t he s u bject will n ot be re place d. I n t he d ose -escalati o n part , t he o nl y  s u bjects t hat m a y  b e 
re place d are t h ose t hat d o n ot c o m plete t he [ADDRESS_838582] c o m plete d t he Safet y F oll o w - u p at 1 0 Wee ks 
( ± 2wee ks) after Last Treat me nt. 
5. 6 Pre m at ure Ter mi n ati o n of t he Tri al 
T he w h ole trial ma y  be disc o nti n ue d pre mat urel y i n t he e ve nt of a n y of t he f oll o wi n g: 
Ne w i nf or mati o n lea di n g t o u nfa v ora ble ris k - be nefit j u d g me nt of t he I M P , f or e xa m ple, d ue t o 
oe vi de nce of i nefficac y  of t he I M P, 
oocc urre nce of si g nifica nt pre vi o usl y  u n k n o w n a d verse reacti o ns or u ne x pecte dl y  h i g h 
i nte nsit y  or i nci de nce of k n o w n a d verse reacti o ns, or 
oot her u nfa v ora ble safet y fi n di n gs. 
( N ote: Evi de nce of i neffic acy m ay arise fr o m t his tri al or fr o m ot her tri als; u nf av or a ble 
s afety fi n di n gs m ay arise fr o m cli nic a l or n o n -cli nic al ex a mi n ati o ns, f or ex a m ple, 
t oxic ol o gy.) 
S p o ns or’s decisi o n t hat c o nti n uati o n of t he trial is u nj ustifia ble f or me dical or et hical reas o ns 
P o or e nr oll me nt of s u bjects ma ki n g c o m pleti o n of t he trial wit hi n a n acce pta ble ti me fra me 
u nli kel y 
Disc o nti n uati o n of de vel o p me nt of t he S p o ns or’s I M P 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838583] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 9 / 1 9 3 Healt h A ut h orities a n d I n de pe n de nt Et hics C o m mittees (I E Cs) / I n stit uti o nal Re vie w B oar ds 
(I R Bs) will be i nf or me d a b o ut t he disc o nti n uati o n of t he trial i n acc or da nce wit h a p plica ble 
re g ulati o ns. 
T he w h o le trial ma y  be ter mi nate d or s us pe n de d u p o n re q uest of Healt h A ut h orities. 
5. [ADDRESS_838584] t he Safet y 
F oll o w - u p visit at 1 0 Wee ks ( ± 2 wee ks) after Last Treat me nt. 
[ADDRESS_838585] u gs Use d i n 
t he Tri al 
T he ter m “I n vesti gati o nal Me dici nal Pr o d uct” refers t o a n acti ve s u bsta nce or a place b o bei n g 
teste d or use d as a refere nce t hera p yi n a cli nical trial, i ncl u di n g pr o d ucts t hat ha ve a mar keti n g 
a ut h orizati o n b ut are f or m ulate d ,pac ka ge d , or a d mi nistere d differe ntl y  fr o m t he a ut h orize d f or m, 
use d f or a n u na ut h orize d i n dicati o n, or use d t o gai n f urt her i nf or mati o n a b o ut t he a ut h orize d f or m .  
T he o nl y  I M P use d i n t his trial is M S B [ADDRESS_838586] is pr o vi de d as eit her a sterile freeze -drie d or a steril eli q ui d 
f or m ulati o n .
Eac h vial of P o w der f or C o nce ntrate f or S ol u ti o n f or I nf usi o n (freeze -dr ie d f or m ulati o n) is 
pac ka ge d i n U nite d States P har mac o peia ( U S P) a n d E ur o pea n P har mac o peia ( P h E ur) t y pe I gl ass 
vial s.  Eac h vial is fille d wit h 4 5 m g of M S B 0 0 1 1 3 5 9 C ( 4 5 m g/ vial) as preser vati ve -free p o w der 
c o ntai ni n g histi di ne, tre hal ose di h y drate, s o di u m c hl ori de, L-met hi o ni ne a n d p ol ys or bate 2 0 
( T wee n 2 0). T he vials are cl ose d wit h a r u b ber st o p per i n l y o p hilizati o n f or mat c o m pl y i n g wit h 
U S P a n d P h E ur a n d seale d wit h a n al u mi n u m plastic cri m pi n g ca p. O nl y e x ci pie nts t hat c o nf or m 
t o t he c urre nt U S P a n d / or P h E ur are use d f or M S B [ADDRESS_838587]. 
T he C o nce ntrate f or S ol uti o n f or I nf usi o n (li q ui d f or m ulati o n) is pac ka ge d at a 1 0 m g / m L 
c o nce ntrati o n i n U S P / P h E ur t y pe I [ADDRESS_838588] s ol uti o n t o all o w 
a n e xtracta ble v ol u me of 6 0 m L  ( 6 0 0 m g/ 6 0 m L).  T he vials are cl ose d wit h r u b ber st o p pers wit h 
t he sa me c o m p ositi o n as use d f or freeze -drie d f or m ulati o n, b ut i n ser u m f or mat c o m pl yi n g wit h 
U S P a n d P h E ur wit h a n al u mi n u m cri m p seal cl os ure.  
T he li q ui d f or m ulati o n, c o m pare d wit h t he freeze -drie d f or m ulati o n, has t he sa me c o m p ositi o n i n 
ter ms of e xci pie nts, q ualitati vel y  a n d q ua ntitati vel y , e xce pt f or t he a d diti o n of water.  O f n ote, 
t here is n o c ha n ge t o t he dr u g s u bsta nce pr ocess. 
F or a p plicati o ns i n cli nical st u dies, t he freeze -drie d f or m ulati o n m ust be rec o nstit ute d wit h 4. 5 m L  
water f or i njecti o n a n d f urt her dil ute d wit h 0. 9 % sali ne s ol uti o n (s o di u m c hl ori de i njecti o n) 
s u p plie d i n a n i nf usi o n ba g.  T he li q ui d f or m ulati o n is dil ute d dire ctl y  w it h 0. 9 % sali ne s ol uti o n.  
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838589] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 0 / 1 9 3 T he esti mate d v ol u mes of deli ver y  a re a ntici pate d t o be n o m ore t ha n 2 5 0 m L, w hic h are cli nicall y 
acce pta ble.  F or s u bjects re q uiri n g d oses t hat w o ul d e xcee d t he ma x i m u m all o wa ble c o nce ntrati o n 
i n 2 5 0 m L (e g, s u bjects i n t he 3 0 m g/ k g c o h ort) , M S B 0 0 1 1 3 5 9 C ma y  b e dil ute d i n 0. 9 % s o di u m 
c hl ori de t o a t otal v ol u me of 5 0 0 m L  p r o vi de d t he fi nal c o nce ntra ti o n ra n ge is 0. 1 6 m g / m L t o 
9. 6 m g/ m L .  Detaile d i nf or mati o n o n i nf usi o n pre parati o n a n d a d mi nistrati o n are pr o vi de d i n t he 
pr ot oc ol a n d ma n ual of pre parati o n. 
S u bjects w h o recei ve d t he freeze -drie d f or m ulati o n bef ore t he i ntr o d ucti o n of t he li q ui d 
f or m ulati o n will re mai n o n t he freeze- drie d f or m ulati o n .
6. 2 D os a ge a n d A d mi nistr ati o n 
S u bjects will recei ve I V i nf usi o n of M S B 0 0 1 1 3 5 9 C o ver 1 h o ur ( -1 0 mi n utes / + 2 0 mi n utes, t hat 
is, o ver 5 0 t o 8 0 mi n utes) o nce e ver y  2  w ee ks as detaile d i n t he Sc he d ules of Assess me nts (see 
Ta ble 1a n d  Ta ble 2).  S u bjects e nr olle d i n t he 3 0 m g/ k g a n d t he [ADDRESS_838590] or y  o f i nf usi o n reacti o n.  M o dificati o ns of t he i nf usi o n rate d ue t o i nf usi o n -relate d 
reacti o ns are descri be d i n Secti o n  6. 5. 4. I n  o r der t o miti gate p ote ntial i nf usi o n -relate d reacti o ns, 
pre me dicati o n wit h a n a nti hista mi ne a n d wit h paraceta m ol (aceta mi n o p he n) (f or e xa m ple, 
2 5- 5 0 m g di p he n h y dra mi ne a n d 5 0 0 -6 5 0 m g paraceta m ol [aceta mi n o p he n] I V or oral e q ui vale nt) 
a p pr o xi matel y  [ADDRESS_838591] 
2i nf usi o ns a n d is o pti o nal a n d at t he discreti o n of t he I n vesti gat or after t he sec o n d i nf usi o n 
( pre me dicati o n is o pti o nal f or all i nf usi o ns f or s u bjects i n t he N S C L C bi o mar ker c o h ort bei n g 
treate d at t he U S N CI ).  If Gra de ≥ [ADDRESS_838592] o p pe d.  Ster oi ds as pre me dicati o n are n ot per mitte d. S pecial 
preca uti o ns f or m o nit ori n g of s u bjects a n d ma na ge me nt of i nf usi o n -relate d reacti o ns / 
h y perse nsiti vit y  i ncl u di n g m o dificati o ns of t he i nf usi o n rate a n d st o p pi n g of trial dr u g are 
descri be d i n Secti o n  6. 5. 4 a n d s u bsecti o ns. 
T he starti n g d ose of M S B 0 0 1 1 3 5 9 C i n t h e d ose -escalati o n p orti o n is 1m g/ k g ( d ose -escalati o n 
acc o r di n g t o 3 + 3 desi g n u p t o 3 0 m g/ k g is i nte n de d) a n d t h e trea t me nt c y cle will be 2 wee ks 
( 1 4 d a y s).  T he first s u bject of eac h c o h ort will be o bser ve d f or at least [ADDRESS_838593] d osi n g at n o less t ha n 4 8- h o ur 
i nter vals bet wee n s u bjects.  T he d ose of M S B 0 0 1 1 3 5 9 C i n t he e x pa nsi o n will be deter mi ne d fr o m 
t he d ose -escalati o n p orti o n of t he trial. 
F or t he d ose -escalati o n c o h orts (e xce pt f or t he 2 4 0 0 m g flat -d ose c o h ort) , t he d ose of 
M S B [ADDRESS_838594] u g a d mi nistrati o n. S u bjects will recei ve M S B 0 0 1 1 3 5 9 C o nce e ver y 
2wee ks u ntil c o nfir me d pr o gressi o n, u nacce pta ble t o xicit y , or a n y criteri o n f or wit h dra wal fr o m 
t he trial or I M P occ urs (see Secti o n  5. 5 ).  Su bjects w h o ha ve e x perie nce d S D, P R , or C R s h o ul d 
c o nti n ue treat me nt t hr o u g h t he e n d of [ADDRESS_838595] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838596] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 1 / 1 9 3 F oll o wi n g safet y a n d PK a nal y sis of t he Escalati o n c o h orts, a flat d ose of 1 2 0 0 m g/i nf usi o n was 
c h ose n f or all e x pa nsi o n c o h orts, e xce pt f or t he N S C L C sec o n d -li ne c o h ort, i n w hic h 4 0 s u bjects 
will recei ve 5 0 0 m g/i nf usi o n a n d 4 0 s u bjects will recei ve 1 2 0 0 m g/i nf usi o n. 
F or s u bjec ts w h o ac hie ve S D, a P R or C R o n M S B [ADDRESS_838597] o p pi n g t hera p y , b ut pri or t o t he e n d of t he trial, 1re -i nitiati o n 
c o urse of treat me nt at t he sa me d ose a n d sc he d ule a n d treat me nt d urati o n u p t o 1 2 m o nt hs is 
all o we d at t he discreti o n of t he I n vesti gat or a n d a gree me nt of t he trial Me dical Res p o nsi ble (see 
Secti o n 5. 1. 6 ). T he I n vesti gat or will nee d t o c o nfir m t hat t he be nefit of re -i nitiati n g treat me nt 
o ut wei g hs a n y r is k i n v ol ve d, s uc h as t hat w hic h le d t o i nitial treat me nt disc o nti n uati o n. M ore o ver, 
f or s u b jects i n w hic h B O R was S D, t he I n vesti gat or s h o ul d c o nfir m n o ot her reas o na ble treat me nt 
o pti o ns are a vaila ble.   S u bjects re -i nitiati n g treat me nt s h o ul d be assesse d acc or di n g t o t he 
Sc he d ules of Assess me nt f or t he E x pa nsi o n p orti o n of t he trial starti n g at Wee k 1, D a y  1  (see  Ta ble 
2) .
6. [ADDRESS_838598] e nr oll me nt will be ma na ge d ma n uall y d uri n g t he escalati o n 
p hase a n d f or t he N S C L C bi o mar ker c o h ort.  E nr ol lme nt f or ot her e x pa nsi o n c o h orts will utilize 
a n i nteracti ve we b res p o nse s y ste m ( I W R S ). 
N S C L C sec o n d -li ne c o h ort 
O nce t he s u bject has pr o vi de d a si g ne d I nf or me d C o nse nt F or m (I C F) a n d meets all i ncl usi o n a n d 
n o e xcl usi o n criteria, t he I n vesti gat or or dele gate will re q uest t he d ose gr o u p assi g n me nt usi n g t he 
I W R S.  Q ualifie d s u bjects will be ra n d o mize d i n a 1: 1 rati o t o recei ve eit her 5 0 0 or 
1 2 0 0 m g/i nf usi o n of M S B 0 0 1 1 3 5 9 C .  T he c o h ort is f ull y  c o ntr olle d b y  t h e I W R S, w hic h assi g ns 
treat me nt i n di vi d ual ( u ni q ue) vial n u m bers f or eac h s u bject.  T he vial n u m ber is li n ke d via t he 
G o o d Ma n ufact uri n g Practice q ualifie d s y ste m t o t he c orres p o n di n g treat me nt as well as t o t he 
s u bject.  All ocati o n of s u bjects will n ot be stratifie d. 
6. 4 N o ni n vesti g ati o n al Me dici n al Pr o d ucts t o be Use d 
I n or der t o miti gate p ote ntial i nf usi o n -relate d reacti o ns, pr e me dicati o n wit h a n a nti hista mi ne a n d 
wit h paraceta m ol (aceta mi n o p he n) (f or e xa m ple, 2 5- 5 0 m g di p he n h y dra mi ne a n d 5 0 0- 6 5 0 m g 
paraceta m ol [aceta mi n o p he n] I V or oral e q ui vale nt) a p pr o xi matel y  [ADDRESS_838599] 2 i nf usi o ns a n d is o pti o nal a n d at t he discreti o n 
of t he I n vesti gat or after t he sec o n d i nf usi o n ( pre me dicati o n is o pti o nal f or all i nf usi o ns f or s u bjects 
i n t he N S C L C bi o mar ker c o h ort bei n g treate d at t he U S N CI ). If Gra de ≥ [ADDRESS_838600] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838601] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 2 / 1 9 3 As wi t h all m o n ocl o nal a nti b o d y  t hera pi[INVESTIGATOR_014], t here is a ris k of aller gic reacti o n i ncl u di n g 
a na p h yl actic s h oc k. M S B 0 0 1 1 3 5 9 C s h o ul d be a d mi nistere d i n a setti n g t hat all o ws f or i m me diate 
access t o a n i nte nsi ve care u nit or e q ui vale nt e n vir o n me nt a n d a d mi nistrati o n of t hera p y  f or 
a na p h yl a xis, s uc h as t he a bilit y  t o i m ple me nt i m me diate res uscitati o n meas ures. Ster oi ds 
( de xa met has o ne 1 0 m g ), e pi [INVESTIGATOR_050] p hri ne ( 1: 1, 0 0 0 dil uti o n), aller g y  m e dicati o ns (I V a nti hista mi nes), 
br o nc h o dilat ors, or e q ui vale nts ,a n d o x y ge n s h o ul d be a vaila ble f or i m me diate access. I nf usi o n of 
M S B [ADDRESS_838602] o p pe d i n case of Gra de ≥ [ADDRESS_838603] a vaila ble me dical 
practice.  G ui deli nes f or ma na ge me nt of i nf usi o n -relate d reacti o ns a n d se vere h y perse nsiti vit y 
reacti o n acc or di n g t o t he N CI are f o u n d i n Secti o n  6. 5. 4. 
F urt her preca uti o ns are pr o vi de d i n Secti o n 6. 5. 4.  F or pr o p h yl a xis of fl u -li ke s y m pt o ms , a 
n o n- ster oi dal a nti -i nfla m mat or y  d r u g ( N S AI D) f or e xa m ple ,i b u pr ofe n [ADDRESS_838604] u g i nter ve nti o ns ( ot her t ha n vita mi ns) a n d a n y c ha n ges 
t o a c o nc o mita nt me dicati o n or ot her i nter ve nti o ns h o ul d als o be rec or de d i n t he e C R F .
6. 5. 1 Per mitte d Me dici nes 
A n y  m e dicati o ns ( ot her t ha n t h ose e xcl u de d b y  t he cli nical trial pr ot oc ol) t hat are c o nsi dere d 
necessar y  t o pr otect s u bject welfare a n d will n ot i nterfere wit h t he trial me dicati o n ma y  b e  g i ve n 
at t he I n vesti gat or’s discreti o n. 
Ot her dr u gs t o be use d f or pr o p h yl a xis, treat me nt of a na p h y lactic reacti o ns, i nf usi o n -relate d 
reacti o ns, a n d se vere h y perse nsiti vit y  r eacti o ns / fl u -li ke s y m pt o ms a n d ir A Es are descri be d i n 
Secti o ns  5. 1. 7. 2, 6. 4, a n d  6. 5. 4. 
Palliati ve ra di ot hera p y deli vere d i n a n or mal or ga n -s pari n g tec h ni q ue m a y  b e a d mi nistere d d uri n g 
t he trial. T he assess me nt of P D will n ot be base d o n t he necessit y f or palliati ve ra di ot hera p y. 
6. 5. [ADDRESS_838605] n ot ha ve ha d c he m ot hera p y, 
ra di ot hera p y ( ot her t ha n palliati ve ra di ot hera p y deli vere d i n a n or mal or ga n -s pari n g te c h ni q ue as 
descri be d i n Secti o n  6. 5. 1 ), maj or s ur ger y , or recei ve d a n ot her i n vesti gati o nal a ge nt wit hi n [ADDRESS_838606] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838607] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 3 / [ADDRESS_838608] n ot be a d mi nistere d d uri n g t he tri al :
I m m u n ot h era p yi ncl u di n g i nterfer o n , i m m u n os u p pressi ve dr u gs (f or e xa m ple , c he m ot hera p y or 
s y ste mic c ortic oster oi ds e xce pt f or s h ort ter m treat me nt of aller gic reacti o ns , e n d oc ri ne 
re place me nt t hera p y at l o w -d ose pre d nis o n e [≤ 1 0 m g dail y] or e q ui vale nt ,or f or t he treat me nt 
of ir A Es or ot her a p pr o priate s h ort -ter m ster oi d use ), or ot her e x peri me ntal p har mace utical 
pr o d ucts. S h ort ter m a d mi nistrati o n of s y ste mic ster oi d or ot her i m m u n os u p pressa nt s uc h as 
i nfli xi ma b or m y c o p he n olate (t hat is , f or aller gic reacti o ns or t he ma na ge me nt of ir A Es) is 
all o we d. Ster oi ds wit h n o or mi ni mal s y ste mic effect (t o pi[INVESTIGATOR_2855], i n halati o n) are all o we d.   
N ote: f or s u bjects wit h gli o blast o ma, ster oi d use is all o we d. 
A def o vir .
Pr o p h y lactic use of c ortic oster oi ds f or i nf usi o n -re late d reacti o ns is pr o hi bite d. 
A n y  li ve vacci ne t hera pi[INVESTIGATOR_014] f or t he pre ve nti o n of i nfecti o us disease .  A d mi nistrati o n of 
i nacti vate d vacci nes is all o we d (f or e xa m ple, i nacti vate d i nfl ue nza vacci nes) .
Bl o o d tra nsf usi o ns a n d er y t hr oi d gr o wt h fact ors are n ot al l o we d d uri n g t he [ADDRESS_838609] will be wit h dra w n fr o m trial treat me nt ( the Me dical M o nit or m a y be c o ntacte d t o disc uss 
w het her t he I M P m ust be disc o nti n ue d ). 
Me dicati o ns ot her t ha n t h ose s pecificall y e xcl u de d i n t his trial (as o utli ne d i n t his secti o n ) ma y  be 
a d mi nistere d f or t he ma na ge me nt of s y m pt o ms ass ociate d wit h t he a d mi nistrati o n of 
M S B [ADDRESS_838610] n ot be a d mi nistere d d uri n g t he trial (a n d wit hi n 2 8 d a y s 
bef ore t he start of trial treat me nt): 
Maj or s ur ger y  (e xcl u di n g pri or dia g n ostic bi o ps y )
Her bal re me dies wit h i m m u n osti m ulati n g pr o perties ( f or e xa m ple , mistle t oe e xtract) or k n o w n 
t o p ote ntiall y  i nterfere wit h maj or or ga n f u ncti o n ( f or e xa m ple , h y perici n) 
S u bjects s h o ul d n ot a b use alc o h ol or ot her dr u gs d uri n g t he trial .
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838611] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 4 / [ADDRESS_838612] u d y  ( i n t he case M T D is n ot reac he d), i n -h o use o bser vati o n i n a 
h os pi[INVESTIGATOR_18552] d setti n g f or at least [ADDRESS_838613] 
(Ta ble 5).  T o facilitate P K a n d bi o mar ker sa m pli n g, s u bjects m a y  r e mai n i n -h o use t h ro u g h a n 
a d diti o nal 2 4 h o urs if necessar y .  A nurse, n urse practiti o ner /p h y sicia n’s assista nt, or p h y sicia n 
will c o m m u nicate wit h t he first s u bject of eac h c o h ort after t he first treat me nt t o assess f or a n y 
si de effects o n or after D a y  [ADDRESS_838614] d ose i n s u bse q ue nt s u bjects. 
O nce t he M T D / d ose t o be use d i n t he e x pa nsi o n p hase of t he st u d y has bee n declare d t here is n o 
waiti n g peri o d bet wee n d osi n g of s u bjects .
T a ble 5 W ait Peri o ds Bet wee n D osi n g of S u bjects Wit hi n a D ose / E x p a nsi o n 
C o h ort 
Bef ore M T D/ P h ase II 
D ose Decl ar ati o n / 
Bef ore D ose Cle ar a nce Bef ore M T D/ P h ase II 
D ose Decl ar ati o n / 
After D ose Cle ar a nce aAfter M T D/ P h ase II 
D ose Decl ar ati o n 
I n -h o use ( h os pi[INVESTIGATOR_1314] o n) o bser vati o n [ADDRESS_838615] 
d ose a n d s u bse q ue nt s u bjects i n a 
c o h ort 5 da ys 4 8 h o urs N o ne 
H C C = he pat ocell ular carci n o ma; M T D = ma xi m u m -t olerate d d ose; S M C = Safet y M o nit ori n g C o m mittee. 
a  S u bjects i n t he H C C asce n di n g -d ose c o h ort ma y be gi n e nr olli n g pri or t o declarati o n of t he M T D / d ose t o be use d i n t he e x pa nsi o n 
p hase of t he st u d y b y t he S M C; h o we ver, t he S M C m ust ha ve cleare d t he starti n g d ose f or t he H C C c o h ort as safe i n t he d ose -
escalati o n p hase of t he st u d y. 
As a r o uti ne preca uti o n, s u bjects all e nr olle d i n t his trial (t hat is, b ot h t he d ose -escalati o n a n d t he 
e x pa nsi o n c o h orts) m ust be o bser ve d f or 2h o urs p ost e n d of i nf usi o n , i n a n area wit h res uscitati o n 
e q ui p me nt a n d e mer ge nc y  a ge nts. At all ti mes d uri n g M S B [ADDRESS_838616] be ass ure d.  I n  o r der t o treat p ossi ble a na p h y lactic reacti o ns, f or 
i nsta nce, de xa met has o ne 1 0 m g a n d e pi [INVESTIGATOR_050] p hri ne i n a 1: [ADDRESS_838617] o p pe d i n case of Gra de ≥ [ADDRESS_838618] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838619] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 5 / 1 9 3 6. 5. 4. 1 I nf usi o n -rel ate d Re acti o n s
I n f usi o n- relate d reacti o ns, i ncl u di n g h y perse nsiti vit y , are defi ne d i n t his secti o n. 
A. S y m pt o ms: 
Fe ver 
C hills 
Ri g ors 
Dia p h oresis 
Hea dac he 
B. Ma na ge me nt (see  Ta ble 6) 
T a ble 6 Tre at me nt M o dific ati o n f or S y m pt o ms of I nf usi o n -rel ate d Re acti o ns 
C a use d b y M S B 0 0 1 1 3 5 9 C 
N CI -C T C A E Gr a de Tre at me nt M o dific ati o n f or M S B 0 0 1 1 3 5 9 C 
Gr a de 1 –mi l d 
Mil d tra nsie nt reacti o n; i nf usi o n i nterr u pti o n n ot 
i n dicate d; i nter ve nti o n n ot i n dicate d. Decrease t he M S B 0 0 1 1 3 5 9 C i nf usi o n rate b y 5 0 % a n d 
m o nit or cl osel y f or a n y w orse ni n g. 
T he t otal i nf usi o n ti me f or M S B 0 0 1 1 3 5 9 C s h o ul d n ot 
e xcee d 1 2 0 mi n utes 
Gr a de 2 –m o der ate 
T hera p y or i nf usi o n i nterr u pti o n i n dicate d b ut res p o n ds 
pr o m ptl y t o s y m pt o matic treat me nt (f or e xa m ple, 
a nti hista mi nes, N S AI Ds, narc otics, I V fl ui ds); 
pr o p h ylactic me dicati o ns i n dicate d f or 2 4 h o urs .St o p M S B 0 0 1 1 3 5 9 C i nf usi o n. 
Res u me i nf usi o n at 5 0 % of pre vi o us rate o nce i nf usi o n- 
relate d reacti o n has res ol ve d or decrease d t o at least 
Gra de 1 i n se verit y, a n d m o nit or cl osel y f or a n y 
w orse ni n g 
Gr a de 3 or Gr a de 4 – se vere or life -t hre ate ni n g 
Gra de 3: Pr ol o n ge d (f or e xa m ple, n ot ra pi [INVESTIGATOR_2478] y res p o nsi ve 
t o s y m pt o matic me dicati o n a n d / or brief i nterr u pti o n of 
i nf usi o n); rec urre nce of s y m pt o ms f oll o wi n g i nitial 
i m pr o ve me nt; h os pi[INVESTIGATOR_1314] o n i n dicate d f or cli nical 
se q uelae. 
Gr a de 4: Life -t hreate ni n g c o nse q ue nces; ur ge nt 
i nter ve nti o n i n dicate d. St o p t he M S B [ADDRESS_838620]. 
S u bjects ha ve t o be wit h dra w n i m me diatel y fr o m 
M S B [ADDRESS_838621] n ot recei ve a n y 
furt her M S B 0 0 1 1 3 5 9 C treat me nt 
I V = i ntra ve n o us; N CI -C T C A E =Nati o nal Ca ncer I nstit ute -C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nt; 
N S AI Ds =n o nster oi dal a nti -i nfla m mat or y dr u gs. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838622] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 6 / 1 9 3 A d diti o n al M o dific ati o ns f or S u bjects Wit h Gr a de 2 I nf usi o n -rel ate d Re acti o ns 
If, i n t he e ve nt of a Gra de 2 i nf usi o n -relate d reacti o n t hat d oes n ot i m pr o ve or w orse ns after 
i m ple me ntati o n of t he m o dificati o ns i n dicate d i n  Ta ble 6(i ncl u di n g re d uci n g t he i nf usi o n rate b y 
5 0 %), t he I n vesti gat or ma y  c o nsi der treat me nt wit h c ortic oster oi ds a n d t he i nf usi o n of I M P s h o ul d 
be st o p pe d f or t hat d a y . At t he ne xt i nf usi o n ,t he I n vesti gat or m a y c o nsi der t he a d diti o n of 
H 2 -bl oc ker a nti hista mi nes (f or e xa m ple , fa m oti di ne or ra niti di ne ), i n a d diti o n t o pre me dicati o n, 
f or select s u bjects. H o we ver, pr o p h y lactic ster oi ds are N O T per mitte d. If t he s u bject has a sec o n d 
i nf usi o n -relate d reacti o n Gra de ≥ [ADDRESS_838623] a vaila ble 
me dical practice. A c o m plete g ui deli ne f or t he e mer ge nc y  t reat me nt of a na p h y lactic reacti o ns 
acc or di n g t o t he W or ki n g Gr o u p of t he Res uscitati o n C o u ncil ( U nite d Ki n g d o m) a n d ca n be f o u n d 
at htt ps:// w w w.res us. or g. u k/ pa ges/rea cti o n. p df. S u bjects s h o ul d be i nstr ucte d t o re p or t a n y 
dela y e d reacti o ns t o t he I n vesti gat or i m me diatel y. 
A. S y m pt o ms 
I m paire d air wa y 
Decrease d o x y ge n sat urati o n ( < 9 2 %) 
C o nf usi o n 
Let har g y 
Hy p ote nsi o n 
Pale /cla m m y  s ki n 
Cya n osis .
B. Ma na ge me nt 
1. E pi [INVESTIGATOR_050] p hri ne i njecti o n a n d I V de xa met has o ne 
2. Patie nt s h o ul d be place d o n car diac, bl o o d press ure, heart rate, a n d o x y ge n sat urati o n 
m o nit or i m me diatel y 
3. Alert i nte nsi ve care u nit f or p ossi ble tra nsfer if re q uire d. 
F or pr o p h yl a xis of fl u -li ke s y m pt o ms , a N S AI D, f or e xa m ple ,i b u pr ofe n 4 0 0 m g or c o m para ble 
N S AI D d ose, m a y  b e a d mi nistere d 2 h o urs bef ore a n d 8h o urs after t he start of eac h d ose of 
M S B 0 0 1 1 3 5 9 C I V i nf usi o n .
6. 5. 4. 3 I m m u ne -Rel ate d A d verse E ve nts 
Si nce i n hi biti o n of P D -L 1 sti m ulates t he i m m u ne s yste m, ir A Es m a y  occ ur.  
Treat me nt of ir A Es is mai nl y  de pe n de nt u p o n se verit y  ( N CI -C T C A E gra de) :
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838624] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 7 / 1 9 3 Gra de 1 t o 2:  treat s y m pt o maticall y  or wit h m o derate d ose ster oi ds, m ore fre q ue nt m o nit ori n g 
Gra de 1 t o 2 ( p ersiste nt):  ma na ge si milar t o hi g h gra de A E ( Gr a de 3 t o 4) 
Gra de 3 t o 4:  treat wit h hi g h- d ose c ortic oster oi ds. 
Treat me nt of ir A Es s h o ul d f oll o w g ui deli nes set f ort h i n  Ta ble 7. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838625] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 8 / 1 9 3 T a ble 7 M a n a ge me nt of I m m u ne -Rel ate d A d verse E ve nts 
G astr oi ntesti n al ir A Es 
Se verit y of D i arr he a /C olitis 
( N CI -C T C A E v 4. 0 3) M a n a ge me nt F oll o w -u p 
Gr a de 1 
Diarr hea: <4 st o ols/ da y o ver Baseli ne 
C olitis: as y m pt o matic C o nti n ue M S B 0 0 1 1 3 5 9 C 
t hera p y 
S y m pt o matic treat me nt ( f or 
e xa m ple, l o pera mi de) Cl ose m o nit ori n g f or w orse ni n g s y m pt o ms 
E d ucate s u bject t o re p ort w orse ni n g i m me diatel y 
If w orse ns: 
Treat as Gra de 2 or 3/ 4 
Gr a de 2 
Diarr hea : [ADDRESS_838626] o ols per da y o ver 
Baseli ne ; I V fl ui ds i n dicate d < 2 4 h o urs ; 
n ot i nterferi n g wit h A D L 
C olitis: a b d o mi nal pai n; bl o o d i n st o ol Dela y M S B 0 0 1 1 3 5 9 C t hera p y 
S y m pt o matic treat me nt If i m pr o ves t o Gra de 1: 
Res u me M S B 0 0 1 1 3 5 9 C t hera p y 
If persists > 5 t o 7 da ys or rec ur: 
0. 5 t o 1 m g/ k g/ da y met h yl pre d nis ol o ne or 
e q ui vale nt 
W he n s y m pt o ms i m p r o ve t o Gra de 1, ta per 
ster oi ds o ver at least 1 m o nt h, c o nsi der 
pr o p h ylactic a nti bi otics f or o p p ort u nistic 
i nfecti o ns, a n d res u me M S B 0 0 1 1 3 5 9 C t hera p y per 
pr ot oc ol. 
If w orse ns or persists > 3 t o 5 da ys wit h oral 
ster oi ds: 
Treat as Gra d e 3 t o 4
Gr a de 3 t o 4 
Diarr hea ( G ra de 3): ≥7 st o ols per da y 
o ver Baseli ne ; i nc o nti ne nce; I V fl ui ds 
≥2 4 h o urs ; i nterferi n g wit h A D L 
C olitis ( G ra de 3):  se vere a b d o mi nal 
pai n, me dical i nter ve nti o n i n dicate d, 
perit o neal si g ns 
Gra de 4: life -t hreate ni n g, perf orati o n Disc o nti n ue MS B 0 0 1 1 3 5 9 C 
t hera p y per pr ot oc ol 
1 t o 2 m g/ k g/ da y 
met h yl pre d nis ol o ne I V or 
e q ui vale nt 
A d d pr o p h ylactic a nti bi otics f or 
o p p ort u nistic i nfecti o ns 
C o nsi der l o wer e n d osc o p y If i m pr o ves: 
C o nti n ue ster oi ds u ntil Gra de 1, t he n ta per o ver at 
least 1 m o nt h 
If per sists > 3 t o 5 da ys, or rec ur safter 
i m pr o ve me nt: 
A d d i nfli xi ma b 5 m g/ k g ( if  n o c o ntrai n dicati o n), 
N ote: I nfli xi ma b s h o ul d n ot be use d i n cases of 
perf orati o n or se psis 
Per ma ne ntl y disc o nti n ue I M P 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838627] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 9 / 1 9 3 Der m at ol o gic al ir A Es 
Gr a de of R as h 
( N CI -C T C A E v 4. 0 3) M a n a ge me nt F oll o w -u p 
Gr a de 1 t o 2 
C o veri n g ≤ 3 0 % b o d y s urface area S y m pt o matic t hera p y ( f or 
e xa m ple, a nti hista mi nes, t o pi[INVESTIGATOR_629068]) 
C o nti n ue M S B 0 0 1 1 3 5 9 C 
t hera p y If persists > 1 t o 2 wee ks or rec urs: 
C o nsi der s ki n bi o ps y 
C o nsi der dela yi n g M S B 0 0 1 1 3 5 9 C t hera p y 
C o nsi der 0. 5 t o 1 m g/ k g/ da y met h yl pre d nis ol o ne 
I V or oral e q ui vale nt. O nce i m pr o vi n g, ta per 
ster oi ds o ver at least 1 m o nt h, c o nsi der 
pr o p h ylactic a nti bi otics f or o p p ort u nistic 
i nfecti o ns, a n d res u me M S B 0 0 1 1 3 5 9 C t hera p y 
If w orse ns: 
Tre at as Gra de 3 t o 4 
Gr a de 3 t o 4 
C o veri n g > 3 0 % b o d y s urface area ; 
life -t hreate ni n g c o nse q ue nces Dela y or disc o nti n ue 
M S B 0 0 1 1 3 5 9 C t hera p y 
C o nsi der s ki n bi o ps y 
Der mat ol o g y c o ns ult 
1 t o 2 m g/ k g/ da y 
met h yl pre d nis ol o ne I V or I V 
e q ui vale nt If i m pr o ves t o Gra de 1: 
Ta per ster oi ds o ver at least 1 m o nt h a n d a d d 
pr o p h ylactic a nti bi otics f or o p p ort u nistic 
i nfecti o ns 
Res u me M S B 0 0 1 1 3 5 9 C t hera p y (e xce pt i n cases 
of T o xic E pi [INVESTIGATOR_629069] -J o h ns o n S y n dr o me) 
P ul m o n ar y ir A Es 
Gr a de of P ne u m o nitis 
( N CI -C T C A E v 4. 0 3) M a n a ge me nt F oll o w -u p 
Gr a de [ADDRESS_838628] e ver y 3 wee ks 
If w orse ns: 
Treat as Gra de 2 or Gra de 3 t o 4 
Gr a de 2 
Mil d t o m o derate ne w s y m pt o ms Dela y M S B 0 0 1 1 3 5 9 C t hera p y 
P ul m o nar y a n d I nfecti o us 
Disease c o ns ults 
M o nit or s y m pt o ms dail y, 
c o nsi der h os pi[INVESTIGATOR_1314] o n 
1 m g/ k g/ da y met h yl -
pre d nis ol o ne I V or oral 
e q ui vale nt 
C o nsi der br o nc h osc o p y , l u n g 
bi o ps y Re -i ma ge e ver y 1 t o 3 da ys 
If i m pr o ves: 
W he n s y m pt o ms ret ur n t o near Baseli ne , ta per 
ster oi ds o ver at least 1 m o nt h a n d t he n res u me 
M S B 0 0 1 1 3 5 9 C t hera p y a n d c o nsi de r pr o p h ylactic 
a nti bi otics 
If n ot i m pr o vi n g after 2 wee ks or w orse ni n g: 
Treat as Gra de [ADDRESS_838629] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838630] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 0 / 1 9 3 Gr a de of P ne u m o nitis 
( N CI -C T C A E v 4. 0 3) M a n a ge me nt F oll o w -u p 
Gr a de 3 t o 4 
Se vere ne w s y m pt o ms; Ne w / w orse ni n g 
h y p o xia; l ife -t hreate ni n g Disc o nti n ue M S B 0 0 1 1 3 5 9 C 
t hera p y 
H os pi[INVESTIGATOR_18552] 
P ul m o nar y a n d I nfecti o us 
Disease c o ns ults 
2 t o 4 m g/ k g/ da y 
met h yl pre d nis ol o ne I V or I V 
e q ui vale nt 
A d d pr o p h ylactic a nti bi otics f or 
o p p ort u nistic i nfecti o ns 
C o nsi der br o nc h osc o p y, l u n g 
bi o ps y If i m pr o ves t o Baseli ne : 
Ta per ster oi ds o ver at least 6 wee ks 
If n ot i m pr o vi n g after 4 8 h o urs or w orse ni n g: 
A d d a d diti o nal i m m u n os u p pressi o n ( f or e xa m ple, 
i nfli xi ma b, c ycl o p h os p ha mi de, I V 
i m m u n o gl o b uli n, or m yc o p he n olate m ofetil) 
Per ma ne ntl y disc o nti n ue I M P 
He p atic ir A Es 
Gr a de of Li ver Test Ele v ati o n 
( N CI -C T C A E v 4. 0 3) M a n a ge me nt F oll o w -u p 
Gr a de 1 
Gra de 1 A S T or A L T > U L N t o 3. 0 x U L N 
a n d /or t otal bilir u bi n > U L N t o 1. 5 x U L N C o nti n ue M S B 0 0 1 1 3 5 9 C 
t hera p y C o nti n ue li ver f u ncti o n m o nit ori n g 
If w orse ns: 
Treat as Gra de 2 or 3 t o 4 
Gr a de 2 
A S T or A L T > 3. 0 t o ≤ 5 x U L N a n d / or 
t otal bilir u bi n > 1. 5 t o ≤ 3 x U L N 
F or s u bjects wit h li ver i n v ol ve me nt at 
Baseli ne ( Baseli ne A S T ≤5. 0 ×U L N, 
A L T ≤5. 0 × U L N, a n d bilir u bi n ≤3. 0) Dela y M S B 0 0 1 1 3 5 9 C 
t hera p y 
I ncrease fre q ue nc y of 
m o nit ori n g t o e ver y 3 da ys 
C o nti n ue M S B 0 0 1 1 3 5 9 C 
t hera p y If ret ur ns t o Baseli ne: 
Res u me r o uti ne m o nit ori n g, res u me 
M S B [ADDRESS_838631] > 5 t o 7 da ys or w orse n: 
0. 5 t o 1 m g/ k g/ da y met h yl pre d nis ol o ne or oral 
e q ui vale nt a n d w he n L F T ret ur ns t o Gra de [ADDRESS_838632] 1 m o nt h, 
c o nsi der pr o p h ylactic a nti bi otics f or o p p ort u nistic 
i nfecti o ns, a n d res u me M S B 0 0 1 1 3 5 9 C t hera p y 
C o nti n ue li ver f u ncti o n m o nit ori n g 
If w orse ns: 
Treat as Gra de s3 t o 4 
Gr a de s3 t o 4 
A S T or A L T > 5 x U L N a n d / or t otal 
bilir u bi n > 3 x U L N Disc o nti n ue M S B 0 0 1 1 3 5 9 C 
t hera p y 
I ncrease fre q ue nc y of 
m o nit ori n g t o e ver y 1 t o 
2da ys If ret ur ns t o Gra de 2: 
Ta per ster oi ds o ver at least 1 m o nt h 
If d oes n ot i m pr o ve i n > 3 t o 5 da ys, w orse ns or 
re b o u n ds: 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838633] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 1 / 1 9 3 F or s u bjects wit h li ver i n v ol ve me nt at 
B aseli ne ( Baseli ne A S T ≤ 5. 0 × U L N, 
A L T ≤ 5. 0 × U L N, a n d bilir u bi n ≤ 3. 0) 1 t o 2 m g/ k g/ da y 
met h yl pre d nis ol o ne I V or I V 
e q ui vale nt 
A d d pr o p h ylactic a nti bi otics 
f or o p p ort u nistic i nfecti o ns 
C o ns ult gastr oe nter ol o gist 
C o nsi der o btai ni n g M RI/ C T 
sca n of li ver a n d li ver bi o ps y 
if cli nicall y warra nte d 
Dela y M S B 0 0 1 1 3 5 9 C 
t hera p y 
I ncrease fre q ue nc y of 
m o nit ori n g t o e ver y 3 da ys A d d m yc o p he n olate m ofetil 1 gra m ( g) t wice dail y 
If n o res p o nse wit hi n a n a d diti o nal 3 t o 5 da ys, 
c o nsi der ot her i m m u n os u p pressa nts per l ocal 
g ui deli nes 
Per ma ne ntl y disc o nti n ue I M P 
If ret ur ns t o Baseli ne: 
Res u me r o uti ne m o nit ori n g, c o nsi der res u mi n g 
M S B [ADDRESS_838634] > 5 t o 7 da ys or w orse n: 
0. 5 t o 1 m g/ k g/ da y met h yl pre d nis ol o ne or oral 
e q ui vale nt a n d w he n L F T ret ur ns t o Gra de [ADDRESS_838635] 1 m o nt h, 
c o nsi der pr o p h ylactic a nti bi otics f or o p p ort u n istic 
i nfecti o ns, a n d res u me M S B 0 0 1 1 3 5 9 C t hera p y. 
If d oes n ot i m pr o ve i n > 3 t o 5 da ys, w orse ns or 
re b o u n ds: 
Disc o nti n ue M S B 0 0 1 1 3 5 9 C t hera p y 
I ncrease fre q ue nc y of m o nit ori n g t o e ver y 1 t o 
2da ys 
1 t o 2 m g/ k g/ da y met h yl pre d nis ol o ne I V or I V 
e q ui vale nt 
A d d pr o p h ylactic a nti bi otics f or o p p ort u nistic 
i nfecti o ns 
C o ns ult gastr oe nter ol o gist 
C o nsi der o btai ni n g M RI/ C T sca n of li ver a n d li ver 
bi o ps y if cli nicall y warra nte d 
If d oes n ot i m pr o ve i n > 3 t o 5 da ys, w orse ns or 
re b o u n ds: 
A d d m yc o p he n olate m ofetil 1 gra m ( g) t wice dail y 
If n o res p o nse wit hi n a n a d diti o nal [ADDRESS_838636] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838637] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 2 / 1 9 3 C ar di ac ir A Es 
M y oc ar ditis M a n a ge me nt F oll o w -u p 
Ne w o nset of car diac si g ns or s y m pt o ms 
a n d / or ne w la b orat or y ca r diac bi o mar ker 
ele vati o ns (e g, tr o p o ni n, creati ne 
ki nase -M B, brai n natri uretic pe pti de) or 
car diac i ma gi n g a b n or malities s u g gesti ve 
of m y ocar ditis Wit h h ol d M S B 0 0 1 1 3 5 9 C 
t hera p y. 
H os pi[INVESTIGATOR_18552]. 
I n t he prese nce of 
life -t hreate ni n g car diac 
dec o m pe nsati o n, c o nsi der 
tra nsfer t o a facilit y 
e x perie nce d i n a d va nce d heart 
fail ure a n d arr h yt h mia 
ma na ge me nt. 
Car di ol o g y c o ns ult t o 
esta blis h eti ol o g y a n d r ule o ut 
i m m u ne -me diate d 
m y o car ditis. 
G ui deli ne base d s u p p orti ve 
treat me n t as per car di ol o g y 
c o ns ult. a
C o nsi der m y ocar dial bi o ps y if 
rec o m me n de d per car di ol o g y 
c o ns ult. If s y m pt o ms i m pr o ve a n d i m m u ne- me diate d 
eti ol o g y is r ule d o ut, re -start M S B 0 0 1 1 3 5 9 C 
t hera p y. 
If s y m pt o ms d o n ot i m pr o ve/ w orse n, viral 
m y o car ditis is e xcl u de d, a n d i m m u ne -me diate d 
eti ol o g y is s us pecte d or c o nfir me d f oll o wi n g 
car di ol o g y c o ns ult, ma na ge as i m m u ne -me diate d 
m y o car ditis. 
I m m u ne -me diate d m y ocar ditis Per ma ne ntl y disc o nti n ue 
M S B 0 0 1 1 3 5 9 C .
G ui deli ne base d s u p p orti ve 
treat me nt as a p pr o priate as 
per car di ol o g y c o ns ult. a
Met h yl pre d nis ol o ne 1 t o 
2m g/ k g/ da y. O nce i m pr o vi n g, ta per ster oi ds o ver at least 
1m o nt h a n d a d d pr o p h ylactic a nti bi otics f or 
o p p ort u nistic i nfecti o ns. 
If n o i m pr o ve me nt or w o rse ni n g, c o nsi der 
a d d iti o nal i m m u n os u p pressa nts (e g ,azat hi o pri ne, 
c y cl os p ori ne A) .
aL ocal g ui deli nes, or e g, E ur o pea n S ociet y of Car di ol o g y or A merica n Heart Ass ociati o n g ui deli nes 
E ur o pea n S ociet y of Car di ol o g y g ui deli nes we bsite: htt ps:// w w w.escar di o. or g/ G ui deli nes/ Cli nical -Practice -G ui deli nes 
A merica n Heart Ass ociati o n g ui deli nes we bsite: 
htt p:// pr ofessi o nal heart. or g/ pr ofessi o nal/ G ui deli nes State me nts/searc hres ults.js p? q = & y = &t = [ADDRESS_838638] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838639] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 3 / 1 9 3 E n d ocri ne ir A Es 
E n d ocri ne Dis or der M a n a ge me nt F oll o w -u p 
As y m pt o matic T S H a b n or malit y C o nti n ue M S B 0 0 1 1 3 5 9 C t hera p y  
If T S H < 0. 5 x L L N , or T S H > 2 x U L N, or c o nsiste ntl y o ut of ra n ge i n 
2s u bse q ue nt meas ure me nts: i ncl u de T 4 at s u bse q ue nt c ycles as cli nicall y 
i n dicate d; c o nsi der e n d ocri n ol o g y c o ns ult 
S y m pt o matic e n d ocri n o pat h y E val uate e n d ocri ne f u ncti o n 
C o nsi der pit uitar y sca n 
S y m pt o matic wit h a b n or mal 
la b orat or y /pit uitar y sca n: 
Dela y M S B 0 0 1 1 3 5 9 C 
t hera p y 
1 t o 2 m g/ k g/ da y 
met h yl pre d nis ol o ne I V or b y 
m o ut h e q ui vale nt 
I nitiate a p pr o priate h or m o ne 
t hera p y 
N o a b n or mal la b orat or y /
pit uitar y M RI sca n b ut 
s y m pt o ms persist: 
Re peat la b orat ories i n 1 t o 
3wee ks / M RI i n 1 m o nt h If i m pr o ves ( wit h or wit h o ut h or m o ne 
re place me nt): 
Ta per ster oi ds o ver at least 1 m o nt h a n d c o nsi der 
pr o p h ylactic a nti bi otics f or o p p ort u nistic 
i nfecti o ns 
Res u me M S B 0 0 1 1 3 5 9 C t hera p y 
S u bjects wit h a dre nal i ns ufficie nc y ma y nee d t o 
c o nti n ue ster oi ds wit h mi neral oc ortic oi d 
c o m p o ne nt 
S us pi[INVESTIGATOR_37180] o n of a dre nal crisis ( f or e xa m ple, 
se vere de h y drati o n, h y p ote nsi o n, s h oc k o ut 
of pr o p orti o n t o c urre nt ill ness )Dela y or disc o nti n ue M S B [ADDRESS_838640] 
If a dre nal crisis r ule d o ut, t he n treat as a b o ve f or s y m pt o matic e n d ocri n o pat h y 
Re n al ir A Es 
Re n al Dis or der M a n a ge me nt F oll o w -u p 
Gra de 1 or Gra de 2 Re peat re nal f u ncti o n 
la b orat or y tests / uri ne 
se di me nt e ver y [ADDRESS_838641] o p treat me nt u ntil ret ur n t o 
baseli ne 
Re nal d ysf u ncti o n / i m m u ne -relate d 
ne p h ritis E val uate re nal f u ncti o n 
C o nsi der b i o ps y t o c o nfir m 
n e p hritis a n d i m m u ne-relate d 
i nfla m mat or y pr ocess If ret ur ns t o Gra de 2: 
Ta per ster oi ds o ver at least [ADDRESS_838642] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838643] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 4 / [ADDRESS_838644] fr o m 
M S B 0 0 1 1 3 5 9 C t hera p y 
1 t o 2 m g/ k g/ da y 
met h yl pre d nis ol o ne I V or I V 
e q ui vale nt 
A d d pr o p h ylactic a nti bi otics 
f or o p p ort u nistic i nfecti o ns If d oes n ot i m pr o ve i n > 3t o 5 da ys, w orse ns or 
re b o u n ds: 
A d d m yc o p he n olate m ofetil 1 gra m ( g) t wice dail y 
If n o res p o nse wit hi n a n a d diti o nal 3 t o 5 da ys, 
c o nsi der ot her i m m u n os u p pressa nts per l ocal 
g ui deli nes 
A D L =acti vities of dail y li vi n g ;A L T =ala ni ne a mi n otra nsferase ;A S T = as partate a mi n otra nsferase ;C T =c o m p ute d 
t o m o gra p h y; ir A E =i m m u ne -relate d a d verse e ve nt; I V =i ntra ve n o us ;L F T =li ver f u ncti o n test ;L L N =l o wer li mit of n or mal ;
M RI =ma g netic res o na nce i ma gi n g ;N CI -C T C A E =Nati o nal Ca ncer I nstit ute -C o m m o n Ter mi n ol o g y Criteria f or A d verse 
E ve nt s; T 4 =free t h yr o xi ne ;T S H =t h yr oi d -sti m ulati n g h or m o ne ;U L N =u p per li mit of n or mal .
6. 5. 4. 4 T G F β I n hi biti o n Me di ate d S ki n Re acti o ns 
S ki n assess me nts are perf or me d at Scree ni n g peri o d a n d e ver y  6 w ee ks f or all s u bjects per 
Sc he d ule of Acti vities (see  Ta ble 1Err or! Refere nce s o urce n ot f o u n d. ). 
S ki n A Es, p ossi bl y  d ue t o T G F β i n hi biti o n, i ncl u di n g h y per kerat osis, K A, a n d/ or c S C C, are A E SI s 
a n d i m p orta nt i de ntifie d ris ks f or M S B 0 0 1 1 3 5 9 C . T he distri b uti o n of lesi o ns te n ds t o be i n 
s u n- e x p ose d areas. 
Ma na ge me nt g ui deli nes f or p ote ntial T G F β i n hi biti o n me diate d s ki n reacti o ns are: 
1. Disc o nti n uati o n or i nterr u pti o n is n ot re q uire d i n m ost cases. C o nti n uati o n of treat me nt s h o ul d 
be e val uate d b y t he I n vesti gat or. 
2. E m ollie nts ma y  c o nti n ue t o be use d. 
3. Dia g n ostic a n d treat me nt pla n s h o ul d be de vel o pe d i n c olla b orati o n bet wee n I n vesti gat or a n d 
der mat ol o gist. I n ge neral, treat me nt of T G F β me diate d s ki n lesi o ns s uc h as h y per kerat osis, 
K A a n d c S C C s h o ul d be base d o n l ocal g ui deli nes/ S o C. Lesi o n e val uati o n s h o ul d i ncl u de 
e xcisi o n bi o ps y  of o ne re prese ntati ve lesi o n t o c o nfir m dia g n osis. 
4. Treat me nt a n d F oll o w -u p f or K A a n d c S C C will de pe n d o n n u m ber a n d l ocalizati o n of lesi o ns. 
F or si n gle lesi o ns: F ull e xcisi o n ma y  be rec o m me n de d. 
I n  case of m ulti pl e lesi o ns or l ocati o n n ot s uita ble f or f ull e xcisi o n, ot her treat me nt o pti o ns 
ma y  be offere d b y t he der mat ol o gist, s uc h as: 
M o hs s ur ger y , cr y ot hera p y, or ot her sta n dar d treat me nt o pti o ns de pe n di n g o n t he 
pat h ol o g y 
Use of reti n oi ds, if rec o m me n de d b y  d er mat ol o gist, ma y  b e c o nsi dere d after disc ussi o n 
wit h Me dical M o nit or. 
5. Cl ose cli nical F oll o w -u p f or r e -e val uati o n, res ol uti o n, or p ote ntial rec urre nce s h o ul d b e 
i m ple me nte d. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838645] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 5 / [ADDRESS_838646] u d y  Me dical M o nit or, as nee de d, f or ma na ge me nt of T G F β me diate d s ki n lesi o ns. 
6. 5. 4. 5 A ne mi a 
Ris k ma na ge me nt meas ures i n a d diti o n t o r o uti ne la b orat or y  tests will i ncl u de: 
S u bjects m ust e nter t he st u d y  wit h H g b val ues at least 9 g/ d L 
R o uti ne m o nit ori n g of H g b, re d bl o o d cells, a n d he mat ocrit will be perf or me d e ver y  w ee k u p 
t o Wee k 5 a n d t he n e ver y  2 wee ks t hereafter ( pri or t o treat me nt) 
I nstr ucti o ns f or st u d y  t reat me nt disc o nti n uati o n or m o dificati o n i n case of a ne mia will be 
pr o vi de d, briefl y descri be d here: 
oD uri n g t he 2 1- D a y -D L T peri o d, a gra de 3 H g b decrease ( < 8. 0 g/ d L) re q uires treat me nt 
disc o nti n uati o n, u nless it res ol ves t o at least 9 g/ d L wit hi n [ADDRESS_838647] e x perie nce s aGra de 3H g b decrease ( < 8. 0 g/ d L ) t hat is cli nicall y  m a na gea ble 
wit h bl o o d tra nsf usi o ns or er y t hr oi d gr o wt h fact or use ,t his d oes n ot re q uire treat me nt 
disc o nti n uati o n 
oEs peciall y if H g b < 7 g/ d L, t he I n vesti gat or s h o ul d c o nsi der bl o o d tra nsf usi o n 
oI n case of a n y Hg b < 8 g/ d L , t he I n vesti ga t or s h o ul d use discreti o n t o i nitiate a ne mia w or k 
u p, i ncl u di n g C o o m bs, ha pt o gl o bi n, i n direct bilir u bi n a n d peri p heral s mear, a n d pr ot hr o m bi n 
ti me (P T ), acti vate d partial t hr o m b o plasti n ti me (a P T T ), i nter nati o nal n or malize d rati o 
(I N R ); H g b, re d bl o o d cell s, a n d he mat ocrit are t o be cl osel y m o nit ore d 
If a s u bject e x perie nces si g nifica nt a ne mia, t he n t he a m o u nt of bl o o d t o be dra w n m a y  b e 
re d uce d b y  n ot ta ki n g bl o o d at selecte d ti me p oi nts f or P D -L [ADDRESS_838648] ors, a n d T G F β.  T he decisi o n t o re d uce t he ti me p oi nts f or t hese 
bi o mar kers will be ta ke n b y  t he I n vesti gat or i n c o ns ultati o n wit h t he Me dical M o nit or.  T his 
will be d oc u me nte d.  Bl o o d will c o nti n ue t o be ta ke n as sc he d ule d f or safet y a nal ys es, P K, a n d 
A D As .
6. 5. 4. 6 Blee di n g A d verse E ve nts 
M uc os al/ N o n -t u m or Blee di n g 
If a Gra de 2 treat me nt -relate d T E A E i m pr o ves t o Gra de ≤ [ADDRESS_838649] u d y  i nter ve nti o n ma y  be c o nti n ue d. 
If a Gra de 2 treat me nt -relate d n o n- t u m or blee di n g d oes n ot i m pr o ve t o Gra de ≤ 1 or c o m pletel y 
res ol ve b y t he da y bef ore t he ne xt i nf usi o n, b ut it is ma na gea ble a n d/ or n ot cli nicall y rele va nt, t he 
Me dical M o nit or s h o ul d be c o ns ulte d t o assess if it is cli nicall y  r eas o na ble t o a d mi nister t he 
f oll o wi n g i nf usi o n. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838650] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 6 / [ADDRESS_838651] be per ma ne ntl y disc o nti n ue d u nless a n 
alter nati ve e x pla nati o n ca n be i de ntifie d (s uc h as c o nc o mita nt use of a ntit hr o m b otic a ge nts, 
tra u matic e ve nt, etc.). I n case of alter nati ve e x pla nati o ns f or t he Gra de [ADDRESS_838652] u d y 
treat me nt s h o ul d be hel d u ntil t he e ve nt rec o vers t o Gra de ≤ 1. 
F or Gra de [ADDRESS_838653] be per ma ne ntl y disc o nti n ue d if n o alter nati ve 
e x pla nati o n is i de ntifie d. 
T u m or Blee di n g 
F or Gra de ≥ [ADDRESS_838654] be hel d u ntil t he e ve nt rec o vers t o Gra de ≤ 1. 
Treat me nt s h o ul d be per ma ne ntl y  d isc o nti n ue d if t he I n vesti gat or c o nsi ders t he partici pa nt t o be 
at ris k f or a d diti o nal se vere blee di n g. 
6. 5. 4. [ADDRESS_838655] u d y  t reat me nt mi g ht be res u me d i n t he s u bse q ue nt 
c y cle. If t he A E re mai ns t he sa me i n s pi[INVESTIGATOR_629070] u ntil t he ne xt treat me nt (sec o n d 
c y cle after t he A E occ urre d) a disc ussi o n wit h t he Me dical M o nit or s h o ul d occ ur a n d c o nsi derati o n 
of a p ossi ble e x te nsi o n of t he d ose i nterr u pti o n f or u p t o [ADDRESS_838656] 
M S B 0 0 1 1 3 5 9 C freeze -drie d f or m ulati o n is prese nte d at a c o nce ntrati o n of 4 5 m g/ vial i n U S P a n d 
P h E ur t y pe I glass vial cl ose d wit h a r u b ber st o p per a n d seale d wit h a n al u mi n u m cri m pi n g ca p.  
M S B 0 0 1 1 3 5 9 C li q ui d f or m ulati o n is prese nte d at a 1 0 m g/ m L c o nce ntrati o n i n a U S P / P h E ur 
t y pe I [ADDRESS_838657] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838658] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 7 / [ADDRESS_838659] u d y i ns ura nce. 
T he c o nte nts of t he M S B 0 0 1 1 3 5 9 C vials are sterile a n d n o n p y r o ge nic, a n d d o n ot c o ntai n 
bacteri ostatic preser vati ves.  A n y  s pi[INVESTIGATOR_3353] t hat occ ur s h o ul d be clea ne d u p usi n g t he facilit y ’s 
sta n dar d clea n u p pr oce d ures f or bi ol o gic pr o d ucts. 
A n y  u n use d p orti o n of t he s ol uti o n s h o ul d be discar de d i n bi o hazar d waste dis p osal wit h fi nal 
dis p osal b y  acce pte d l ocal a n d nati o nal sta n dar ds of i nci nerati o n. 
6. [ADDRESS_838660] Acc o u nt a bilit y 
T he I n vesti gat or (i n Ja pa n, hea d of t he st u d y  site )is res p o nsi ble f or e ns uri n g I M P acc o u nta bilit y , 
i ncl u di n g rec o nciliati o n of dr u gs a n d mai nte na nce of rec or ds. I n  Ja pa n, t he hea d of t he st u d y  site 
ca n dele gate t h e c o ntr ol of a n d acc o u nta bilit y f or t he I M Pt o a n i n vesti gati o nal pr o d uct st ora ge 
ma na ger .
U p o n recei pt of I M P, t he res p o nsi ble pers o n (i n Ja pa n, t he hea d of t he st u d y  s ite or t he 
i n vesti gati o nal pr o d uct st ora ge ma na ger ) will c hec k f or acc urate deli ver y  a n d ac k n o wle d ge 
recei pt b y si g ni n g or i nitiali n g a n d dati n g t he a p pr o priate d oc u me ntati o n a n d r et ur ni n g it t o t he 
l ocati o n s pecifie d . A c o p y  will be arc hi ve d f or t he I n vesti gat or Site File. 
I M P dis pe nsi n g will be rec or de d o n t he a p pr o priate dr u g acc o u nta bilit y  f or ms s o t hat acc urate 
rec or ds will be a vaila ble f or verificati o n at eac h m o nit ori n g visi t. 
Trial site I M P acc o u nta bilit y  rec or ds will i ncl u de t he f oll o wi n g :
C o nfir mati o n of I M P recei pt , i n g o o d c o n diti o n a n d i n t he defi ne d te m perat ure ra n ge. 
T he i n ve nt or y  of I M P pr o vi de d f or t he cli nical trial a n d pre pare d at t he site. 
T he use of eac h d ose b yeac h s u bject. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838661] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 8 / 1 9 3 T he dis p ositi o n (i ncl u di n g ret ur n, if a p plica ble) of a n y u n use d I M P. 
Dates, q ua ntities, batc h n u m bers, vial n u m bers, e x pir y dates, f or m ulati o n (f or I M P pre pare d 
at t he site), a n d t he i n di vi d ual s u bject trial n u m bers. 
T he I n vesti gat or site s h o ul d mai ntai n rec or ds , w hic h a de q uatel y d oc u me nt t h at s u bjects were 
pr o vi de d t he d oses s pecifie d i n t his pr ot oc ol, a n d all I M Ps pr o vi de d were f ull y  r ec o ncile d.   I n  
Ja pa n, the hea d of t he st u d y  s ite s h o ul d mai ntai n rec or ds t hat all I M Ps pr o vi de d were f ull y 
rec o ncile d .
U n use d I M P m ust n ot be use d f or a n y  p ur p ose ot her t ha n t he prese nt trial. N o I M P t hat is 
dis pe nse d t o a s u bject ma y be re dis pe nse d t o a differe nt s u bject. 
T he S p o ns or’s M o nit or will peri o dicall y  c ollect a n d re vie w t he I M P acc o u nta bilit y  f or ms a n d 
w here a p plica ble, will c hec k all ret ur ns ( b ot h u n use d a n d use d c o ntai ners) bef ore arra n gi n g f or 
t heir ret ur n or a ut h orizi n g t heir destr ucti o n b y t he trial site .
At t he c o ncl usi o n or ter mi nati o n of t his trial , trial site pers o n nel a n d t he Cli nical Trial Mo nit or will 
c o n d uct a fi nal pr o d uct s u p pl y  i n ve nt or y  o n t he I n vesti gati o nal Dr u g Acc o u nta bilit y  F or ms a n d all 
u n use d c o ntai ners will be destr o ye d. I nstr ucti o ns f or destr ucti o n of pr o d uct will be pr o vi de d t o 
t he site. T he Cli nical Trial Mo nit or will be s u p plie d wit h a c o p y f or fili n g of t he I n vesti gati o nal 
Dr u g Acc o u nta bilit y  F or ms. T his d oc u me ntati o n m ust c o ntai n a rec or d of cli nical s u p plies use d, 
u n use d ,a n d destr o ye d a n d s hall i ncl u de i nf or mati o n o n 
all a d mi nistere d u nits, 
all u n use d u nits ,
all des tr o y e d u nits ( d uri n g t he trial), 
all destr o y ed u nits at t he e n d of t he trial, 
date of destr ucti o n(s), 
na me a n d si g nat ure of t he In vesti g at or / p har macist / hea d of t he st u d y  s ite or t he i n vesti gati o nal 
pr o d uct st ora ge ma na ger .
It m ust be e ns ure d at eac h tr ial site t hat t he I M P is n ot use d 
after t he e x pir y  date, a n d 
after t he retest date u nless t he I M Pis rea nal yz e d a n d its retest date e xte n de d. 
T his is t o be cl osel y  m o nit ore d b y  t he Cli nical Trial M o nit or .
Destr ucti o n of use d a n d u n use d st u d y  i nter ve nti o n(s ) s h o ul d be perf or me d at site if all o we d b y 
l ocal la w o nl y after S p o ns or a ut h orizati o n. If t hat is n ot p ossi ble, t he S p o ns or/ desi g nee will b e 
res p o nsi ble. 
F urt her g ui da nce a n d i nf or mati o n f or t he fi nal dis p ositi o n of u n use d st u d y  i nter ve nti o n(s) are 
pr o vi d e d i n t he P har mac y Ma n ual. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838662] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 9 / [ADDRESS_838663] C o m pli a nce 
I n t his trial, s u bjec ts will recei ve I M P ( M S B 0 0 1 1 3 5 9 C I V i nf usi o ns) at t he i n vesti gati o nal site. 
Well -trai ne d me dical staff will m o nit or a n d perf or m t he I M Pa d mi nistrati o n. T he i nf or mati o n of 
eac h I M P a d mi nistrati o n i ncl u di n g t he date, ti me, a n d d ose of I M P will be rec or de d o n t he e C R F. 
T he In vesti gat or will ma ke s ure t hat t he i nf or mati o n e ntere d i nt o t he e C R F re gar di n g I M P 
a d mi nistrati o n is acc urate f or ea c h s u bject. A n y  reas o n f or n o n c o m plia nce s h o ul d be d oc u me nte d. 
N o nc o m plia nce is defi ne d as a s u bject missi n g > [ADDRESS_838664] a d mi nistere d treat me nt is l o n ger t ha n 4 wee ks f or n o n me dical reas o ns, t he 
criteria of i ns ufficie nt c o m plia nce are met as well.   C o nti n uati o n of treat me nt s h o ul d be disc usse d 
wit h t he Me dical M o nit or. 
6. 1 0 Bli n di n g 
N ot a p plica ble .
6. 1 1 E mer ge nc y U n bli n di n g 
N ot a p plica ble. 
6. 1 2 Tre at me nt of O ver d ose 
A n o ver d ose is defi ne d as a n y  d ose 5 % greater t ha n t he hi g hest d ose i ncl u de d i n t he cli nical trial 
pr ot oc ol. A n y o ver d ose m ust be rec or de d i n t he trial me dicati o n secti o n of t he e C R F. 
F or m o nit ori n g p ur p oses, a n y  case of o ver d ose, w het her or n ot ass ociate d wit h a n A E (seri o us or 
n o nseri o us ), m ust be re p orte d t o t he S p o ns or’s Gl o bal Dr u g Safet y de part me nt i n a n e x pe dite d 
ma n ner usi n g t he Seri o us A d verse E ve nt Pa per Re p ort F or m f oll o wi n g t he sa me ti meli nes as S A E 
re p orti n g i n a d diti o n t o e nteri n g t he O ver d ose i n t he A E secti o n of t he e C R F (see Secti o n  7. 4. 1. 4 ).
T here are n o k n o w n s y m pt o ms of M S B 0 0 1 1 3 5 9 C o ver d ose t o date. T he In vesti gat or s h o ul d 
m o nit or cl osel y  f or A Es s h o ul d a n o ver d ose occ ur a n d use his or her cli nical j u d g me nt i n pr o vi di n g 
s y m pt o matic /s u p p orti ve care as me dicall y  i n dicate d.  T here is n o k n o w n a nti d ote f or 
M S B [ADDRESS_838665] has c o m plete d t he trial or has wit h dra w n earl y, us ual treat me nt will be 
a d mi nistere d, if re q uire d, i n acc or da nce wit h t he trial site’s sta n dar d of care a n d ge nerall y  a cce pte d 
me dical practice a n d de pe n di n g o n t he s u bject’s i n di vi d ual me dical nee ds. 
U p o n wit h dra wal fr o m t he trial, s u bjects m a y  r ecei ve w hate ver care t he y  a n d t heir p h y sicia ns a gree 
u p o n. S u bjects will be f oll o we d f or s ur vi val a n d A Es as s pecifie d i n Secti o n  7. 1. 4. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838666] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 0 / [ADDRESS_838667]’s r o uti ne me dical care, t he 
I n vesti gat or will e ns ure t hat t he s u bject or t he s u bject’s le gal re prese ntati ve has pr o vi de d writte n 
i nf or me d c o nse nt acc or di n g t o t he pr oce d ure descri be d i n Secti o n 9. 2. 
7. 1. 1 Scree ni n g a n d B aseli ne Pr oce d ures a n d Assess me nts 
T here is a 2 8- d a y  w as h o ut / rec o ver y  p eri o d f or pri or a ntica ncer treat me nt (f or e xa m ple , 
c y t ore d ucti ve t hera p y , ra di ot hera p y [ wit h t he e xce pti o n of palliati ve ra di ot hera p y deli vere d i n a 
n or mal or ga n- s pari n g tec h ni q ue ], i m m u ne t hera p y, or c y t o ki ne t he r a p y  e xce pt f or er y t hr o p oieti n) 
a n d maj or s ur ger y bef ore t he start of trial treat me nt ( Secti o n 5. 3. 2) .  He mat ol o g y, he m o stase ol o g y 
a n d c he mistr y  l a b orat or y  sa m ples m ust be dra w n a n d re vie we d wit hi n 4 8 h o urs pri or t o d ose 
a d mi nistrati o n .
D uri n g t he Scree ni n g peri o d a n d bef ore a n y trial -relate d i n vesti gati o ns a n d assess me nts are starte d, 
t he s u bjects will be as ke d t o si g n t he rele va nt I C Fs. T he s u bjects’ i nf or mati o n t hat will be 
d oc u me nte d d uri n g Scree ni n g i ncl u des t he de m o gra p hic i nf or mati o n ( birt h date, se x, et h nicit y , 
a n d race) a n d t he c o m plete me dical hist or y ,i ncl u di n g t he hist or y  o f t he t u m or disease a n d pri or 
a ntica ncer t hera pi[INVESTIGATOR_014], pre vi o us me dicati o ns ( pri or [ADDRESS_838668] o si g ni n g of I C F), c o nc o mita nt 
me dicati o ns, a n d baseli ne me dical c o n diti o n (t he i nf or mati o n of c o nc o mita nt me dicati o ns a n d A Es 
will be m o nit ore d t hr o u g h o ut t he trial treat me nt peri o d). M ore o ver, a n E mer ge nc y  M e dical 
S u p p ort car d will be ha n de d o ut at t he baseli ne assess me nts visit. 
D uri n g Scree ni n g , s u bjects will u n der g o a c o m plete p h y sical e xa mi nati o n ,der mat ol o gical 
assess me nts (a ssess me nts f or s ki n lesi o ns or ras h wit h bi o ps y  o f s us pi[INVESTIGATOR_37180] o us lesi o ns ), rec or di n g 
vital si g ns ,i ncl u di n g b o d y  w ei g ht a n d hei g ht ( hei g ht o nl y  a t Scree ni n g) , 1 2- lea d electr ocar di o gra m 
(E C G ), o p ht hal m ol o g y  e xa mi nati o n i ncl u di n g slit la m p i ncl usi ve of t he a nteri or se g me nt a n d 
i ncl u di n g vis ual ac uit y, a n d a deter mi nati o n of t he E C O G P S (A p pe n di x 1).
T he Scree ni n g la b orat or y  e xa mi nati o n i ncl u des he mat ol o g y , he m ostase ol o g y ,f ull ser u m 
c he mistr y , ser u m electr o p h oresis ( d ose escalati o n o nl y ), a n d f ull uri nal ys is. A dre n oc ortic otr o pic 
h or m o ne (d ose -escalati o n c o h orts o nl y wit h t he e xce pti o n of t he bac kfill c o h orts ), a nti n uclear 
a nti b o d y  ( A N A s), r he u mat oi d fact or ( R F), free t h y r o xi ne ( T 4), a n d T S H will als o be assesse d at 
Scree ni n g . 
D uri n g Scree ni n g , a ser u m β- h u ma n c h ori o nic g o na d otr o pi n ( β -H C G) pre g na nc y  t est will be 
perf or me d f or fe males of c hil d beari n g p ote ntial a n d bl o o d H B V a n d H C V testi n g will be 
perf or me d f or all Scree ni n g s u bjects as t hese c o n diti o ns are trial e ntr y  e xcl usi o n criteria (e xce pt 
f or s u bjects i n t he H C C e x pa nsi o n c o h ort, see Secti o n 5. 3. 1. 2 ). A fe male is c o nsi dere d of 
c hil d beari n g p ote ntial (t hat is fertile )f oll o wi n g me narc he a n d u ntil bec o mi n g p ost me n o pa usal 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838669] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 1 / [ADDRESS_838670] me n o pa usal state is defi ne d as n o 
me nses f or 1 2 m o nt hs wit h o ut a n alter nati ve me dical ca use. A hi g h f ollicle -sti m ulati n g h or m o ne 
( F S H) le vel ( > 4 0 mI U/ m L ) i n t he p ost me n o pa usal ra n g e m a y b e use d t o c o nfir m a 
p ost me n o pa usal state i n fe males n ot usi n g h or m o nal c o ntrace pti o n or h or m o nal re place me nt 
t her a p y. 
T he t u m or e val uati o n (t y pe / sta gi n g, etc.) will be perf or me d usi n g C T sca n or M RI  ( if M RI is 
use d, C T of c hest is ma n dat or y [f or trial sites i n c o u ntries wit h ra diati o n e x p os ure c o ntr ol f or 
s u bjects, o nl y  M RI  m a y be use d] ;f or s u bjects i n t he H C C c o h ort, c o ntrast is ma n dat or y ) as well 
as t u m or mar kers or a n y ot her esta blis he d met h o ds (see Secti o n 7. 2. 5 f or details). B o ne sca ns 
s h o ul d be perf or me d as cli nicall y  i n dicate d.  A brai n C T / M RI sca n (eit her, c o ntrast preferre d) is 
re q uire d at Scree ni n g if n ot perf or me d wit hi n t he pre vi o u s 6 wee ks. 
C ollecti o n of t u m or bi o psies or arc hi ve d s ur gical s peci me n will als o be d o ne d uri n g t his peri o d, if 
a p plica ble ( o pti o nal f or t he d ose -escalati o n p hase). S u bjects i n t he e x pa nsi o n c o h ort sare re q uire d 
t o pr o vi de t u m or tiss ue sa m ples, see Secti o n  5. 3. 1 a n d Secti o n  7. 6. 2. 3 f or details .  
Baseli ne sa m ples f or A D As (t he ter m f or A D A o n t he C R F is h u ma n -a nti h u ma n a nti b o dies 
[H A H A ]) a n d P Gt (i ncl u di n g c ha n ges i n ge ne e x pressi o n t hr o u g h ge ne e x pressi o n e val uati o n 
s h o ul d be c ollecte d [see  Ta ble 3] ). 
F or s u bjects i n t he H C C [ADDRESS_838671] o ma, mela n o ma, o varia n ca ncer, S C C H N, T N B C, cer vical ca ncer, a n d 
N S C L Csec o n d -li ne a n d a nti -P D -1/ P D -L [ADDRESS_838672] -re p orte d o utc o mes / s y m pt o m 
se verit yassess me nts (P GI S, F H SI - 8, E O R T C Q L Q-C 3 0, E O R T C Q L Q -C X 2 4, E O R T C 
Q L Q -B N 2 0, E O R T C Q L Q -H C C 1 8 -M, E O R T C Q L Q -O E S 1 8, E O R T C Q L Q -O V 2 8 , a n d/ or 
N S C L C- S A Q ) will be a d mi nistere d a n d c o m plete d b y t he s u bjects at Scree ni n g t o c ollect baseli ne 
data a b o ut t heir s y m pt o m se verit y. 
F or s u bjects i n t he N S C L C sec o n d -li ne c o h ort, o nce a s u bject has bee n deter mi ne d t o meet all 
i ncl us i o n a n d n o e xcl usi o n criteria, t he s u bject will be ra n d o mize d as descri be d i n Secti o n 6. 3. 
St u d y  treat me nt s h o ul d start ≤ 4 da y s after ra n d o mizati o n .
7. 1. 2 Tre at me nt Peri o d 
F or t his pr ot oc ol , a c y cle is defi ne d as 1 4 da y s.  I n  t his trial, t he treat me nt will be gi ve n u ntil 
c o nfir me d pr o gressi o n, u nacce pta ble t o xicit y , or a n y  c riteri o n f or wit h dra wal fr o m t he trial or I M P 
occ urs (see Secti o n 5. 5) .Su bjects w h o ha ve e x perie nce d aS D, P R ,or C R s h o ul d c o nti n ue 
treat me nt t hr o u g h t he e n d of [ADDRESS_838673] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838674] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 2 / [ADDRESS_838675] u d y a n d will be treate d 
a n d m o nit ore d acc or di n g t o t he Sc he d ule of Assess me nt f or t he E x pa n si o n p orti o n of t he trial 
starti n g at Wee k 1, Da y  1 (see  Ta ble 2).
S u bjects will be as ke d t o visit t he i n vesti gati o nal site acc or di n g t o t he Sc he d ules of Assess me nts 
(see  Ta ble 1a n d  Ta ble 2) .A ti me wi n d o w of u p t o 3 da y s bef ore or 1 da y af ter t he sc he d ule d visit 
da y  ( -3 / + 1 da y s) will be per mitte d f or all st u d y  pr oce d ures (e xce pt o n Da y  2  a n d t he Da y  4 4- 5 0 
visit ). I n a d diti o n, t he t u m or e val uati o n (see Secti o n 7. 3 ) has a t u m or asses s me nt visiti n g ti me 
wi n d o w of 5d a y s pri or t o d osi n g (- 5 d a y s).   F urt her m ore, if a n y Scree ni n g pr oce d ures are 
c o n d ucte d wit hi n 3d a y s pri or t o D a y  1 o f trial treat me nt ( Wee k 1, Da y 1), t he assess me nts 
sc he d ule d o n Wee k 1, D a y  [ADDRESS_838676] d osi n g at n o less t ha n 4 8 -h o ur i nter vals bet wee n s u bjects. 
D uri n g t he treat me nt peri o d, t he f oll o wi n g assess me nts will be perf or me d (see  Ta ble 1a n d  Ta ble 
3f or t he detaile d sc he d ule): 
D L Ts will be assesse d d uri n g t he first 2 1 d a y sof trial treat me nt f or eac h d ose le vel of t he 
d ose -escalati o n part (see Secti o n  5. 1. 3. 2 )
A Es a n d c o nc o mita nt me dicati o ns will be d oc u me nte d at eac h st u d y  visit 
E C O G P S will be assesse d pri or t o trial treat me nt o n Da y  1  ( u nless t he Scree ni n g E C O G P S 
was perf or me d wit hi n 3 da y s pri or t o Da y  1) a n d acc or di n g t o  Ta ble 1t hereafter 
P h y sical e xa mi nati o n will be perf or me d pri or t o trial treat me nt o n D a y  1 ( Wee k 1), D a y  2 , 
D a y 8, a n d t he n pri or t o trial treat me nt acc or di n g t o  Ta ble 1
E y e si g ns a n d s y m pt o ms s h o ul d be c hec ke d.  If cli nicall y re le va nt fi n di n gs t he n a n a p pr o priate 
o p ht hal m ol o g y  e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt 
a n d wit h vis ual ac uit y  s h o ul d be o btai ne d wit hi n [ADDRESS_838677] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838678] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 3 / 1 9 3 Der mat ol o gical assess me nts (a ssess me nts f or s ki n lesi o ns or ras h wit h bi o ps y  o f s us pi[INVESTIGATOR_37180] o us 
lesi o ns acc or di n g t o  Ta ble 1)
Vital si g ns i ncl u di n g b o d y wei g ht, will be as sesse d pri or t o trial treat me nt acc or di n g t o  Ta ble 1
T he 1 2- lea d E C G will be assesse d pri or t o a n d as s o o n as p ossi ble after i nf usi o n acc or di n g t o 
Ta ble 1
T he la b orat or y  h e mat ol o g y  a n d he m ostase ol o g y tests will be assesse d pri or t o trial treat me nt 
acc or di n g t o Ta ble 1. C o m plete bl o o d c o u nt res ults m ust be dra w n a n d re vie we d wit hi n 
4 8 h o u rs pri or t o d ose a d mi nistrati o n 
F ull ser u m c he mistr y (i ncl u d es c ore c he mistr y )a n d c ore ser u m c he mistr y  will be assesse d pri or 
t o trial treat me nt acc or di n g t o  Ta ble 1.  Sa m ples f or c ore c he mistr y  r es ults m ust be dra w n a n d 
re vie we d wit hi n 4 8 h o urs pri or t o d ose a d mi nistrati o n 
Sa m ples f or A N As a n d R F acc or di n g t o  Ta ble 1
Ser u m electr o p h oresis at Wee k 1 3 ( Visit 1 0) 
Abasic uri nal ys is will be perf or me d pri or t o trial treat me nt acc or di n g t o  Ta ble 1
Aser u m H C G pre g na nc y  t est will be re q uire d at Scree ni n g, uri ne or ser u m β- H C G pre g na nc y  
test will be perf or me d acc or di n g t o  Ta ble 1.   Res ults of t he m ost rece nt pre g na nc y  t est s h o ul d 
be a vaila ble pri or t o ne xt d osi n g (if a p plica ble) 
T he t u m or e val uati o n (see Secti o n 7. 3 ) will be perf or me d at Wee k 7, a n d t he n o nce e ver y  
6wee ks, wit h a t u m or assess me nt visiti n g ti me w i n d o w of 5 da ys pri or t o d osi n g .  F or s u bjects 
c o nti n ui n g treat me nt be y o n d 1 2 m o nt hs (i n c o ns ultati o n wit h t he Me dical M o nit or) ,t u m or 
e val uati o ns s h o ul d ta ke place e ver y  1 2 wee ks 
P K sa m ples will be dra w n as detaile d i n  Ta ble 3
Free T 4 a n d T S H will be meas ure d pri or t o trial treat me nt acc or di n g t o  Ta ble 1
A D A sa m ples will be dra w n as detaile d i n Ta ble 3.   T he ter m f or A D A o n t he C R F is 
h u ma n -a nti h u ma n a nti b o dies ( H A H A )
P D -L 1  tar get occ u pa nc y  sa m ples will be dra w n as detaile d i n  Ta ble 3(see Secti o n 7. 6. 1) 
T he i m m u n o m o nit ori n g a n d s ol u ble fact ors will be perf or me d as detaile d i n Ta ble 3a n d as 
descri be d i n Secti o n 7. 6. 1. 2 
Sa m ples f or T G F β 1, 2 a n d 3 deter mi nati o n a n d q ua ntificati o n of ph os p h or y late d S M A D 2/ 3 
( p S M A D 2/ 3) will be dra w n as detaile d i n  Ta ble 3( n ote: Sa m ples f or p S M A D 2/ 3 will n ot be 
c ollecte d i n t he bac kfill ,3 0 m g/ k g , or 2 4 0 0 m g flat -d ose d ose -escalati o n c o h orts) 
Bl o o d sa m ples f or ge ne e x pressi o n e val uati o n will be c ollecte d acc or di n g t o  Ta ble 3(pri or t o 
st u d y  dr u g a d mi nistrati o n w here a p plica ble) 
F or s u bjects u n der g oi n g t he o pti o nal Wee k 7 bi o ps y , t he bi o p s y s h o ul d be perf or me d wit hi n 
7da y s after t he Wee k 7 I M P a d mi nistrati o n (Ta ble 3) .
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838679] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 4 / 1 9 3 7. 1. 2. 2 E x p a nsi o n P h ase Tre at me nt Peri o d 
D uri n g t he treat me nt peri o d, t he f oll o wi n g assess me nts will be perf or me d (see  Ta ble 2a n d  Ta ble 
3f or t he detaile d sc he d ule): 
F or s u bjects i n t he H C C [ADDRESS_838680] o ma, mela n o ma, o varia n ca ncer, S C C H N, T N B C, cer vical ca ncer, 
a n d N S C L Csec o n d -li ne a n d a nti -P D -1/ P D -L [ADDRESS_838681] -re p orte d o utc o mes / 
s y m pt o m se verit yassess me nts (P GI S, F H SI -8, E O R T C Q L Q- C 3 0, E O R T C Q L Q- C X 2 4, 
E O R T C Q L Q- B N 2 0, E O R T C Q L Q- H C C 1 8 -M, E O R T C Q L Q- O E S 1 8, E O R T C Q L Q- O V 2 8 , 
a n d/ or N S C L C- S A Q ) will be c o m plete d pri or t o a n y  st u d y -relate d pr oce d ures as i n dicate d i n 
Ta ble 2
A Es a n d c o nc o mita nt me dicati o ns will be d oc u me nte d i n eac h st u d y visit 
F or a n y bi o psies or ot her pr oce d ures res ulti n g i n tiss ue ac q uisiti o n, official pat h ol o g y  r e p orts 
m ust be file d a n d a vaila ble f or re vie w if re q ueste d 
E C O G P S will be assesse d pri or t o trial treat me nt o n Da y  1  ( u nless t he Scree ni n g E C O G P S 
was perf or me d wit hi n 3 da y s pri or t o Da y  1) a n d acc or di n g t o  Ta ble 2t hereafter 
P h y sical e xa mi nati o n will be perf or me d pri or t o trial treat me nt o n Da y  1  ( Wee k 1) a n d t he n 
pri or t o trial treat me nt acc or di n g t o  Ta ble 2
E y e si g ns a n d s y m pt o ms s h o ul d be c hec ke d.  If cli nicall y rele va nt fi n di n gs t he n a n a p pr o priate 
o p ht hal m ol o g y  e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g m e nt 
a n d wit h vis ual ac uit y  s h o ul d be o btai ne d wit hi n 2 da y s
Der mat ol o gical assess me nts (a ssess me nts f or s ki n lesi o ns or ras h wit h bi o ps y  o f s us pi[INVESTIGATOR_37180] o us 
lesi o ns acc or di n g t o  Ta ble 2) 
Vital si g ns , i ncl u di n g b o d y  wei g ht, will be assesse d pri or t o trial treat me nt acc or di n g t o  Ta ble 
2
The 1 2 -lea d E C G will be assesse d acc or di n g t o  Ta ble 2
T he la b orat or y  h e mat ol o g y  a n d he m ostase ol o g y tests will be assesse d pri or t o trial treat me nt 
acc or di n g t o Ta ble 2.  C o m plete bl o o d c o u nt res ults m ust be dra w n a n d re vie we d wit hi n 
[ADDRESS_838682] o p i n H g b val ue, es peciall y H g b < 8 g/ d L, r o uti ne m o nit ori n g of 
H g b, re d bl o o d cells, a n d he mat o crit s h o ul d be perf or me d wee kl y
F ull ser u m c he mistr y (i ncl u d es c ore c he mistr y )a n d c ore ser u m c he mistr y  will be assesse d pri or 
t o trial treat me nt acc or di n g t o  Ta ble 2.  Sa m ples f or c ore c he mistr y  r es ults m ust be dra w n a n d 
re vie we d wit hi n 4 8 h o u rs pri or t o d ose a d mi nistrati o n   
Abasic uri nal ys is will be perf or me d pri or t o trial treat me nt e ver y  acc or di n g t o Ta ble 2
Sa m ples f or A N As a n d R F acc or di n g t o  Ta ble 2
Aser u m H C G pre g na nc y  t est will be re q uire d at Scree ni n g, uri ne or ser u m β- H C G pre g na nc y  
test will be perf or me d acc or di n g t o  Ta ble 2.  Res ults of t he m ost rece nt pre g na nc y  t est s h o ul d 
be a vaila ble pri or t o ne xt d osi n g (if a p plica ble) 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838683] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 6 / 1 9 3 E O R T C Q L Q- B N 2 0, E O R T C Q L Q- H C C 1 8 -M, E O R T C Q L Q- O E S 1 8, E O R T C Q L Q- O V 2 8 , 
a n d/ or N S C L C- S A Q )will be c o m plete d pri or t o a n y  s t u d y -relate d pr oce d ures as i n dicate d i n 
Ta ble 2
D oc u me nta ti o n of A Es a n d c o nc o mita nt me dicati o n 
P h y sical e xa mi nati o n i ncl u di n g vital si g ns a n d b o d y  wei g ht 
E y e si g ns a n d s y m pt o ms s h o ul d be c hec ke d.  If cli nicall y rele va nt fi n di n gs t he n a n a p pr o priate 
o p ht hal m ol o g y  e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt 
a n d wit h vis ual ac uit y  s h o ul d be o btai ne d wit hi n 2 da y s
Der mat ol o gical assess me nts (a ssess me nts f or s ki n lesi o ns or ras h wit h bi o ps y  o f s us pi[INVESTIGATOR_37180] o us 
lesi o ns )
La b orat or y  he mat ol o g y , he m ostase ol o g y ,f ull ser u m c he mistr y , a n d basic uri nal y sis 
Sa m ples f or A N As a n d R F ( Escalati o n p hase) 
E C O G perf or ma nce stat us will be assesse d 
Bl o o d sa m ples f or ge ne e x pressi o n e val uati o n ( e x pa nsi o n c o h orts o nl y )
O pti o nal “ pr o gressi o n bi o ps y ” f or s u bjects w h o ha d ac hie ve d at least S D f or ≥[ADDRESS_838684] u d y  t reat me nt d ue t o a n assess me nt of P D.  T he o pti o nal 
“ pr o gressi o n bi o ps y” will be use d t o e val uate t he p ote ntial mec ha nis ms of t u m or esca pe. 
7. 1. [ADDRESS_838685] -Tre at me nt F oll o w -u p 
7. 1. 4. 1 2 8 -D a y S afet y F oll o w -u p Visit 
A Safet y F oll o w - u p visit is sc he d ule d 4 wee ks ( 2 8 ± 5 d a y s) after t he last a d mi nistrati o n of 
M S B [ADDRESS_838686] 
treat me nt, assess me nts ass ociate d wit h t he 2 8- D a y  S afet y  F oll o w -u p visit ma y  be c o n d ucte d at t he 
E n d - of- Treat me nt visit.   T he 2 8- D a y  S afet y F oll o w -u p visit will c o m prise a f ull assess me nt f or 
safet y, i m m u n o ge nicit y, a n d t u m or res p o nse as a p pr o priate, w hic h will i ncl u de t he f oll o wi n g (refer 
t o  Ta ble 1, Ta ble 2, a n d  Ta ble 3):
F or s u bjects i n t he H C C [ADDRESS_838687] o ma, mela n o ma, o varia n ca ncer, S C C H N, T N B C, cer vical ca ncer, 
a n d N S C L Csec o n d -li ne a n d a nti -P D -1/ P D -L [ADDRESS_838688] -re p orte d o utc o mes / 
s y m pt o m se verit yassess me nts (P GI S, F H SI -8, E O R T C Q L Q-C 3 0, E O R T C Q L Q- C X 2 4, 
E O R T C Q L Q- B N 2 0, E O R T C Q L Q- H C C 1 8 -M, E O R T C Q L Q- O E S 1 8, E O R T C Q L Q- O V 2 8 , 
a n d/ or N S C L C- S A Q )will be c o m plete d pri or t o a n y  s t u d y -relate d pr oce d ures as i n dicate d i n 
Ta ble 2
A Es, c o nc o m ita nt me dicati o ns 
Vital si g ns a n d b o d y wei g ht 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838689] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 7 / 1 9 3 P h y sical e xa mi nati o ns 
E y e si g ns a n d s y m pt o ms s h o ul d be c hec ke d.  If cli nicall y rele va nt fi n di n gs t he n a n a p pr o priate 
o p ht hal m ol o g y  e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt 
a n d wit h vis ual ac uit y  s h o ul d be o btai ne d wit hi n 2 da y s
Der mat ol o gical assess me nts (a ssess me nts f or s ki n lesi o ns or ras h wit h bi o ps y  o f s us pi[INVESTIGATOR_37180] o us 
lesi o ns )
T he 1 2 -lea d E C G 
T he la b orat or y  he mat ol o g y , he m ostase ol o g y , f ull ser u m c he mistr y , ser u m electr o p h oresis tests 
( d ose escalati o n o nl y ), a n d f ull uri nal y sis 
E C O G perf o r ma nce stat us will be assesse d 
T he uri ne β -H C G pre g na nc y  test (i n fe males of c hil d beari n g p ote ntial) 
T he t u m or e val uati o n ( o nl y  t o be perf or me d, if n o disease pr o gres si o n was d oc u m e nte d 
pre vi o usl y )
Free T 4 a n d T S H 
Sa m ples f or A N As a n d R F ( E x pa nsi o n c o h orts )
P K sa m ple 
A D A sa m ple (see Secti o n 7. 7. 1 ).  T he ter m f or A D A o n t he C R F is h u ma n -a nti h u ma n 
a nti b o dies ( H A H A )
T he i m m u n o m o nit ori n g a n d s ol u ble fact ors will be perf or me d as descri be d i n Secti o n 7. 6. 1. 2 
a n d Secti o n 7. 6. 2. 2 a n d Ta ble 1, Ta ble 2, a n d  Ta ble 3
Sa m ples f or T G F β deter mi nati o n a n d p S M A D 2/ 3 ( d ose -escalati o n p hase o nl y ; n ote: Sa m ples 
f or p S M A D 2/ 3 will n ot be c ollecte d i n t he bac kfill or 3 0 m g/ k g d ose -escalati o n c o h orts ) 
q ua ntificati o n as descri be d i n  Ta ble 3
Sa m ples f or viral l oa d testi n g ( H B V, H C V) a n d al p ha -fet o pr otei n ( H C C sec o n d -li ne c o h ort, 
b ot h asce n di n g d ose a n d e x pa nsi o n) 
Bl o o d sa m ples f or ge ne e x pressi o n e val uati o n f or s u bjects wit h P D ( d ose -escalati o n c o h orts 
o nl y ). 
7. 1. 4. 2 S afet y F oll o w -u p Visit 
All s u bjects will ha ve a s u bse q ue nt visit sc he d ule d 1 0 wee ks ( ± 2 wee ks) after t he last 
a d mi nistrati o n of M S B 0 0 1 1 3 5 9 C .  If a n ot her a nti ne o plastic t hera p y i s a d mi nistere d bef ore t he e n d 
of t he 1 0- wee ks peri o d, t he 1 0- W ee k Safet y F oll o w -u p visit mi g ht be c o n d ucte d as a p h o ne call 
wit h o ut p h y sical or la b orat or y  a ssess me nts. Ot her wise, t he visit will i ncl u de t he f oll o wi n g f ull 
assess me nt of safet y para meters (refer t o  Ta ble 1, Ta ble 2, a n d  Ta ble 3):
A Es t hat are dee me d attri b uta ble t o trial dr u g b y  t he I n vesti gat or a n d c o nc o mita nt me di cati o ns 
(i ncl u di n g f urt her a nti- ca ncer t hera p y)will be d oc u me nte d 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838690] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 8 / 1 9 3 Vital si g ns a n d b o d y  wei g ht will be meas ure d 
P h y sica l e xa mi nati o n will be perf or me d 
E y e si g ns a n d s y m pt o ms s h o ul d be c hec ke d.  If cli nicall y rele va nt fi n di n gs t he n a n a p pr o priate 
o p ht hal m o l o g y  e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt 
a n d wit h vis ual ac uit y  s h o ul d be o btai ne d wit hi n 2 da y s
Der mat ol o gical assess me nts (a ssess me nts f or s ki n lesi o ns or ras h wit h bi o ps y  o f s us pi[INVESTIGATOR_37180] o us 
lesi o ns )
E C O G perf or ma nce stat us will be assesse d 
1 2- lea d E C G will be assesse d 
La b orat or y  testi n g c o nsisti n g of t he f oll o wi n g will be assesse d: 
oHe mat ol o g y , he m ostase ol o g y , f ull ser u m c he mistr y , a n d uri nal ys is 
oT 4, a n d T S H le vels 
Sa m ples f or A N As a n d R F ( E x pa nsi o n c o h orts )
P K sa m ple will be c ollecte d 
A D A sa m ple .  T he ter m f or A D A o n t he C R F is h u ma n -a nti h u ma n a nti b o dies ( H A H A) 
Sa m ples f or viral l oa d testi n g ( H B V, H C V; H C C sec o n d -li ne c o h ort, b ot h asce n di n g d ose a n d 
e x pa nsi o n) 
A uri ne β -H C G pre g na nc y  test (i n w o me n of c hil d beari n g p ote ntial) will be c o n d ucte d. 
N ote:   After at least 5 0 s u bjects acr oss t he d ose escalati o n a n d all e x pa nsi o n c o h orts ha ve bee n 
e val uate d f or safet y b y  t he S M C, wit h a p pr o priate S M C safet y rec o m me n dati o n t he 1 0- Wee k 
Safet y  F oll o w -u p visit ma y  be c o n d ucte d b y  p h o ne wit h o ut t he sc he d ule d asses s me nts .
7. 1. 4. 3 L o n g -ter m F oll o w -u p / Tri al Ter mi n ati o n 
All S A Es o n g oi n g at t he [ADDRESS_838691] is d oc u me nte d as 
“l ost t o f oll o w - u p”.   I n  a d diti o n, all trial dr u g -relate d S A Es occ urri n g after 2 8- D a y  S afet y 
F oll o w -u p visit a n d on g oi n g at t he Safet y F oll o w - u p visit ha ve t o be f oll o we d u p i n t he sa me 
ma n ner. 
S u bjects wit h o ut P D at t he 2 8- Da y  S afet y F oll o w -u p visit will be f oll o we d u p f or disease 
pr o gressi o n ( C T / M RI  s ca ns e ver y [ADDRESS_838692] assess me nt 1 2 wee ks after t h e pre vi o us 
t u m or assess me nt [sc he d ule d ti me p oi nt ]) u ntil P D .  
After t he 2 8- D a y  S afet y F oll o w -u p visit, s u bjects will be f oll o we d q uarterl y  ( ± 1 4 d a y s) f or 
s ur vi val (i ncl u di n g assess me nt of a n y  f urt her a ntica ncer t hera p y).  T he s ur vi val f oll o w - u p will 
c o n ti n ue u ntil [ADDRESS_838693] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838694] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 9 / 1 9 3 After c o m pleti o n of t he F oll o w - u p peri o d or at disc o nti n uati o n of t he trial, w hate ver is 
a p plica ble /c o mes first, t he a p pr o priate e C R F secti o n f or Trial Ter mi nati o n m ust be c o m plete d. 
7. 1. [ADDRESS_838695] n ot e xcee d 1 2 0 m L / da y  a n d 
[ADDRESS_838696] be perf or me d d uri n g t he Scree ni n g 
peri o d. 
7. 2. 1 De m o gr a p hic D at a 
T he f oll o wi n g de m o gra p hic data will be rec o rde d :
S u bject i de ntifier 
Date of birt h 
Se x 
Et h nicit y 
Race .
7. 2. [ADDRESS_838697] i ncl u des: 
Detaile d hist or y  o f t he t u m or ,i ncl u di n g hist o pat h ol o gical dia g n osis, gra di n g a n d sta gi n g i n 
acc or da nce wit h t he U ni o n I n ter nati o nale C o ntre le Ca ncer T u m or N o de Metastasis 
Classificati o n at di a g n osis ( UI C C T N M) 
oT he M cate g or y  ( M 0 or M 1) of t he t u m or at t he ti me of st u d y  e ntr y , base d o n scree ni n g 
assess me nts 
All t hera p y use d f or pri or treat me nt of t he t u m or (i ncl u di n g s ur ger y , ra di ot hera p y a n d 
c he m ot hera p y, i m m u n ot hera p y, etc )
A n y  o t her c o n diti o ns t hat were treate d wit h c he m ot hera p y, ra di ati o n t hera p y,  o r i m m u n ot hera p y 
C urre nt ca ncer si g ns a n d s y m pt o ms a n d si de effects fr o m c urre nt a n d / or pre vi o us a ntica ncer 
treat me nts 
C urre nt ca ncer disease stat us 
B R C A , t u m or H P V a n d t u m or mis matc h- re pair stat us d oc u me ntati o n, if k n o w n 
S m o ki n g hist or y (f or N S C L C a n d cer vical ca ncer e x pa nsi o n c o h ort so nl y ).
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838698] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 0 / [ADDRESS_838699]’s eli gi bilit y  t o t he trial, a c o m plete me dical hist or y  o f eac h s u bject 
will be c ollecte d a n d d oc u me nte d d uri n g Scree ni n g , w hic h will i ncl u de, b ut ma y n ot be li mite d t o, 
t he f oll o wi n g: 
Past a n d c o nc o mita nt n o n -ma li g na nt diseases a n d treat me nts 
All me dicati o ns ta ke n a n d pr oce d ures carrie d o ut wit hi n [ADDRESS_838700] descri be d i n Secti o n 5. 3. 2. 
7. 2. 4 Vit al Si g ns a n d P h ysic al E x a mi n ati o n 
Vital si g ns i ncl u di n g b o d y  t e m perat ure, res pi[INVESTIGATOR_1305] y  r ate, heart rate (after 5- mi n ute rest), a n d arterial 
bl o o d press ure (after [ADDRESS_838701]) ,bo d y  wei g ht a n d hei g ht will be rec or de d at st u d y  e ntr y . 
Ph y sical e xa m i nati o n swill be perf or me d acc or di n g t o Ta ble 1a n d Ta ble 2. A n op ht hal m ol o g y 
e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt a n d wit h vis ual ac uit y
s h o ul d be c o n d ucte d. 
T he E C O G P S will be d oc u me nte d d uri n g t he Scree ni n g p hase. 
7. 2. 5 C T or M RI Sc a ns f or T u m or Assess me nt at B aseli ne 
A C T sca n or M RI (if M RI  i s use d, C T of c hest is ma n dat or y [f or trial sites i n c o u ntries wit h 
ra diati o n e x p os ure c o ntr ol f or s u bjects, o nl y  M RI  m a y be use d ]; f or s u bjects i n t he H C C c o h ort, 
m ulti p has e C T wit h c o ntrast is ma n dat or y ) of t he c hest, a b d o me n, a n d pel vis (at a mi ni m u m a n d 
ot her esta blis he d assess me nts of t u m or b ur de n if C T / M RI  i ma gi n g is n ot s ufficie nt f or t he 
i n di vi d ual s u bject; ot her re gi o ns as s pecificall y  r e q uire d f or s pecific t u m or in dicati o ns) will be 
perf or me d wit hi n 2 8 da ys pri or t o trial treat me nt start i n or der t o d oc u me nt t he baseli ne stat us of 
t he t u m or disease usi n g R E CI S T 1. 1 tar get a n d n o n- tar get lesi o ns a n d sec o n daril y  u si n g m R E CI S T 
f or s u bjects i n t he H C C c o h ort (see ve n d or ma n ual) .  F or s u bjects i n t he gli o blast o ma c o h ort, t he 
assess me nt will be ma de acc or di n g t o R A N O . H o we ver, if t he res ults of a C T sca n or M RI 
perf or me d wit hi n [ADDRESS_838702] treat me nt are a vaila ble, t he Scree ni n g C T / M RI  d oes n ot 
nee d t o be perf or me d. 
A brai n C T / M RI sca n (eit her, c o ntrast preferre d) is re q uire d at Scree ni n g if n ot perf or me d wit hi n 
t he pre vi o us 6 wee ks. T hereafter, brai n C T /M RI sca n s h o ul d be d o ne if cli nicall y  i n dicate d b y  
de vel o p me nt of ne w s pecific s y m pt o ms. 
Ab o ne sca n s h o ul d be d o ne at Scree ni n g as cli nicall y  i n dicate d. 
7. 2. [ADDRESS_838703] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838704] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 1 / [ADDRESS_838705] 
f ulfills all t he trial e ntr y criteria as liste d i n Secti o n 5. 3. 1 a n d d oes n ot meet a n y of t he trial 
e xcl usi o n criteria f or la b orat or y  p ara meters as liste d i n Secti o n 5. 3. 2 . Detaile d descri pti o n of 
la b orat or y  assess me nts is pr o vi de d i n Secti o n  7. 4. 3. 
7. 3 Effic ac y Assess me nts 
F or all s u bjects i n all c o h orts, t u m or res p o nse assess me nt will be perf or me d b y  C T sca n or M RI 
(if M RI  i s use d, C T of c hest is ma n dat or y [f or trial sites i n c o u ntries wit h ra diati o n e x p os ure c o ntr ol 
f or s u bjects, o nl y  M RI ma y be use d], f or s u bjects i n t he H C C c o h ort, m ulti p hase C T wit h c o ntrast 
is ma n dat or y ) i ma gi n g of t he c hest / a b d o me n / pel vis ( pl us ot her re gi o ns as s pecificall y  r e q uire d 
f or s pecific t u m or t y p es) a n d ot her esta blis he d assess me nts of t u m or b ur de n if C T / M R I i ma gi n g 
is i ns ufficie nt f or t he i n di vi d ual s u bject.  A ll t he sca ns perf or me d at Baseli ne a n d ot her i ma gi n g 
perf or me d as cli nicall y  r e q uire d ( ot her s u p p orti ve i ma gi n g) nee d t o be re peate d at s u bse q ue nt 
visits.  I n ge neral, lesi o ns detecte d at Baseli ne nee d t o be f oll o we d usi n g t he sa me i ma gi n g 
met h o d ol o g y a n d prefera bl y  t he sa me i ma gi n g e q ui p me nt at s u bse q ue nt t u m or e val uati o n visits. 
A brai n C T / M RI  s ca n (eit her, wit h c o ntrast preferre d) is re q uire d at Scree ni n g if n ot perf or me d 
wit hi n t he pre vi o us 6 wee ks.  T hereafter brai n C T / M RI  s ca n s h o ul d be perf or me d, if cli nicall y 
i n dicate d b y  d e vel o p me nt of ne w s pecific s y m pt o ms. A b o ne sca n s h o ul d be perf or me d at 
Scree ni n g a n d b e y o n d as cli nicall y  i n dicate d. S ki n metastasis ca n be use d as tar get lesi o ns 
acc or di n g t o R E CI S T 1. [ADDRESS_838706] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838707] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 2 / 1 9 3 desi g nate 1 or m ore of t he f oll o wi n g meas ures of t u m or stat us t o f oll o w f or deter mi ni n g res p o nse: 
C T or M RI  i ma ges of pri mar y  a n d / or metastatic t u m or masses, p h y sical e xa mi nati o n fi n di n gs, 
a n d t he res ults of ot her assess me nts. All a vaila ble i ma ges c ollecte d d uri n g t he trial peri o d will be 
c o nsi dere d. T he m ost a p pr o priate meas ures t o e val uate t he t u m or stat us of a s u bject s h o ul d be 
use d. T he meas ure(s) t o be c h ose n f or se q ue ntial e val uati o n d uri n g t he trial ha ve t o c orres p o n d t o 
t h e meas ures use d t o d oc u me nt t he pr o gressi ve t u m or stat us t hat q ualifies t he s u bject f or 
e nr oll me nt. T he t u m or res p o nse assess me nt will be assess e d a n d liste d acc or di n g t o t he Sc he d ule 
of A ssess me nts (refer t o  Ta ble 1a n d  Ta ble 2).
T he f oresee n treat me nt d urati o n is u ntil disease pr o gressi o n verifie d b y  a s ca n s u bse q ue nt t o t he 
i nitial d oc u me ntati o n of P D , u nacce pta ble t o xicit y , or a n y criteri o n f or wit h dra wal fr o m t h e trial 
or I M P occ urs (see Secti o n  5. 5 ).Bef ore st o p pi n g t he tre at me nt, pr o gressi ve dise ase s h o ul d be 
c o nfir me d b y i m a gi n g 4 t o 6 wee k s(prefer a bl y 6 wee ks ,b ut n ot l ater) after pr o gressi o n h as 
bee n di a g n ose d acc or di n g t o R E CI S T 1. 1. If pr o gressi o n is base d o n t he occ urre nce of a n e w 
lesi o n i n a n area n ot sca n ne d at Baseli ne, a f urt her o n- st u d y  s ca n 6wee ks later s h o ul d be 
c o nsi dere d bef ore perf or mi n g t he 2 8 -D a y  S afet y F oll o w - u p visit. Treat me nt m a y  b e c o nti n ue d 
des pi[INVESTIGATOR_171636] o gressi o n acc or di n g t o R E CI S T 1. 1 at a n y ti me if: 
T here are n o ne w s y m pt o ms or w orse ni n g of e xisti n g s y m pt o ms. 
T here is n o decrease i n E C O G P S .
T he I n vesti gat or d oes n ot c o nsi der it necessa r y  t o a d mi nister a sal va ge t hera p y . 
T he treat me nt s h o ul d be st o p pe d i m me diatel y , if t he s u bject d oes n ot t olerate M S B [ADDRESS_838708] u g 
or res ults i n cli nicall y  si g nif ica nt pr o gressi o n / deteri orati o n. 
T u m or res p o nses t o treat me nt will be assi g ne d base d o n t he e val uati o n of t he res p o nse of tar get, 
n o n- tar get, a n d ne w lesi o ns acc or di n g t o R E CI S T 1. 1 (all meas ure me nts s h o ul d be rec or de d i n 
metric n otati o n) a n d sec o n daril y usi n g m R E CI S T f or s u bjects i n t he H C C c o h ort (see 
Secti o n 7. 3. 2) .F or s u bjects i n t he gli o blast o ma c o h ort, t he assess me nt will be ma de acc or di n g t o 
R A N O. 
T o assess o bjecti ve res p o nse, t he t u m or b ur de n at baseli ne will be esti mate d a n d use d f or 
c o m paris o n wit h s u bse q ue nt meas ure me nts. At baseli ne, t u m or lesi o ns will be cate g orize d i n 
tar get a n d n o n- tar get lesi o ns acc or di n g t o R E CI S T 1. [ADDRESS_838709] be d o ne n o 
s o o ner t h a n 4 wee ks ( prefer a bl y at t he sc he d ule d 6- wee k i nter v al) . 
T he In vesti gat or ma y  perf or m sca ns i n a d diti o n t o a sc he d ule d trial sca n f or me dical reas o ns or if 
t h e I n vesti gat or s us pects P D . 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838710] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 3 / [ADDRESS_838711] u d y acc or di n g t o t he I n vesti gat or’s decisi o n a n d i n a gree me nt wit h t he s u bject i n 
case of P D acc or di n g t o R E CI S T 1. 1 , m R E CI S T ( H C C) ,or R A N O ( gli o blast o ma) . 
Su bjects w h o ha ve e x perie nce d S D, P R ,or C R s h o ul d c o nti n ue treat me nt t hr o u g h t he e n d of 
[ADDRESS_838712] 
ma y  b e nefit fr o m treat me nt b e y o n d 1 2 m o nt hs, it ma y  b e per miss i ble after disc ussi o n wit h t he 
Me dical M o nit or a n d t he S p o ns or Me dical Res p o nsi ble .S u bjects re -i nitiati n g treat me nt s h o ul d be 
assesse d acc or di n g t o t he Sc he d ule of Assess me nts ( see Secti o n  5. 1. 6 ).
7. 3. 1 I m m u ne -rel ate d Res p o nse C riteri a 
T he ir R E CI S T is o nl y  a ssesse d b y  t he i n de pe n de nt ra di ol o g y  r e vie w, n ot as a n I n vesti gat or 
assess me nt. 
Bel o w is a s u m mar y  of ir R E CI S T (f or m ore c o m pre he nsi ve i nf or mati o n, refer t o B o h nsac k 2 0 1 4 ).
1. T otal meas ure d t u m or b ur de n ( T M T B) : Baseli ne -selecte d tar get lesi o ns a n d ne w meas ura ble 
lesi o ns s h o ul d N O T be assesse d se paratel y.   Meas ure me nts of t h ose lesi o ns s h o ul d be 
c o m bi ne d i nt o t he T M T B , a n d o ne c o m bi ne d assess me nt pr o vi de d. 
2. Ne w Meas ura ble Lesi o ns: I n  i r R E CI S T, criteria f or u ni di me nsi o nal lesi o n meas ur eme nt a p pl y 
t o b ot h tar get a n d ne w meas ura ble lesi o ns: a mi ni m u m [ADDRESS_838713] dia meter f or 
n o n- n o dal lesi o ns, a n d a mi ni m u m 1 5 m m i n s h ort a xis f or l y m p h n o des.   S maller lesi o ns 
c o ntri b ute t o t he n o n- tar get or ne w n o n - meas ura ble t u m or b ur de n, b ut d o n ot get meas ure d. 
3. ir P R if n o Tar g et Lesi o ns: If ne w meas ura ble lesi o ns a p pear i n s u bjects wit h n o tar get lesi o ns 
at Baseli ne, ir P D will be assesse d. T hat ir P D ti me p oi nt will be c o nsi dere d a ne w Baseli ne, 
a n d all s u bse q ue nt ti me p oi nt swill be c o m pare d wit h it f or res p o nse assess me nt. A n 
assess me nt of ir P R is p ossi ble if t he T M T B of ne w meas ura ble lesi o ns decreases b y  ≥ 3 0 % 
c o m pare d wit h t he first ir P D d oc u me ntati o n. 
4. N o n -Tar g et Lesi o ns: I n  ali g n me nt wit h R E CI S T 1. 1, Baseli ne selecte d n o n -tar get lesi o ns ca n 
ne ver c o n vert t o meas ura ble lesi o ns, n ot e ve n if t he y i ncrease i n size at s u bse q ue nt ti me p oi nt s 
a n d bec o me meas ura ble.   O nl y  t r ue ne w lesi o ns ca n be meas ure d a n d c o ntri b ute t o t he T M T B. 
E xa m ple: A s u bject has m ulti ple l u n g metastases, all s maller t ha n 1 0 m m a n d selecte d as n o- tar get 
lesi o ns at Baseli ne. If, at a s u bse q ue nt ti me p oi nt s o me of t hese n o n- tar get lesi o ns i ncrease a n d 
bec o me > 1 0 m m, a n d 1ne w lesi o n > 1 0 m m a p pears, o nl y the ne w meas ura ble lesi o n will 
c o ntri b ute t o t he T M T B, a n d n ot t he Baseli ne selecte d n o n- tar get lesi o n t hat i ncrease d i n size. 
Ot her wise s uc h a n i ncrease w o ul d ma ke persisti n g n o n- tar get lesi o ns s witc h i nt o t he ne w 
meas ura ble lesi o n cate g or y ,w hic h w o ul d be i nacc urate, as t he lesi o n e xiste d at Baseli ne. 
5. ir P D Base d o n N o n -Tar g et Lesi o ns: In ir R E CI S T ,a s u bsta ntial a n d u ne q ui v ocal i ncrease of 
n o n-tar get lesi o ns is i n dicati ve of pr o gressi o n. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838714] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 7 / 1 9 3 ≥ [ADDRESS_838715] 
e nlar gi n g lesi o n(s) s h o ul d be selecte d; ho we ver, e m p hasis s h o ul d als o be place d o n lesi o ns t hat 
all o w re pr o d uci ble re peate d meas ure me nts. Occas i o nall y, t he lar gest lesi o ns ma y  n ot le n d 
t he msel ves t o re pr o d uci ble meas ure me nts, a n d t he ne xt lar gest lesi o ns t hat ca n be meas ure d 
re pr o d uci bl y s h o ul d be selecte d. 
F or s u bjects w h o ha ve m ulti ple lesi o ns of w hic h o nl y  1or 2are i ncreasi n g i n size, t he enlar gi n g 
lesi o ns s h o ul d be c o nsi dere d t he tar get lesi o ns f or e val uati o n of res p o nse. T he ot her lesi o ns will 
be c o nsi dere d n o ntar get lesi o ns a n d s h o ul d als o be rec or de d. 
D E FI NI TI O N O F R A DI O G R A P HI C R E S P O N S E 
Ra di o gra p hic res p o nse s h o ul d be deter mi ne d i n c o m paris o n wit h t he t u m or meas ure me nt o btai ne d 
at pretreat me nt Baseli ne f or deter mi nati o n of res p o nse, a n d t he s mallest t u m or meas ure me nt at 
eit her pretreat me nt Baseli ne or after i nitiati o n of t hera p y s h o ul d be use d f or deter mi nati o n of 
pr o gressi o n. Ta ble 9lists t he criteria f or ra di o gra p hic c ha n ges after t hera p y. I n t he e ve nt t hat t he 
ra di o gra p hic c ha n ges are e q ui v ocal a n d it is u nclear w het her t he s u bject is sta ble or has de vel o pe d 
pr o gressi ve disease, it is per missi ble t o c o nti n ue treat me nt a n d o bser ve t he s u bject cl osel y , f or 
e xa m ple at 4- wee k i nter vals. If s u bse q ue nt i ma gi n g st u dies de m o nstrate t hat pr o gressi o n has 
occ urre d, t he date of pr o gressi o n s h o ul d b e t he date of t he sca n at w hi c h t his iss ue was first raise d.  
All meas ura ble a n d n o n meas ura ble lesi o ns s h o ul d be assesse d usi n g t he sa me tec h ni q ues as at 
Baseli ne . I deall y , s u bjects s h o ul d be i ma ge d o n t he sa me M RI sca n ner, or at least wit h t he sa me 
ma g ne t stre n gt h, f or t he d urati o n of t he st u d y  t o re d uce diffic ulties i n i nter preti n g c ha n ges. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838716] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 8 / [ADDRESS_838717] ors 
Assess me nt Criteri a 
C o m plete res p o nse Re q uires all of t he f o ll o wi n g: c o m plete disa p peara nce of all e n ha nci n g meas ura ble 
a n d n o n meas ura ble disease s ustai ne d f or at least 4 w ee ks; n o ne w lesi o ns; sta ble or 
i m pr o ve d n o ne n ha nci n g ( T 2/ F L AI R) lesi o ns; s u bject s m ust be off c ortic oster oi ds ( or 
o n p h ysi ol o gic re place me nt d oses o nl y); a n d sta ble or i m pr o ve d cli nicall y. 
N ote: S u bjects wit h n o n meas ura ble disease o nl y ca n n ot ha ve a c o m plete res p o nse; 
t he best res p o nse p ossi ble is sta ble disease. 
Partial res p o nse Re q uires all of t he f oll o wi n g: ≥ 5 0 % decrease c o m pare d wit h base li ne i n t he s u m of 
pr o d ucts of per pe n dic ular dia meters of all meas ura ble e n ha nci n g lesi o ns s ustai ne d f or 
at least 4 w ee ks; n o pr o gressi o n of n o n meas ura ble disease; n o ne w lesi o ns; sta ble or 
i m pr o ve d n o ne n ha nci n g ( T 2/ F L AI R) l esi o ns o n sa me or l o wer d ose of c ortic oster oi ds 
c o m pare d wit h baseli ne sca n; t he c ortic oster oi d d ose at t he ti me of t he sca n 
e val uati o n s h o ul d be n o greater t ha n t he d ose at ti me of baseli ne sca n; a n d sta ble or 
i m pr o ve d cli nicall y. 
N ote: S u bjects wit h n o n meas ura ble disease o nl y ca n n ot h a ve a partial res p o nse; t he 
best res p o nse p ossi ble is sta ble disease. 
Sta ble disease Re q uires all of t he f oll o wi n g: d oes n ot q ualif y f or c o m plete res p o nse, pa rtial 
res p o nse, or pr o gressi o n; sta ble n o ne n ha nci n g ( T 2/ F L AI R) lesi o ns o n sa me or l o w er 
d ose of c ortic oster oi ds c o m pare d wit h baseli ne sca n. I n t he e ve nt t hat t he 
c ortic oster oi d d ose w as i ncrease d f or ne w s y m pt o ms a n d si g ns wit h o ut c o nfir mati o n 
of disease pr o gressi o n o n ne ur oi m a gi n g, a n d s u bse q ue nt f oll o w -u p i ma gi n g s h o ws 
t hat t his i ncrease i n c ortic oster oi ds w as re q uire d beca use of disease pr o gressi o n, t he 
last sca n c o nsi dere d t o s h o w sta ble disease will be t he sca n o btai ne d w he n t he 
c ortic oster oi d d ose w as e q ui vale nt t o t he baseli ne d ose. 
Pr o gressi ve disease Defi ne d b y a n y of t he f oll o wi n g: ≥ 2 5 % i ncrease i n s u m of t he pr o d ucts of 
per pe n dic ular dia meters of e n ha nci n g lesi o ns c o m pare d wit h t he s mallest t u m or 
meas ure me nt o btai ne d eit her at baseli ne (if n o decrease) or best res p o nse, o n sta ble or 
i ncreasi n g d oses of c ortic oster oi ds *; si g nifica nt i ncrease i n T 2/ F L AI R n o ne n ha nci n g 
lesi o n o n sta ble or i ncreasi n g d oses of c ortic oster oi ds c o m pare d wit h baseli ne sca n or 
best res p o nse after i nitiati o n of t hera p y *n ot ca use d b y c o m or bi d e ve nts (e g, ra diati o n 
t hera p y, de m yeli nati o n, isc he mic i nj ur y, i nfecti o n, seiz ures, p ost o perati ve c ha n ges, or 
ot her treat me nt effects); a n y ne w lesi o n; clear cli nical deteri orati o n n ot attri b uta ble t o 
ot her ca uses a part fr o m t he t u m or (e g, seiz ures, me dicati o n a d verse effects, 
c o m plicati o ns of t hera p y, cere br o vasc ular e ve nts, i nfecti o n, a n d s o o n) or c ha n ges i n 
c ortic oster oi d d ose; fail ure t o ret ur n f or e val uati o n as a res ult of deat h or deteri orati n g 
c o n diti o n; or clear pr o gressi o n of n o n meas ura ble disease. 
A b bre viati o ns: M RI, ma g netic res o na nce i ma gi n g; F L A I R, fl ui d -atte n uate d i n versi o n rec o ver y. 
N O T E. All meas ura ble a n d n o n meas ura ble lesi o ns m ust be assesse d usi n g t he sa me tec h ni q ues as at baseli ne. 
* Sta ble d oses of c ortic oster oi ds i ncl u de s u bjects n ot o n c ortic oster oi ds. 
T he defi niti o n of cli nical deteri orati o n is left t o t he discreti o n of t he I n vesti gat or , b ut it is 
rec o m me n de d t hat a decli ne i n t he K P S fr o m [ADDRESS_838718] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838719] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 9 / 1 9 3 M U L TI F O C A L T U M O R S 
F or m ultif ocal lesi o ns, pr o gressi ve disease is defi ne d as ≥2 5 % i ncrease i n t he s u m of pr o d ucts of 
per pe n dic ular dia meters of all meas ura ble lesi o ns c o m pare d wit h t he s mallest t u m or meas ure me nts 
after i nitiati o n of t hera p y (Ta ble 9). T he a p peara nce of a ne w lesi o n or u ne q ui v ocal pr o gressi o n 
of n o ntar get lesi o ns will als o be c o nsi dere d pr o gressi o n. Partial res p o nse is defi ne d as ≥ 5 0 % 
decrease, c o m pare d wit h Baseli ne, i n t he s u m of pr o d ucts of per pe n dic ular dia meters of all 
meas ura ble lesi o ns s ustai ne d f or at least [ADDRESS_838720] a ble Dise ase Pr o gressi ve Dise ase 
T 1 ga d oli ni u m 
e n ha nci n g disease N o ne ≥ 5 0 % decrease < 5 0 % decrease b ut 
<2 5 % i ncrease ≥ 2 5 % i ncrease 
T 2/ F L AI R Sta ble or decrease Sta ble or decrease Sta ble or decrease I ncrease * 
N e w  Lesi o n N o ne N o ne N o ne Prese nt * 
C ortic oster oi ds N o ne Sta ble or decrease Sta ble or decrease N ot a p plica ble * * 
Cli nical stat us Sta ble or i ncrease Sta ble or i ncrease Sta ble or i ncrease Decrease * 
Re q uire me nt f or 
res p o nse All All All A n y * 
F L AI R =fl ui d- atte n uate d i n versi o n rec o ver y; R A N O = Res p o nse A ssess me nt i n Ne ur o -O nc ol o g y .
* Pr o gressi o n occ urs w he n t his criteri o n is prese nt. 
* * I ncrease i n c ortic oster oi ds al o ne will n ot be ta ke n i nt o acc o u nt i n deter mi ni n g pr o gre ssi o n i n t he a bse nce of 
persiste nt cli nical deteri orati o n. 
7. [ADDRESS_838721] (see Secti o n 7. 4. 1. 2) . 
Gi ve n t he i nte n de d M o A , partic ular atte nti o n will be gi ve n t o A Es t hat ma y f oll o w t he e n ha nce d 
T-cell acti vati o n s uc h as persiste nt ras h, diarr hea a n d c olitis, a ut oi m m u ne he patitis, art hritis, 
gl o mer ul o ne p hritis, car di o m y o pat h y, u veitis a n d ot her i nfla m mat or y  e ye c o n diti o ns , or ot her 
i m m u ne -relate d reacti o ns. O p ht hal m ol o gic e xa mi nati o ns s h o ul d be c o nsi dere d, w he n cli nicall y 
i n dicate d, f or si g ns or s y m pt o ms of u veitis. F urt her m ore, d ue t o t he a nti -T G Fβ acti vit y , partic ular 
atte nti o n will als o be gi ve n t o e ve nts ass ociate d wit h, a ne mia, a n d ras h wit h h y per kerat osis /
kerat oaca nt h o ma a n d s q ua m o us cell carci n o ma of t he s ki n .
T he re p orti n g peri o d f or A E s is descri be d i n Secti o n 7. 4. 1. 3. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838722] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 0 / 1 9 3 T he safet y assess me nts will be perf or me d acc or di n g t o t he Sc he d ule sof Assess me nt s ( see Ta ble 1
a n d  Ta ble 2).
7. 4. [ADDRESS_838723], re gar dless of ca usal relati o ns hi p wit h t his treat me nt. A n 
A E ca n t heref ore be a n y  u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y 
fi n di n g), s y m pt o m, or disease te m p orall y ass ociate d wit h t he use of a me dici nal pr o d uct, w het her 
or n ot c o nsi dere d relate d t o t he me dici nal pr o d uct. 
F or s ur gical or dia g n ostic pr oce d ures, t he c o n diti o n /ill ness lea di n g t o s uc h a pr oce d ure is 
c o nsi dere d as t he A E rat her t ha n t he pr oce d ure itself. 
I n  c ase of a fatalit y , t h e ca use of deat h is c o nsi dere d as a n A E, a n d t he deat h is c o nsi dere d as its 
O U T C O M E. 
T he I n vesti gat or is re q uire d t o gra de t he se verit yor t o xicit y of eac h A E .
I n vesti g at ors will refere nce t he N CI -C T C A E v4. 0 3 ( p u blicati o n date: 1 4 J u ne 2 0 1 0 ), a descri pti ve 
ter mi n ol o g y  t hat ca n be use d f or A E re p orti n g .
A ge neral gra di n g (se verit y /i nte nsit y ; hereafter referre d t o as se verit y) scale is pr o vi de d at t he 
be gi n ni n g of t he a b o ve refere nce d d oc u me nt, a n d s pecific e ve nt G ra des are als o pr o vi de d. 
If a partic ular A E’s se verit y is n ot s pecificall y gra de d b y t he g ui da nce d oc u me nt, t he I n vesti gat or 
is t o use t he ge neral N CI -C T C A E defi niti o ns of Gra de [ADDRESS_838724] 
me dical j u d g me nt. 
Gr a de 1: Mil d 
Gr a de 2: M o derate 
Gr a de 3: Se vere 
Gr a de 4: Life -t hreate ni n g or disa bli n g 
Gr a de 5: Deat h 
Acc or di n g t o t he S p o ns or ’s c o n ve nti o n, a n y cli nical A E wit h se verit y of Gra de [ADDRESS_838725] als o 
be re p ort e d as a n S A E as per Secti o n 7. 4. 1. 4 ; h o we ver, a la b orat or y  a b n or malit y  of Gra de [ADDRESS_838726] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838727] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 1 / 1 9 3 If deat h occ urs , t he pri mar y  c a use of deat h or e ve nt lea di n g t o deat h s h o ul d be rec or de d a n d 
re p orte d as a n S A E. “ Fatal” will be rec or de d as t he o utc o me of t h is s pecific e ve nt a n d deat h will 
n ot be rec or de d as se parate e ve nt. O nl y , i f n o ca use of deat h ca n be re p orte d ( f or e xa m ple, s u d de n 
deat h, u ne x plai ne d deat h), t he deat h per se mi g ht t he n be re p orte d as a n S A E. 
I n vesti gat ors m ust als o s y ste maticall y  a ssess t he ca usal relati o ns hi p of A Es t o t he I M P usi n g t he 
f oll o wi n g defi ni ti o ns.  D ecisi ve fact ors f or t he assess me nt of ca usal relati o ns hi p of a n A E t o t he 
M S B [ADDRESS_838728] or y , c o nc o mita nt 
me dicati o n, c o urse of t he u n derl yi n g disease, trial pr oce d ures. 
U nrel ate d: N ot reas o na bl y relate d t o t he I M P. T he A E c o ul d n ot me dicall y  ( p har mac ol o gicall y
/cli nicall y ) be attri b ute d t o t he I M P u n der st u d y i n t his cli nical trial pr ot oc ol. A 
reas o na bl e alter nati ve e x pla nati o n m ust be a vaila ble. 
Rel ate d: Reas o na bl y relate d t o t he I M P.  T he A E c o ul d me dicall y ( p har mac ol o gicall y /
cli ni call y ) be attri b ute d t o t he I M P u n der st u d y  i n t his cli nical trial pr ot oc ol. 
A b n or m al L a b or at or y Fi n di n gs a n d Ot her A b n o r m al I n vesti g ati o n al Fi n di n gs 
A b n or mal la b orat or y  f i n di n gs a n d ot her a b n or mal i n vesti gati o nal fi n di n gs (f or e xa m ple, o n a n 
E C G trace) s h o ul d n ot be re p orte d as A Es u nless t he y  a re ass ociate d wit h cli nical si g ns a n d 
s y m pt o ms, lea d t o treat me nt disc o nti n uati o n or are c o nsi dere d ot her wise me dicall y  i m p orta nt b y  
t he I n vesti gat or. If ala b orat or y a b n or malit y  f ulfills t hese criteria, t he i de ntifie d me dical c o n diti o n 
(f or e xa m ple, a ne mia, i ncrease d A L T) m ust be re p orte d as t he A E rat her t ha n t he a b n or mal val ue 
it self. 
7. 4. 1. 1. [ADDRESS_838729] u g Re acti o n ( A D R) 
A n A D R is defi ne d i n t his trial as a n y A E assesse d as relate d t o M S B 0 0 1 1 3 5 9 C b y  t he In vesti gat or 
a n d /or S p o ns or .
7. 4. 1. 1. 2 Seri o us A d verse E ve nt s
A n S A E is a n y  u nt o war d me dical occ urre nce t hat at a n y  d ose: 
Res ults i n deat h, 
Is  life -t hreate ni n g (N ote: T he ter m “life -t hreate ni n g” refers t o a n e ve nt i n w hic h t he s u bject is 
at ris k of deat h at t he ti me of t he e ve nt , n ot a n e ve nt t hat h y p ot heticall y  m i g ht ha ve ca use ddeat h 
if it was m ore se vere ), 
Re q uires i n patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n g sa n e xisti n g h os pi[INVESTIGATOR_1314] o n, 
Res ults i n persiste nt or si g nifica nt disa bilit y or i nca pacit y, 
Is a c o n ge nital a n o mal yor birt h defect, or 
Is ot her wise c o nsi dere d t o be me dicall y i m p orta nt. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838730] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 2 / 1 9 3 N ote: I m p orta nt me dical e ve nts t hat ma y  n ot res ult i n deat h, be life -t hreate ni n g, or re q uire 
h os pi[INVESTIGATOR_1314] o n ma y  be c o nsi dere d as S A Es w he n, base d u p o n a p pr o priate me dical j u d g me nt, t he y 
ma y  j e o par dize t he s u bject or m a y  r e q uire me dical or s ur gical i nter ve nti o n t o pre ve nt o ne of t he 
o utc o mes liste d a b o ve.  E xa m pl es of s uc h e ve nts i ncl u de aller gic br o nc h os pas m re q uiri n g 
i nte nsi ve treat me nt i n a n e mer ge nc y r o o m or at h o me, bl o o d d yscrasias or c o n v ulsi o ns t hat d o n ot 
res ult i n i n patie nt h os pi[INVESTIGATOR_1314] o n, or t he de vel o p me nt of dr u g de pe n de nc y  o r dr u g a b use. A n y t y p e 
of ne w (sec o n dar y ) ca ncer i ncl u di n g s q ua m o us cell ca ncer of t he s ki n s h o ul d be c o nsi dere d as 
me dicall y  i m p orta nt c o n diti o n. 
F or t he p ur p oses of re p orti n g, a n y s us pecte d tra ns missi o n of a n i nfecti o us a ge nt via a n I M P  i s als o 
c o nsi dere d aS A E , as descri be d i n Secti o n 7. 4. 1. 4 .
E ve nts Th at D o N ot Meet t he Defi niti o n of a n S A E 
Electi ve h os pi[INVESTIGATOR_1314] o ns t o a d mi nister, or t o si m plif y  t rial treat me nt or trial pr oce d ures (f or 
e xa m ple , a n o ver ni g ht sta y  t o facilitate c he m ot hera p y a n d relate d h y drati o n t hera p y a p plicati o n) 
are n ot c o nsi dere d S A Es. H o we ver, all e ve nts lea di n g t o u n pla n ne d h os pi[INVESTIGATOR_1314] o ns or u n pla n ne d 
pr ol o n gati o n of a n electi ve h os pi[INVESTIGATOR_1314] o n (f or e xa m ple, u n desira ble effects of a n y  a d mi nistere d 
treat me nt) m ust be d oc u me nte d a n d re p orte d as S A Es. 
7. 4. 1. 1. 3 E ve nts N ot t o Be C o nsi dere d as A Es /S A Es 
Me dical c o n diti o ns prese nt at t he i nitial trial visit t hat d o n ot w orse n i n se verit y  o r fre q ue nc y  d uri n g 
t he trial are defi ne d as Baseli ne Me dical C o n diti o ns, a n d are n ot t o be c o nsi dere d A Es. 
A E / S A Es O bser ve d i n Ass oci ati o n W it h Dise ase Pr o gressi o n 
Pr o gressi o n of t he disease / dis or der bei n g st u die d assesse d b y  m eas ure me nt of lesi o ns o n 
ra di o gra p hs or ot her met h o ds as we ll as ass ociate d cli nical si g ns or s y m pt o ms (i ncl u di n g 
la b orat or y  a b n or malities) s h o ul d n ot be re p orte d as a n A E / S A E , u nless t he s u bject’s ge neral 
c o n diti o n is m ore se vere t ha n e x pecte d a n d / or u nless t he o utc o me is fatal wit hi n t he A E re p orti n g 
peri o d (as defi ne d i n Secti o n 7. 4. 1. 3 ).
7. 4. 1. 1. [ADDRESS_838731] ( A E SI) f or S afet y 
M o nit ori n g 
T he A E SIs f or M S B [ADDRESS_838732]’s c o n diti o n will be rec or de d as A Es, 
w het her re p orte d b y t he s u bject or o bser ve d b y  t he I n vesti gat or. 
C o m plete, acc urate a n d c o nsiste n t data o n all A Es e x perie nce d f or t he d urati o n of t he re p orti n g 
peri o d ( defi ne d bel o w) will be re p orte d o n a n o n g oi n g basis i n t he a p pr o priate secti o n of t he e C R F.  
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838733] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 3 / [ADDRESS_838734] be a d diti o nall y  d oc u me nte d a n d re p orte d 
usi n g t he a p pr o priate S A E Re p ort F or m or t he A E SI  R e p ort F or m ,res pecti vel y as descri be d i n 
Secti o n 7. 4. 1. 4 .
It is i m p orta nt t hat eac h A E re p ort i ncl u de a descri pti o n of t he e ve nt, its d urati o n (o nset a n d 
res ol uti o n dates a n d ti mes t o be c o m plete d w he n it is i m p orta nt t o assess t he ti me of A E o nset 
relati ve t o t he rec or de d treat me nt a d mi nistrati o n ti me ), its se verit y, its ca usal relati o ns hi p wit h t he 
trial tre at me nt, a n y ot her p ote ntial ca usal fact ors, a n y  t reat me nt gi ve n or ot her acti o n ta ke n , 
i ncl u di n g d ose m o dificati o n or disc o nti n uati o n of t he I M P, a n d its o utc o me. I n  a d diti o n, seri o us 
cases s h o ul d be i de ntifie d a n d t he a p pr o priate seri o us ness criteria d oc u me nte d. If a n A E 
c o nstit utes a D L T t his has t o be d oc u me nte d acc or di n gl y. 
S pecific g ui da nce ca n be f o u n d i n t he e C R F C o m pleti o n a n d M o nit ori n g C o n ve nti o ns. 
7. 4. 1. [ADDRESS_838735] is i ncl u de d i nt o t he trial 
( date a n d ti me of first si g nat ure of i nf or me d c o nse nt) a n d c o nti n ues t hr o u g h t he trial’s 2 8- Da y 
Safet y  F oll o w -u p visit, defi ne d as 2 8 da ys ( ± 5 da ys) after l ast trial dr u g a d mi nistrati o n.  After t he 
[ADDRESS_838736] u g b y  t he 
I n vesti gat or s h o ul d be d oc u me nte d u ntil t he 1 0 -Wee k Safet y F oll o w -u p visit , defi ne d as 1 0wee ks 
( ± 2wee ks) after t he last tr ial dr u g a d mi nistrati o n. 
A n y  S A E assesse d as relate d t o M S B [ADDRESS_838737] 
i m me diatel y  ( wit hi n a ma xi m u m 2 4 h o urs after bec o mi n g a ware of t he e ve nt) i nf or m t he S p o ns or 
or its desi g nee usi n g t he S A E Re p ort F or m f oll o wi n g s pecific c o m pleti o n i nstr ucti o ns. 
I n e xce pti o nal circ u msta nces, a S A E ( or f oll o w -u p i nf or mati o n) ma y  be re p orte d b y  tele p h o ne; i n 
t hese cases ,S A E Re p ort For m m ust be pr o vi de d i m me diatel y  t hereafter .
Re p orti n g pr oce d ures a n d ti meli nes are t he sa me f or a n y  n e w i nf or mati o n o n a pre vi o usl y  re p orte d 
S A E ( = f oll o w -u p). 
Rele va nt pa ges fr o m t he e C R F m a y  b e pr o vi de d i n parallel (f or e xa m ple, me dical hist or y , 
c o nc o mita nt dr u gs). A d diti o nal d oc u me nts ma y  b e pr o vi de d b y  t he I n vesti gat or, if a vaila ble (f or 
e xa m ple, la b orat or y  r es ults, h os pi[INVESTIGATOR_134577] p ort, a n d a ut o ps y re p ort). I n all cases, t he i nf or mati o n 
pr o vi de d o n t he S A E Re p ort For m m ust be c o nsiste nt wit h t he data a b o ut t he e ve nt rec or de d i n t he 
e C R F.   
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838738] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 4 / [ADDRESS_838739] f or f oll o w - u p i nf or mati o n (f or e xa m ple, a d diti o nal 
i nf or mati o n, o utc o me fi nal e val uati o n, ot her rec or ds w here nee de d) or t o a n y q uesti o n t he S p o ns or 
or desi g nee ma y ha ve o n t he A E wit hi n t he sa me ti meli nes as t h ose n ote d a b o ve f or i nitial re p orts.  
T his is necessar y t o e ns ure a pr o m pt assess me nt of t he e ve nt b y  t he S p o ns or or desi g nee a n d (as 
a p plica ble) t o all o w t he S p o ns or t o meet strict re g ulat or y  t i meli nes ass ociate d wit h e x pe dite d 
safet y re p orti n g o bli gati o ns. 
Re q uests f or f oll o w -u p will us uall y  be ma de via t he res p o nsi ble M o nit or, alt h o u g h i n e xce pti o nal 
circ u msta nces t he Gl o bal Dr u g Safet y de part me nt ma y  c o ntact t he I n vesti gat or directl y t o o btai n 
f urt her i nf or mati o n or t o disc uss t he e ve nt. 
A d verse E ve nts of S peci al I nterest 
I n t he e ve nt of a n o nseri o u sGra de ≥ [ADDRESS_838740] c o m plete t he A E SI  R e p ort 
F or m a n d pr o vi de it t o t he S p o ns or / desi g nee i m me diatel y  ( wit hi n 2 4 h o urs) f oll o wi n g t he s pecific 
c o m pleti o n i nstr ucti o ns.  S eri o us A E SI s ha ve t o be re p orte d i n a n e x pe dite d ma n ner as S A Es as 
o utli ne d a b o ve. F or Gra de 1 a n d Gra de 2 n o nseri o us A E SI s, t he A E SI  R e p ort F or m s h o ul d be 
pr o vi de d t o t he S p o ns or / desi g nee wit hi n 5 w or ki n g d a y s f oll o wi n g t he s pecific c o m pleti o n 
i nstr ucti o ns. 
D ose - L i m iti n g To xicities 
Eac h e ve nt meet i n g t he criteria of a D L T (see Secti o n 5. 1. 3. 3 ) has t o be rec or de d i n t he e C R F 
wit hi n 2 4 h o urs after bec o mi n g a ware of t he e ve nt.  S eri o us D L Ts ha ve t o be re p orte d i n a n 
e x pe dite d ma n ner as S A Es as o utli ne d a b o ve. 
7. 4. 1. 5 S afet y Re p orti n g t o He alt h A ut h orities, I n de pe n de nt Et hics 
C o m mittees / I nstit uti o n al Re vie w B o ar ds a n d I n vesti g at ors 
T he S p o ns or will se n d a p pr o priate safet y n otificati o ns t o Healt h A ut h orities i n acc or da n ce wit h 
a p plica ble la ws a n d re g ulati o ns. 
T he I n vesti gat or m ust c o m pl y  w it h a n y a p plica ble site -s pecific re q uire me nts relate d t o t he 
re p orti n g of S A Es ( partic ular l y deat hs) i n v ol vi n g trial s u bjects t o t he I E C /I R B t hat a p pr o ve d t he 
trial. 
I n acc or da nce wit h I C H G C P g ui deli nes , t he S p o ns or or desi g nee will i nf or m t he I n vesti gat or of 
“fi n di n gs t hat c o ul d a d versel y affect t he safet y of s u bjects, i m pact t he c o n d uct of t he trial ,or alter 
t he I E C’s /I R B’s a p pr o val /fa v ora bl e o pi [INVESTIGATOR_9384] o n t o c o nti n ue t he trial ”. I n partic ular a n d i n li ne wit h 
res pecti ve re g ulati o ns, t he S p o ns or /desi g nee will i nf or m t he I n vesti gat or of A Es t hat are b ot h 
seri o us a n d u ne x pecte d a n d are c o nsi dere d t o be relate d t o t he a d mi nistere d pr o d uct (s us pecte d 
u ne x p ecte d seri o us a d verse reacti o n s [ S U S A Rs ]). T he I n vesti gat or s h o ul d place c o pi[INVESTIGATOR_167759] y 
Re p orts i n t he I n vesti gat or Site File. Nati o nal re g ulati o ns wit h re gar d t o Safet y  R e p ort 
n otificati o ns t o I n vesti gat ors will be ta ke n i nt o acc o u nt. 
W he n s pecificall y re q uire d b y  r e g ulati o ns a n d g ui deli nes, t he S p o ns or or desi g nee will pr o vi de 
a p pr o priate Safet y  R e p orts directl y  t o t he c o ncer ne d lea d I E C / I R B a n d will mai ntai n rec or ds of 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838741] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 5 / [ADDRESS_838742] re p orti n g is n ot clearl y defi ne d b y  n ati o nal or site -s pecific 
re g ulati o ns, the I n vesti gat or will be res p o nsi ble f or pr o m ptl y  n otif y i n g t he c o ncer ne d I E C /I R B 
of a n y Safet y Re p orts pr o vi de d b y  t he S p o ns or or desi g nee a n d of fili n g c o pi[INVESTIGATOR_167760] d 
c orres p o n de nce i n t he I n vesti gat or Site File. 
F or trials c o vere d b y t he E ur o pea n Directi ve 2 0 0 1/ 2 0/ E C, t he S p o ns or’s res p o nsi bilities re gar di n g 
t he re p orti n g of S A Es /S U S A Rs /Safet y  I ss ues will be carrie d o ut i n acc or da nce wit h t hat 
Directi ve a n d wit h t he relate d Detaile d G ui da nce. 
7. 4. 1. 6 M o nit ori n g of S u bjects Wit h A d verse E ve nts 
A d verse e ve nts are rec or de d a n d assesse d c o nti n u o usl y  t hr o u g h o ut t he trial (see Secti o n 7. 4. 1. 3 ) 
a n d are assesse d f or fi nal o utc o me at t he [ADDRESS_838743] u g b y  t h e I n vesti gat or s h o ul d 
be d oc u me nte d u ntil t he 1 0- Wee k Safet y F oll o w -u p visit, defi ne d as 1 0 wee ks ( ± 2wee ks) after 
t he last trial dr u g a d mi nistrati o n .
All S A Es o n g oi n g at t he [ADDRESS_838744] is d oc u me nte d as 
“l ost t o f oll o w - u p ”.  I n a d diti o n, all trial dr u g -relate d S A Es occ urri n g after t he [ADDRESS_838745] u g E x p os ure 
O nl y  p re g na ncies c o nsi dere d b y  t he I n vesti gat or t o be relate d t o trial treat me nt (f or e xa m ple, 
res ulti n g fr o m a dr u g i nteracti o n wit h a c o ntrace pti ve me dicati o n) are c o nsi dere d t o be A E s; 
ho we ver, all pre g na ncies wit h a n esti mate d c o nce pti o n date d uri n g t he peri o d defi ne d i n 
Secti o n 7. 4. 1. [ADDRESS_838746] be rec or de d b y  c o n ve nti o n i n t he A E pa ge /secti o n of t he eC R F. T he sa me 
r ule a p plies t o pre g na ncies i n fe male s u bjects a n d t o pre g na ncies i n fe male part ners of male 
s u bjects. T he I n ve sti gat or m ust als o n otif y  t he S p o ns or or desi g nee i n a n e x pe dite d ma n ner of a n y 
pre g na nc y  u si n g t he Pa per Pre g na nc y  R e p ort F or m, w hic h m ust be tra ns mitte d acc or di n g t o t he 
sa me ti meli nes as descri be d f or S A E re p orti n g i n Secti o n 7. 4. 1. [ADDRESS_838747] 
s ustai ns a n e ve nt a n d t he Pare nt -C hil d /Fet us A d verse E ve nt Re p ort F or m if t he c hil d /fet us 
s ustai ns a n e ve nt. 
A n y  a b n or mal o utc o me m ust be re p orte d i n a n e x pe dite d ma n ner as descri be d i n Secti o n 7. 4. 1. 4,  
w hile n or mal o utc o mes m ust be re p orte d wit hi n [ADDRESS_838748] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838749] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 6 / [ADDRESS_838750]’s me dical rec or d or s o urce d oc u me nts. Bl o o d sa m ples f or t he tests liste d 
i n  Ta ble 1 1 will be ta ke n fr o m n o n -faste d s u bjects d uri n g t he Scree ni n g p hase , at t he 2 8- D a y  S afet y 
F oll o w -u p visit, a n d d uri n g t he treat me nt p hase as s pecifie d i n t he Sc he d ules of Assess me nts 
(Ta ble 1a n d  Ta ble 2) . C o m plete bl o o d c o u nt a n d c ore ser u m c he mistr y  m ust be c hec ke d wit hi n 
4 8 h o urs pri or t o eac h d ose a d mi nistrati o n .
Ser u m electr o p h oresis, A C T H ( d ose -escalati o n c o h orts o nl y ), A N A, R F, T 4, T S H, a n d uri nal y sis 
will be assesse d at t he ti me p oi nts defi ne d i n t he Sc he d ules of Assess me nts (Ta ble 1a n d  Ta ble 2) . 
If c o nfir mati o n of a s u bject’s p ost me n opa usal stat us is necessar y , a F S H le vel will als o be 
perf or me d at Scree ni n g , see Secti o n 7. 1. 1. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838751] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 7 / 1 9 3 T a ble 1 1 Re q uire d L a b or at or y P a nel Tests 
F ull C he m istr y He m at ol o g y 
Al b u mi n A bs ol ute l y m p h oc yte c o u nt 
Al kali ne p h os p hatase * Abs ol ute ne utr o p hil c o u nt 
Ala ni ne a mi n otra nsferase * He mat ocrit 
A m ylase He m o gl o bi n 
As partate a mi n otra nsferase * Platelet c o u nt 
Ga m ma - gl uta m yltra nsferase R B C c o u nt 
Bl o o d urea nitr o ge n /t otal urea * W hite bl o o d cell c o u nt a n d differe ntial c o u nt 
Calci u m * Re d bl o o d cell m or p h ol o g y * * 
C hl ori de * Retic ul oc ytes 
C h olester ol Mea n c or p usc ular he m o gl o bi n 
Creati ne ki nase Mea n c or p usc ular v ol u me 
Creati ni ne * Mea n c or p usc ular he m o gl o bi n c o nce ntrati o n 
C-reacti ve pr otei n 
Gl uc ose * He m ost ase ol o g y 
Lactate de h y dr o ge nase Acti vate d partial t hr o m b o plasti n ti me 
Li pase Pr ot hr o m bi n ti me /i nter nati o nal n or malize d rati o 
P h os p h or us / p h os p hates * 
Ma g nesi u m * B asic Uri n al ysis ( di pstic k, i ncl u di n g macr osc o pic a p peara nce, bilir u bi n, 
bl o o d, c ol or, gl uc ose, ket o nes, le u k oc yte esterase, nitrite, p H, pr otei n, s pecific 
gra vit y, ur o bili n o ge n) 
F ull uri nal ysis ( di pstic k pl us micr osc o pic e val uati o n) t o be perf or me d o nl y at 
t he Scree ni n g a n d 2 8 -Da y Safet y F oll o w -u p visits a n d a basic uri nal ysis pri or 
t o eac h a d mi nistrati o n of t he I M P .P otassi u m * 
S o di u m * 
T otal bilir u bi n / i n direct bilir u bi n *
T otal pr otei n 
Uric aci d T otalit y of bi n di n g A D A s
Tri gl yceri des A F P ( H C C c o h ort o nl y) 
A C T H ( d ose -esc al ati o n c o h orts o nl y) , A N A, R F, T S H, a n d T 4 
H or m o ne 
F ollicle -sti m ulati n g h or m o ne (if a p plica ble) He p atitis Scree ni n g a
He patitis B s urface a nti ge n ,he patitis B c ore a nti b o d y 
He patitis B D N A ( q ua ntitati ve P C R) a
He patitis C A nti b o d y, He patitis C R N A ( q ua ntitati ve P C R) a
He patitis D a nti b o d y b
AC T H =a dre n oc ortic otr o pic h or m o ne; A D A = a nti dr u g a nti b o d y; A N A = a nti n uclear a nti b o d y; H C C = he pat ocell ular carci n o ma; 
I M P =I n vesti gati o nal Me dici nal Pr o d uct; P C R = p ol y merase c hai n reacti o n; R F =r he u mat oi d fact or; T S H =t h yr oi d -sti m ulati n g 
h or m o ne ;T 4 =f ree t h yr o xi ne .
* C ore ser u m c he mistries 
* * Onl y  i n case of a ne mia o nset assesse d as relate d t o st u d y treat me nt   
aIf he patitis B s urface a nti ge n p ositi ve a n d he patitis B c ore a nti b o d y p ositi ve, t he n refle x t o q ua ntitati ve H B V D N A ( P C R) ; i f 
he patitis B c ore a nti b o d y p ositi ve al o ne, t he n refle x t o q ua ntitati ve he patitis B D N A ( P C R); i f he patitis C a nti b o d y p ositi ve, 
t he n refle x t o q ua ntitati ve he patitis C R N A ( P C R) .  If s u b ject is p ositi ve f or he patitis B or C, t he n viral l oa d will be f oll o we d 
b y q ua ntitati ve P C R acc or di n g t o  Ta ble 3. 
b If he patitis B s urface a nti ge n or he patitis B D N A p ositi vit y at Scree ni n g t he n m ust c hec k f or he patitis D stat us ( he patitis D 
anti b o d y) .
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838752] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 8 / [ADDRESS_838753] a ble. 
7. 4. 4 Vit al Si g ns, P h ysic al E x a mi n ati o ns, a n d Ot her Assess me nts 
T he E C O G P S will be assesse d at S cree ni n g a n d at s u bse q u e nt visits as i n dicate d i n t he Sc he d ule s
of A ssess me nts (Ta ble 1a n d  Ta ble 2) a n d d oc u me nte d i n t he e C R F. 
Bo d y  wei g ht will be meas ure d at S cree ni n g a n d at s u bse q ue nt visits as i n dicate d i n t he Sc he d ules 
of Assess me nts (Ta ble 1a n d  Ta ble 2) a n d d oc u me nte d i n t he eC R F. B o d y  h ei g ht will be meas ure d 
at Scree ni n g o nl y. 
A p h ysical e xa mi nati o n will be c o n d ucte d at Scree ni n g a n d at s u bse q ue nt visits as i n dicate d i n t he 
Sc he d ules of Assess me nts (Ta ble 1a n d  Ta ble 2) a n d d oc u me nte d i n t he eC R F ( detaile d descri pti o n 
i n Secti o n 7. 1) . An y  a b n or malities arisi n g or w orse ni n g after t he si g ni n g of t he I C F s h o ul d be 
d oc u me nte d i n t he eC R F A d verse E ve nt secti o n (see Secti o n 7. 4. 1) . A b n or mal fi n di n gs are t o be 
reassesse d at s u bse q ue nt visits. 
A n op ht hal m ol o g y  e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt 
a n d wit h vis ual ac uit ys h o ul d be c o n d ucte d at Scre e ni n g.  A t s u bse q ue nt visits, e y e si g ns a n d 
s y m pt o ms s h o ul d be c hec ke d.  I f t here are a n y cli nicall y  r ele va nt fi n di n gs t he n a n a p pr o priate 
o p ht hal m ol o g y  e xa mi nati o n i ncl u di n g slit la m p e val uati o n i ncl usi ve of t he a nteri or se g me nt a n d 
wit h vis ual ac uit y  s h o ul d be o btai ne d wit hi n 2 da ys. 
Di gital 1 2- lea d E C Gs will be rec or de d i n tri plicate at Scree ni n g a n d at trial visits as i n dicate d i n 
t he Sc he d ules of Assess me nts (Ta ble 1a n d  Ta ble 2) u ntil Wee k 1 3 ( Visit 1 0). S u bse q ue nt E C Gs 
will be o btai ne d as si n gle rec or di n gs. F or im me diate safet y assess me nts ,1 E C G will be l ocall y 
a nal yz e d at eac h ti me p oi nt (see Secti o n 7. 2. 6) . All E C Gs o btai ne d i n tri plicate will be f or mall y 
a nal yze d t o e val uate w het her M S B 0 0 1 1 3 5 9 C has a n y effects o n car diac electr o p h ysi ol o g y ,a n d i n 
partic ular re p olarizati o n .  Alt h o u g h precli nical data s h o ws n o car di o vasc ular si g nal, wee kl y E C G 
assess me nts wit h tri plicates a n d di gital rec or di n g are j ustifie d d ue t o t he nee d t o c haracterize 
e x p os ure /Q Tc relati o ns hi ps t o facilitate f ut ure cli nical rati o nale. 
All ne wl y  d ia g n ose d or w orse ni n g c o n diti o ns, si g ns a n d s y m pt o ms o bser ve d si nce Scree ni n g, 
w het her relate d t o trial treat me nt or n ot, are t o be re p orte d as A Es. 
F or fe male s u bjects of c hil d beari n g p ote ntial, ser u m β- H C G pre g na nc y  t est will be carrie d o ut 
d uri n g t he Scree ni n g p hase. A uri ne or ser u m β- H C G test will be perf or me d acc or di n g t o  Ta ble [ADDRESS_838754] me n o pa usal (a ge -relate d a me n orr hea ≥ 1 2 c o nsec uti ve 
m o nt hs a n d if nee de d F S H > 4 0 mI U/ m L [i n t he p ost me n o pa usal ra n ge] as o utli ne d i n 
Secti o n 7. 1. 1 ), or w h o h a ve u n der g o ne h y sterect o m y  or  b ilateral o o p h orect o m y  a re e xe m pt fr o m 
pre g na nc y  t esti n g. If necessar y  t o c o nfir m p ost me n o pa usal stat us, a n F S H will be dra w n at 
Scree ni n g. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838755] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 5 / 1 9 3 F H SI - 8 :  T he F H SI -8 is a patie nt -re p orte d o utc o me q uesti o n naire desi g ne d t o assess s y m pt o ms i n 
patie nts wit h pa ncreatic a n d he pat o biliar y  c a ncers ( Y o u nt 2 0 0 2 ).  I t is a n 8- ite m i n de x pai n 
( 3 ite ms), fati g ue ( 2 ite ms), wei g ht l oss, na usea, a n d ja u n dice, wit h eac h ite m sc ore d o n a 5- p oi nt 
scale ( 0 = n ot at all; 4 = ver y  m uc h). 
F or s u bjects i n t he H C C e x pa nsi o n c o h ort ,s y m pt o m se verit y will be assesse d usi n g t he P GI Sa n d 
a m o difie d versi o n of a ca ncer -s pecific i nstr u me nt f or t he assess me nt of he pat o biliar y  s y m pt o ms 
(E O R T C Q L Q -H C C 1 8 - M ) as i n dicate d i n t he Sc he d ules of Assess me nts (Ta ble 2) .
E O R T C Q L Q -H C C 1 8 - M:   T he E O R T C Q L Q -H C C 1 8 -M is a m o difie d versi o n of t he E O R T C’s 
H C C -s pecific m o d ule (Blaze b y  2 0 0 4 ).  I t c o nsists of 1 7 patie nt -re p orte d ite ms i nte n de d pr o vi de 
c o m pre he nsi ve H C C -relate d s y m pt o m c o vera ge w hile mi ni mizi n g patie nt assess me nt b ur de n.  T he 
E O R T C Q L Q -H C C 1 8 -M i ncl u des 7 ite ms fr o m t he E O R T C Q L Q -C 3 0 meas uri n g d y s p nea 
( 1 ite m), fati g ue ( 3 ite ms), l oss of a p petite ( 1 ite m), a n d na usea a n d v o miti n g ( 2 ite ms).  T h e 
E O R T C Q L Q- H C C 1 8 -M i ncl u des a n a d diti o nal 1 0 ite ms fr o m t he E O R T C’s H C C -s pecific 
m o d ule meas uri n g se nse of taste ( 1 ite m), wasti n g ( 1 ite m), a b d o mi nal bl oati n g ( 1 ite m), ja u n dice 
( 1 ite m), pr urit us ( 1 ite m), s h o ul der pai n ( 1 ite m), a b d o mi nal pai n ( 1 ite m), fe ver ( 2 ite ms), a n d 
earl y satiet y ( 1 ite m).  E ac h of t hese ite ms is rate d o n a 4- p oi nt res p o nse scale ( 1 = n ot at all; 
4=ver y  m uc h). 
For s u bjects i n t he es o p ha geal a de n ocarci n o ma c o h ort o nl y , s y m pt o m se verit y will be assesse d 
usi n g t he P GI S, select ite ms fr o m t he E O R T C QL Q -C [ADDRESS_838756] ite ms fr o m t he E O R T C 
Q L Q -O E S 1 8 as i n dicate d i n t he Sc he d ul eof Assess me nts (Ta ble 2) .  F or t he es o p ha geal 
a de n ocarci n o ma c o h ort, t he selecte d E O R T C Q L Q -C 3 0 ite ms meas ure fati g ue ( 3 ite ms) a n d pai n 
( 2 ite ms). 
E O R T C Q L Q -O E S 1 8 :  T he E O R T C Q L Q -O E S 1 8 is a n 1 8- ite m patie nt -re p orte d o utc o me 
q uesti o n naire create d t o meas ure f u ncti o ni n g, s y m pt o ms, a n d healt h -relate d q ualit y of life iss ues 
s pecific t o es o p ha geal ca ncer (Blaze b y 2 0 0 3 ).  A  s u bset of t he E O R T C Q L Q -O E S 1 8 ite ms ha ve 
bee n selecte d f or a d mi nistrati o n i n t he es o p ha geal a de n ocarci n o ma c o h ort t o re d uce patie nt b ur de n 
w hile all o wi n g f or ke y  t u m or -relate d s y m p t o ms t o be assesse d.  T he selecte d E O R T C 
Q L Q -O E S 1 8 ite ms meas ure d y s p ha gia ( 3 ite ms) a n d refl u x pai n ( 2 ite ms). Eac h of t hese ite ms is 
rate d o n a 4 -p oi nt res p o nse scale ( 1 = n ot at all; 4 = ver y  m uc h). 
For s u bjects i n t he gli o blast o ma c o h ort o nl y , s y m pt o m se verit y will be assesse d usi n g t he P GI S 
a n d select ite ms fr o m t he E O R T C Q L Q -B N 2 0 as i n dicate d i n t he Sc he d ule of Assess me nts (Ta ble 
2) . 
E O R T C Q L Q -B N 2 0 :T he E O R T C Q L Q -B N 2 0 is a 2 0- ite m patie nt -re p orte d o utc o me 
q uesti o n naire create d t o meas ure f u ncti o ni n g, s y m pt o ms, a n d healt h -relate d q ualit y of life iss ues 
s pecific t o brai n ca ncer (Ta p h o or n 2 0 1 0 ). A s u bset of t he E O R T C Q L Q -B N [ADDRESS_838757] o ma c o h ort t o re d uce patie nt b ur de n w hile all o wi n g f or 
ke y  f u ncti o nal i m pacts of t he pri mar y  t u m or t o be assesse d. T he selecte d E O R T C Q L Q- B N 2 0 
ite ms meas ure m ot or d y sf u ncti o n ( 3 ite ms), c o m m u nicati o n deficit ( 3 ite ms), a n d dr o wsi ness 
( 1 ite m). Eac h of t hese ite ms is rate d o n a 4- p oi nt res p o nse scale ( 1 = n ot at all; 4 = ver y  m uc h). 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838758] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 8 / 1 9 3 T a ble 1 2 T he 9 5 % E x act ( Cl o p per -Pe ars o n) C o nfi de nce I nter v als f or O R R Base d 
o n 3 0 E nr olle d S u bjects 
O R R 9 5 % E x act C o nfi de nce I nter v al 
0. 2 0 ( 0. 0 7 7, 0. 3 8 6) 
0. 3 0 ( 0. 1 4 7, 0. 4 9 4) 
0. 4 0 ( 0. 2 2 7, 0. 5 9 4) 
0. 5 0 ( 0. 3 1 3, 0. 6 8 7) 
0. 6 0 ( 0. 4 0 6, 0. 7 7 3) 
0. 7 0 ( 0. 5 0 6, 0. 8 5 3) 
H C C asce n di n g -d ose c o h ort 
I n o r der t o f urt her assess t he t olera bilit y a n d safet y of M S B 0 01 1 3 5 9 C i n s u bjects wit h H C C, u p t o 
3 6 s u bjects m a y  b e e nr olle d i n t he asce n di n g d ose part of t he H C C c o h ort.  S i x s u bjects will be 
e nr olle d at 3 m g/ k g o nce t he 3 m g / k g d ose le vel i n t he d ose escalati o n part of t he trial has bee n 
cleare d b y  t he S M C.  T hirt y  s u bjects will be e nr olle d at a 1 2 0 0 m g  f lat d ose o nce t he 20 m g/ k g 
d ose le vel i n t he d ose escalati o n part of t he trial has bee n cleare d b y  t he S M C.  
H C C sec o n d -li ne or s or afe ni b -i nt oler a nt c o h ort 
U p t o 7 0 s u bjects will be e nr olle d i n t he H C C sec o n d -li ne or s orafe ni b -i nt olera nt c o h ort at t he d ose 
sele cte d b y  t he S M C d uri n g t he d ose -escalati o n part of t he trial, f or t he p ur p ose of assessi n g 
efficac y  base d o n t he B O R .  A n i nitial e nr oll me nt of 3 0 s u bjects will accr ue if > 6 of 3 0 s u bjects 
i n t he H C C 1 2 0 0 m g flat -d ose asce n di n g -d ose c o h ort ha ve a res p o nse (t hat is a n O R R of at least 
2 0 % ).  T he pri mar y  a nal ysis will be [ADDRESS_838759] starte d treat me nt .  T he a nal ys is 
will i ncl u de t he 3 0 s u bjects fr o m t he H C C 1 2 0 0 m g flat -d ose asce n di n g -d ose c o h ort a n d 
3 0 s u bjects fr o m t he H C C sec o n d -li ne or s orafe ni b -i nt olera nt c o h ort (ass u mes a si milar tar get 
p o p ulati o n as per t he i ncl usi o n criteria) .  A n a d diti o nal 4 0 s u bjects ma y  s u bse q ue ntl y  be e nr olle d 
i n or der t o gat her a d diti o nal safet y data .
Wit h 60 s u bjects treat e d ( 3 0 s u bjects fr o m t he H C C 1 2 0 0 m g flat -d ose asce n di n g -d ose c o h ort an d 
3 0 s u bjects fr o m t he H C C sec o n d -li ne or s orafe ni b -i nt olera nt c o h ort) , t he st u d y  h as a p pr o xi matel y
8 8 % p o wer t o r ule o ut a ≤ 2 0 % O R R ( n ull h y p ot hesis) w he n t he tr ue O R R is 3 5 % at t he 1 0 % t y p e 
I err or rate ( 1- si de d ). 
N S C L C a nti -P D -1/ anti -P D -L [ADDRESS_838760] u d y  h as a p pr o xi matel y  9 2 % a n d 9 9 % p o wer t o r ule o ut a ≤ 5 % O R R 
( n ull h y p ot hesis) w he n t he tr ue O R R is 1 5 % a n d 2 0 %, res pecti vel y, at t he 5 % t y pe I err or rate 
( 1- si de d ). 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838761] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 9 / 1 9 3 Mel a n o m a anti -P D -1/ anti -P D -L [ADDRESS_838762] orati o n of a nti -P D -L 1  r etreat me nt a n d i nitial cli nical res p o nses 
as a wa y  t o s h o w c o nfi de nce i n t he pr o of - of- mec ha nis m of t he a d diti o n of T G F βi n hi biti o n t o t he 
a nti -P D -L 1 mec ha nis m.  Wit h 3 0 s u bjects w h o were treate d wit h pr i or a nti -P D - 1 / a nti -P D -L [ADDRESS_838763] u d y  has 8 7 % p o wer t o r ule o ut a 5 % O R R w he n t he tr ue O R R is 2 0 % wit h 1-si de d 
0. 1 al p ha. 
N S C L C sec o n d -li ne c o h ort 
Wit h 3 0 sec o n d -li ne s u bjects treate d at 1 2 0 0 m g/i nf usi o n , t he st u d y  h as a p pr o xi matel y  8 2 % p o wer 
t o r ule o ut a ≤ 2 0 % O R R ( n ull h y p ot hesis) w he n t he tr ue O R R is 4 0 % at t he 1 0 % t y pe I err or rate 
( 1 -si de d). 
A n i nteri m a nal y sis will occ ur w he n t he 3 0 s u bjects are e val ua bl e f or res p o nse assess me nt at 
1 2 wee ks (t hat is , ha ve eit her c o m plete d t he sec o n d t u m or reassess me nt at Wee k [ADDRESS_838764] u d y  bef ore Wee k 1 2).   If ≤ [ADDRESS_838765] u d y  has a p pr o xi matel y  7 9 % p o wer t o r ule o ut a ≤ 1 0 % O R R ( n ull 
h y p ot hesis) w he n t he tr ue O R R is 2 5 % at t he 1 0 % t y pe I err or rate ( 1- si de d ). 
O v ari a n c a ncer , T N B C, a n d es o p h a ge al a de n oc arci n o m a c o h orts 
Wit h [ADDRESS_838766] u d y  has a p pr o xi matel y  8 7 % p o wer t o r ule o ut a ≤ 1 5 % O R R ( n ull 
h y p ot hesis) w he n t he tr ue O R R is 3 5 % at t he 1 0 % t y pe I err or rate ( 1- si de d ). 
Gli o bl ast o m a c o h ort 
Wit h [ADDRESS_838767] u d y  h as a p pr o xi matel y  9 7% p o wer t o r ule o ut a ≤ 5 0 % D C R(n ull 
h y p ot hesis) w he n t he tr ue D C R is 8 0 % at t he 5 % t y pe I err or rate ( 1- si de d ).
S C C H N c o h ort 
Wit h [ADDRESS_838768] u d y  has a p pr o xi matel y  8 7 % p o wer t o r ule o ut a ≤ 1 5 % O R R ( n ull 
h y p ot hesis) w he n t he tr ue O R R is 3 5 % at t he 1 0 % t y pe I err or rate ( 1 -si de d). 
All e x p a nsi o n c o h orts 
E xce pt f or t he gli o blast o ma c o h ort, t he pri mar y  e fficac y  e n d p oi nt f or t he d ose e x pa nsi o n -part of 
t he trial is t he c o nfir me d B O R acc or di n g t o R E CI S T 1. 1 as a dj u dicate d b y  t he I n de pe n de nt 
E n d p oi nt Re vie w C o m mittee (I R C) a n d will be e val uate d b y  c o nfir me d O R R .  F or gli o blast o ma, 
t he pri mar y  e n d p oi nt will be disease c o ntr ol .  
F or eac h c o h ort se paratel y (e xce pt f or t he H C C c o h ort) , u p o n c o nti n uati o n of t he c o h ort u p t o t he 
tar gete d sa m ple size, t he pri mar y  a nal ys is will occ ur [ADDRESS_838769] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838770] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 6 0 / [ADDRESS_838771] e nr olle d.  F or t he H C C c o h ort, t he pri mar y  a nal ys is will be after 6 0 s u bjects (i ncl u di n g 
3 0 s u bjects fr o m t he asce n di n g d ose a n d 3 0 s u bjects fr o m t he s ec o n d li ne e x pa nsi o n c o h ort). 
T he t otal sa m ple size f or t he e x pa nsi o n c o h orts is e x pecte d t o be u p t o a p pr o xi matel y  5 6 6 s u bjects. 
8. 2 R a n d o miz ati o n 
N S C L C sec o n d -li ne c o h ort 
Q ualifie d s u bjects will be ra n d o mize d at a 1: 1 rati o t o recei ve eit her 5 0 0 or 120 0 m g /i nf usi o n 
M S B [ADDRESS_838772] eli gi bilit y as descri be d i n Secti o n 6. 3 .
N ot a p plica ble f or s u bjects n ot i ncl u de d i n t he N S C L C sec o n d -li ne c o h ort. 
8. 3 E n d p oi nts 
8. 3. 1 Pri m ar y E n d p oi nts 
T he pri mar y  e n d p oi nts f or t he d ose -escalati o n part of t h e trial are t he: 
N u m ber, se verit y , a n d d urati o n of T E A Es acc or di n g t o t he N CI -C T C A E v 4. 0 3 
N u m ber, se verit y a n d d urati o n of treat me nt -relate d A Es f or all d ose gr o u ps / i n dicati o ns 
acc or di n g t o C T C A E v 4. 0 3 
Occ urre nce of D L Ts d uri n g t he first 3 wee ks ( 2 1 da y s) of treat me nt i n t he d ose -escalati o n part 
of t he trial 
E xce pt f or t he gli o blast o ma c o h ort, the pri mar y efficac y  e n d p oi nt f or t he d ose -e x pa nsi o n part of 
t he trial is t he c o nfir me d B O R acc or di n g t o R E CI S T 1. 1 as a dj u dicate d b y t he I R C ( Secti o n 2. 2. 2) 
a n d will be e val uate d b y c o nfir me d O R R . F or gli o blast o ma, t he pri mar y  e n d p oi nt will be disease 
c o ntr ol acc or di n g t o R A N O as a dj u dicate d b y t he I R C .
8. 3. 2 Sec o n d ar y E n d p oi nts 
T he s ec o n dar y  e n d p oi nts f or t he d ose -escalati o n part of t he trial are t he: 
M S B 0 0 1 1 3 5 9 C P K pr ofile (f or d ose escalati o n), i ncl u di n g A U C , C ma x , C mi n , a n d t1/ 2 
Ser u m titers of a nti M S B 0 0 1 1 3 5 9 C a nti b o dies 
B O R acc or di n g t o R E CI S T 1. 1 per I n vesti gat or assess me nt 
T he sec o n dar y  e n d p oi nts f or t he e x pa nsi o n part of t he trial are t he: 
M S B 0 0 1 1 3 5 9 C P K pr ofile (f or d ose escalati o n), i ncl u di n g A U C, C ma x , C mi n , a n d t1/ 2 
Ser u m titers of a nti M S B [ADDRESS_838773] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838774] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 6 4 / [ADDRESS_838775]. C o u nts of missi n g o bser vati o ns 
will be i ncl u de d i n t he de n o mi nat or a n d prese nte d as a se parate cate g or y  i f n ot ot her wise s pecifie d 
i n t he S A P .
T he D L T A nal ys is Set is t he u n derl yi n g data set f or t he M T D deter mi nati o n. Safet y a nal ys es will 
be perf or me d o n t he Safet y  A nal ys is Set.  B aseli ne s u m maries a n d efficac y a na l y ses will be 
perf or me d o n t he F ull A nal y sis Set. A nal ys es of P K varia bles will be perf or me d o n t he P K 
A nal y sis Set .  A nal ys is of ser u m titers of A nti -M S B 0 0 1 1 3 5 9 C A nti b o dies (A D A ) will be 
perf or me d o n t he I m m u n o ge nicit y A nal ys is Set.  
 
T he esti mati o n of P K para meters will be perf or me d usi n g Wi n N o nli n ®Versi o n 5. 0 or hi g her. All 
ot her statistical a nal ys es will be perf or me d usi n g S A S ®Versi o n 9. 1. [ADDRESS_838776] data fr o m t he d ose -escalati o n part will be 
re p orte d. 
I n a d diti o n, f or t he fi nal statistical a nal y sis, t he f oll o wi n g will be a nal yz e d: 
At eac h d ose le vel, t he n u m ber a n d pr o p orti o n of s u bjects i n t he D L T A nal y sis Set w h o 
e x perie nce a D L T d uri n g t he D L T e val uati o n peri o d. 
At eac h d ose le vel, t he n u m ber a n d pr o p orti o n of T E A Es e x perie nce d b y  s u bjects i n t he D L T 
A nal y sis Set d uri n g t he D L T e val uati o n peri o d. 
T he M T D will be deter mi ne d acc or di n g t o t he d ose -escalati o n pla n descri be d i n Secti o n 5. 1. 3. [ADDRESS_838777] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838778] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 6 5 / [ADDRESS_838779] o ma c o h ort, t he he pri mar y  e fficac y  para meter i n t he e x pa nsi o n part is t he 
B O R acc or di n g t o R E CI S T 1. 1 as a dj u dicate d b y  t he I R C ( Secti o n 2. 2. 2 )a n d will be e val uate d b y 
c o nfir me d O R R .  F or gli o blast o ma, t he pri mar y  e fficac y  p ara meter will be disease c o ntr ol 
acc or di n g t o R A N O as a dj u dicate d b y t he I R C. 
T he pri mar y  a nal ys is of t he B O R will be c o n d ucte d i n t he F ull A nal ys is Set. T he n u m ber a n d 
pr o p orti o n of B O R ( defi ne d as C R + P R) will be ta b ulate d. F or t he gli o blast o ma c o h ort, t he 
pr o p orti o n of B O R of C R, P R, or S D ≥ 1 2 wee ks acc or di n g t o R A N O will be ta b ulate d .T he 
2- si de d 9 5 % Cl o p per -Pears o n CI will be c o nstr ucte d . 
F or a B O R of P R or C R, c o nfir mati o n of t he res p o nse acc or di n g t o R E CI S T 1. 1 ( Eise n ha uer 2 0 0 9) 
or R A N O f or s u bjects wit h gli o blast o ma (We n 2 0 1 0 ) will be re q uire d f or t he fi nal a nal ys is.  T he 
i nteri m a nal ys is will be base d o n u nc o nfir me d res p o nse. T he res p o nse at eac h sc he d ule d t u m or 
assess me nt a n d t he B O R will be liste d f or eac h s u bject.  T he O R R, defi ne d as t he pr o p orti o n of 
s u bjects wit h B O R of P R o r C R, will be ta b ulate d f or eac h c o h ort . 
8. 5. 3 A n al ysis of Ot her E n d p oi nts 
8. 5. 3. 1 Effic ac y P ar a meters 
Cli nical efficac y  para meters will be a nal yz e d descri pti vel y  i n t he F ull A nal y sis Set .  
F or t he d ose escalati o n part of t he trial, t he sec o n dar y  e fficac y  e n d p oi nt is BO R acc or di n g t o 
R E CI S T 1. 1 per In vesti gat or assess me nt. F or a B O R of P R or C R, c o nfir mati o n of t he res p o nse 
acc or di n g t o R E CI S T 1. 1 (Eise n ha uer 2 0 0 9 ) will be re q uire d. T he res p o nse at eac h sc he d ule d 
t u m or assess me nt a n d t he B O R will be liste d f or eac h s u bject. T he O R R , defi ne d as t he pr o p orti o n 
of s u bjects wit h B O R of P R or C R, will be ta b ulate d b y  d ose le vel. 
F or t he d ose -e x pa nsi o n part of t he trial, t he f oll o wi n g sec o n dar y  e fficac y  e n d p oi nts will be 
asse sse d: 
D urati o n of res p o nse, acc or di n g t o R E CI S T 1. [ADDRESS_838780] wit h a c o nfir me d res p o nse a n d will be a nal yz e d usi n g t he Ka pla n -Meier met h o d 
D C R , defi ne d as t he pr o p orti o n of s u bjects wit h B O R of C R, P R, or S D f or ≥ 1 2 wee ks will be 
ta b ulat e d wit hi n eac h e x pa nsi o n c o h ort 
P F S a n d T T P ti me (acc or di n g t o R E CI S T 1. 1 a n d a dj u dicate d b y t he I R C) a n d O S ti me will be 
prese nte d i n listi n gs a n d a nal yz e d usi n g t he Ka pla n -Meier met h o d i n eac h e x pa nsi o n c o h ort 
se parat el y  if t he c o h ort e nr olls t he f ull pla n ne d n u m ber of s u bjects 
8. 5. 3. 2 P h ar m ac o k i netic Pr ofile 
Plas ma c o nce ntrati o ns of M S B 0 0 1 1 3 5 9 C will be deter mi ne d b y  a  v ali date d met h o d at t he ti mes 
liste d i n Sc he d ules of Assess me nts (refer t o  Ta ble 1a n d  Ta ble 2).
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838781] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 6 6 / 1 9 3 T he f oll o wi n g P K para meters will be esti mate d a n d re p orte d i n t he P K A nal y sis Set :
A U C 0-t ( d ose escalati o n p orti o n , H C C, a n d N S C L C bi o mar ker c o h orts o nl y ): Area u n der t he 
c o nce ntrati o n -ti m e c ur ve fr o m t he ti me of d osi n g t o t he ti me of t he last o bser vati o n (calc ulate d 
b y  li near tra pez oi dal s u m mati o n). 
A U C 0- ∞ ( d ose escalati o n p orti o n , H C C, a n d N S C L C bi o mar ker c o h orts o nl y ): Area u n der t he 
c o nce ntrati o n -ti me c ur ve fr o m t he ti me of d osi n g e xtra p olate d t o i nfi nit y  ( calc ulate d b y  t he 
li near tra pez oi dal s u m mati o n a n d e xtra p olate d t o i nfi nit y  usi n g C last / λz). 
λz( d ose escalati o n p orti o n , H C C, a n d N S C L C bi o mar ker c o h orts o nl y ): Ter mi nal eli mi nati o n 
rate c o nsta nt. T he val ue of λzis deter mi ne d fr o m t he sl o pe of t he re gressi o n li ne of l o g 
(c o nce ntrati o n) vs. ti me wit h t he f oll o wi n g c o nstrai nts: (i) t here m ust be at least 3 c o nsec uti ve 
meas ura ble c o nce ntrati o ns, (ii) all c o nce ntrati o ns m ust be decli ni n g wit h ti me, a n d (iii) t he 
c orrelati o n c oeffic ie nt (r) of re gressi o n m ust be ≥ 0. 9 5. 
Cma x : Ma xi m u m ser u m c o nce ntrati o n o bser ve d p ost d ose .
Cmi n : Mi ni m u m ser u m c o nce ntrati o n o bser ve d p ost d ose .
tma x ( d ose escalati o n p orti o n , H C C, a n d N S C L C bi o mar ker c o h orts o nl y ): Ti me at w hic h t he 
Cma x occ urs. 
t½( d ose escalati o n , H C C, a n d N S C L C bi o mar ker c o h orts o nl y) : Eli mi nati o n half -life, 
deter mi ne d as 0. 6 9 3/ λ z.
T he P K para meters will be s u m marize d usi n g descri pti ve statistics. I n di vi d ual as well as mea n 
c o nce ntrati o n -ti me pl ots will be de pi[INVESTIGATOR_21043] d. 
U nres ol ve d missi n g data ma y  b e i m p ute d w he n t he a nal ys is i nte grit y i s affecte d. T he c o nser vati ve 
pri nci ple will be use d f or data i m p utati o n. 
8. 5. 3. 3 Ser u m Titers of A nti -M S B 0 0 1 1 3 5 9 C A nti b o dies ( A D A )
I m m u n o ge nicit y testi n g strate g y  will be i m ple me nte d a n d c o n d ucte d i n li ne w it h: 
I m m u n o ge nicit y Assess me nt of Bi otec h n ol o g y -Deri ve d T hera pe utic Pr otei ns 
( E M E A/ C H M P/ B M W P/ 1 4 3 2 7/ 2 0 0 6). 
I m m u n o ge nicit y assess me nt of m o n ocl o nal a nti b o dies i nte n de d f or i n vi v o cli nical use 
(E ur o pea n Me dici nes A ge nc y [ E M A] / C H M P/ B M W P/ 8 6 2 8 9/ 2 0 1 0). 
F o o d a n d Dr u g A d mi nistrati o n ( 2 0 0 9, draft) G ui da nce f or I n d ustr y : Assa y  D e vel o p me nt f or 
I m m u n o ge nicit y Testi n g of T hera pe utic Pr otei ns. 
A q ualifie d met h o d t hat uses a n aci d diss ociati o n ste p t o detect A D As i n t he prese nce of e xcess 
dr u g i n h u ma n ser u m will be a p pli e d. Re m o val of dr u g after aci d treat me nt is n ot re q uire d. T he 
A D A titers of p ositi ve sa m ples will be deter mi ne d. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838782] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 6 8 / 1 9 3 8. 5. 4. 3 P h ysic al E x a mi n ati o n, I ncl u di n g Vit al Si g ns a n d 1 2 -le a d 
Electr oc ar di o gr a m 
Vital si g ns ( b o d y te m perat ure, res pi[INVESTIGATOR_1305] y  r ate, heart rate, a n d bl o o d press ure) , e y e si g ns a n d 
s y m pt o ms base d o n S yste m Or ga n Class of “e ye dis or ders” ,a n d 1 2 -lea d E C G rec or de d acc or di n g 
t o t he Sc he d ule sof Assess me nts (refer t o  Ta ble 1a n d  Ta ble 2) will be prese nte d. 
F urt her details will be pr o vi de d i n t he S A P base d o n c urre nt safet y e x perie nce a p pl yi n g t he latest 
Me d D R A versi o n. 
8. [ADDRESS_838783] o ma c o h ort , t he e n d p oi nts i n t hese i nteri m a nal y ses are 
O R R (c o nfir mati o n is n ot re q uire d).  F or gli o blast o ma, t he e n d p oi nt i n t he i nteri m a nal ys is will be 
D C R. T here is n o m ulti plicit y a dj ust me nt is a p plie d t o t he i nteri m a nal ys es.  T he decisi o n r ules at 
t he i nteri m a nal y ses ser ve as g ui da nce a n d are n o n- bi n di n g.  I n t he a bse nce of a c o ntr ol ar m , 
o utc o mes i n t his si n gle ar m st u d y  h a ve t o be i nter prete d wit h ca uti o n, b ot h at i nteri m a n d fi nal 
a nal ys es. 
H C C asce n di n g -d ose c o h ort 
A n i nteri m a nal y sis will be c o n d ucte d [ADDRESS_838784] d ose. 
If ≤ 6res p o nses are o bser ve d i n t he [ADDRESS_838785] o p pe d.  T his decisi o n criteri o n has 3 9 % 
pr o ba bilit y  of rejecti n g t he n ull h y p ot hesis if t he tr ue res p o nse rate is 2 0 % a n d 6% pr o ba bilit y  of 
rejecti n g t he alter nati ve h y p ot hesis if t he tr ue res p o nse rate is 35 %. 
E nr oll me nt of H C C sec o n d -li ne or s orafe ni b -i nt olera nt c o h ort will n ot be st o p pe d f or t he p ur p ose 
of c o n d ucti n g t his i nteri m a nal y sis b ut will st o p if f utilit y  is met as s pecifie d. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838786] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 6 9 / 1 9 3 H C C sec o n d -li ne or s or afe ni b -i nt oler a nt c o h ort 
N o i nteri m a nal ys is is pla n ne d. 
N S C L C a nti -P D - 1 / a nti -P D -L [ADDRESS_838787] i n t his c o h ort starte d 
treat me nt. 
If ≤ [ADDRESS_838788] o p pe d.  T his decisi o n criteri o n has 3 2 % pr o ba bilit y  o f rejecti n g n ull h y p ot hesi s if t he tr ue 
res p o nse rate is 5 % a n d 5% pr o ba bilit y  o f rejecti n g alter nati ve h y p ot hesi s if t he tr ue res p o nse 
rate is 1 5 %. 
If [ADDRESS_838789] 4 0 s u bjects ha ve c o m plete d t u m or assess me nt at Wee k 2 4. After a re vie w 
of t he t otalit y  of data, i ncl u di n g d urati o n of res p o nse, D C R , a n d safet y, t he S p o ns or will ma ke 
a decisi o n as t o w het her t o res u me t he accr ual. 
If ≥ 5 res p o nses are o bser ve d at t he i nteri m a nal ys is, a n a d diti o na l 4 0 s u bjects will be e nr olle d.  
Wit h 5 res p o nses a n d usi n g B a y esia n pri nci pal, t he p osteri or pr o ba bilit y  o f tr ue O R R bei n g 
a b o ve 1 5 % (alter nati ve h y p ot hesis) is a p pr o xi matel y  4 1 % a n d t he p osteri or pr o ba bilit y  of tr ue 
OR R bei n g bel o w 5 % ( n ull h y p ot hesis) is a p pr o xi matel y  2 %. 
Mel a n o m a a nti -P D - 1 / a nti -P D -L [ADDRESS_838790] i n t he c o h ort starte d 
treat me nt.  I f ≤ [ADDRESS_838791] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838792] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 0 / [ADDRESS_838793] of t he trial at t he site a n d will e ns ure t hat t he trial 
is perf or me d i n acc or da nce wit h t h is pr ot oc ol, t he et hical pri nci ples o utli ne d i n t he Declarati o n of 
Helsi n ki, I C H G C P ,t he sta n dar ds sti p ulate d i n Article 1 4, Para gra p h 3, a n d Article 8 0- 2 of t he 
P har mace utical Affairs La w i n Ja pa n; a n d t he “ Mi nisterial Or di na nce o n t he Sta n dar ds f or t he 
I m ple me ntati o n of Cli nical St u dies o n P har mace utical Pr o d uct” ( G C P) i n Ja pa n , a n d a n y  o t her 
a p plica ble re g ulati o ns. The I n vesti gat or m ust e ns ure t hat o nl y  s u bjects w h o ha ve gi ve n i nf or me d 
c o nse nt are i ncl u de d i n t he trial. T hr o u g h o ut t his cli nical trial pr ot oc ol, In vesti gat or refers t o b ot h 
t he pri nci pal i n vesti gat or a n d a n y s u bi n vesti gat ors .
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838794] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 1 / 1 9 3 Acc or di n g t o U nite d States C o de of Fe deral Re g ulati o ns Part 5 4. 2 (e), f or trials c o n d ucte d i n a n y 
c o u ntr y  t hat c o ul d res ult i n a pr o d uct s u b missi o n t o t he U nite d States F D A f or mar keti n g a p pr o val 
a n d c o ul d c o ntri b ute si g nifica ntl y  t o t he de m o nstrati o n of efficac y  a n d s afet y  o f a n I M P ( w hic h 
are c o nsi dere d “c o vere d cli nical trials” b y  t he F D A), t he I n vesti gat or a n d all s u b in vesti gat ors are 
o bli ge d t o discl ose a n y f i na ncial i nterest w hic h t he y , t heir s p o uses or t heir de pe n de nt c hil dre n m a y  
ha ve i n t he S p o ns or or t he S p o ns or’s pr o d uct u n der st u d y. T his i nf or mati o n is re q uire d d uri n g t he 
trial a n d f or [ADDRESS_838795] is < [ADDRESS_838796]’s 
pare nt or g uar dia n i n a d diti o n t o t he s u bject’s v ol u ntar y  w ritte n c o nse nt.   A de q uate i nf or mati o n 
m ust t heref ore be gi ve n t o t he s u bject b y  t he I n vesti gat or or a n a p pr o priate desi g nee (if l ocal 
re g ulati o ns per mit) bef ore i nf or me d c o nse nt is o btai ne d. 
A s u bject i nf or mati o n s heet m ust be pre pare d i n t he l ocal la n g ua ge i n acc or da nce wit h Ja pa n G C P 
a n d I C H G C P a n d will be pr o vi de d b y  t he S p o ns or f or t he p ur p ose of o btai ni n g i nf or me d c o nse nt. 
I n a d diti o n t o pr o vi di n g t his writte n i nf or mati o n t o a p ote ntial s u bject, t he I n vesti gat or or a 
desi g nate will i nf or m t he s u bject ver ball y  o f all perti ne nt as pects of t he trial, usi n g la n g ua ge c h ose n 
s o t hat t he i nf or mati o n ca n be f ull y  a n d rea dil y  u n derst o o d b y  l a y pers o ns. T he s u bject will be gi ve n 
s ufficie nt ti me t o rea d t he i nf or mati o n a n d t he o p p ort u nit y  t o as k q uest i o ns a n d t o re q uest 
a d diti o nal i nf or mati o n a n d clarificati o n. 
If per mitte d b y  n ati o nal re g ulati o ns, a pers o n ot her t ha n t he I n vesti gat or ma y  i nf or m t he s u bject 
a b o ut t he trial a n d si g n t he I C F, as a b o ve .
If per mitte d b y  n ati o nal re g ulati o ns, a pers o n ot her t ha n t he I n vesti gat or ma y  i nf or m t he s u bject 
a b o ut t he trial a n d si g n t he I C F, as a b o ve. 
After t he i nf or mati o n is pr o vi de d b y  t he I n vesti gat or, t he I C Fm ust be si g ne d a n d date d b y  t he 
s u bject or t he s u bject’s le gal re prese ntati ve a n d t he I n vesti gat or. 
F o r all trial sites, the si g ne d a n d date d declarati o n of i nf or me d c o nse nt will re mai n at t he 
I n vesti gat or’s site, a n d m ust be safel y arc hi ve d s o t hat t he f or ms ca n be retrie ve d at a n y ti me f or 
m o nit ori n g, a u diti n g a n d i ns pecti o n p ur p oses. A c o p y  o f t he si g n e d a n d date d i nf or mati o n a n d 
I C Fs h o ul d be pr o vi de d t o t he s u bject pri or t o partici pati o n. 
W he ne ver i m p orta nt ne w i nf or mati o n bec o mes a vaila ble t hat ma y  b e rele va nt t o i nf or me d c o nse nt, 
t he I n vesti gat or will re vise t he s u bject i nf or mati o n s heet a n d a n y  o t h er writte n i nf or mati o n t o be 
pr o vi de d t o t he s u bjects a n d s u b mit t he m t o t he I R B f or re vie w a n d o pi [INVESTIGATOR_9384] o n. Usi n g t he a p pr o ve d 
re vise d s u bject i nf or mati o n s heet a n d ot her writte n i nf or mati o n, the I n vesti gat or will e x plai n t he 
c ha n ges t o t he pre vi o us versi o n t o eac h tr ial s u bject a n d o btai n ne w writte n c o nse nt f or c o nti n ue d 
partici pati o n i n t he trial. The s u bject will be gi ve n s ufficie nt ti me t o rea d t he i nf or mati o n a n d t he 
o p p ort u nit y  t o as k q uesti o ns a n d t o re q uest a d diti o nal i nf or mati o n a n d clarificati o n ab o ut t he 
c ha n ges. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838797] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 2 / [ADDRESS_838798]’s i de ntifier i n t he trial as well as i n t he cli nical trial data base. 
T he s u bject’s data c ollecte d i n t he trial will be st ore d u n der t his n u m ber.  O nl y  t he I n vesti gat or 
will be a ble t o li n k t he s u bject’s trial data t o t he s u bject via a n i de ntificati o n list ke pt at t he site. 
T he s u bject’s ori gi nal me dical data t hat are re vie we d at t he site d uri n g s o urce data verificati o n b y 
t he M o nit or, a u dits, a n d He alt h A ut h orit y  i ns pecti o ns will be ke pt strictl y  c o nfi de ntial. 
Data pr otecti o n a n d pri vac y  r e g ulati o ns will be o bser ve d i n ca pt uri n g, f or war di n g, pr ocessi n g, a n d 
st ori n g s u bject data.  S u bjects will be i nf or me d acc or di n gl y a n d will be re q ueste d t o gi ve t he ir 
c o nse nt o n data ha n dli n g pr oce d ures i n acc or da nce wit h nati o nal re g ulati o ns .
Bl o o d a n d t u m or tiss ue sa m ples f or P Gt a n d bi o mar kers will be st ore d f or u p t o 1 0 years after trial 
c o m pleti o n. D uri n g t his ti me, t he sa m ples ma y be rea nal yz e d f or ne wl y i de nt ifie d mar kers or wit h 
ne w or i m pr o ve d tec h n ol o g y. After 1 0 years, t he sa m ples will be destr o y e d or f ull y  a n o n y mize d 
or a ne w I E C /I R B a p pr o val a n d i nf or me d c o nse nt will be re q ueste d t o kee p t he sa m ples f or a n 
a d diti o nal peri o d. If t u m or tiss ue re mai ns, t he site will be n otifie d a n d t he t u m or tiss ue will be 
ret ur ne d t o t he site u p o n re q uest. If t he site d oes n ot re q uest t he ret ur n of t he t u m or tiss ue, it will 
be destr o ye d. 
9. [ADDRESS_838799] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838800] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 3 / [ADDRESS_838801] u d y a n d i m pair 
t he healt h of t he s u bjects, e xce pt f or A Es ca use d b y a n i nte nti o nal a n d /or si g nifica n t de viati o n o n 
t he part of t he I n vesti gat or, t he st u d y site, a n d /or t he s u bject. T he Sp o ns or will pr o vi de i ns ura nce 
t o f ulfill t his res p o nsi bilit y .
9. 6 I n de pe n de nt Et hics C o m mittee or I nstit uti o n al Re vie w B o ar d 
Pri or t o c o m me nce me nt of t he trial at a gi ve n site, t he cli nical trial pr ot oc ol will be s u b mitte d 
t o get her wit h its ass ociate d d oc u me nts (s uc h as t he I C F) t o t he res p o nsi ble I E C / I R B f or its 
fa v ora ble o pi [INVESTIGATOR_9384] o n / a p pr o val.  T he writte n fa v ora ble o pi [INVESTIGATOR_9384] o n / a p pr o val of t he I E C / I R B will be 
file d i n t he I n vesti gat or Site File, a n d a c o p y will be file d wit h t he C R O. 
T he trial m ust n ot start at a site bef ore t he S p o ns or has o btai ne d writte n c o nfir mati o n of fa v ora ble 
o pi [INVESTIGATOR_9384] o n / a p pr o val fr o m t he c o ncer ne d I E C / I R B.  T he I E C / I R B will be as ke d t o pr o vi de 
d oc u me ntati o n of t he date of t he meeti n g at w hic h t he fa v ora ble o pi [INVESTIGATOR_9384] o n / a p pr o val was gi ve n, a n d 
of t he me m bers a n d v oti n g me m bers prese nt at t he meeti n g.  W ritte n e vi de nce of fa v ora ble 
o pi [INVESTIGATOR_9384] o n /a p pr o val t hat clearl y i de ntifies t he trial, t he cli nical trial pr ot oc ol versi o n a n d t he S u bject 
I n f or mati o n a n d I C F versi o n re vie we d s h o ul d be pr o vi de d.  W here p ossi ble, c o pi[INVESTIGATOR_1309] t he meeti n g 
mi n utes s h o ul d be o btai ne d. 
A me n d me nts t o t he cli nical trial will als o be s u b mitte d t o t he c o ncer ne d I E C / I R B, bef ore 
i m ple me ntati o n i n case of s u bsta ntial c ha n ges (see Secti o n 1 0. 5 ).  Rele va nt safet y i nf or mati o n will 
be s u b mitte d t o t he I E C / I R B d uri n g t he c o urse of t he trial i n acc or da nce wit h nati o nal re g ulati o ns 
a n d re q uire me nts. 
9. 7 He alt h A ut h orities 
T he cli nical trial pr ot oc ol a n d a n y a p plica ble d oc u me ntati o n (f or e xa m ple, I n vesti gati o nal 
Me dici nal Pr o d uct D ossier, S u bject I nf or mati o n a n d I C F) will be s u b mitte d or n otifie d t o t he 
Healt h A ut h orities i n acc or da nce wit h all l ocal a n d nati o nal re g ulati o ns f or eac h site .
1 0 Tri al M a n a ge me nt 
1 0. 1 Electr o nic C ase Re p ort F or m H a n dli n g 
Refer t o t he Ma n ual of O perati o ns f or e C R F ha n dli n g g ui deli nes.  
T he I n ves ti gat or or desi g nee will be res p o nsi ble f or e nteri n g trial data i n t he e C R F pr o vi de d b y  
t he C R O a n d f oll o w t he data sta n dar ds of t he S p o ns or. It  i s t he In vesti gat or’s res p o nsi bilit y  t o 
e ns ure t he acc urac y  of t he data e ntere d i n t he e C R Fs. 
T he data will be e ntere d i nt o a vali date d data base. T he C R O will be res p o nsi ble f or data re vie w 
a n d pr ocessi n g, i n acc or da nce wit h t he S p o ns or’s data ma na ge me nt pr oce d ures. Data base l oc k 
will occ ur o nce q ualit y  c o ntr ol pr oce d ure, a n d q ualit y  a ss ura nce pr oce d ures (if a p plica ble) ha ve 
bee n c o m plete d. All P D F files of t he e C R Fs will be pr o vi de d t o t he In vesti gat ors at t he c o m pleti o n 
of t he trial. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838802] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 4 / [ADDRESS_838803] file ( me dical file, ori gi nal me dical rec or ds) o n pa per or 
electr o nicall y  f or e ver y s u bject i ncl u de d i n t he trial. T his file will c o ntai n t he a vaila ble 
de m o gra p hic a n d me dical i nf or mati o n f or t he s u bject, a n d s h o ul d be as c o m plete as p ossi ble. I n 
partic ular, t he f oll o wi n g data s h o ul d be a vaila ble i n t his file: 
S u bject’s f ull na me 
Date of birt h 
Se x 
Race 
Hei g ht 
Wei g ht 
Me dical h ist or y  a n d c o nc o mita nt diseases 
Pri or a n d c o nc o mita nt t hera pi[INVESTIGATOR_014] (i ncl u di n g c ha n ges d uri n g t he trial) 
T u m or disease i nf or mati o n 
Trial i de ntificati o n ( E M R 2 0 0 6 4 7- 0 0 1) 
Date of s u bje ct’s i ncl usi o n i nt o t he trial ( t hat is , d ate of gi vi n g i nf or me d c o nse nt) 
S u bject n u m ber i n t he trial 
Dates of t he s u bject’s visits t o t he site 
A n y  me dical e xa mi nati o ns a n d cli nical fi n di n gs pre defi ne d i n t he cli nical trial pr ot oc ol 
All A Es o bser ve d i n t he s u bject 
Dat e of s u bject’s e n d of trial 
Date of a n d reas o n f or earl y wit h dra wal of t he s u bject fr o m t he t rial or fr o m I M P, if a p plica ble .
It m ust be p ossi ble t o i de ntif y  eac h s u bject b y  usi n g t his s u bject file. 
A d diti o nall y , a n y ot her d oc u me nts c o ntai ni n g s o urce data m ust be file d. T his i ncl u des ori gi nal 
pri nt o uts of data rec or de d or ge nerate d b y  a ut o mate d i nstr u m e nts, p h ot o gra p hic ne gati ves, X-ra y s, 
C T or M RI  s ca n i ma ges, E C G rec or di n gs, la b orat or y  v al ue listi n gs, etc. S uc h d oc u me nts m ust 
bear at least t he s u bject n u m ber a n d t he date w he n t he pr oce d ure was perf or me d. I n f or mati o n 
s h o ul d be pri nte d b y  t he i nstr u me nt use d t o perf or m t he assess me nt or meas ure me nt, if p ossi ble. 
I n f or mati o n t hat ca n n ot be pri nte d b ya n a ut o mate d i nstr u me nt will be e ntere d ma n uall y. Me dical 
e val uati o n of s uc h rec or ds s h o ul d be d oc u me nte d as necessar y  a n d t he d oc u me ntati o n si g ne d a n d 
date d b y t he In vesti gat or. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838804] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 5 / [ADDRESS_838805] 
1 5 ye ars ( or l o n ger, i n acc or da nce wit h t he l ocal re q uire me nts of Ja pa n G C P or as ot her wise 
n otifie d b y  t he S p o ns or) after t he e n d of t he trial. T he d oc u me n ts t o be arc hi ve d i ncl u de t he S u bject 
I d e ntificati o n Li st a n d t he si g ne d s u bject I C Fs . If arc hi vi n g of t he I n vesti gat or Site File is n o l o n ger 
p ossi ble at t he site, t he I n vesti gat or m ust n otif y  t he S p o ns or /desi g nee. 
All ori gi nal s u bject files ( me dical r e c or ds ) m ust be st ore d at t he site ( h os pi[INVESTIGATOR_307], researc h i nstit ute, 
or practice) f or t he l o n gest p ossi ble ti me per mitte d b y  t he a p plica ble re g ulati o ns, a n d /or as per 
I C H G C P g ui deli nes, w hic he ver is l o n ger. I n a n y  c ase, t he I n vesti gat or s h o ul d e ns ure t hat n o 
destr ucti o n of me dical rec or ds is perf or me d wit h o ut t he writte n a p pr o val of t he S p o ns or. 
I n Ja pa n, the hea d of t he st u d y  s ite m ust retai n all rec or ds, i ncl u di n g d oc u me nts a n d data, w hic h 
relate t o t he cli nical st u d y  i n acc or da nce wit h Ja pa n G C P.   T he hea d of t he st u d y  site m ust retai n 
t he rec or ds at t he site ( h os pi[INVESTIGATOR_307], researc h i nstit ute, or practice) f or t he l o n gest p ossi ble ti me 
per mitte d b y  Ja pa n G C P , a n d /or as per I C H G C P g ui deli nes, w hic he ver is l o n ger. I n  a n y  c ase, 
t he hea d of t he st u d y  s ite sh o ul d e ns ure t hat n o destr ucti o n of me dical rec or ds is perf or me d wit h o ut 
t he writte n a p pr o val of t he S p o ns or.   T he In vesti gat or m ust retai n rec or ds, i ncl u di n g d oc u me nts 
a n d data, w hic h relate t o t he cli nical st u d y  i n acc or da nce wit h t he i nstr ucti o ns fr o m t he hea d of t he 
st u d y  site .
[ADDRESS_838806] .
1 0. 5 C h a n ges t o t he Cli nic al Tri al Pr ot oc ol 
C ha n ges t o t he cli nical tr ial pr ot oc ol will be d oc u me nte d i n writi n g . S u bsta nti ve a me n d me nts will 
us uall y  re q uire s u b missi o n t o t he Healt h A ut h orities a n d t o t he rele va nt I E C /I R B f or a p pr o val or 
fa v ora ble o pi [INVESTIGATOR_9384] o n. I n s uc h cases, t he a me n d me nt will be i m ple me nte d o nl y  a fter a p pr o val or 
fa v ora ble o pi [INVESTIGATOR_9384] o n has bee n o btai ne d. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838807] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 6 / 1 9 3 Mi n or ( n o ns u bsta ntial) pr ot oc ol a me n d me nts, i ncl u di n g a d mi nistrati ve c ha n ges, will be file d b y  
t he S p o ns or a n d at t he site. T he y  w ill be s u b mitte d t o t he rele va nt I E C /I R B or t o Healt h 
A ut h orities o nl y  w h e re re q ueste d b y p e rti ne nt re g ulati o ns. A n y  a me n d me nt t hat c o ul d affect t he 
s u bject’s a gree me nt t o partici pate i n t he trial re q uires a d diti o nal i nf or me d c o nse nt pri or t o 
i m ple me ntati o n f oll o wi n g t he pr ocess as descri be d i n Secti o n 9. [ADDRESS_838808] p u blicati o n will be a p u blicati o n of t he res ults of t he a nal y sis of t he pri mar y  e n d p oi nt(s) 
t hat will i ncl u de data fr o m all trial sites t hat partici pate d i n t he d ose -escalati o n part of t he trial. 
T he In vesti gat or will i nf or m t he S p o ns or i n a d va nc e a b o ut a n y pla ns t o p u blis h or prese nt data 
fr o m t he trial. A n y p u blicati o ns a n d prese ntati o ns of t he res ults (a bstracts i n j o ur nals or 
ne ws pa pers, oral prese ntati o ns, etc.), eit her i n w h ole or i n part, b y  I n vesti gat ors or t heir 
re prese ntati ves will re q u ire pre s u b missi o n re vie w b y  t he S p o ns or. 
T he S p o ns or will n ot s u p press or vet o p u blicati o ns b ut mai ntai ns t he ri g ht t o dela y  p u blicati o n i n 
or der t o pr otect i ntellect ual pr o pert y ri g hts. 
[ADDRESS_838809] u d y  site a n d t he In vesti g at or will retai n all rec or ds as descri be d i n Secti o n  1 0. 3. 
T he Sp o ns or a n d a n y pers o n w h o esta blis hes a n I E C /I R B m ust retai n all rec or ds, i ncl u di n g 
d oc u me nts a n d data, w hic h relate t o t he cli nical trial f or t he re q uire d peri o d i n acc or da nce wit h 
Ja pa n G C P .
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838810] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 7 / 1 9 3 1 1 Refere nces Cite d i n t he Te xt 
Aar o ns o n N. K., A h me dzai S., B ulli n ger M. et al. T he E O R T C c ore q ualit y of life q uesti o n naire: 
I nteri m res ults of a n i nter nati o nal fiel d st u d y . I n: Os o ba D. e d. Effect of Ca ncer o n Q ualit y  o f Life. 
B oca Rat o n, F L: C R C Press 1 9 9 1: 1 8 5- 2 0 3. 
A da ms S, et al. Safet y  a n d cli nical acti vit y  o f atez oliz u ma b (a nti -P D -L 1 ) i n c o m bi nati o n wit h na b -
paclita xel i n patie nts wit h tri ple -ne gati ve breast ca ncer, A bstract n u m ber: 8 5 0 4 7 7. 1 0t h Dece m ber, 
0 7. 3 0  Sa n A nt o ni o, T X, U nite d States. 
Attia P, P ha n G Q, Ma ker A V, et al. A ut oi m m u nit y  c orrelates wit h t u m or re gressi o n i n pa tie nts 
wit h metastatic mela n o ma treate d wit h a nti -c y t ot o xic T- l y m p h oc y te a nti ge n - 4. J Cli n O nc ol 
2 0 0 5 ; 2 3( 2 5): 6 0 4 3 - 5 3. 
Baratelli F, Lee J M, Hazra S, et al. P G E( 2) c o ntri b utes t o T G F -beta i n d uce d T re g ulat or y  c ell 
f u ncti o n i n h u ma n n o n -s mall ce ll l u n g ca nce r. A m J Tra nsl Res 2 0 1 0; 2( 4): 3 5 6 - 6 7. 
Blaze b y J M, C o nr o y  T , Ha m merli d E, et al . Cli nical a n d ps y c h o metric vali dati o n of a n E O R T C 
q uesti o n naire m o d ule, t he E O R T C Q L Q -O E S 1 8, t o assess q ualit y  o f life i n patie nts w it h 
oes o p ha geal ca ncer. E ur J Ca ncer. 2 0 0 3 J ul 3 1; 3 9( 1 0): 1 3 8 4 - 9 4. 
Blaze b y J M, C urrie E, Zee B C Y, et al . De vel o p me nt of a q uesti o n naire m o d ule t o s u p ple me nt t he 
E O R T C Q L Q- C 3 0 t o assess q ualit y  of life i n patie nts wit h he pat ocell ular carci n o ma, t he E O R T C 
Q L Q -H C C 1 8. E ur J Ca ncer 2 0 0 4; 4 0( 1 6): 2 4 3 9 -4 4. 
B o h n sac k O, H o os A, L u dajic K. A da ptati o n of t he i m m u ne relate d res p o n se criteria: ir R E CI S T 
A n n O nc ol 2 0 1 4; 2 5(s u p pl 4): 1 1 P oster 1 0 7 0. 
Bra h mer J R, T y k o di S S, C h o w L Q M, et al. Safet y a n d acti vit y of a nti -P D -L 1 a nti b o d y i n patie nts 
wit h a d va nce d ca ncer. N E n gl J Me d 2 0 1 2; 3 6 6( 2 6): 2 4 5 5 -6 5. 
Br u na A, Dar ke n R S, R oj o F, et al. Hi g h T G F β -s ma d acti vit y  c o nfers p o or pr o g n osis i n gli o ma 
patie nts a n d pr o m otes cell pr oliferati o n de pe n di n g o n t he met h y lati o n of t he P D G F -B ge ne. Ca ncer 
Cell 2 0 0 7; 1 1: [ADDRESS_838811] u dies wit h a nti -C T L A- 4 a nti b o dies i n n o n- 
me la n o ma i n dicati o ns. Se mi n O nc ol 2 0 1 0; 3 7( 5): [ADDRESS_838812] or -β 1 m o n ocl o nal a nti b o d y  ( T β M 1) i n patie nts wit h metastatic ca nce r. 
I nt J O nc ol 2 0 1 4; 4 5( 6): [ADDRESS_838813] D P. Ha n d b o o k of Statistics i n Cli nical O nc ol o g y, 2 n d E diti o n. C R C Press 
2 0 0 6. 
Cli nical Trial Facilitati o n Gr o u p, Rec o m me n dati o ns relate d t o co ntrace pti o n a n d pre g na nc y  t esti n g 
i n cli nical trials, A d vis or y  n o n- bi n di n g g ui da nce s u p p orte d b y  n ati o nal c o m pete nt a ut h orities, 
R o me 2 0 1 4- 0 9- 1 5 2 0 1 4, htt p:// w w w. h ma.e u/filea d mi n/ dateie n/ H u ma n Me dici nes/ 0 1 -A b o ut 
H M A/ W or ki n g Gr o u ps/ C T F G/ [ADDRESS_838814] or -beta 1 t o t he a d va nci n g e d ges of pri mar y  t u m ors a n d t o l y m p h n o de metastases of 
h u ma n ma m mar y  carci n o ma. A m J Pat h ol 1 9 9 3; 1 4 3: [ADDRESS_838815] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838816] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 8 / 1 9 3 Desr uissea u S, Pal mari J, Gi usti C, et al. Deter mi nati o n of T G F[ beta] [ADDRESS_838817] ca ncers a n d its relati o ns hi p wit h s ur vi val. Br J Ca ncer 2 0 0 6; 9 4: 2 3 9 - 2 4 6. 
Di Giac o m o A M, Bia gi oli M, Mai o M . T he e mer gi n g t o xicit y  pr ofiles of a nti- C T L A- 4 a nti b o dies 
acr oss cli nical i n dicati o ns. Se mi n O nc ol 2 0 1 1; 3 7( 5): 4 9 9- 5 0 7. 
D oi T, Pi [INVESTIGATOR_43154] -Pa ul S A, Jalal SI , e t al. Pe m br oliz u ma b ( M K -3 4 7 5) f or patie nts ( pts) wit h a d va nce d 
es o p ha geal carci n o ma: Preli mi nar y  r es ults fr o m K E Y N O T E - 0 2 8 . J Cli n O nc ol 2 0 1 5; 3 3 (s u p pl; 
a bstr 4 0 1 0) .  
D ola n D E, G u pta S. P D -1 pat h wa y  i n hi bit ors: c ha n gi n g t he la n dsca pe of ca ncer i m m u n ot hera p y . 
Ca ncer C o ntr ol 2 0 1 4; 2 1( 3): 2 3 1- 3 7. 
D o n k or M K, Sar kar A, Li M O. T G F -β 1 pr o d uce d b y  a cti vate d C D( +) T-cells a nta g o nize d T- cell 
s ur veilla nce of t u m or de vel o p me nt. O nc oi m m u n ol o g y  2 0 1 2; 1( 2): 1 6 2 - 7 1. 
Eise n ha uer E A, T herasse P, B o gaerts J, et al. Ne w res p o nse e val uati o n criteria i n s oli d t u m o urs: 
Re vise d R E CI S T g ui deli ne ( versi o n 1. 1). E ur J Ca ncer 2 0 0 9; 4 5: 2 2 8 - 4 7. 
El -K h o ueir y A B, Meler o I, Cr oce nzi T S, et al. P hase I/ II safet y a n d a ntit u m or acti vit y  o f 
ni v ol u ma b i n patie nts wit h a d va nce d he pat ocell ular carci n o ma ( H C C). Cli n O nc ol 2 0 1 5; 3 3 (s u p pl; 
a bstr L B A 1 0 1 ). 
E M A/ C H M P/ B M W P/ 8 6 2 8 9/ 2 0 1 0 . G ui deli ne o n I m m u n o ge nicit y  a ssess me nt of m o n ocl o nal 
a nti b o dies i nt e n de d f or i n vi v o cli nical use. 
E M E A/ C H M P/ B M W P/ 1 4 3 2 7/ 2 0 0 6 . G ui deli ne o n I m m u n o ge nicit y Assess me nt of 
Bi otec h n ol o g y- Deri ve d T hera pe utic Pr otei ns .
E M E A/ C H M P/I C H/ 6 4 6 1 0 7/ [ADDRESS_838818] or -beta 
( T G F -β) 1 rece pt or ki nase i n hi bit or, L Y 2 1 5 7 2 9 9 m o n o h y drate ( L Y), i n patie nts wit h a d va nce d 
he pat ocell ular carci n o ma ( H C C). J Cli n O nc ol 2 0 1 4; (s u p pl 3; a bstr L B A 1 7 3). 
F D A, [ADDRESS_838819] or beta 1 c orrelate 
wit h disease pr o gressi o n i n h u ma n c ol o n ca ncer. Ca ncer E pi [INVESTIGATOR_32450] o g y , Bi o mar kers & Pre ve nti o n: 
A P u blicati o n of t he A merica n Ass ociati o n f or Ca ncer Researc h, C os p o ns ore d b y  t he A merica n 
S ocie t y  of Pre ve nti ve O nc ol o g y  1 9 9 5; 4: [ADDRESS_838820] or -beta rece pt or t y pe I a n d t y pe II i n h u ma n pit uitar y  a de n o mas. Cli n 
Ne ur o pat h ol 1 9 9 8; 1 7: [ADDRESS_838821] -li ne ni v ol u ma b ( A nti -P D -1; B M S -9 3 6 5 5 8, 
O N O -4 5 3 8) m o n ot he ra p y  i n a d va nce d N S C L C: safet y, efficac y, a n d c orrelati o n of o utc o mes wit h 
P D -L 1  stat us. J Cli n O nc ol 2 0 1 4; 3 2: 5s, (s u p pl; a bstr 8 0 2 4). 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838822] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 9 / [ADDRESS_838823] o pat h ol o g y  2 0 0 0; 3 6: [ADDRESS_838824] ca ncer. Ca ncer Res 1 9 9 2; 5 2: 6 9 4 9 -
6 9 5 2. 
G o u die D R, D’ Alessa n dr o M, Merri ma n B, et al. M ulti ple self -heali n g s q ua m o us e pit heli o ma is 
ca use d b y a disease -s pecific s pectr u m of m utati o ns i n T G F B R 1. Nat Ge net 2 0 1 1; 4 3( 4) [ADDRESS_838825] u d y  o f t he relia bilit y  a n d vali dit y 
of a disease -s pecific q uesti o n naire m o d ule (t he Q L Q -O V 2 8) i n assessi n g t he q ualit y of life of 
patie n ts wit h o varia n ca ncer. E ur J Ca ncer. 2 0 0 3 J ul 3 1; 3 9( 1 0): 1 4 0 2 - 8. 
Grei mel E R, K ulja nic Vlasic K, Wal de nstr o m A C, et al. T he E ur o pea n Or ga ni sati o n f or Researc h 
a n d Treat me nt of Ca ncer ( E O R T C) Q ualit y -of -Life q uesti o n naire cer vical ca ncer m o d ule. Ca ncer 
2 0 0 6; 1 0 7( 8): 1 8 1 2 - 2 2. 
Ha ma nis hi J, Ma n dai M, I ke da T, et al. Safet y a n d a ntit u m or acti vit y  o f a nti -P D -1 a nti b o d y , 
ni v ol u ma b, i n patie nts wit h plati n u m -resista nt o varia n ca ncer. J Cli n O nc ol 2 0 1 5; 3 3 4 0 1 5- 2 2. 
Ha o N B, L ü M H, Fa n Y H, et al. Macr o p ha ges i n t u m or micr oe n vir o n me nts a n d t he pr o gressi o n 
of t u m ors. Cli n De v I m m u n ol 2 0 1 2;i d [ADDRESS_838826] or -beta 1 i n d uces t u m or str o ma 
a n d re d uces t u m or i nfiltrate i n cer vical ca ncer. H u m Pat h ol 2 0 0 2; 3 3( 1 2): 1 1 9 3 - 9. 
Hazel ba g S, Ke nter G G, G orter A, et al. Pr o g n ostic rele va nce of T G F -beta 1 a n d P AI -1 i n cer vi cal 
ca ncer. I nt J Ca ncer 2 0 0 4; 1 1 2( 6): [ADDRESS_838827] of differe nt P D -L 1 e x pressi o n patter ns 
i n s q ua m o us cell carci n o ma a n d a de n ocarci n o ma of t he cer vi x. M o d Pat h ol 2 0 1 6; 2 9( 7) 7 5 3 - 6 3. 
H otc h kiss R S, M ol da wer L L. Parallels bet wee n ca ncer a n d i nfecti o us disease. N E n gl J M e d 2 0 1 4; 
3 7 1( 4): [ADDRESS_838828] or -[ beta] rece pt or ge ne i n gli o mas. Ca ncer Lett 1 9 9 7; 1 1 2: [ADDRESS_838829] or -beta -me diate d 
a ut ocri ne gr o wt h re g ulati o n of gli o mas as detecte d wit h p h os p h or ot hi oate a ntise nse 
oli g o n ucle oti des. I nt J Ca ncer 1 9 9 6; 6 5: 3 3 2 - 3 3 7. 
Je o n H S, Je n J. T G F -beta si g nali n g a n d t he r ole of i n hi bit or y  S ma ds i n n o n- s mall cell l u n g ca ncer. 
J T h orac O nc ol 2 0 1 0 A pr; 5( 4): [ADDRESS_838830] o ne E, et al . U p date o n i m m u n ol o gic t hera p y  w it h a nti -C T L A - 4 
a nti b o dies i n mela n o ma: i de ntificati o n of cli nical a n d bi ol o gical res p o nse patter ns, i m m u ne -relate d 
a d verse e ve nts, a n d t he ir ma na ge me nt. Se mi n O nc ol 2 0 1 0; 3 7( 5): [ADDRESS_838831] or -β le vels 
i n ser u m a n d s oli d or ga n tis s ues b y  bi oassa y . B M C Res N otes 2 0 1 2; 5: [ADDRESS_838832] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838833] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 0 / 1 9 3 Kjell ma n C, Ol ofss o n S P, Ha nss o n O, et al. E x pressi o n of T G F -β is of or ms, T G F -β rece pt ors, a n d 
S ma d m olec ules at differe nt sta ges of h u ma n gli o ma. I n t J Ca ncer 2 0 0 0; 8 9: 2 5 1 - 2 5 8. 
K o mi y a ma S, K ura has hi T, Is hi ka wa M, et al. E x pressi o n of T G F ß 1 a n d its rece pt ors is ass ociate d 
wit h bi ol o gical feat ures of o varia n ca ncer a n d se nsiti vit y  t o paclita xel/ car b o plati n. O nc ol Re p 
2 0 1 1; 2 5: 1 1 3 1 - 1 1 3 8. 
K u bicz k o va l, Se dlari k o va L, Haje k R et al. T G F β -a n e xcelle nt ser va nt b ut a ba d master. J Tra nsl 
Me d 2 0 1 2; 1 0: 1 8 3 .
Le D T, Ura m J N, Wa n g H, et al. P D - 1 bl oc ka de i n t u m ors wit h mis matc h -re pair deficie nc y . N 
E n gl J Me d 2 0 1 5; 3 7 2: 2 5 0 9 - 2 0. 
Leas k A, A bra ha m, D. T G F -β si g nali n g a n d t he fi br otic res p o nse. Fase b J 2 0 0 4; 1 8: 8 1 6 - 2 7. 
Le br u n, J. T he dual role of T G F b i n hu ma n ca ncer:  f r o m tu m or s u p pressi o n t o ca ncer metastasis 
2 0 1 2, I nter n Sc h olarl y R es Net w or k. 
Le nci o ni, R, Ll o vet, J M. M o difie d R E CI S T ( m R E CI S T) assess me nt f or he pat ocell ular carci n o ma. 
Se mi n L i ver Dis 2 0 1 0; 3 0: 5 2 -6 0. 
L o n ni n g S, Ma n nic k J, Mc P hers o n JM. A nti b o d y tar geti n g of T G F -β i n ca ncer patie nts. C urr 
P har m Bi otec h n ol 2 0 1 1; 1 2( 1 2): 2 1 7 6- 1 8 9. 
Mc Carrier K P, At ki ns o n T M, De B us k K P, et al .Q ualitati ve de vel o p me nt a n d co nte nt vali dit y  o f 
t he N o n -s mall Cell L u n g Ca ncer S y m pt o m Assess me nt Q uesti o n naire ( N S C L C- S A Q), a
patie nt -re p orte d o utc o me instr u me nt . Cli n T her 2 0 1 6; 3 8( 4): [ADDRESS_838834] or beta 
rece pt o r t y pe I a n d t y pe II d ual i n hi bit or, as a t hera pe utic a p pr oac h t o s u p pressi n g pa ncreatic ca ncer 
metastasis. M ol Ca ncer T her 2 0 0 8; 7: [ADDRESS_838835] u d y  o fG C 1 0 0 8 (fres oli m u ma b): a h u ma n 
tra nsf or mi n g gr o wt h fact or -beta ( T G F β) m o n ocl o nal a nti b o d y  i n patie nts wit h a d va nce d mali g na nt 
mela n o ma or re nal carci n o ma. P L o S O ne 2 0 1 4; 9( 3):e 9 0 3 5 3. 
M u C Y, H ua n g J A, C he n Y et al. Hi g h e x pressi o n of P D -L 1 i n l u n g ca ncer ma y  c o ntri b ute t o p o or 
pr o g n osis a n d t u m or cells i m m u ne esca pe t hr o u g h s u p pressi n g t u m or i nfiltrati n g de n dritic cells 
mat urati o n. Me d O nc ol 2 0 1 1 Se p; 2 8( 3): 6 8 2- 8 8. 
Oettle H, Hil bi g A, Se ufferlei n T, et al. P hase I/ II st u d y  of  t ra be derse n ( A P 1 2 0 0 9) m o n ot hera p y 
f or t he treat me nt of p atie nts wit h a d va nce d pa ncreatic ca ncer, mali g na nt mela n o ma a n d c ol orectal 
carci n o ma. J Cli n O nc ol 2 0 1 1; 2 9:s u p pl;a bstr 2 5 1 3. 
O ka da H, Weller M, H ua n g R, et al. I m m u n ot hera p y  r es p o nse a n d assess me nt i n ne ur o -o nc ol o g y  
(i R A N O) : A re p ort of t he R A N O w or ki n g gr o u p. La ncet O nc ol 2 0 1 5; 1 6( 1 5):e [ADDRESS_838836] u g resista nce i n s q ua m o us 
cell carci n o ma. Cell 2 0 1 5; 1 6 0: 9 6 3- 7 6. 
P ha n G Q, Ya n g J C, S herr y  R M, et al. Ca ncer re gressi o n a n d a ut oi m m u nit y i n d uce d b y  c y tot o xic 
T l y m p h oc y te -ass ociate d a nti ge n 4 bl oc ka de i n patie nts wit h metastatic mela n o ma. Pr oc Natl Aca d 
Sci U S A 2 0 0 3 ; 1 0 0( 1 4): [ADDRESS_838837] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838838] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 1 / 1 9 3 R o bert C, L o n g G V, Bra d y  B, et al. Ni v ol u ma b i n pre vi o usl y u ntreate d mela n o ma wit h o ut B R A F 
m utati o n. N E n gl J Me d 2 0 1 5; 3 7 2 : [ADDRESS_838839] o ma ( G B M): C H E C K M A T E - 1 4 3. J Cli n Onc ol 
2 0 1 5 ; 3 3 (s u p pl; a bstr 3 0 1 0 ). 
Se gal N H, A nt o nia SJ, Bra h mer J R, et al. Preli mi nar y  d ata fr o m a m ulti -ar m e x pa nsi o n st u d y  o f 
M E DI 4 7 3 6, a n a nti -P D -L 1 a nti b o d y. J Cli n O nc ol 2 0 1 4; 3 2: 5s (s u p pl; a bstr 3 0 0 2). 
Sei wert T Y, Ha d da d RI , G u pta S, et al. A ntit u m or acti vit y  a n d safet y of pee m br oliz u ma b i n 
patie nts ( pts) wit h a d va nce d s q ua m o us cell carci n o ma of t he hea d a n d nec k ( S C H H N: Preli mi nar y 
res ults fr o m t he K E Y N O T E- 0 1 2 e x pa nsi o n c o h ort . J Cli n O nc ol 2 0 1 5 ; 3 3: (s u p pl; a bstr L B A 6 0 0 8 ). 
S mir ne C, Ca ma n d o na M, Ala bis o O, Bell o ne G, E ma n uelli G: Hi g h ser u m le vels of tra nsf or mi n g 
gr o wt h fact or -beta 1, interle u ki n - [ADDRESS_838840] or i n pa ncreatic 
a de n ocarci n o ma patie nts. Mi ner va Gastr oe nter ol Diet ol 1 9 9 9; 4 5: 2 1 -2 7. 
S o n g S, Y ua n P, W u H, et al . De n dritic cells wit h a n i ncrease d P D -L 1 b y  T G F β i n d uce T- cell 
a ner g y  f or t he c yt ot o xicit y of he pat ocell ular carci n o ma cells. I nter nati o nal I m m u n o p har mac ol o g y 
2 0 1 4; 2 0: 1 1 7 - 1 2 3. 
S o uza -F o nseca -G ui maraes F, S m y t h MJ. M y el oi d T G F - β res p o nsi ve ness pr o m otes metastases. 
Ca ncer Disc o v 2 0 1 3; 3( 8); [ADDRESS_838841] or β e x pressi o n re prese nts a n 
i m p orta nt pr o g n ostic para me ter f or s ur gicall y  r esecte d n o n- s mall cell l u n g ca ncer. H u ma n 
Pat h ol o g y  2 0 1 2; 4 3: [ADDRESS_838842] a ntit u m or 
i m m u nit y . Cli n Ca ncer Res 2 0 0 4 ; 1 0( 1 7): 5 9 0 7 -9 1 8. 
Sz n ol M, L o n g o D L. Release t he h o u n ds! Acti vati n g t he T -cell res p o nse t o ca ncer. N E n gl J Me d 
2 0 1 5; 3 7 2( 4): [ADDRESS_838843] u d y  of t he E O R T C 
brai n ca ncer m o d ule ( E O R T C Q L Q- B N 2 0) f or assessi n g healt h -relate d q ualit y  o f life a n d 
s y m pt o ms i n brai n ca ncer patie nts. E u rJ Ca ncer. 2 0 1 0 A pr 3 0; 4 6( 6): 1 0 3 3 - 4 0. 
T o palia n S L , Dra ke C G, Par d oll D M. Tar geti n g t he P D -1/ B 7 -H 1 ( P D -L 1 ) pat h wa y  t o acti vate 
a nti -t u m or i m m u nit y . C urr O pi n i n I m m u n ol 2 0 1 2a ; 2 4: 2 0 7 -2 1 2. 
T o palia n S L , H o di F S, Bra h mer J R, et al. Safet y, acti vit y a n d i m m u ne c orrelates of a nti -P D - 1 
a nti b o d y  i n ca ncer. N E n gl J Me d 2 0 1 2 b; 3 6 6( 2 6): [ADDRESS_838844] u d y  o f fres oli m u ma b, a n 
a nti -T G F -β a nti b o d y , i n treat me nt -resista nt pri mar y  f ocal se g me ntal gl o mer ul oscler osis.  K i d ne y 
I nt 2 0 1 1; 7 9( 1 1): [ADDRESS_838845] or -beta -re g ulate d mec ha nis m. 
Ca ncer Res 2 0 0 8; 6 8( 2): [ADDRESS_838846] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838847] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 2 / 1 9 3 We ber J S, K u d c ha d kar R R, Gi b ne y  G T, et al U p date d s ur vi val, t o xicit y  a n d bi o mar kers of 
ni v ol u ma b wit h/ wit h o ut pe pti de vacci ne i n patie nts naï ve t o, or pr o gresse d o n , i pi[INVESTIGATOR_45769] m u ma b. J Cli n 
O nc ol 2 0 1 4; 3 2:s u p pl;a bstr 3 0 0 9. 
We n P Y, Mac d o nal d D R, Rear d o n D A, et al. U p date d res p o nse assess me nt criteria f or hi g h -gra de 
gli o mas: res p o nse assess me nt i n ne ur o -o nc ol o g y  w or ki n g gr o u p. J Cli n O nc ol 2 0 1 0; 2 8( 1 1): 
1 9 6- 7 2. 
W olc h o k J D, Ne y ns B, Li nette G, et al . I p ili m u ma b m o n ot hera p y  i n patie nts wit h pretreate d 
a d va nce d mela n o ma: a ra n d o mis e d, d o u ble -bli n d, m ultice ntre, p hase 2, d ose -ra n gi n g st u d y . La ncet 
O nc ol 2 0 1 0; 1 1: [ADDRESS_838848] or -beta a n d t he i m m u ne res p o nse: 
i m plicati o ns f or a ntica ncer t hera p y. Cli n Ca ncer Res 2 0 0 7; 1 3( 1 8 Pt 1): [ADDRESS_838849] o ma. I nt J Ca ncer 1 9 9 5; 6 2: 3 8 6 - 3 9 2. 
Y o u nt S, Cella D, We bster K, et al. Assess me nt of patie nt -re p orte d cli nical o utc o me i n pa ncreatic 
a n d ot her he pat o biliar y  c a ncers: T he F A C T He pat o biliar y  S y m pt o m I n de x. J Pai n S y m pt o m 
Ma na g 2 0 0 2; 2 4: [ADDRESS_838850] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838851] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 3 / [ADDRESS_838852] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838853] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 4 / [ADDRESS_838854] at us 
E C O G P S a
Gra de E C O G 
0 F ull y acti ve, a ble t o carr y o n all pre -disease perf or ma nce wit h o ut restricti o n 
1 Restricte d i n p h ysicall y stre n u o us acti vit y b ut a m b ulat or y a n d a ble t o carr y o ut w or k of a li g ht or 
se de ntar y nat ure, f or e xa m ple, li g ht h o use w or k, office w or k 
2 A m b ulat or y a n d ca pa ble of all self -care, b ut u na ble t o carr y o ut a n y w o r k acti vities; u p a n d a b o ut 
> 5 0 % of w a ki n g h o urs 
3 Ca pa ble of o nl y li mite d self -care, c o nfi ne d t o be d or c hair > 5 0 % of wa ki n g h o urs 
4 C o m pletel y disa ble d; ca n n ot carr y o n a n y self -care; t otall y c o nfi ne d t o be d or c hair 
[ADDRESS_838855] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838856] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 5 / 1 9 3 A p pe n di x 2G ui d a nce o n C o ntr ace pti o n 
Birt h c o ntr ol met h o ds c o nsi dere d as hi g hl y effecti ve 
Ali g ne d wit h t he Cli nical Trials Facilitati o n Gr o u p (C T F G 2 0 1 4 ) “ Rec o m me n dati o ns relate d t o 
c o ntrace pti o n a n d pre g na nc y  t esti n g i n cli nical trials” met h o ds t hat ca n ac hie ve a fail ure rate of 
less t ha n 1 % per year w he n use d c o nsiste ntl y a n d c orrectl y are c o nsi dere d as hi g hl y effecti ve birt h 
c o ntr ol met h o ds, s uc h as :
c o m bi ne d (estr o ge n a n d pr o gester o ne c o ntai ni n g) h or m o nal c o ntrace pti o n ass ociate d wit h 
i n hi biti o n of o v ulati o n 1( oral, i ntra va gi nal, tra ns der mal) 
pr o gester o ne - o nl y h or m o nal c o ntrace pti o n ass ociate d wit h i n hi biti o n of o v ulati o n 1( oral, 
i njecta ble, i m pla nta ble 2, 3 )
i ntra uteri ne de vice (I U D) 2
i ntra uteri ne h or m o ne -releasi n g s ys te m (I U S) 2
bilateral t u bal occl usi o n 2
vasect o mize d part ner 2, 4
se x ual a bsti ne nce [ADDRESS_838857]. Peri o dic a bsti ne nce (e. g., cale n dar, o v ulati o n, 
s y m pt ot her mal, p ost -o v ulati o n met h o ds) a n d wit h dra wal are n ot acce pta ble met h o ds of c o ntrace pti o n .
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838858] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 6 / [ADDRESS_838859] N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838860] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 7 / 1 9 3 Si g n at ure P a ge –Pr ot oc ol Le a d 
Tri al Title: A P hase I, o pe n -la bel, m ulti ple -asce n di n g d ose trial 
t o i n vesti gate t he safet y, t olera bilit y , 
p har mac o ki netics, bi ol o gical a n d cli nical acti vit y  o f 
M S B 0 0 1 1 3 5 9 C i n s u bjects wit h metastatic or 
l ocall y  a d va nce d s oli d t u m ors a n d e x pa nsi o n t o 
selecte d i n dicati o ns 
I N D N u m ber: 
E u dr a C T N u m ber: 2 0 1 5- 0 0 4 3 6 6- 2 8 
Cli nic al Tri al Pr ot oc ol D ate / Versi o n: 2 2 J u ne 2 0 2 1 / Versi o n 7. 2- B E -E S -I T -F R 
Pr ot oc ol Le a d: 
I a p pr o ve t he desi g n of t he cli nical trial: 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Si g nat ure Date of Si g nat ure 
Na me, aca de mic de gree: 
F u ncti o n / Title: 
I nstit uti o n: Merc k Bi o p har ma C o. Lt d. 
( Affiliate of Merc k K Ga A, Dar msta dt, Ger ma n y) 
A d dress: 
Tele p h o ne n u m ber: 
Fa x n u m ber: 
E- mail a d dress: 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838861] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 9 / 1 9 3 Si g n at ure P a ge –Pri nci p al I n vesti g at or 
Tri al Title A P hase I, o pe n -la bel, m ulti ple -asce n di n g d ose 
trial t o i n vesti gate t he safet y, t olera bilit y,  
p har mac o ki netics, bi ol o gical a n d cli nical acti vit y 
of M S B [ADDRESS_838862] a C T N u m ber 2 0 1 5- 0 0 4 3 6 6- 2 8 
Cli nic al Tri al Pr ot oc ol D ate / Versi o n 2 2 J u ne 2 0 2 1 / Versi o n 7. 2- B E -E S -I T -F R 
Ce nter N u m ber 
Pri nci p al I n vesti g at or 
I, t he u n dersi g ne d, a m res p o nsi ble f or t he c o n d uct of t he trial at t his site a n d affir m t hat I 
u n dersta n d a n d will c o n d uct t he trial acc or di n g t o t he cli nical trial pr ot oc ol, a n y  a p pr o ve d pr ot oc ol 
a me n d me nts, I n ter nati o nal C o u ncil f or Har m o nisati o n G o o d Cl i nical Practice ( T o pic E 6) a n d all 
a p plica ble Healt h A ut h orit y  r e q uire me nts a n d nati o nal la ws , a n d i n Ja pa n, t he Declarati o n of 
Helsi n ki, t he sta n dar ds sti p ulate d i n Article 1 4, Para gra p h 3, a n d Article 8 0- 2 of t he 
P har mace utical Affairs La w i n Ja pa n; a n d t he “ Mi nisterial Or di na nce o n t he Sta n dar ds f or t he 
I m ple me ntati o n of Cli nical St u dies o n P har mace utical Pr o d uct” ( G o o d Cli nical Practice) i n Ja pa n .
I als o affir m t hat I u n dersta n d t hat Healt h A ut h orities ma y re q uire t he S p o ns ors of cli nical trials t o 
o bta i n a n d s u p pl y  d etails a b o ut o w ners hi p i nterests i n t he S p o ns or or I n vesti gati o nal Me dici nal 
Pr o d uct a n d a n y  ot her fi na ncial ties wit h t he S p o ns or. T he S p o ns or will use a n y  s uc h i nf or mati o n 
s olel y  f or t he p ur p ose of c o m pl y i n g wit h t he re g ulat or y  r e q uire me nt s. I t heref ore a gree t o s u p pl y 
t he S p o ns or wit h a n y necessar y  i nf or mati o n re gar di n g o w ners hi p i nterest a n d fi na ncial ties 
i ncl u di n g t h ose of m y s p o use a n d de pe n de nt c hil dre n, a n d t o pr o vi de u p dates as necessar y t o meet 
Healt h A ut h orit y  re q uire me nts. 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Si g nat ure Date of Si g nat ure 
Na me, aca de mic de gree: 
F u ncti o n / Title: 
I nstit uti o n: 
A d dress: 
Tele p h o ne n u m ber: 
Fa x n u m ber: 
E- mail a d dress: 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI C CI 
M 7 8 2 4 ( M S B 0 0 1 1 3 5 9 C ) M S B [ADDRESS_838863] atic or L oc all y A d v a nce d S oli d T u m ors 
E M R 2 0 0 6 4 7 - 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 9 1 / [ADDRESS_838864] a nti al 
( Y e s/ N o ) D at e R e gi o n or C o u ntr y I n cl u d e d i n t h e 
c urr e nt d o c u m e nt     
( Y/ N) 
A me n d me nt [ADDRESS_838865] o ber 2 0 1 5 Gl o bal Yes 
A me n d me nt 3. 1 N o 1 2 Ja n uar y 2 0 1 6 Bel gi u m, Ger ma n y, 
Ital y, S pai n, a n d U nite d 
Ki n g d o m Yes 
A me n d me nt 3. 2 N o 0 9 Fe br uar y 2 0 1 6 Bel gi u m, Ger ma n y, 
Ital y, S pai n, a n d U nite d 
Ki n g d o m N o 
A me n d me nt 3. 3 Yes 1 8 A pril 2 0 1 6 All c o u ntries e xce pt 
V H P - partici pati n g 
c o u ntries ( Bel gi u m, 
Ger ma n y, Ital y, S pai n, 
a n d U nite d Ki n g d o m )Yes 
A me n d me nt 3. [ADDRESS_838866] 2 0 1 6 All c o u ntries e xce pt 
V H P - partici pati n g 
c o u ntries ( Bel gi u m, 
Ger ma n y, Ital y, S pai n, 
a n d U nite d Ki n g d o m )Yes 
A me n d me nt 3. [ADDRESS_838867] 2 0 1 6 V H P - partici pati n g 
c o u ntries ( Bel gi u m, 
Ger ma n y, Ital y, S pai n, 
a n d U nite d Ki n g d o m )Yes 
A me n d me nt 3. [ADDRESS_838868] 2 0 1 7 U nite d States Yes 
A me n d me nt 5. 4 N o t a p plica ble 0 9 J ul y 2 0 1 8 U nite d States Yes 
A me n d me nt 6. 0 Yes 3 1 Ja n uar y 2 0 1 9 Gl o bal Yes 
A me n d me nt 6. 1 Yes 0 4 J u ne 2 0 1 9 V H P - partici pati n g 
c o u ntries (Bel gi u m, 
Fra nce, Ger ma n y, Ital y, 
S pai n, a n d U nite d 
Ki n g d o m) )Yes 
T he mai n p ur p ose of t his pr ot oc ol a me n d me nt ( Versi o n 7. 2- B E -E S -I T -F R , 2 2 J u ne 2 0 2 1) is t o 
u p date t he ris k classificati o n a n d ris k mi ni mizati o n meas ures.  T he e n d of trial is als o re vise d. 
D oc u me nt N o. 
O bject N o. 
Gl o bal Versi o n I D: C CI C CI 
C CI 